<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1">
  <url>
    <loc>https://www.trianglehealth.com/phase-1/15-gpc3-car-t-cells-nct06815432/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815432.jpg</video:thumbnail_loc>
      <video:title>15.GPC3-CAR T cells (NCT06815432) | Triangle</video:title>
      <video:description>15.GPC3-CAR T cells trial for Glioblastoma Multiforme of Brain (NCT06815432). GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma. The body has different ways of fighting infection and disease.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815432.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:44:59.499Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/15-gpc3-car-t-cells-nct06815432/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815432.jpg</video:thumbnail_loc>
      <video:title>ensayo: 15.GPC3-CAR T cells (NCT06815432) | Triangle</video:title>
      <video:description>15.GPC3-CAR T cells trial for Glioblastoma Multiforme of Brain (NCT06815432). GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma. The body has different ways of fighting infection and disease.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815432.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:44:59.499Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/15-gpc3-car-t-cells-nct06815432/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815432.jpg</video:thumbnail_loc>
      <video:title>исследование: 15.GPC3-CAR T cells (NCT06815432) | Triangle</video:title>
      <video:description>15.GPC3-CAR T cells trial for Glioblastoma Multiforme of Brain (NCT06815432). GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma. The body has different ways of fighting infection and disease.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815432.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:44:59.499Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/177lu-psma-617-nct07223034/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07223034.jpg</video:thumbnail_loc>
      <video:title>177Lu-PSMA-617 for Glioma (NCT07223034) | Triangle</video:title>
      <video:description>177Lu-PSMA-617 trial for Glioma (NCT07223034). 177Lu-PSMA-617 in People With Gliomas. The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07223034.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:45:39.436Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/177lu-psma-617-nct07223034/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07223034.jpg</video:thumbnail_loc>
      <video:title>177Lu-PSMA-617 para Glioma (NCT07223034) | Triangle</video:title>
      <video:description>177Lu-PSMA-617 trial for Glioma (NCT07223034). 177Lu-PSMA-617 in People With Gliomas. The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07223034.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:45:39.436Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/177lu-psma-617-nct07223034/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07223034.jpg</video:thumbnail_loc>
      <video:title>177Lu-PSMA-617 для Glioma (NCT07223034) | Triangle</video:title>
      <video:description>177Lu-PSMA-617 trial for Glioma (NCT07223034). 177Lu-PSMA-617 in People With Gliomas. The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07223034.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:45:39.436Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/177lu-rhpsma-10-1-nct06066437/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066437.jpg</video:thumbnail_loc>
      <video:title>177Lu rhPSMA-10.1 for Prostate Cancer (NCT06066437) | Triangle</video:title>
      <video:description>177Lu rhPSMA-10.1 trial for Prostate Cancer (NCT06066437). NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial. To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066437.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:47:42.318Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/177lu-rhpsma-10-1-nct06066437/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066437.jpg</video:thumbnail_loc>
      <video:title>177Lu rhPSMA-10.1 para Prostate Cancer (NCT06066437) | Triangle</video:title>
      <video:description>177Lu rhPSMA-10.1 trial for Prostate Cancer (NCT06066437). NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial. To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066437.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:47:42.318Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/177lu-rhpsma-10-1-nct06066437/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066437.jpg</video:thumbnail_loc>
      <video:title>177Lu rhPSMA-10.1 для Prostate Cancer (NCT06066437) | Triangle</video:title>
      <video:description>177Lu rhPSMA-10.1 trial for Prostate Cancer (NCT06066437). NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial. To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066437.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:47:42.318Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/18f-v-6-bp-nct05452005/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05452005.jpg</video:thumbnail_loc>
      <video:title>[18F]-αvβ6-BP for Metastatic… (NCT05452005) | Triangle</video:title>
      <video:description>[18F]-αvβ6-BP trial for Metastatic Non-Small Cell Lung Cancer (NCT05452005). Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer. This study investigates…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05452005.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:32:10.364Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/18f-v-6-bp-nct05452005/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05452005.jpg</video:thumbnail_loc>
      <video:title>[18F]-αvβ6-BP para Metastatic… (NCT05452005) | Triangle</video:title>
      <video:description>[18F]-αvβ6-BP trial for Metastatic Non-Small Cell Lung Cancer (NCT05452005). Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer. This study investigates…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05452005.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:32:10.364Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/18f-v-6-bp-nct05452005/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05452005.jpg</video:thumbnail_loc>
      <video:title>[18F]-αvβ6-BP для Metastatic… (NCT05452005) | Triangle</video:title>
      <video:description>[18F]-αvβ6-BP trial for Metastatic Non-Small Cell Lung Cancer (NCT05452005). Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer. This study investigates…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05452005.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:32:10.364Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/2141-v11-nct07818018/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07818018.jpg</video:thumbnail_loc>
      <video:title>2141-V11 for Advanced Esophageal… (NCT07818018) | Triangle</video:title>
      <video:description>2141-V11 trial for Advanced Esophageal, Gastric or GEJ Cancer (NCT07818018). 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma. The purpose of this study is to find out whether adding the drug…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07818018.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:53:48.428Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/2141-v11-nct07818018/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07818018.jpg</video:thumbnail_loc>
      <video:title>2141-V11 para Advanced… (NCT07818018) | Triangle</video:title>
      <video:description>2141-V11 trial for Advanced Esophageal, Gastric or GEJ Cancer (NCT07818018). 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma. The purpose of this study is to find out whether adding the drug…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07818018.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:53:48.428Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/2141-v11-nct07818018/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07818018.jpg</video:thumbnail_loc>
      <video:title>2141-V11 для Advanced Esophageal… (NCT07818018) | Triangle</video:title>
      <video:description>2141-V11 trial for Advanced Esophageal, Gastric or GEJ Cancer (NCT07818018). 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma. The purpose of this study is to find out whether adding the drug…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07818018.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:53:48.428Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/8-12-day-production-of-car-t-cells-nct04186520/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04186520.jpg</video:thumbnail_loc>
      <video:title>8/12-Day Production of Car-T Cells (NCT04186520) | Triangle</video:title>
      <video:description>8/12-Day Production of Car-T Cells trial for Non Hodgkin Lymphoma (NHL) (NCT04186520). CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies. This is a Phase I/II, interventional, single-arm, open-label, treatment study…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04186520.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:44:28.776Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/8-12-day-production-of-car-t-cells-nct04186520/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04186520.jpg</video:thumbnail_loc>
      <video:title>ensayo: 8/12-Day Production of… (NCT04186520) | Triangle</video:title>
      <video:description>8/12-Day Production of Car-T Cells trial for Non Hodgkin Lymphoma (NHL) (NCT04186520). CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies. This is a Phase I/II, interventional, single-arm, open-label, treatment study…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04186520.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:44:28.776Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/8-12-day-production-of-car-t-cells-nct04186520/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04186520.jpg</video:thumbnail_loc>
      <video:title>исследование: 8/12-Day Production… (NCT04186520) | Triangle</video:title>
      <video:description>8/12-Day Production of Car-T Cells trial for Non Hodgkin Lymphoma (NHL) (NCT04186520). CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies. This is a Phase I/II, interventional, single-arm, open-label, treatment study…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04186520.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:44:28.776Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/abcd-nk-nct06158828/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06158828.jpg</video:thumbnail_loc>
      <video:title>ABCD-NK for Acute Myeloid… (NCT06158828) | Triangle</video:title>
      <video:description>ABCD-NK trial for Acute Myeloid Leukemia, Pediatric (NCT06158828). Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML. This trial represents a single institution phase I/II…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06158828.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:04:39.701Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/abcd-nk-nct06158828/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06158828.jpg</video:thumbnail_loc>
      <video:title>ABCD-NK para Acute Myeloid… (NCT06158828) | Triangle</video:title>
      <video:description>ABCD-NK trial for Acute Myeloid Leukemia, Pediatric (NCT06158828). Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML. This trial represents a single institution phase I/II…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06158828.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:04:39.701Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/abcd-nk-nct06158828/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06158828.jpg</video:thumbnail_loc>
      <video:title>ABCD-NK для Acute Myeloid… (NCT06158828) | Triangle</video:title>
      <video:description>ABCD-NK trial for Acute Myeloid Leukemia, Pediatric (NCT06158828). Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML. This trial represents a single institution phase I/II…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06158828.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:04:39.701Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/abemaciclib-nct04923542/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04923542.jpg</video:thumbnail_loc>
      <video:title>Radiosurgery + Abemaciclib (NCT04923542) | Triangle</video:title>
      <video:description>Radiosurgery + Abemaciclib trial for HR+/HER2- Breast Cancer Brain Metastases (NCT04923542). SR &amp; Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases. This is a single arm study of abemaciclib and endocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04923542.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:37:11.013Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/abemaciclib-nct04923542/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04923542.jpg</video:thumbnail_loc>
      <video:title>ensayo: Radiosurgery + Abemaciclib (NCT04923542) | Triangle</video:title>
      <video:description>Radiosurgery + Abemaciclib trial for HR+/HER2- Breast Cancer Brain Metastases (NCT04923542). SR &amp; Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases. This is a single arm study of abemaciclib and endocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04923542.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:37:11.013Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/abemaciclib-nct04923542/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04923542.jpg</video:thumbnail_loc>
      <video:title>исследование: Radiosurgery + Abemaciclib (NCT04923542) | Triangle</video:title>
      <video:description>Radiosurgery + Abemaciclib trial for HR+/HER2- Breast Cancer Brain Metastases (NCT04923542). SR &amp; Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases. This is a single arm study of abemaciclib and endocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04923542.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:37:11.013Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/acalabrutinib-nct05256641/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05256641.jpg</video:thumbnail_loc>
      <video:title>Acalabrutinib Maintenance for High… (NCT05256641) | Triangle</video:title>
      <video:description>Acalabrutinib Maintenance trial for High-Risk Large B-Cell Lymphoma After Cellular Therapy (NCT05256641). Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma. This phase Ib/II trial studies the side effects and efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05256641.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:51:48.930Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/acalabrutinib-nct05256641/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05256641.jpg</video:thumbnail_loc>
      <video:title>ensayo: Acalabrutinib Maintenance (NCT05256641) | Triangle</video:title>
      <video:description>Acalabrutinib Maintenance trial for High-Risk Large B-Cell Lymphoma After Cellular Therapy (NCT05256641). Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma. This phase Ib/II trial studies the side effects and efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05256641.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:51:48.930Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/acalabrutinib-nct05256641/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05256641.jpg</video:thumbnail_loc>
      <video:title>Acalabrutinib Maintenance для High… (NCT05256641) | Triangle</video:title>
      <video:description>Acalabrutinib Maintenance trial for High-Risk Large B-Cell Lymphoma After Cellular Therapy (NCT05256641). Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma. This phase Ib/II trial studies the side effects and efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05256641.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:51:48.930Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ad-hcmv-flt3l-nct06914479/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06914479.jpg</video:thumbnail_loc>
      <video:title>Ad-hCMV-Flt3L for Recurrent… (NCT06914479) | Triangle</video:title>
      <video:description>Ad-hCMV-Flt3L trial for Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant (NCT06914479). Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06914479.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:26:18.809Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ad-hcmv-flt3l-nct06914479/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06914479.jpg</video:thumbnail_loc>
      <video:title>Ad-hCMV-Flt3L para Recurrent… (NCT06914479) | Triangle</video:title>
      <video:description>Ad-hCMV-Flt3L trial for Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant (NCT06914479). Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06914479.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:26:18.809Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ad-hcmv-flt3l-nct06914479/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06914479.jpg</video:thumbnail_loc>
      <video:title>Ad-hCMV-Flt3L для Recurrent… (NCT06914479) | Triangle</video:title>
      <video:description>Ad-hCMV-Flt3L trial for Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant (NCT06914479). Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06914479.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:26:18.809Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ad5-ycd-muttksr39rep-adp-adenovirus-nct05686798/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05686798.jpg</video:thumbnail_loc>
      <video:title>Ad5-yCD/mutTKSR39rep-ADP adenovirus (NCT05686798) | Triangle</video:title>
      <video:description>Ad5-yCD/mutTKSR39rep-ADP adenovirus trial for Malignant Glioma of Brain (NCT05686798). Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. The primary goal of this Phase I study is to determine the maximum…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05686798.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:18:10.958Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ad5-ycd-muttksr39rep-adp-adenovirus-nct05686798/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05686798.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ad5-yCD/mutTKSR39rep-ADP… (NCT05686798) | Triangle</video:title>
      <video:description>Ad5-yCD/mutTKSR39rep-ADP adenovirus trial for Malignant Glioma of Brain (NCT05686798). Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. The primary goal of this Phase I study is to determine the maximum…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05686798.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:18:10.958Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ad5-ycd-muttksr39rep-adp-adenovirus-nct05686798/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05686798.jpg</video:thumbnail_loc>
      <video:title>исследование… (NCT05686798) | Triangle</video:title>
      <video:description>Ad5-yCD/mutTKSR39rep-ADP adenovirus trial for Malignant Glioma of Brain (NCT05686798). Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. The primary goal of this Phase I study is to determine the maximum…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05686798.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:18:10.958Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/adaptive-stereotactic-body-radiation-nct05880667/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05880667.jpg</video:thumbnail_loc>
      <video:title>Adaptive Stereotactic Body… (NCT05880667) | Triangle</video:title>
      <video:description>Adaptive Stereotactic Body Radiation trial for Abdominopelvic Metastases (NCT05880667). Adaptive Radiation for Abdominopelvic Metastases. Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05880667.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:21:41.880Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/adaptive-stereotactic-body-radiation-nct05880667/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05880667.jpg</video:thumbnail_loc>
      <video:title>ensayo: Adaptive Stereotactic… (NCT05880667) | Triangle</video:title>
      <video:description>Adaptive Stereotactic Body Radiation trial for Abdominopelvic Metastases (NCT05880667). Adaptive Radiation for Abdominopelvic Metastases. Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05880667.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:21:41.880Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/adaptive-stereotactic-body-radiation-nct05880667/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05880667.jpg</video:thumbnail_loc>
      <video:title>исследование: Adaptive… (NCT05880667) | Triangle</video:title>
      <video:description>Adaptive Stereotactic Body Radiation trial for Abdominopelvic Metastases (NCT05880667). Adaptive Radiation for Abdominopelvic Metastases. Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05880667.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:21:41.880Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/adclec-syn1-car-t-cells-nct05748197/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05748197.jpg</video:thumbnail_loc>
      <video:title>ADCLEC.syn1 CAR T cells for Acute… (NCT05748197) | Triangle</video:title>
      <video:description>ADCLEC.syn1 CAR T cells trial for Acute Myeloid Leukemia (NCT05748197). ADCLEC.syn1 in People With Acute Myeloid Leukemia. The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05748197.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:14:11.987Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/adclec-syn1-car-t-cells-nct05748197/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05748197.jpg</video:thumbnail_loc>
      <video:title>ADCLEC.syn1 CAR T cells para Acute… (NCT05748197) | Triangle</video:title>
      <video:description>ADCLEC.syn1 CAR T cells trial for Acute Myeloid Leukemia (NCT05748197). ADCLEC.syn1 in People With Acute Myeloid Leukemia. The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05748197.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:14:11.987Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/adclec-syn1-car-t-cells-nct05748197/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05748197.jpg</video:thumbnail_loc>
      <video:title>ADCLEC.syn1 CAR T cells для Acute… (NCT05748197) | Triangle</video:title>
      <video:description>ADCLEC.syn1 CAR T cells trial for Acute Myeloid Leukemia (NCT05748197). ADCLEC.syn1 in People With Acute Myeloid Leukemia. The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05748197.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:14:11.987Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/adenosine-a2b-receptor-antagonist-pbf-1129-nct05234307/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05234307.jpg</video:thumbnail_loc>
      <video:title>Adenosine A2B Receptor Antagonist… (NCT05234307) | Triangle</video:title>
      <video:description>Adenosine A2B Receptor Antagonist PBF-1129 trial for Metastatic Lung Non-Small Cell Carcinoma (NCT05234307). PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer. This phase I trial studies the side effects and best dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05234307.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:14:26.908Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/adenosine-a2b-receptor-antagonist-pbf-1129-nct05234307/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05234307.jpg</video:thumbnail_loc>
      <video:title>ensayo: Adenosine A2B Receptor… (NCT05234307) | Triangle</video:title>
      <video:description>Adenosine A2B Receptor Antagonist PBF-1129 trial for Metastatic Lung Non-Small Cell Carcinoma (NCT05234307). PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer. This phase I trial studies the side effects and best dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05234307.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:14:26.908Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/adenosine-a2b-receptor-antagonist-pbf-1129-nct05234307/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05234307.jpg</video:thumbnail_loc>
      <video:title>исследование: Adenosine A2B… (NCT05234307) | Triangle</video:title>
      <video:description>Adenosine A2B Receptor Antagonist PBF-1129 trial for Metastatic Lung Non-Small Cell Carcinoma (NCT05234307). PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer. This phase I trial studies the side effects and best dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05234307.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:14:26.908Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/adept-nct07346144/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07346144.jpg</video:thumbnail_loc>
      <video:title>ADePT for Glioblastoma (GBM) (NCT07346144) | Triangle</video:title>
      <video:description>ADePT trial for Glioblastoma (GBM) (NCT07346144). An AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma. The goal of this clinical trial is to first define the Safety and Optimal…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07346144.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:34:10.300Z</video:publication_date>
      <video:duration>241</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/adept-nct07346144/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07346144.jpg</video:thumbnail_loc>
      <video:title>ADePT para Glioblastoma (GBM) (NCT07346144) | Triangle</video:title>
      <video:description>ADePT trial for Glioblastoma (GBM) (NCT07346144). An AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma. The goal of this clinical trial is to first define the Safety and Optimal…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07346144.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:34:10.300Z</video:publication_date>
      <video:duration>241</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/adept-nct07346144/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07346144.jpg</video:thumbnail_loc>
      <video:title>ADePT для Glioblastoma (GBM) (NCT07346144) | Triangle</video:title>
      <video:description>ADePT trial for Glioblastoma (GBM) (NCT07346144). An AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma. The goal of this clinical trial is to first define the Safety and Optimal…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07346144.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:34:10.300Z</video:publication_date>
      <video:duration>241</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/adv-hsv-tk-gene-therapy-nct03596086/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03596086.jpg</video:thumbnail_loc>
      <video:title>ADV/HSV-tk (gene therapy) (NCT03596086) | Triangle</video:title>
      <video:description>ADV/HSV-tk (gene therapy) trial for Recurrent Glioblastoma or Grade III Astrocytoma (NCT03596086). HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM. Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03596086.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:38:25.320Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/adv-hsv-tk-gene-therapy-nct03596086/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03596086.jpg</video:thumbnail_loc>
      <video:title>ensayo: ADV/HSV-tk (gene therapy) (NCT03596086) | Triangle</video:title>
      <video:description>ADV/HSV-tk (gene therapy) trial for Recurrent Glioblastoma or Grade III Astrocytoma (NCT03596086). HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM. Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03596086.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:38:25.320Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/adv-hsv-tk-gene-therapy-nct03596086/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03596086.jpg</video:thumbnail_loc>
      <video:title>исследование: ADV/HSV-tk (gene therapy) (NCT03596086) | Triangle</video:title>
      <video:description>ADV/HSV-tk (gene therapy) trial for Recurrent Glioblastoma or Grade III Astrocytoma (NCT03596086). HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM. Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03596086.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:38:25.320Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/allogeneic-anti-ny-eso-1-tcr-il-15-transduced-cord-blood-nct06066359/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066359.jpg</video:thumbnail_loc>
      <video:title>NY-ESO-1 TCR/IL-15 Cord Blood NK… (NCT06066359) | Triangle</video:title>
      <video:description>NY-ESO-1 TCR/IL-15 Cord Blood NK Cells trial for Relapsed/Refractory Myeloma (NCT06066359). Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma. To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066359.mp4</video:content_loc>
      <video:publication_date>2026-10-18T20:20:59.738Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/allogeneic-anti-ny-eso-1-tcr-il-15-transduced-cord-blood-nct06066359/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066359.jpg</video:thumbnail_loc>
      <video:title>ensayo: NY-ESO-1 TCR/IL-15 Cord… (NCT06066359) | Triangle</video:title>
      <video:description>NY-ESO-1 TCR/IL-15 Cord Blood NK Cells trial for Relapsed/Refractory Myeloma (NCT06066359). Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma. To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066359.mp4</video:content_loc>
      <video:publication_date>2026-10-18T20:20:59.738Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/allogeneic-anti-ny-eso-1-tcr-il-15-transduced-cord-blood-nct06066359/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066359.jpg</video:thumbnail_loc>
      <video:title>исследование: NY-ESO-1 TCR/IL-15… (NCT06066359) | Triangle</video:title>
      <video:description>NY-ESO-1 TCR/IL-15 Cord Blood NK Cells trial for Relapsed/Refractory Myeloma (NCT06066359). Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma. To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06066359.mp4</video:content_loc>
      <video:publication_date>2026-10-18T20:20:59.738Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/anti-cd19-cd20-cd22-car-t-cells-nct05418088/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05418088.jpg</video:thumbnail_loc>
      <video:title>Anti-CD19/CD20/CD22 CAR T-Cells (NCT05418088) | Triangle</video:title>
      <video:description>Anti-CD19/CD20/CD22 CAR T-Cells trial for Recurrent Acute Lymphoblastic Leukemia (NCT05418088). Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05418088.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:03:37.569Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/anti-cd19-cd20-cd22-car-t-cells-nct05418088/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05418088.jpg</video:thumbnail_loc>
      <video:title>ensayo: Anti-CD19/CD20/CD22 CAR T-Cells (NCT05418088) | Triangle</video:title>
      <video:description>Anti-CD19/CD20/CD22 CAR T-Cells trial for Recurrent Acute Lymphoblastic Leukemia (NCT05418088). Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05418088.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:03:37.569Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/anti-cd19-cd20-cd22-car-t-cells-nct05418088/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05418088.jpg</video:thumbnail_loc>
      <video:title>исследование: Anti-CD19/CD20/CD22… (NCT05418088) | Triangle</video:title>
      <video:description>Anti-CD19/CD20/CD22 CAR T-Cells trial for Recurrent Acute Lymphoblastic Leukemia (NCT05418088). Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05418088.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:03:37.569Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/anti-cd30-bispecific-antibody-armed-anti-cd3-activated-a-nct05544968/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05544968.jpg</video:thumbnail_loc>
      <video:title>CD30-Armed T Cells for Relapsed… (NCT05544968) | Triangle</video:title>
      <video:description>CD30-Armed T Cells trial for Relapsed or Refractory Hodgkin Lymphoma and CD30+ Lymphomas (NCT05544968). Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies. This first-in-human trial will assess the safety,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05544968.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:24:17.450Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/anti-cd30-bispecific-antibody-armed-anti-cd3-activated-a-nct05544968/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05544968.jpg</video:thumbnail_loc>
      <video:title>CD30-Armed T Cells para Relapsed… (NCT05544968) | Triangle</video:title>
      <video:description>CD30-Armed T Cells trial for Relapsed or Refractory Hodgkin Lymphoma and CD30+ Lymphomas (NCT05544968). Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies. This first-in-human trial will assess the safety,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05544968.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:24:17.450Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/anti-cd30-bispecific-antibody-armed-anti-cd3-activated-a-nct05544968/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05544968.jpg</video:thumbnail_loc>
      <video:title>CD30-Armed T Cells для Relapsed… (NCT05544968) | Triangle</video:title>
      <video:description>CD30-Armed T Cells trial for Relapsed or Refractory Hodgkin Lymphoma and CD30+ Lymphomas (NCT05544968). Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies. This first-in-human trial will assess the safety,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05544968.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:24:17.450Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/anti-garp-chimeric-antigen-receptor-t-cells-nct06964737/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964737.jpg</video:thumbnail_loc>
      <video:title>Anti-GARP Chimeric Antigen… (NCT06964737) | Triangle</video:title>
      <video:description>Anti-GARP Chimeric Antigen Receptor T Cel… trial for Recurrent Malignant Glioma (NCT06964737). Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas. This phase I trial tests the safety, side effects,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964737.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:14:47.450Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/anti-garp-chimeric-antigen-receptor-t-cells-nct06964737/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964737.jpg</video:thumbnail_loc>
      <video:title>ensayo: Anti-GARP Chimeric… (NCT06964737) | Triangle</video:title>
      <video:description>Anti-GARP Chimeric Antigen Receptor T Cel… trial for Recurrent Malignant Glioma (NCT06964737). Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas. This phase I trial tests the safety, side effects,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964737.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:14:47.450Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/anti-garp-chimeric-antigen-receptor-t-cells-nct06964737/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964737.jpg</video:thumbnail_loc>
      <video:title>исследование: Anti-GARP Chimeric… (NCT06964737) | Triangle</video:title>
      <video:description>Anti-GARP Chimeric Antigen Receptor T Cel… trial for Recurrent Malignant Glioma (NCT06964737). Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas. This phase I trial tests the safety, side effects,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964737.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:14:47.450Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/archer-nct05950139/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05950139.jpg</video:thumbnail_loc>
      <video:title>ARCHER for NSCLC Stage IV (NCT05950139) | Triangle</video:title>
      <video:description>ARCHER trial for NSCLC Stage IV (NCT05950139). Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC. The purpose of this study is to evaluate the safety of a cancer peptide…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05950139.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:16:22.405Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/archer-nct05950139/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05950139.jpg</video:thumbnail_loc>
      <video:title>ARCHER para NSCLC Stage IV (NCT05950139) | Triangle</video:title>
      <video:description>ARCHER trial for NSCLC Stage IV (NCT05950139). Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC. The purpose of this study is to evaluate the safety of a cancer peptide…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05950139.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:16:22.405Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/archer-nct05950139/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05950139.jpg</video:thumbnail_loc>
      <video:title>ARCHER для NSCLC Stage IV (NCT05950139) | Triangle</video:title>
      <video:description>ARCHER trial for NSCLC Stage IV (NCT05950139). Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC. The purpose of this study is to evaluate the safety of a cancer peptide…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05950139.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:16:22.405Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/astatine-at-211-anti-cd45-monoclonal-antibody-bc8-b10-nct03670966/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03670966.jpg</video:thumbnail_loc>
      <video:title>211At-BC8-B10 Before Stem Cell… (NCT03670966) | Triangle</video:title>
      <video:description>211At-BC8-B10 Before Stem Cell Transplant trial for High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966). 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome.…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03670966.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:54:56.345Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/astatine-at-211-anti-cd45-monoclonal-antibody-bc8-b10-nct03670966/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03670966.jpg</video:thumbnail_loc>
      <video:title>ensayo: 211At-BC8-B10 Before Stem… (NCT03670966) | Triangle</video:title>
      <video:description>211At-BC8-B10 Before Stem Cell Transplant trial for High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966). 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome.…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03670966.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:54:56.345Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/astatine-at-211-anti-cd45-monoclonal-antibody-bc8-b10-nct03670966/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03670966.jpg</video:thumbnail_loc>
      <video:title>исследование: 211At-BC8-B10… (NCT03670966) | Triangle</video:title>
      <video:description>211At-BC8-B10 Before Stem Cell Transplant trial for High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966). 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome.…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03670966.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:54:56.345Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/astx727-nct03922555/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03922555.jpg</video:thumbnail_loc>
      <video:title>ASTX727 for Recurrent/Progressive… (NCT03922555) | Triangle</video:title>
      <video:description>ASTX727 trial for Recurrent/Progressive Non-Enhancing IDH-Mutant Glioma (NCT03922555). ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas. this research study is evaluating the highest dose of ASTX727 that can be administered…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03922555.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:27:47.951Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/astx727-nct03922555/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03922555.jpg</video:thumbnail_loc>
      <video:title>ASTX727 para Recurrent/Progressive… (NCT03922555) | Triangle</video:title>
      <video:description>ASTX727 trial for Recurrent/Progressive Non-Enhancing IDH-Mutant Glioma (NCT03922555). ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas. this research study is evaluating the highest dose of ASTX727 that can be administered…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03922555.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:27:47.951Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/astx727-nct03922555/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03922555.jpg</video:thumbnail_loc>
      <video:title>ASTX727 для Recurrent/Progressive… (NCT03922555) | Triangle</video:title>
      <video:description>ASTX727 trial for Recurrent/Progressive Non-Enhancing IDH-Mutant Glioma (NCT03922555). ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas. this research study is evaluating the highest dose of ASTX727 that can be administered…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03922555.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:27:47.951Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/atezolizumab-nct05096715/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05096715.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab + Bevacizumab + SBRT (NCT05096715) | Triangle</video:title>
      <video:description>Atezolizumab + Bevacizumab + SBRT trial for Unresectable Hepatocellular Carcinoma (NCT05096715). Atezolizumab+Bevacizumab+SBRT in Unresectable HCC. This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05096715.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:53:25.515Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/atezolizumab-nct05096715/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05096715.jpg</video:thumbnail_loc>
      <video:title>ensayo: Atezolizumab +… (NCT05096715) | Triangle</video:title>
      <video:description>Atezolizumab + Bevacizumab + SBRT trial for Unresectable Hepatocellular Carcinoma (NCT05096715). Atezolizumab+Bevacizumab+SBRT in Unresectable HCC. This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05096715.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:53:25.515Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/atezolizumab-nct05096715/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05096715.jpg</video:thumbnail_loc>
      <video:title>исследование: Atezolizumab +… (NCT05096715) | Triangle</video:title>
      <video:description>Atezolizumab + Bevacizumab + SBRT trial for Unresectable Hepatocellular Carcinoma (NCT05096715). Atezolizumab+Bevacizumab+SBRT in Unresectable HCC. This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05096715.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:53:25.515Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/atra-nct06536413/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536413.jpg</video:thumbnail_loc>
      <video:title>ATRA for Relapsed/Refractory… (NCT06536413) | Triangle</video:title>
      <video:description>ATRA trial for Relapsed/Refractory Multiple Myeloma (NCT06536413). ATRA and Carfilzomib in Plasma Cell Myeloma Patients. This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536413.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:30:56.587Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/atra-nct06536413/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536413.jpg</video:thumbnail_loc>
      <video:title>ATRA para Relapsed/Refractory… (NCT06536413) | Triangle</video:title>
      <video:description>ATRA trial for Relapsed/Refractory Multiple Myeloma (NCT06536413). ATRA and Carfilzomib in Plasma Cell Myeloma Patients. This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536413.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:30:56.587Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/atra-nct06536413/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536413.jpg</video:thumbnail_loc>
      <video:title>ATRA для Relapsed/Refractory… (NCT06536413) | Triangle</video:title>
      <video:description>ATRA trial for Relapsed/Refractory Multiple Myeloma (NCT06536413). ATRA and Carfilzomib in Plasma Cell Myeloma Patients. This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536413.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:30:56.587Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/autologous-anti-psca-car-4-1bb-tcrzeta-cd19t-expressing-nct05805371/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05805371.jpg</video:thumbnail_loc>
      <video:title>PSCA-Targeting CAR-T Cells (NCT05805371) | Triangle</video:title>
      <video:description>PSCA-Targeting CAR-T Cells trial for Castration-Resistant Prostate Carcinoma (NCT05805371). PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer. This phase Ib…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05805371.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:03:43.423Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/autologous-anti-psca-car-4-1bb-tcrzeta-cd19t-expressing-nct05805371/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05805371.jpg</video:thumbnail_loc>
      <video:title>ensayo: PSCA-Targeting CAR-T Cells (NCT05805371) | Triangle</video:title>
      <video:description>PSCA-Targeting CAR-T Cells trial for Castration-Resistant Prostate Carcinoma (NCT05805371). PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer. This phase Ib…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05805371.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:03:43.423Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/autologous-anti-psca-car-4-1bb-tcrzeta-cd19t-expressing-nct05805371/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05805371.jpg</video:thumbnail_loc>
      <video:title>исследование: PSCA-Targeting CAR-T Cells (NCT05805371) | Triangle</video:title>
      <video:description>PSCA-Targeting CAR-T Cells trial for Castration-Resistant Prostate Carcinoma (NCT05805371). PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer. This phase Ib…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05805371.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:03:43.423Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/avasopasem-nct07137871/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07137871.jpg</video:thumbnail_loc>
      <video:title>Avasopasem for Metastatic Hormone… (NCT07137871) | Triangle</video:title>
      <video:description>Avasopasem trial for Metastatic Hormone Receptor-Positive Breast Cancer (NCT07137871). Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy. This study aims…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07137871.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:34:39.210Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/avasopasem-nct07137871/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07137871.jpg</video:thumbnail_loc>
      <video:title>Avasopasem para Metastatic… (NCT07137871) | Triangle</video:title>
      <video:description>Avasopasem trial for Metastatic Hormone Receptor-Positive Breast Cancer (NCT07137871). Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy. This study aims…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07137871.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:34:39.210Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/avasopasem-nct07137871/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07137871.jpg</video:thumbnail_loc>
      <video:title>Avasopasem для Metastatic Hormone… (NCT07137871) | Triangle</video:title>
      <video:description>Avasopasem trial for Metastatic Hormone Receptor-Positive Breast Cancer (NCT07137871). Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy. This study aims…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07137871.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:34:39.210Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/axatilimab-nct06523556/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06523556.jpg</video:thumbnail_loc>
      <video:title>Axatilimab for Advanced… (NCT06523556) | Triangle</video:title>
      <video:description>Axatilimab trial for Advanced Myeloproliferative Neoplasms, MDS/MPN and High-Risk CMML (NCT06523556). Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06523556.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:31:08.763Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/axatilimab-nct06523556/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06523556.jpg</video:thumbnail_loc>
      <video:title>Axatilimab para Advanced… (NCT06523556) | Triangle</video:title>
      <video:description>Axatilimab trial for Advanced Myeloproliferative Neoplasms, MDS/MPN and High-Risk CMML (NCT06523556). Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06523556.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:31:08.763Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/axatilimab-nct06523556/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06523556.jpg</video:thumbnail_loc>
      <video:title>Axatilimab для Advanced… (NCT06523556) | Triangle</video:title>
      <video:description>Axatilimab trial for Advanced Myeloproliferative Neoplasms, MDS/MPN and High-Risk CMML (NCT06523556). Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06523556.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:31:08.763Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/b7-h3-cd28z-cart-nct07390539/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07390539.jpg</video:thumbnail_loc>
      <video:title>B7-H3.CD28Z.CART for Central… (NCT07390539) | Triangle</video:title>
      <video:description>B7-H3.CD28Z.CART trial for Central Nervous System Neoplasms (NCT07390539). B7-H3.CD28Z.CART in CNS Neoplasms. The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07390539.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:48:02.130Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/b7-h3-cd28z-cart-nct07390539/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07390539.jpg</video:thumbnail_loc>
      <video:title>B7-H3.CD28Z.CART para Central… (NCT07390539) | Triangle</video:title>
      <video:description>B7-H3.CD28Z.CART trial for Central Nervous System Neoplasms (NCT07390539). B7-H3.CD28Z.CART in CNS Neoplasms. The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07390539.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:48:02.130Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/b7-h3-cd28z-cart-nct07390539/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07390539.jpg</video:thumbnail_loc>
      <video:title>B7-H3.CD28Z.CART для Central… (NCT07390539) | Triangle</video:title>
      <video:description>B7-H3.CD28Z.CART trial for Central Nervous System Neoplasms (NCT07390539). B7-H3.CD28Z.CART in CNS Neoplasms. The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07390539.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:48:02.130Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/bcma-tgf-car-t-cells-0-50-x-10-6-cells-kg-nct05976555/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05976555.jpg</video:thumbnail_loc>
      <video:title>Phase I Trial of BCMA-TGF-BETA… (NCT05976555) | Triangle</video:title>
      <video:description>Phase I Trial of BCMA-TGF-BETA CAR-T Cell… trial for Multiple Myeloma (NCT05976555). BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma. This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05976555.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:53:56.312Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/bcma-tgf-car-t-cells-0-50-x-10-6-cells-kg-nct05976555/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05976555.jpg</video:thumbnail_loc>
      <video:title>ensayo: Phase I Trial of… (NCT05976555) | Triangle</video:title>
      <video:description>Phase I Trial of BCMA-TGF-BETA CAR-T Cell… trial for Multiple Myeloma (NCT05976555). BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma. This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05976555.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:53:56.312Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/bcma-tgf-car-t-cells-0-50-x-10-6-cells-kg-nct05976555/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05976555.jpg</video:thumbnail_loc>
      <video:title>исследование: Phase I Trial of… (NCT05976555) | Triangle</video:title>
      <video:description>Phase I Trial of BCMA-TGF-BETA CAR-T Cell… trial for Multiple Myeloma (NCT05976555). BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma. This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05976555.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:53:56.312Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/bevacizumab-nct01269853/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01269853.jpg</video:thumbnail_loc>
      <video:title>Bevacizumab for Glioblastoma Multiforme (NCT01269853) | Triangle</video:title>
      <video:description>Bevacizumab trial for Glioblastoma Multiforme (NCT01269853). Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA. The high-grade malignant brain tumors,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01269853.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:21:47.182Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/bevacizumab-nct01269853/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01269853.jpg</video:thumbnail_loc>
      <video:title>Bevacizumab para Glioblastoma Multiforme (NCT01269853) | Triangle</video:title>
      <video:description>Bevacizumab trial for Glioblastoma Multiforme (NCT01269853). Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA. The high-grade malignant brain tumors,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01269853.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:21:47.182Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/bevacizumab-nct01269853/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01269853.jpg</video:thumbnail_loc>
      <video:title>Bevacizumab для Glioblastoma Multiforme (NCT01269853) | Triangle</video:title>
      <video:description>Bevacizumab trial for Glioblastoma Multiforme (NCT01269853). Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA. The high-grade malignant brain tumors,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01269853.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:21:47.182Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/brachytherapy-nct06543576/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06543576.jpg</video:thumbnail_loc>
      <video:title>External Beam Radiation and… (NCT06543576) | Triangle</video:title>
      <video:description>External Beam Radiation and Brachytherapy trial for Stage IVB Cervical Cancer (NCT06543576). External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer. This phase I/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06543576.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:36:35.000Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/brachytherapy-nct06543576/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06543576.jpg</video:thumbnail_loc>
      <video:title>ensayo: External Beam Radiation… (NCT06543576) | Triangle</video:title>
      <video:description>External Beam Radiation and Brachytherapy trial for Stage IVB Cervical Cancer (NCT06543576). External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer. This phase I/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06543576.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:36:35.000Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/brachytherapy-nct06543576/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06543576.jpg</video:thumbnail_loc>
      <video:title>исследование: External Beam… (NCT06543576) | Triangle</video:title>
      <video:description>External Beam Radiation and Brachytherapy trial for Stage IVB Cervical Cancer (NCT06543576). External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer. This phase I/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06543576.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:36:35.000Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/brite-nct04903795/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903795.jpg</video:thumbnail_loc>
      <video:title>BRiTE for Newly Diagnosed Glioblastoma (NCT04903795) | Triangle</video:title>
      <video:description>BRiTE trial for Newly Diagnosed Glioblastoma (NCT04903795). BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma. This Phase 1 study will assess the safety of a novel brain Bispecific T cell engager (BRiTE)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903795.mp4</video:content_loc>
      <video:publication_date>2026-10-28T03:40:05.741Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/brite-nct04903795/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903795.jpg</video:thumbnail_loc>
      <video:title>BRiTE para Newly Diagnosed Glioblastoma (NCT04903795) | Triangle</video:title>
      <video:description>BRiTE trial for Newly Diagnosed Glioblastoma (NCT04903795). BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma. This Phase 1 study will assess the safety of a novel brain Bispecific T cell engager (BRiTE)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903795.mp4</video:content_loc>
      <video:publication_date>2026-10-28T03:40:05.741Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/brite-nct04903795/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903795.jpg</video:thumbnail_loc>
      <video:title>BRiTE для Newly Diagnosed Glioblastoma (NCT04903795) | Triangle</video:title>
      <video:description>BRiTE trial for Newly Diagnosed Glioblastoma (NCT04903795). BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma. This Phase 1 study will assess the safety of a novel brain Bispecific T cell engager (BRiTE)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903795.mp4</video:content_loc>
      <video:publication_date>2026-10-28T03:40:05.741Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/c7r-gd2-cart-cells-iv-and-icv-infusion-nct04099797/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04099797.jpg</video:thumbnail_loc>
      <video:title>C7R-GD2.CART cells (IV and ICV… (NCT04099797) | Triangle</video:title>
      <video:description>C7R-GD2.CART cells (IV and ICV infusion) trial for Diffuse Intrinsic Pontine Glioma (NCT04099797). C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B). In this study, there are two treatment groups called Cohort 1 and Cohort 2.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04099797.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:26:10.154Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/c7r-gd2-cart-cells-iv-and-icv-infusion-nct04099797/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04099797.jpg</video:thumbnail_loc>
      <video:title>ensayo: C7R-GD2.CART cells (IV… (NCT04099797) | Triangle</video:title>
      <video:description>C7R-GD2.CART cells (IV and ICV infusion) trial for Diffuse Intrinsic Pontine Glioma (NCT04099797). C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B). In this study, there are two treatment groups called Cohort 1 and Cohort 2.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04099797.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:26:10.154Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/c7r-gd2-cart-cells-iv-and-icv-infusion-nct04099797/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04099797.jpg</video:thumbnail_loc>
      <video:title>исследование: C7R-GD2.CART cells… (NCT04099797) | Triangle</video:title>
      <video:description>C7R-GD2.CART cells (IV and ICV infusion) trial for Diffuse Intrinsic Pontine Glioma (NCT04099797). C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B). In this study, there are two treatment groups called Cohort 1 and Cohort 2.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04099797.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:26:10.154Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/car-70-il15-transduced-cb-nk-cells-nct05092451/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05092451.jpg</video:thumbnail_loc>
      <video:title>CAR.70/IL15-transduced CB-NK cells (NCT05092451) | Triangle</video:title>
      <video:description>CAR.70/IL15-transduced CB-NK cells trial for B-Cell Lymphoma (NCT05092451). CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05092451.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:32:10.330Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/car-70-il15-transduced-cb-nk-cells-nct05092451/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05092451.jpg</video:thumbnail_loc>
      <video:title>ensayo: CAR.70/IL15-transduced… (NCT05092451) | Triangle</video:title>
      <video:description>CAR.70/IL15-transduced CB-NK cells trial for B-Cell Lymphoma (NCT05092451). CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05092451.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:32:10.330Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/car-70-il15-transduced-cb-nk-cells-nct05092451/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05092451.jpg</video:thumbnail_loc>
      <video:title>исследование… (NCT05092451) | Triangle</video:title>
      <video:description>CAR.70/IL15-transduced CB-NK cells trial for B-Cell Lymphoma (NCT05092451). CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05092451.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:32:10.330Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/car-t-cell-nct05003895/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05003895.jpg</video:thumbnail_loc>
      <video:title>CAR-T cell for Hepatocellular Carcinoma (NCT05003895) | Triangle</video:title>
      <video:description>CAR-T cell trial for Hepatocellular Carcinoma (NCT05003895). GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies. Background: A new cancer treatment takes a person s own T cells,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05003895.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:02:25.642Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/car-t-cell-nct05003895/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05003895.jpg</video:thumbnail_loc>
      <video:title>CAR-T cell para Hepatocellular Carcinoma (NCT05003895) | Triangle</video:title>
      <video:description>CAR-T cell trial for Hepatocellular Carcinoma (NCT05003895). GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies. Background: A new cancer treatment takes a person s own T cells,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05003895.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:02:25.642Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/car-t-cell-nct05003895/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05003895.jpg</video:thumbnail_loc>
      <video:title>CAR-T cell для Hepatocellular Carcinoma (NCT05003895) | Triangle</video:title>
      <video:description>CAR-T cell trial for Hepatocellular Carcinoma (NCT05003895). GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies. Background: A new cancer treatment takes a person s own T cells,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05003895.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:02:25.642Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/car-t-cell-nct06768905/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06768905.jpg</video:thumbnail_loc>
      <video:title>Iomab-B Followed by CAR-T Cell… (NCT06768905) | Triangle</video:title>
      <video:description>Iomab-B Followed by CAR-T Cell Therapy trial for Non Hodgkin Lymphoma (NCT06768905). IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL. This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06768905.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:51:51.422Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/car-t-cell-nct06768905/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06768905.jpg</video:thumbnail_loc>
      <video:title>ensayo: Iomab-B Followed by CAR-T… (NCT06768905) | Triangle</video:title>
      <video:description>Iomab-B Followed by CAR-T Cell Therapy trial for Non Hodgkin Lymphoma (NCT06768905). IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL. This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06768905.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:51:51.422Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/car-t-cell-nct06768905/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06768905.jpg</video:thumbnail_loc>
      <video:title>исследование: Iomab-B Followed by… (NCT06768905) | Triangle</video:title>
      <video:description>Iomab-B Followed by CAR-T Cell Therapy trial for Non Hodgkin Lymphoma (NCT06768905). IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL. This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06768905.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:51:51.422Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/care-t-cells-nct04715191/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04715191.jpg</video:thumbnail_loc>
      <video:title>CARE T cells for Liver Cancer (NCT04715191) | Triangle</video:title>
      <video:description>CARE T cells trial for Liver Cancer (NCT04715191). Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors. Patients may be considered if…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04715191.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:00:56.585Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/care-t-cells-nct04715191/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04715191.jpg</video:thumbnail_loc>
      <video:title>CARE T cells para Liver Cancer (NCT04715191) | Triangle</video:title>
      <video:description>CARE T cells trial for Liver Cancer (NCT04715191). Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors. Patients may be considered if…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04715191.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:00:56.585Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/care-t-cells-nct04715191/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04715191.jpg</video:thumbnail_loc>
      <video:title>CARE T cells для Liver Cancer (NCT04715191) | Triangle</video:title>
      <video:description>CARE T cells trial for Liver Cancer (NCT04715191). Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors. Patients may be considered if…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04715191.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:00:56.585Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/carlotta01-nct05836896/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05836896.jpg</video:thumbnail_loc>
      <video:title>CARLOTTA01 for Neoplasms (NCT05836896) | Triangle</video:title>
      <video:description>CARLOTTA01 trial for Neoplasms (NCT05836896). Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05836896.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:47:57.323Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/carlotta01-nct05836896/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05836896.jpg</video:thumbnail_loc>
      <video:title>CARLOTTA01 para Neoplasms (NCT05836896) | Triangle</video:title>
      <video:description>CARLOTTA01 trial for Neoplasms (NCT05836896). Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05836896.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:47:57.323Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/carlotta01-nct05836896/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05836896.jpg</video:thumbnail_loc>
      <video:title>CARLOTTA01 для Neoplasms (NCT05836896) | Triangle</video:title>
      <video:description>CARLOTTA01 trial for Neoplasms (NCT05836896). Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05836896.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:47:57.323Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cart-nct07319676/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07319676.jpg</video:thumbnail_loc>
      <video:title>CART for B-cell Lymphoma Refractory (NCT07319676) | Triangle</video:title>
      <video:description>CART trial for B-cell Lymphoma Refractory (NCT07319676). Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas. This is a single center, open label, phase 1 lead in to determine Recommended Phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07319676.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:27:21.015Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cart-nct07319676/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07319676.jpg</video:thumbnail_loc>
      <video:title>CART para B-cell Lymphoma Refractory (NCT07319676) | Triangle</video:title>
      <video:description>CART trial for B-cell Lymphoma Refractory (NCT07319676). Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas. This is a single center, open label, phase 1 lead in to determine Recommended Phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07319676.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:27:21.015Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cart-nct07319676/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07319676.jpg</video:thumbnail_loc>
      <video:title>CART для B-cell Lymphoma Refractory (NCT07319676) | Triangle</video:title>
      <video:description>CART trial for B-cell Lymphoma Refractory (NCT07319676). Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas. This is a single center, open label, phase 1 lead in to determine Recommended Phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07319676.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:27:21.015Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/carv3-team-e-t-cells-nct05660369/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05660369.jpg</video:thumbnail_loc>
      <video:title>CARv3-TEAM-E T cells for Glioblastoma (NCT05660369) | Triangle</video:title>
      <video:description>CARv3-TEAM-E T cells trial for Glioblastoma (NCT05660369). CARv3-TEAM-E T Cells in Glioblastoma. The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05660369.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:18:12.097Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/carv3-team-e-t-cells-nct05660369/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05660369.jpg</video:thumbnail_loc>
      <video:title>CARv3-TEAM-E T cells para Glioblastoma (NCT05660369) | Triangle</video:title>
      <video:description>CARv3-TEAM-E T cells trial for Glioblastoma (NCT05660369). CARv3-TEAM-E T Cells in Glioblastoma. The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05660369.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:18:12.097Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/carv3-team-e-t-cells-nct05660369/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05660369.jpg</video:thumbnail_loc>
      <video:title>CARv3-TEAM-E T cells для Glioblastoma (NCT05660369) | Triangle</video:title>
      <video:description>CARv3-TEAM-E T cells trial for Glioblastoma (NCT05660369). CARv3-TEAM-E T Cells in Glioblastoma. The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05660369.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:18:12.097Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd123-car-t-nct04318678/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04318678.jpg</video:thumbnail_loc>
      <video:title>CD123-CAR T for AML/MDS (NCT04318678) | Triangle</video:title>
      <video:description>CD123-CAR T trial for AML/MDS (NCT04318678). CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML). The CD123-CAR T-cell therapy is a new treatment that is being investigated for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04318678.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:51:36.484Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd123-car-t-nct04318678/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04318678.jpg</video:thumbnail_loc>
      <video:title>CD123-CAR T para AML/MDS (NCT04318678) | Triangle</video:title>
      <video:description>CD123-CAR T trial for AML/MDS (NCT04318678). CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML). The CD123-CAR T-cell therapy is a new treatment that is being investigated for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04318678.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:51:36.484Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd123-car-t-nct04318678/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04318678.jpg</video:thumbnail_loc>
      <video:title>CD123-CAR T для AML/MDS (NCT04318678) | Triangle</video:title>
      <video:description>CD123-CAR T trial for AML/MDS (NCT04318678). CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML). The CD123-CAR T-cell therapy is a new treatment that is being investigated for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04318678.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:51:36.484Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd19-car-t-cells-nct03676504/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03676504.jpg</video:thumbnail_loc>
      <video:title>CD19.CAR T Cells for Acute… (NCT03676504) | Triangle</video:title>
      <video:description>CD19.CAR T Cells trial for Acute Lymphoblastic Leukemia, Adult (NCT03676504). Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR. Adult patients with r/r acute…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03676504.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:57:41.650Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd19-car-t-cells-nct03676504/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03676504.jpg</video:thumbnail_loc>
      <video:title>CD19.CAR T Cells para Acute… (NCT03676504) | Triangle</video:title>
      <video:description>CD19.CAR T Cells trial for Acute Lymphoblastic Leukemia, Adult (NCT03676504). Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR. Adult patients with r/r acute…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03676504.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:57:41.650Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd19-car-t-cells-nct03676504/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03676504.jpg</video:thumbnail_loc>
      <video:title>CD19.CAR T Cells для Acute… (NCT03676504) | Triangle</video:title>
      <video:description>CD19.CAR T Cells trial for Acute Lymphoblastic Leukemia, Adult (NCT03676504). Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR. Adult patients with r/r acute…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03676504.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:57:41.650Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd19-cd22-car-transduced-t-cells-nct05442515/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05442515.jpg</video:thumbnail_loc>
      <video:title>CD19/CD22-CAR-transduced T cells (NCT05442515) | Triangle</video:title>
      <video:description>CD19/CD22-CAR-transduced T cells trial for B-Non Hodgkin Lymphoma (NCT05442515). CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies. Background: Acute…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05442515.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:41:12.518Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd19-cd22-car-transduced-t-cells-nct05442515/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05442515.jpg</video:thumbnail_loc>
      <video:title>ensayo: CD19/CD22-CAR-transduced T cells (NCT05442515) | Triangle</video:title>
      <video:description>CD19/CD22-CAR-transduced T cells trial for B-Non Hodgkin Lymphoma (NCT05442515). CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies. Background: Acute…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05442515.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:41:12.518Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd19-cd22-car-transduced-t-cells-nct05442515/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05442515.jpg</video:thumbnail_loc>
      <video:title>исследование… (NCT05442515) | Triangle</video:title>
      <video:description>CD19/CD22-CAR-transduced T cells trial for B-Non Hodgkin Lymphoma (NCT05442515). CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies. Background: Acute…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05442515.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:41:12.518Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd19car-cd28-cd3zeta-egfrt-expressing-tn-mem-t-lymphocyt-nct05625594/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05625594.jpg</video:thumbnail_loc>
      <video:title>CD19-CAR T Cells for CNS Lymphoma (NCT05625594) | Triangle</video:title>
      <video:description>CD19-CAR T Cells for CNS Lymphoma trial for Central Nervous System Lymphoma (NCT05625594). Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05625594.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:51:05.646Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd19car-cd28-cd3zeta-egfrt-expressing-tn-mem-t-lymphocyt-nct05625594/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05625594.jpg</video:thumbnail_loc>
      <video:title>ensayo: CD19-CAR T Cells for CNS… (NCT05625594) | Triangle</video:title>
      <video:description>CD19-CAR T Cells for CNS Lymphoma trial for Central Nervous System Lymphoma (NCT05625594). Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05625594.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:51:05.646Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd19car-cd28-cd3zeta-egfrt-expressing-tn-mem-t-lymphocyt-nct05625594/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05625594.jpg</video:thumbnail_loc>
      <video:title>исследование: CD19-CAR T Cells… (NCT05625594) | Triangle</video:title>
      <video:description>CD19-CAR T Cells for CNS Lymphoma trial for Central Nervous System Lymphoma (NCT05625594). Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05625594.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:51:05.646Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd19x22-car-t-cells-nct05098613/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05098613.jpg</video:thumbnail_loc>
      <video:title>CD19x22 CAR T Cells (NCT05098613) | Triangle</video:title>
      <video:description>CD19x22 CAR T Cells trial for Non-Hodgkin Lymphoma (NCT05098613). Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients. This open-label, single arm phase 1 trial aims to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05098613.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:38:05.923Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd19x22-car-t-cells-nct05098613/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05098613.jpg</video:thumbnail_loc>
      <video:title>ensayo: CD19x22 CAR T Cells (NCT05098613) | Triangle</video:title>
      <video:description>CD19x22 CAR T Cells trial for Non-Hodgkin Lymphoma (NCT05098613). Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients. This open-label, single arm phase 1 trial aims to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05098613.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:38:05.923Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd19x22-car-t-cells-nct05098613/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05098613.jpg</video:thumbnail_loc>
      <video:title>исследование: CD19x22 CAR T Cells (NCT05098613) | Triangle</video:title>
      <video:description>CD19x22 CAR T Cells trial for Non-Hodgkin Lymphoma (NCT05098613). Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients. This open-label, single arm phase 1 trial aims to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05098613.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:38:05.923Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd19x22-car-t-nct06559189/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06559189.jpg</video:thumbnail_loc>
      <video:title>CD19x22 CAR T for B-cell Acute… (NCT06559189) | Triangle</video:title>
      <video:description>CD19x22 CAR T trial for B-cell Acute Lymphoblastic Leukemia (NCT06559189). CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL. This study will evaluate the safety and tolerability of administering a novel…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06559189.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:19:38.258Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd19x22-car-t-nct06559189/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06559189.jpg</video:thumbnail_loc>
      <video:title>CD19x22 CAR T para B-cell Acute… (NCT06559189) | Triangle</video:title>
      <video:description>CD19x22 CAR T trial for B-cell Acute Lymphoblastic Leukemia (NCT06559189). CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL. This study will evaluate the safety and tolerability of administering a novel…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06559189.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:19:38.258Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd19x22-car-t-nct06559189/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06559189.jpg</video:thumbnail_loc>
      <video:title>CD19x22 CAR T для B-cell Acute… (NCT06559189) | Triangle</video:title>
      <video:description>CD19x22 CAR T trial for B-cell Acute Lymphoblastic Leukemia (NCT06559189). CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL. This study will evaluate the safety and tolerability of administering a novel…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06559189.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:19:38.258Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd22cart-cell-nct04815356/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04815356.jpg</video:thumbnail_loc>
      <video:title>CD22CART cell for Hairy Cell Leukemia (NCT04815356) | Triangle</video:title>
      <video:description>CD22CART cell trial for Hairy Cell Leukemia (NCT04815356). Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant. Background: CAR (Chimeric Antigen Receptor) T cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04815356.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:29:24.481Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd22cart-cell-nct04815356/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04815356.jpg</video:thumbnail_loc>
      <video:title>CD22CART cell para Hairy Cell Leukemia (NCT04815356) | Triangle</video:title>
      <video:description>CD22CART cell trial for Hairy Cell Leukemia (NCT04815356). Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant. Background: CAR (Chimeric Antigen Receptor) T cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04815356.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:29:24.481Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd22cart-cell-nct04815356/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04815356.jpg</video:thumbnail_loc>
      <video:title>CD22CART cell для Hairy Cell Leukemia (NCT04815356) | Triangle</video:title>
      <video:description>CD22CART cell trial for Hairy Cell Leukemia (NCT04815356). Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant. Background: CAR (Chimeric Antigen Receptor) T cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04815356.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:29:24.481Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd371-specific-ysnvz-i-18-car-t-cells-nct06017258/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06017258.jpg</video:thumbnail_loc>
      <video:title>CD371-specific/YSNVz/I-18 CAR T… (NCT06017258) | Triangle</video:title>
      <video:description>CD371-specific/YSNVz/I-18 CAR T cells trial for Refractory Acute Myeloid Leukemia (NCT06017258). CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia. The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06017258.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:55:09.528Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd371-specific-ysnvz-i-18-car-t-cells-nct06017258/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06017258.jpg</video:thumbnail_loc>
      <video:title>ensayo: CD371-specific/YSNVz/I-18… (NCT06017258) | Triangle</video:title>
      <video:description>CD371-specific/YSNVz/I-18 CAR T cells trial for Refractory Acute Myeloid Leukemia (NCT06017258). CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia. The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06017258.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:55:09.528Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd371-specific-ysnvz-i-18-car-t-cells-nct06017258/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06017258.jpg</video:thumbnail_loc>
      <video:title>исследование… (NCT06017258) | Triangle</video:title>
      <video:description>CD371-specific/YSNVz/I-18 CAR T cells trial for Refractory Acute Myeloid Leukemia (NCT06017258). CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia. The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06017258.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:55:09.528Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cd79b-19-car-t-cells-nct06026319/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06026319.jpg</video:thumbnail_loc>
      <video:title>CD79b-19 CAR T cells (NCT06026319) | Triangle</video:title>
      <video:description>CD79b-19 CAR T cells trial for Non-hodgkin Lymphoma (NCT06026319). CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma. This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06026319.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:34:23.611Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cd79b-19-car-t-cells-nct06026319/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06026319.jpg</video:thumbnail_loc>
      <video:title>ensayo: CD79b-19 CAR T cells (NCT06026319) | Triangle</video:title>
      <video:description>CD79b-19 CAR T cells trial for Non-hodgkin Lymphoma (NCT06026319). CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma. This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06026319.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:34:23.611Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cd79b-19-car-t-cells-nct06026319/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06026319.jpg</video:thumbnail_loc>
      <video:title>исследование: CD79b-19 CAR T cells (NCT06026319) | Triangle</video:title>
      <video:description>CD79b-19 CAR T cells trial for Non-hodgkin Lymphoma (NCT06026319). CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma. This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06026319.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:34:23.611Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cdx-1140-nct05029999/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05029999.jpg</video:thumbnail_loc>
      <video:title>CDX-1140 + CDX-301 + PLD (NCT05029999) | Triangle</video:title>
      <video:description>CDX-1140 + CDX-301 + PLD trial for Metastatic HER2-Negative Breast Cancer (NCT05029999). CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer. This research study is being done to find out if the immunotherapy drugs called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05029999.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:46:47.250Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cdx-1140-nct05029999/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05029999.jpg</video:thumbnail_loc>
      <video:title>ensayo: CDX-1140 + CDX-301 + PLD (NCT05029999) | Triangle</video:title>
      <video:description>CDX-1140 + CDX-301 + PLD trial for Metastatic HER2-Negative Breast Cancer (NCT05029999). CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer. This research study is being done to find out if the immunotherapy drugs called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05029999.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:46:47.250Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cdx-1140-nct05029999/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05029999.jpg</video:thumbnail_loc>
      <video:title>исследование: CDX-1140 + CDX-301 + PLD (NCT05029999) | Triangle</video:title>
      <video:description>CDX-1140 + CDX-301 + PLD trial for Metastatic HER2-Negative Breast Cancer (NCT05029999). CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer. This research study is being done to find out if the immunotherapy drugs called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05029999.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:46:47.250Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/chimeric-antigen-receptor-t-cell-therapy-nct06815029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815029.jpg</video:thumbnail_loc>
      <video:title>Chimeric Antigen Receptor T-Cell… (NCT06815029) | Triangle</video:title>
      <video:description>Chimeric Antigen Receptor T-Cell Therapy trial for Recurrent Glioblastoma (NCT06815029). Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815029.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:09:19.890Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/chimeric-antigen-receptor-t-cell-therapy-nct06815029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815029.jpg</video:thumbnail_loc>
      <video:title>ensayo: Chimeric Antigen Receptor… (NCT06815029) | Triangle</video:title>
      <video:description>Chimeric Antigen Receptor T-Cell Therapy trial for Recurrent Glioblastoma (NCT06815029). Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815029.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:09:19.890Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/chimeric-antigen-receptor-t-cell-therapy-nct06815029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815029.jpg</video:thumbnail_loc>
      <video:title>исследование: Chimeric Antigen… (NCT06815029) | Triangle</video:title>
      <video:description>Chimeric Antigen Receptor T-Cell Therapy trial for Recurrent Glioblastoma (NCT06815029). Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06815029.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:09:19.890Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/chimeric-antigen-receptor-t-cells-nct05225363/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05225363.jpg</video:thumbnail_loc>
      <video:title>Chimeric Antigen Receptor T-cells (NCT05225363) | Triangle</video:title>
      <video:description>Chimeric Antigen Receptor T-cells trial for Platinum-Resistant Ovarian Carcinoma (NCT05225363). Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05225363.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:16:36.738Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/chimeric-antigen-receptor-t-cells-nct05225363/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05225363.jpg</video:thumbnail_loc>
      <video:title>ensayo: Chimeric Antigen Receptor… (NCT05225363) | Triangle</video:title>
      <video:description>Chimeric Antigen Receptor T-cells trial for Platinum-Resistant Ovarian Carcinoma (NCT05225363). Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05225363.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:16:36.738Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/chimeric-antigen-receptor-t-cells-nct05225363/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05225363.jpg</video:thumbnail_loc>
      <video:title>исследование: Chimeric Antigen… (NCT05225363) | Triangle</video:title>
      <video:description>Chimeric Antigen Receptor T-cells trial for Platinum-Resistant Ovarian Carcinoma (NCT05225363). Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05225363.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:16:36.738Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ciml-nk-cells-nct05580601/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05580601.jpg</video:thumbnail_loc>
      <video:title>CIML-NK Cells (NCT05580601) | Triangle</video:title>
      <video:description>CIML-NK Cells trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT05580601). Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed &amp; Refractory Acute Myeloid Leukemia (AML). The objective of this study is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05580601.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:44:37.918Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ciml-nk-cells-nct05580601/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05580601.jpg</video:thumbnail_loc>
      <video:title>ensayo: CIML-NK Cells (NCT05580601) | Triangle</video:title>
      <video:description>CIML-NK Cells trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT05580601). Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed &amp; Refractory Acute Myeloid Leukemia (AML). The objective of this study is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05580601.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:44:37.918Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ciml-nk-cells-nct05580601/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05580601.jpg</video:thumbnail_loc>
      <video:title>исследование: CIML-NK Cells (NCT05580601) | Triangle</video:title>
      <video:description>CIML-NK Cells trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT05580601). Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed &amp; Refractory Acute Myeloid Leukemia (AML). The objective of this study is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05580601.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:44:37.918Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ciml-nk-nct04024761/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04024761.jpg</video:thumbnail_loc>
      <video:title>CIML NK for Acute Myeloid Leukemia (NCT04024761) | Triangle</video:title>
      <video:description>CIML NK trial for Acute Myeloid Leukemia (NCT04024761). CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation. This research study is studying cytokine induced memory-like…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04024761.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:26:00.391Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ciml-nk-nct04024761/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04024761.jpg</video:thumbnail_loc>
      <video:title>CIML NK para Acute Myeloid Leukemia (NCT04024761) | Triangle</video:title>
      <video:description>CIML NK trial for Acute Myeloid Leukemia (NCT04024761). CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation. This research study is studying cytokine induced memory-like…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04024761.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:26:00.391Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ciml-nk-nct04024761/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04024761.jpg</video:thumbnail_loc>
      <video:title>CIML NK для Acute Myeloid Leukemia (NCT04024761) | Triangle</video:title>
      <video:description>CIML NK trial for Acute Myeloid Leukemia (NCT04024761). CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation. This research study is studying cytokine induced memory-like…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04024761.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:26:00.391Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cladribine-nct04375631/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04375631.jpg</video:thumbnail_loc>
      <video:title>CLAG-M/FLAG-Ida + TBI for Relapsed… (NCT04375631) | Triangle</video:title>
      <video:description>CLAG-M/FLAG-Ida + TBI trial for Relapsed or Refractory AML, MDS or CMML (NCT04375631). CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04375631.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:15:48.988Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cladribine-nct04375631/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04375631.jpg</video:thumbnail_loc>
      <video:title>ensayo: CLAG-M/FLAG-Ida + TBI (NCT04375631) | Triangle</video:title>
      <video:description>CLAG-M/FLAG-Ida + TBI trial for Relapsed or Refractory AML, MDS or CMML (NCT04375631). CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04375631.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:15:48.988Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cladribine-nct04375631/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04375631.jpg</video:thumbnail_loc>
      <video:title>CLAG-M/FLAG-Ida + TBI для Relapsed… (NCT04375631) | Triangle</video:title>
      <video:description>CLAG-M/FLAG-Ida + TBI trial for Relapsed or Refractory AML, MDS or CMML (NCT04375631). CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04375631.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:15:48.988Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cladribine-nct04797767/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04797767.jpg</video:thumbnail_loc>
      <video:title>Venetoclax Plus CLAG-M for Acute… (NCT04797767) | Triangle</video:title>
      <video:description>Venetoclax Plus CLAG-M trial for Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767). Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms. This phase I/II trial finds the best dose, side effects…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04797767.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:13:31.199Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cladribine-nct04797767/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04797767.jpg</video:thumbnail_loc>
      <video:title>Venetoclax Plus CLAG-M para Acute… (NCT04797767) | Triangle</video:title>
      <video:description>Venetoclax Plus CLAG-M trial for Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767). Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms. This phase I/II trial finds the best dose, side effects…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04797767.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:13:31.199Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cladribine-nct04797767/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04797767.jpg</video:thumbnail_loc>
      <video:title>Venetoclax Plus CLAG-M для Acute… (NCT04797767) | Triangle</video:title>
      <video:description>Venetoclax Plus CLAG-M trial for Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767). Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms. This phase I/II trial finds the best dose, side effects…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04797767.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:13:31.199Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/combination-treatment-cxrpt-of-external-beam-radiation-x-nct04892303/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04892303.jpg</video:thumbnail_loc>
      <video:title>Radiation + Radioactive Iodine (NCT04892303) | Triangle</video:title>
      <video:description>Radiation + Radioactive Iodine trial for Recurrent Differentiated Thyroid Cancer (NCT04892303). Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer. The goal of this study is to evaluate combined radioactive…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04892303.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:56:04.344Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/combination-treatment-cxrpt-of-external-beam-radiation-x-nct04892303/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04892303.jpg</video:thumbnail_loc>
      <video:title>ensayo: Radiation + Radioactive Iodine (NCT04892303) | Triangle</video:title>
      <video:description>Radiation + Radioactive Iodine trial for Recurrent Differentiated Thyroid Cancer (NCT04892303). Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer. The goal of this study is to evaluate combined radioactive…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04892303.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:56:04.344Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/combination-treatment-cxrpt-of-external-beam-radiation-x-nct04892303/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04892303.jpg</video:thumbnail_loc>
      <video:title>исследование: Radiation +… (NCT04892303) | Triangle</video:title>
      <video:description>Radiation + Radioactive Iodine trial for Recurrent Differentiated Thyroid Cancer (NCT04892303). Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer. The goal of this study is to evaluate combined radioactive…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04892303.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:56:04.344Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cord-blood-derived-expanded-allogeneic-natural-killer-ce-nct04991870/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04991870.jpg</video:thumbnail_loc>
      <video:title>Phase I CB-NK-TGF-ßR2-/NR3C1- in… (NCT04991870) | Triangle</video:title>
      <video:description>Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM trial for Recurrent Gliosarcoma (NCT04991870). Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM. This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04991870.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:30:40.833Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cord-blood-derived-expanded-allogeneic-natural-killer-ce-nct04991870/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04991870.jpg</video:thumbnail_loc>
      <video:title>ensayo: Phase I… (NCT04991870) | Triangle</video:title>
      <video:description>Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM trial for Recurrent Gliosarcoma (NCT04991870). Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM. This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04991870.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:30:40.833Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cord-blood-derived-expanded-allogeneic-natural-killer-ce-nct04991870/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04991870.jpg</video:thumbnail_loc>
      <video:title>исследование: Phase I… (NCT04991870) | Triangle</video:title>
      <video:description>Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM trial for Recurrent Gliosarcoma (NCT04991870). Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM. This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04991870.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:30:40.833Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/crd3874-si-nct07661095/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07661095.jpg</video:thumbnail_loc>
      <video:title>CRD3874-SI for Relapsed or… (NCT07661095) | Triangle</video:title>
      <video:description>CRD3874-SI trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT07661095). CRD3874-SI in People With Leukemia. The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07661095.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:39:57.037Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/crd3874-si-nct07661095/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07661095.jpg</video:thumbnail_loc>
      <video:title>CRD3874-SI para Relapsed or… (NCT07661095) | Triangle</video:title>
      <video:description>CRD3874-SI trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT07661095). CRD3874-SI in People With Leukemia. The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07661095.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:39:57.037Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/crd3874-si-nct07661095/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07661095.jpg</video:thumbnail_loc>
      <video:title>CRD3874-SI для Relapsed or… (NCT07661095) | Triangle</video:title>
      <video:description>CRD3874-SI trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT07661095). CRD3874-SI in People With Leukemia. The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07661095.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:39:57.037Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cscc-nct05377905/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05377905.jpg</video:thumbnail_loc>
      <video:title>MNA-D for Cutaneous Squamous Cell… (NCT05377905) | Triangle</video:title>
      <video:description>MNA-D trial for Cutaneous Squamous Cell Carcinoma (NCT05377905). Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC). The purpose of this study is to test a new method of experimental treatment for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05377905.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:20:02.316Z</video:publication_date>
      <video:duration>55</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cscc-nct05377905/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05377905.jpg</video:thumbnail_loc>
      <video:title>MNA-D para Cutaneous Squamous… (NCT05377905) | Triangle</video:title>
      <video:description>MNA-D trial for Cutaneous Squamous Cell Carcinoma (NCT05377905). Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC). The purpose of this study is to test a new method of experimental treatment for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05377905.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:20:02.316Z</video:publication_date>
      <video:duration>55</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cscc-nct05377905/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05377905.jpg</video:thumbnail_loc>
      <video:title>MNA-D для Cutaneous Squamous Cell… (NCT05377905) | Triangle</video:title>
      <video:description>MNA-D trial for Cutaneous Squamous Cell Carcinoma (NCT05377905). Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC). The purpose of this study is to test a new method of experimental treatment for…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05377905.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:20:02.316Z</video:publication_date>
      <video:duration>55</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cue-102-nct06917885/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06917885.jpg</video:thumbnail_loc>
      <video:title>CUE-102 for Recurrent Glioblastoma (NCT06917885) | Triangle</video:title>
      <video:description>CUE-102 trial for Recurrent Glioblastoma (NCT06917885). CUE-102 in Recurrent Glioblastoma. The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06917885.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:00:30.896Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cue-102-nct06917885/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06917885.jpg</video:thumbnail_loc>
      <video:title>CUE-102 para Recurrent Glioblastoma (NCT06917885) | Triangle</video:title>
      <video:description>CUE-102 trial for Recurrent Glioblastoma (NCT06917885). CUE-102 in Recurrent Glioblastoma. The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06917885.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:00:30.896Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cue-102-nct06917885/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06917885.jpg</video:thumbnail_loc>
      <video:title>CUE-102 для Recurrent Glioblastoma (NCT06917885) | Triangle</video:title>
      <video:description>CUE-102 trial for Recurrent Glioblastoma (NCT06917885). CUE-102 in Recurrent Glioblastoma. The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06917885.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:00:30.896Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cyclosporine-nct03128034/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03128034.jpg</video:thumbnail_loc>
      <video:title>Cyclosporine for Acute… (NCT03128034) | Triangle</video:title>
      <video:description>Cyclosporine trial for Acute Lymphoblastic Leukemia (NCT03128034). 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03128034.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:22:44.004Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cyclosporine-nct03128034/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03128034.jpg</video:thumbnail_loc>
      <video:title>Cyclosporine para Acute… (NCT03128034) | Triangle</video:title>
      <video:description>Cyclosporine trial for Acute Lymphoblastic Leukemia (NCT03128034). 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03128034.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:22:44.004Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cyclosporine-nct03128034/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03128034.jpg</video:thumbnail_loc>
      <video:title>Cyclosporine для Acute… (NCT03128034) | Triangle</video:title>
      <video:description>Cyclosporine trial for Acute Lymphoblastic Leukemia (NCT03128034). 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03128034.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:22:44.004Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06138587/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06138587.jpg</video:thumbnail_loc>
      <video:title>Preemptive CIML NK Cell Therapy (NCT06138587) | Triangle</video:title>
      <video:description>Preemptive CIML NK Cell Therapy trial for Acute Myeloid Leukemia (NCT06138587). Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation. The purpose of this research study is to test the safety and efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06138587.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:07:27.932Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06138587/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06138587.jpg</video:thumbnail_loc>
      <video:title>ensayo: Preemptive CIML NK Cell Therapy (NCT06138587) | Triangle</video:title>
      <video:description>Preemptive CIML NK Cell Therapy trial for Acute Myeloid Leukemia (NCT06138587). Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation. The purpose of this research study is to test the safety and efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06138587.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:07:27.932Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06138587/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06138587.jpg</video:thumbnail_loc>
      <video:title>исследование: Preemptive CIML NK… (NCT06138587) | Triangle</video:title>
      <video:description>Preemptive CIML NK Cell Therapy trial for Acute Myeloid Leukemia (NCT06138587). Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation. The purpose of this research study is to test the safety and efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06138587.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:07:27.932Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06152809/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06152809.jpg</video:thumbnail_loc>
      <video:title>CIML NK cells for AML for Acute… (NCT06152809) | Triangle</video:title>
      <video:description>CIML NK cells for AML trial for Acute Myeloid Leukemia (NCT06152809). CIML NK Cells With Venetoclax for AML. The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06152809.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:52:08.328Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06152809/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06152809.jpg</video:thumbnail_loc>
      <video:title>CIML NK cells for AML para Acute… (NCT06152809) | Triangle</video:title>
      <video:description>CIML NK cells for AML trial for Acute Myeloid Leukemia (NCT06152809). CIML NK Cells With Venetoclax for AML. The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06152809.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:52:08.328Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06152809/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06152809.jpg</video:thumbnail_loc>
      <video:title>CIML NK cells for AML для Acute… (NCT06152809) | Triangle</video:title>
      <video:description>CIML NK cells for AML trial for Acute Myeloid Leukemia (NCT06152809). CIML NK Cells With Venetoclax for AML. The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06152809.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:52:08.328Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06321484/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06321484.jpg</video:thumbnail_loc>
      <video:title>CIML NK cells for ovarian cancer (NCT06321484) | Triangle</video:title>
      <video:description>CIML NK cells for ovarian cancer trial for Platinum-resistant Ovarian Cancer (NCT06321484). Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer. The goal of this research study is to evaluate the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06321484.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:18:12.439Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06321484/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06321484.jpg</video:thumbnail_loc>
      <video:title>ensayo: CIML NK cells for ovarian cancer (NCT06321484) | Triangle</video:title>
      <video:description>CIML NK cells for ovarian cancer trial for Platinum-resistant Ovarian Cancer (NCT06321484). Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer. The goal of this research study is to evaluate the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06321484.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:18:12.439Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06321484/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06321484.jpg</video:thumbnail_loc>
      <video:title>исследование: CIML NK cells for… (NCT06321484) | Triangle</video:title>
      <video:description>CIML NK cells for ovarian cancer trial for Platinum-resistant Ovarian Cancer (NCT06321484). Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer. The goal of this research study is to evaluate the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06321484.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:18:12.439Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/danvatirsen-nct05986240/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05986240.jpg</video:thumbnail_loc>
      <video:title>Danvatirsen (NCT05986240) | Triangle</video:title>
      <video:description>Danvatirsen trial for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT05986240). Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS &amp; AML. This is a Phase 1 study investigating the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05986240.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:28:14.263Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/danvatirsen-nct05986240/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05986240.jpg</video:thumbnail_loc>
      <video:title>ensayo: Danvatirsen (NCT05986240) | Triangle</video:title>
      <video:description>Danvatirsen trial for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT05986240). Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS &amp; AML. This is a Phase 1 study investigating the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05986240.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:28:14.263Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/danvatirsen-nct05986240/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05986240.jpg</video:thumbnail_loc>
      <video:title>исследование: Danvatirsen (NCT05986240) | Triangle</video:title>
      <video:description>Danvatirsen trial for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT05986240). Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS &amp; AML. This is a Phase 1 study investigating the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05986240.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:28:14.263Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/db107-rrv-nct06504381/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06504381.jpg</video:thumbnail_loc>
      <video:title>DB107-RRV for High Grade Glioma (NCT06504381) | Triangle</video:title>
      <video:description>DB107-RRV trial for High Grade Glioma (NCT06504381). DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma. This is a multicenter, open-label study of DB107-RRV…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06504381.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:21:10.556Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/db107-rrv-nct06504381/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06504381.jpg</video:thumbnail_loc>
      <video:title>DB107-RRV para High Grade Glioma (NCT06504381) | Triangle</video:title>
      <video:description>DB107-RRV trial for High Grade Glioma (NCT06504381). DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma. This is a multicenter, open-label study of DB107-RRV…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06504381.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:21:10.556Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/db107-rrv-nct06504381/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06504381.jpg</video:thumbnail_loc>
      <video:title>DB107-RRV для High Grade Glioma (NCT06504381) | Triangle</video:title>
      <video:description>DB107-RRV trial for High Grade Glioma (NCT06504381). DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma. This is a multicenter, open-label study of DB107-RRV…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06504381.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:21:10.556Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/dc-aml-fusion-vaccine-nct07374029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07374029.jpg</video:thumbnail_loc>
      <video:title>DC/AML Fusion Vaccine for Acute… (NCT07374029) | Triangle</video:title>
      <video:description>DC/AML Fusion Vaccine trial for Acute Myeloid Leukemia (NCT07374029). Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML. The goal of this research study is to test if the combination of a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07374029.mp4</video:content_loc>
      <video:publication_date>2026-10-18T23:50:25.080Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/dc-aml-fusion-vaccine-nct07374029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07374029.jpg</video:thumbnail_loc>
      <video:title>DC/AML Fusion Vaccine para Acute… (NCT07374029) | Triangle</video:title>
      <video:description>DC/AML Fusion Vaccine trial for Acute Myeloid Leukemia (NCT07374029). Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML. The goal of this research study is to test if the combination of a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07374029.mp4</video:content_loc>
      <video:publication_date>2026-10-18T23:50:25.080Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/dc-aml-fusion-vaccine-nct07374029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07374029.jpg</video:thumbnail_loc>
      <video:title>DC/AML Fusion Vaccine для Acute… (NCT07374029) | Triangle</video:title>
      <video:description>DC/AML Fusion Vaccine trial for Acute Myeloid Leukemia (NCT07374029). Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML. The goal of this research study is to test if the combination of a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07374029.mp4</video:content_loc>
      <video:publication_date>2026-10-18T23:50:25.080Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/dc-mm-fusion-vaccine-nct07377435/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07377435.jpg</video:thumbnail_loc>
      <video:title>DC/MM Fusion Vaccine for Multiple… (NCT07377435) | Triangle</video:title>
      <video:description>DC/MM Fusion Vaccine trial for Multiple Myeloma (NCT07377435). DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM. This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07377435.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:05:11.975Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/dc-mm-fusion-vaccine-nct07377435/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07377435.jpg</video:thumbnail_loc>
      <video:title>DC/MM Fusion Vaccine para Multiple… (NCT07377435) | Triangle</video:title>
      <video:description>DC/MM Fusion Vaccine trial for Multiple Myeloma (NCT07377435). DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM. This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07377435.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:05:11.975Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/dc-mm-fusion-vaccine-nct07377435/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07377435.jpg</video:thumbnail_loc>
      <video:title>DC/MM Fusion Vaccine для Multiple… (NCT07377435) | Triangle</video:title>
      <video:description>DC/MM Fusion Vaccine trial for Multiple Myeloma (NCT07377435). DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM. This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07377435.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:05:11.975Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/decipher-nct05504707/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05504707.jpg</video:thumbnail_loc>
      <video:title>DecipHER for Triple Negative… (NCT05504707) | Triangle</video:title>
      <video:description>DecipHER trial for Triple Negative Breast Cancer (NCT05504707). DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer. The purpose of the study is to find out if an investigational vaccine called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05504707.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:50:15.187Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/decipher-nct05504707/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05504707.jpg</video:thumbnail_loc>
      <video:title>DecipHER para Triple Negative… (NCT05504707) | Triangle</video:title>
      <video:description>DecipHER trial for Triple Negative Breast Cancer (NCT05504707). DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer. The purpose of the study is to find out if an investigational vaccine called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05504707.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:50:15.187Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/decipher-nct05504707/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05504707.jpg</video:thumbnail_loc>
      <video:title>DecipHER для Triple Negative… (NCT05504707) | Triangle</video:title>
      <video:description>DecipHER trial for Triple Negative Breast Cancer (NCT05504707). DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer. The purpose of the study is to find out if an investigational vaccine called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05504707.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:50:15.187Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/dnajb1-prkaca-peptide-vaccine-nct04248569/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04248569.jpg</video:thumbnail_loc>
      <video:title>DNAJB1-PRKACA peptide vaccine (NCT04248569) | Triangle</video:title>
      <video:description>DNAJB1-PRKACA peptide vaccine trial for Fibrolamellar Hepatocellular Carcinoma (FLC) (NCT04248569). DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma. The primary…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04248569.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:26:30.203Z</video:publication_date>
      <video:duration>233</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/dnajb1-prkaca-peptide-vaccine-nct04248569/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04248569.jpg</video:thumbnail_loc>
      <video:title>ensayo: DNAJB1-PRKACA peptide vaccine (NCT04248569) | Triangle</video:title>
      <video:description>DNAJB1-PRKACA peptide vaccine trial for Fibrolamellar Hepatocellular Carcinoma (FLC) (NCT04248569). DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma. The primary…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04248569.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:26:30.203Z</video:publication_date>
      <video:duration>233</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/dnajb1-prkaca-peptide-vaccine-nct04248569/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04248569.jpg</video:thumbnail_loc>
      <video:title>исследование: DNAJB1-PRKACA… (NCT04248569) | Triangle</video:title>
      <video:description>DNAJB1-PRKACA peptide vaccine trial for Fibrolamellar Hepatocellular Carcinoma (FLC) (NCT04248569). DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma. The primary…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04248569.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:26:30.203Z</video:publication_date>
      <video:duration>233</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/dt2216-nct06964009/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964009.jpg</video:thumbnail_loc>
      <video:title>DT2216 for Platinum-Resistant… (NCT06964009) | Triangle</video:title>
      <video:description>DT2216 trial for Platinum-Resistant Ovarian Cancer (NCT06964009). DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer. The purpose of this research study is determining the highest dose of the study drug DT2216 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964009.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:34:09.298Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/dt2216-nct06964009/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964009.jpg</video:thumbnail_loc>
      <video:title>DT2216 para Platinum-Resistant… (NCT06964009) | Triangle</video:title>
      <video:description>DT2216 trial for Platinum-Resistant Ovarian Cancer (NCT06964009). DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer. The purpose of this research study is determining the highest dose of the study drug DT2216 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964009.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:34:09.298Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/dt2216-nct06964009/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964009.jpg</video:thumbnail_loc>
      <video:title>DT2216 для Platinum-Resistant… (NCT06964009) | Triangle</video:title>
      <video:description>DT2216 trial for Platinum-Resistant Ovarian Cancer (NCT06964009). DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer. The purpose of this research study is determining the highest dose of the study drug DT2216 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06964009.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:34:09.298Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/dupilumab-nct06088771/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06088771.jpg</video:thumbnail_loc>
      <video:title>Dupilumab for Non-Small Cell Lung Cancer (NCT06088771) | Triangle</video:title>
      <video:description>Dupilumab trial for Non-Small Cell Lung Cancer (NCT06088771). Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC. This is a phase 1/2 study of combined treatment with dupilumab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06088771.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:25:56.284Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/dupilumab-nct06088771/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06088771.jpg</video:thumbnail_loc>
      <video:title>Dupilumab para Non-Small Cell… (NCT06088771) | Triangle</video:title>
      <video:description>Dupilumab trial for Non-Small Cell Lung Cancer (NCT06088771). Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC. This is a phase 1/2 study of combined treatment with dupilumab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06088771.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:25:56.284Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/dupilumab-nct06088771/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06088771.jpg</video:thumbnail_loc>
      <video:title>Dupilumab для Non-Small Cell Lung Cancer (NCT06088771) | Triangle</video:title>
      <video:description>Dupilumab trial for Non-Small Cell Lung Cancer (NCT06088771). Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC. This is a phase 1/2 study of combined treatment with dupilumab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06088771.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:25:56.284Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/durable-nct05987644/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05987644.jpg</video:thumbnail_loc>
      <video:title>Alectinib ± Radiosurgery (NCT05987644) | Triangle</video:title>
      <video:description>Alectinib ± Radiosurgery trial for ALK-Positive Lung Cancer With Brain Metastases (NCT05987644). Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05987644.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:31:09.578Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/durable-nct05987644/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05987644.jpg</video:thumbnail_loc>
      <video:title>Alectinib ± Radiosurgery para ALK… (NCT05987644) | Triangle</video:title>
      <video:description>Alectinib ± Radiosurgery trial for ALK-Positive Lung Cancer With Brain Metastases (NCT05987644). Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05987644.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:31:09.578Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/durable-nct05987644/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05987644.jpg</video:thumbnail_loc>
      <video:title>исследование: Alectinib ± Radiosurgery (NCT05987644) | Triangle</video:title>
      <video:description>Alectinib ± Radiosurgery trial for ALK-Positive Lung Cancer With Brain Metastases (NCT05987644). Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05987644.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:31:09.578Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/durvalumab-nct03011814/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03011814.jpg</video:thumbnail_loc>
      <video:title>Durvalumab for Recurrent… (NCT03011814) | Triangle</video:title>
      <video:description>Durvalumab trial for Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma (NCT03011814). Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma. This randomized phase I/II…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03011814.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:34:34.687Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/durvalumab-nct03011814/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03011814.jpg</video:thumbnail_loc>
      <video:title>Durvalumab para Recurrent… (NCT03011814) | Triangle</video:title>
      <video:description>Durvalumab trial for Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma (NCT03011814). Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma. This randomized phase I/II…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03011814.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:34:34.687Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/durvalumab-nct03011814/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03011814.jpg</video:thumbnail_loc>
      <video:title>Durvalumab для Recurrent… (NCT03011814) | Triangle</video:title>
      <video:description>Durvalumab trial for Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma (NCT03011814). Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma. This randomized phase I/II…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03011814.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:34:34.687Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/durvalumab-tremelimumab-nct05932199/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05932199.jpg</video:thumbnail_loc>
      <video:title>Durvalumab + Tremelimumab (NCT05932199) | Triangle</video:title>
      <video:description>Durvalumab + Tremelimumab trial for Resectable Pleural Mesothelioma (NCT05932199). Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma. Objectives: The investigators will test whether combination of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05932199.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:23:27.851Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/durvalumab-tremelimumab-nct05932199/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05932199.jpg</video:thumbnail_loc>
      <video:title>ensayo: Durvalumab + Tremelimumab (NCT05932199) | Triangle</video:title>
      <video:description>Durvalumab + Tremelimumab trial for Resectable Pleural Mesothelioma (NCT05932199). Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma. Objectives: The investigators will test whether combination of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05932199.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:23:27.851Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/durvalumab-tremelimumab-nct05932199/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05932199.jpg</video:thumbnail_loc>
      <video:title>исследование: Durvalumab + Tremelimumab (NCT05932199) | Triangle</video:title>
      <video:description>Durvalumab + Tremelimumab trial for Resectable Pleural Mesothelioma (NCT05932199). Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma. Objectives: The investigators will test whether combination of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05932199.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:23:27.851Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/eagd-t-cell-nct03533816/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03533816.jpg</video:thumbnail_loc>
      <video:title>EAGD T-cell for Acute Myeloid Leukemia (NCT03533816) | Triangle</video:title>
      <video:description>EAGD T-cell trial for Acute Myeloid Leukemia (NCT03533816). Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. Gamma delta T-cells are…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03533816.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:21:45.403Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/eagd-t-cell-nct03533816/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03533816.jpg</video:thumbnail_loc>
      <video:title>EAGD T-cell para Acute Myeloid Leukemia (NCT03533816) | Triangle</video:title>
      <video:description>EAGD T-cell trial for Acute Myeloid Leukemia (NCT03533816). Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. Gamma delta T-cells are…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03533816.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:21:45.403Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/eagd-t-cell-nct03533816/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03533816.jpg</video:thumbnail_loc>
      <video:title>EAGD T-cell для Acute Myeloid Leukemia (NCT03533816) | Triangle</video:title>
      <video:description>EAGD T-cell trial for Acute Myeloid Leukemia (NCT03533816). Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. Gamma delta T-cells are…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03533816.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:21:45.403Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/egfr-inhibitor-eras-801-nct07089641/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07089641.jpg</video:thumbnail_loc>
      <video:title>ERAS-801 for EGFR-Altered… (NCT07089641) | Triangle</video:title>
      <video:description>ERAS-801 trial for EGFR-Altered IDH-Wildtype Glioblastoma or Gliosarcoma (NCT07089641). ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07089641.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:17:24.377Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/egfr-inhibitor-eras-801-nct07089641/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07089641.jpg</video:thumbnail_loc>
      <video:title>ERAS-801 para EGFR-Altered… (NCT07089641) | Triangle</video:title>
      <video:description>ERAS-801 trial for EGFR-Altered IDH-Wildtype Glioblastoma or Gliosarcoma (NCT07089641). ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07089641.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:17:24.377Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/egfr-inhibitor-eras-801-nct07089641/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07089641.jpg</video:thumbnail_loc>
      <video:title>ERAS-801 для EGFR-Altered… (NCT07089641) | Triangle</video:title>
      <video:description>ERAS-801 trial for EGFR-Altered IDH-Wildtype Glioblastoma or Gliosarcoma (NCT07089641). ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07089641.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:17:24.377Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/eli-002-7p-nct07671339/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07671339.jpg</video:thumbnail_loc>
      <video:title>ELI-002 7P for KRAS-Mutant… (NCT07671339) | Triangle</video:title>
      <video:description>ELI-002 7P trial for KRAS-Mutant Pancreatic Cancer (NCT07671339). ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer. The researchers are doing this study to find out whether ELI-002 7P in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07671339.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:58:15.255Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/eli-002-7p-nct07671339/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07671339.jpg</video:thumbnail_loc>
      <video:title>ELI-002 7P para KRAS-Mutant… (NCT07671339) | Triangle</video:title>
      <video:description>ELI-002 7P trial for KRAS-Mutant Pancreatic Cancer (NCT07671339). ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer. The researchers are doing this study to find out whether ELI-002 7P in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07671339.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:58:15.255Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/eli-002-7p-nct07671339/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07671339.jpg</video:thumbnail_loc>
      <video:title>ELI-002 7P для KRAS-Mutant… (NCT07671339) | Triangle</video:title>
      <video:description>ELI-002 7P trial for KRAS-Mutant Pancreatic Cancer (NCT07671339). ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer. The researchers are doing this study to find out whether ELI-002 7P in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07671339.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:58:15.255Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/emapalumab-nct06996119/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06996119.jpg</video:thumbnail_loc>
      <video:title>Emapalumab for AML or MDS… (NCT06996119) | Triangle</video:title>
      <video:description>Emapalumab trial for AML or MDS Undergoing Reduced-Intensity Transplant (NCT06996119). Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06996119.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:55:22.743Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/emapalumab-nct06996119/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06996119.jpg</video:thumbnail_loc>
      <video:title>Emapalumab para AML or MDS… (NCT06996119) | Triangle</video:title>
      <video:description>Emapalumab trial for AML or MDS Undergoing Reduced-Intensity Transplant (NCT06996119). Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06996119.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:55:22.743Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/emapalumab-nct06996119/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06996119.jpg</video:thumbnail_loc>
      <video:title>Emapalumab для AML or MDS… (NCT06996119) | Triangle</video:title>
      <video:description>Emapalumab trial for AML or MDS Undergoing Reduced-Intensity Transplant (NCT06996119). Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06996119.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:55:22.743Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/emavusertib-nct07107750/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07107750.jpg</video:thumbnail_loc>
      <video:title>Emavusertib + Chemoimmunotherapy (NCT07107750) | Triangle</video:title>
      <video:description>Emavusertib + Chemoimmunotherapy trial for Untreated Advanced Biliary Tract Cancer (NCT07107750). Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer. Based…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07107750.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:45:55.581Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/emavusertib-nct07107750/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07107750.jpg</video:thumbnail_loc>
      <video:title>ensayo: Emavusertib + Chemoimmunotherapy (NCT07107750) | Triangle</video:title>
      <video:description>Emavusertib + Chemoimmunotherapy trial for Untreated Advanced Biliary Tract Cancer (NCT07107750). Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer. Based…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07107750.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:45:55.581Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/emavusertib-nct07107750/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07107750.jpg</video:thumbnail_loc>
      <video:title>исследование: Emavusertib +… (NCT07107750) | Triangle</video:title>
      <video:description>Emavusertib + Chemoimmunotherapy trial for Untreated Advanced Biliary Tract Cancer (NCT07107750). Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer. Based…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07107750.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:45:55.581Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/enfortumab-vedotin-nct04878029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04878029.jpg</video:thumbnail_loc>
      <video:title>Cabozantinib + Enfortumab Vedotin (NCT04878029) | Triangle</video:title>
      <video:description>Cabozantinib + Enfortumab Vedotin trial for Locally Advanced or Metastatic Urothelial Cancer (NCT04878029). Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer. This phase I/Ib trial seeks to find out the best…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04878029.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:58:21.716Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/enfortumab-vedotin-nct04878029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04878029.jpg</video:thumbnail_loc>
      <video:title>ensayo: Cabozantinib + Enfortumab… (NCT04878029) | Triangle</video:title>
      <video:description>Cabozantinib + Enfortumab Vedotin trial for Locally Advanced or Metastatic Urothelial Cancer (NCT04878029). Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer. This phase I/Ib trial seeks to find out the best…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04878029.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:58:21.716Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/enfortumab-vedotin-nct04878029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04878029.jpg</video:thumbnail_loc>
      <video:title>исследование: Cabozantinib +… (NCT04878029) | Triangle</video:title>
      <video:description>Cabozantinib + Enfortumab Vedotin trial for Locally Advanced or Metastatic Urothelial Cancer (NCT04878029). Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer. This phase I/Ib trial seeks to find out the best…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04878029.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:58:21.716Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/epcoritamab-nct06536049/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536049.jpg</video:thumbnail_loc>
      <video:title>Epcoritamab + Ibrutinib (NCT06536049) | Triangle</video:title>
      <video:description>Epcoritamab + Ibrutinib trial for Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT06536049). Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. This phase Ib/II trial evaluates the safety,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536049.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:43:27.652Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/epcoritamab-nct06536049/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536049.jpg</video:thumbnail_loc>
      <video:title>ensayo: Epcoritamab + Ibrutinib (NCT06536049) | Triangle</video:title>
      <video:description>Epcoritamab + Ibrutinib trial for Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT06536049). Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. This phase Ib/II trial evaluates the safety,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536049.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:43:27.652Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/epcoritamab-nct06536049/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536049.jpg</video:thumbnail_loc>
      <video:title>исследование: Epcoritamab + Ibrutinib (NCT06536049) | Triangle</video:title>
      <video:description>Epcoritamab + Ibrutinib trial for Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT06536049). Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. This phase Ib/II trial evaluates the safety,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06536049.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:43:27.652Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/epcoritamab-nct06672705/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06672705.jpg</video:thumbnail_loc>
      <video:title>Epcoritamab for Relapsed or… (NCT06672705) | Triangle</video:title>
      <video:description>Epcoritamab trial for Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder (NCT06672705). Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders. This phase Ib trial tests the safety and effectiveness…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06672705.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:39:08.970Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/epcoritamab-nct06672705/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06672705.jpg</video:thumbnail_loc>
      <video:title>Epcoritamab para Relapsed or… (NCT06672705) | Triangle</video:title>
      <video:description>Epcoritamab trial for Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder (NCT06672705). Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders. This phase Ib trial tests the safety and effectiveness…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06672705.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:39:08.970Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/epcoritamab-nct06672705/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06672705.jpg</video:thumbnail_loc>
      <video:title>Epcoritamab для Relapsed or… (NCT06672705) | Triangle</video:title>
      <video:description>Epcoritamab trial for Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder (NCT06672705). Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders. This phase Ib trial tests the safety and effectiveness…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06672705.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:39:08.970Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/eradicate-nct07198724/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07198724.jpg</video:thumbnail_loc>
      <video:title>Elacestrant + T-DXd (NCT07198724) | Triangle</video:title>
      <video:description>Elacestrant + T-DXd trial for HR-Positive, HER2-Low or Ultralow Metastatic Breast Cancer (NCT07198724). ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07198724.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:09:33.284Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/eradicate-nct07198724/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07198724.jpg</video:thumbnail_loc>
      <video:title>ensayo: Elacestrant + T-DXd (NCT07198724) | Triangle</video:title>
      <video:description>Elacestrant + T-DXd trial for HR-Positive, HER2-Low or Ultralow Metastatic Breast Cancer (NCT07198724). ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07198724.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:09:33.284Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/eradicate-nct07198724/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07198724.jpg</video:thumbnail_loc>
      <video:title>исследование: Elacestrant + T-DXd (NCT07198724) | Triangle</video:title>
      <video:description>Elacestrant + T-DXd trial for HR-Positive, HER2-Low or Ultralow Metastatic Breast Cancer (NCT07198724). ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07198724.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:09:33.284Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/fenofibrate-nct06191133/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06191133.jpg</video:thumbnail_loc>
      <video:title>Fenofibrate for Cervical… (NCT06191133) | Triangle</video:title>
      <video:description>Fenofibrate trial for Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer (NCT06191133). Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma. Normally, p53 helps prevent tumors from forming in the body.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06191133.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:33:53.681Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/fenofibrate-nct06191133/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06191133.jpg</video:thumbnail_loc>
      <video:title>Fenofibrate para Cervical… (NCT06191133) | Triangle</video:title>
      <video:description>Fenofibrate trial for Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer (NCT06191133). Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma. Normally, p53 helps prevent tumors from forming in the body.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06191133.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:33:53.681Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/fenofibrate-nct06191133/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06191133.jpg</video:thumbnail_loc>
      <video:title>Fenofibrate для Cervical… (NCT06191133) | Triangle</video:title>
      <video:description>Fenofibrate trial for Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer (NCT06191133). Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma. Normally, p53 helps prevent tumors from forming in the body.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06191133.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:33:53.681Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/fgfr4-car-t-cells-nct06865664/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06865664.jpg</video:thumbnail_loc>
      <video:title>FGFR4-CAR T Cells for Rhabdomyosarcoma (NCT06865664) | Triangle</video:title>
      <video:description>FGFR4-CAR T Cells trial for Rhabdomyosarcoma (NCT06865664). FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma. Background: Rhabdomyosarcoma (RMS)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06865664.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:20:55.536Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/fgfr4-car-t-cells-nct06865664/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06865664.jpg</video:thumbnail_loc>
      <video:title>FGFR4-CAR T Cells para Rhabdomyosarcoma (NCT06865664) | Triangle</video:title>
      <video:description>FGFR4-CAR T Cells trial for Rhabdomyosarcoma (NCT06865664). FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma. Background: Rhabdomyosarcoma (RMS)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06865664.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:20:55.536Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/fgfr4-car-t-cells-nct06865664/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06865664.jpg</video:thumbnail_loc>
      <video:title>FGFR4-CAR T Cells для Rhabdomyosarcoma (NCT06865664) | Triangle</video:title>
      <video:description>FGFR4-CAR T Cells trial for Rhabdomyosarcoma (NCT06865664). FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma. Background: Rhabdomyosarcoma (RMS)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06865664.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:20:55.536Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/fhd-286-nct07283094/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07283094.jpg</video:thumbnail_loc>
      <video:title>FHD-286 + Decitabine/Venetoclax (NCT07283094) | Triangle</video:title>
      <video:description>FHD-286 + Decitabine/Venetoclax trial for Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT07283094). FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia. This is a Phase 1, uncontrolled, single-arm, open-label,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07283094.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:45:17.350Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/fhd-286-nct07283094/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07283094.jpg</video:thumbnail_loc>
      <video:title>ensayo: FHD-286 + Decitabine/Venetoclax (NCT07283094) | Triangle</video:title>
      <video:description>FHD-286 + Decitabine/Venetoclax trial for Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT07283094). FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia. This is a Phase 1, uncontrolled, single-arm, open-label,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07283094.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:45:17.350Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/fhd-286-nct07283094/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07283094.jpg</video:thumbnail_loc>
      <video:title>исследование: FHD-286 +… (NCT07283094) | Triangle</video:title>
      <video:description>FHD-286 + Decitabine/Venetoclax trial for Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT07283094). FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia. This is a Phase 1, uncontrolled, single-arm, open-label,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07283094.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:45:17.350Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/flinn-nct07355205/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07355205.jpg</video:thumbnail_loc>
      <video:title>N-803 + Nivolumab/Ipilimumab (NCT07355205) | Triangle</video:title>
      <video:description>N-803 + Nivolumab/Ipilimumab trial for Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer (NCT07355205). First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer. This is a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07355205.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:10:32.820Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/flinn-nct07355205/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07355205.jpg</video:thumbnail_loc>
      <video:title>ensayo: N-803 + Nivolumab/Ipilimumab (NCT07355205) | Triangle</video:title>
      <video:description>N-803 + Nivolumab/Ipilimumab trial for Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer (NCT07355205). First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer. This is a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07355205.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:10:32.820Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/flinn-nct07355205/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07355205.jpg</video:thumbnail_loc>
      <video:title>исследование: N-803 +… (NCT07355205) | Triangle</video:title>
      <video:description>N-803 + Nivolumab/Ipilimumab trial for Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer (NCT07355205). First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer. This is a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07355205.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:10:32.820Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/flt3-mertk-inhibitor-mrx-2843-nct04762199/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04762199.jpg</video:thumbnail_loc>
      <video:title>MRX-2843 + Osimertinib (NCT04762199) | Triangle</video:title>
      <video:description>MRX-2843 + Osimertinib trial for Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NCT04762199). MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer. This phase Ib trial evaluates the best dose and side effects of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04762199.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:27:17.703Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/flt3-mertk-inhibitor-mrx-2843-nct04762199/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04762199.jpg</video:thumbnail_loc>
      <video:title>ensayo: MRX-2843 + Osimertinib (NCT04762199) | Triangle</video:title>
      <video:description>MRX-2843 + Osimertinib trial for Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NCT04762199). MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer. This phase Ib trial evaluates the best dose and side effects of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04762199.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:27:17.703Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/flt3-mertk-inhibitor-mrx-2843-nct04762199/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04762199.jpg</video:thumbnail_loc>
      <video:title>исследование: MRX-2843 + Osimertinib (NCT04762199) | Triangle</video:title>
      <video:description>MRX-2843 + Osimertinib trial for Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NCT04762199). MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer. This phase Ib trial evaluates the best dose and side effects of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04762199.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:27:17.703Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/fluoxetine-nct06225011/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225011.jpg</video:thumbnail_loc>
      <video:title>Fluoxetine for Colorectal… (NCT06225011) | Triangle</video:title>
      <video:description>Fluoxetine trial for Colorectal Adenocarcinoma Planning Surgery (NCT06225011). Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer. This phase I trial tests whether…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225011.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:54:16.415Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/fluoxetine-nct06225011/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225011.jpg</video:thumbnail_loc>
      <video:title>Fluoxetine para Colorectal… (NCT06225011) | Triangle</video:title>
      <video:description>Fluoxetine trial for Colorectal Adenocarcinoma Planning Surgery (NCT06225011). Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer. This phase I trial tests whether…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225011.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:54:16.415Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/fluoxetine-nct06225011/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225011.jpg</video:thumbnail_loc>
      <video:title>Fluoxetine для Colorectal… (NCT06225011) | Triangle</video:title>
      <video:description>Fluoxetine trial for Colorectal Adenocarcinoma Planning Surgery (NCT06225011). Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer. This phase I trial tests whether…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225011.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:54:16.415Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/folfox-nct04808323/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04808323.jpg</video:thumbnail_loc>
      <video:title>MRI-Guided Adaptive RT for Locally… (NCT04808323) | Triangle</video:title>
      <video:description>MRI-Guided Adaptive RT trial for Locally Advanced Rectal Adenocarcinoma (NCT04808323). MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer. This study is a prospective, open-label, phase I design.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04808323.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:28:59.496Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/folfox-nct04808323/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04808323.jpg</video:thumbnail_loc>
      <video:title>ensayo: MRI-Guided Adaptive RT (NCT04808323) | Triangle</video:title>
      <video:description>MRI-Guided Adaptive RT trial for Locally Advanced Rectal Adenocarcinoma (NCT04808323). MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer. This study is a prospective, open-label, phase I design.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04808323.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:28:59.496Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/folfox-nct04808323/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04808323.jpg</video:thumbnail_loc>
      <video:title>MRI-Guided Adaptive RT для Locally… (NCT04808323) | Triangle</video:title>
      <video:description>MRI-Guided Adaptive RT trial for Locally Advanced Rectal Adenocarcinoma (NCT04808323). MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer. This study is a prospective, open-label, phase I design.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04808323.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:28:59.496Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/folr1-car-t-cells-nct06609928/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06609928.jpg</video:thumbnail_loc>
      <video:title>FOLR1 CAR T-cells for Recurrent… (NCT06609928) | Triangle</video:title>
      <video:description>FOLR1 CAR T-cells trial for Recurrent Childhood Acute Myeloid Leukemia (NCT06609928). FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia. This phase I trial tests…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06609928.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:14:00.614Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/folr1-car-t-cells-nct06609928/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06609928.jpg</video:thumbnail_loc>
      <video:title>FOLR1 CAR T-cells para Recurrent… (NCT06609928) | Triangle</video:title>
      <video:description>FOLR1 CAR T-cells trial for Recurrent Childhood Acute Myeloid Leukemia (NCT06609928). FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia. This phase I trial tests…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06609928.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:14:00.614Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/folr1-car-t-cells-nct06609928/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06609928.jpg</video:thumbnail_loc>
      <video:title>FOLR1 CAR T-cells для Recurrent… (NCT06609928) | Triangle</video:title>
      <video:description>FOLR1 CAR T-cells trial for Recurrent Childhood Acute Myeloid Leukemia (NCT06609928). FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia. This phase I trial tests…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06609928.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:14:00.614Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/fostamatinib-nct06639724/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06639724.jpg</video:thumbnail_loc>
      <video:title>Fostamatinib for Pancreatic… (NCT06639724) | Triangle</video:title>
      <video:description>Fostamatinib trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06639724). Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer. This is a Phase 1b trial evaluating the combination of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06639724.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:53:06.080Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/fostamatinib-nct06639724/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06639724.jpg</video:thumbnail_loc>
      <video:title>Fostamatinib para Pancreatic… (NCT06639724) | Triangle</video:title>
      <video:description>Fostamatinib trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06639724). Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer. This is a Phase 1b trial evaluating the combination of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06639724.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:53:06.080Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/fostamatinib-nct06639724/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06639724.jpg</video:thumbnail_loc>
      <video:title>Fostamatinib для Pancreatic… (NCT06639724) | Triangle</video:title>
      <video:description>Fostamatinib trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06639724). Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer. This is a Phase 1b trial evaluating the combination of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06639724.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:53:06.080Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/g207-nct03911388/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03911388.jpg</video:thumbnail_loc>
      <video:title>G207 for Neoplasms, Brain (NCT03911388) | Triangle</video:title>
      <video:description>G207 trial for Neoplasms, Brain (NCT03911388). HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors. This study is a clinical trial to determine the safety of inoculating G207 (an…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03911388.mp4</video:content_loc>
      <video:publication_date>2026-09-12T13:45:09.092Z</video:publication_date>
      <video:duration>252</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/g207-nct03911388/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03911388.jpg</video:thumbnail_loc>
      <video:title>G207 para Neoplasms, Brain (NCT03911388) | Triangle</video:title>
      <video:description>G207 trial for Neoplasms, Brain (NCT03911388). HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors. This study is a clinical trial to determine the safety of inoculating G207 (an…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03911388.mp4</video:content_loc>
      <video:publication_date>2026-09-12T13:45:09.092Z</video:publication_date>
      <video:duration>252</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/g207-nct03911388/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03911388.jpg</video:thumbnail_loc>
      <video:title>G207 для Neoplasms, Brain (NCT03911388) | Triangle</video:title>
      <video:description>G207 trial for Neoplasms, Brain (NCT03911388). HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors. This study is a clinical trial to determine the safety of inoculating G207 (an…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03911388.mp4</video:content_loc>
      <video:publication_date>2026-09-12T13:45:09.092Z</video:publication_date>
      <video:duration>252</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/gavel-nct07439211/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07439211.jpg</video:thumbnail_loc>
      <video:title>GAVEL for Acute Myeloid Leukemia (NCT07439211) | Triangle</video:title>
      <video:description>GAVEL trial for Acute Myeloid Leukemia (NCT07439211). Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia. This study is to evaluate the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07439211.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:33:52.929Z</video:publication_date>
      <video:duration>57</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/gavel-nct07439211/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07439211.jpg</video:thumbnail_loc>
      <video:title>GAVEL para Acute Myeloid Leukemia (NCT07439211) | Triangle</video:title>
      <video:description>GAVEL trial for Acute Myeloid Leukemia (NCT07439211). Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia. This study is to evaluate the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07439211.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:33:52.929Z</video:publication_date>
      <video:duration>57</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/gavel-nct07439211/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07439211.jpg</video:thumbnail_loc>
      <video:title>GAVEL для Acute Myeloid Leukemia (NCT07439211) | Triangle</video:title>
      <video:description>GAVEL trial for Acute Myeloid Leukemia (NCT07439211). Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia. This study is to evaluate the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07439211.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:33:52.929Z</video:publication_date>
      <video:duration>57</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/gc511b-car-t-cell-nct07249879/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07249879.jpg</video:thumbnail_loc>
      <video:title>GC511B CAR-T Cell (NCT07249879) | Triangle</video:title>
      <video:description>GC511B CAR-T Cell trial for Relapsed/Refractory Small Cell Lung Cancer (NCT07249879). This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07249879.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:53:53.917Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/gc511b-car-t-cell-nct07249879/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07249879.jpg</video:thumbnail_loc>
      <video:title>ensayo: GC511B CAR-T Cell (NCT07249879) | Triangle</video:title>
      <video:description>GC511B CAR-T Cell trial for Relapsed/Refractory Small Cell Lung Cancer (NCT07249879). This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07249879.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:53:53.917Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/gc511b-car-t-cell-nct07249879/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07249879.jpg</video:thumbnail_loc>
      <video:title>исследование: GC511B CAR-T Cell (NCT07249879) | Triangle</video:title>
      <video:description>GC511B CAR-T Cell trial for Relapsed/Refractory Small Cell Lung Cancer (NCT07249879). This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07249879.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:53:53.917Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/gd2-car-t-cells-nct04196413/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04196413.jpg</video:thumbnail_loc>
      <video:title>GD2 CAR T cells for Glioma of… (NCT04196413) | Triangle</video:title>
      <video:description>GD2 CAR T cells trial for Glioma of Spinal Cord (NCT04196413). GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) &amp; Spinal Diffuse Midline Glioma(DMG). The primary purpose of this study is to test whether CAR T…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04196413.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:20:59.968Z</video:publication_date>
      <video:duration>250</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/gd2-car-t-cells-nct04196413/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04196413.jpg</video:thumbnail_loc>
      <video:title>GD2 CAR T cells para Glioma of… (NCT04196413) | Triangle</video:title>
      <video:description>GD2 CAR T cells trial for Glioma of Spinal Cord (NCT04196413). GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) &amp; Spinal Diffuse Midline Glioma(DMG). The primary purpose of this study is to test whether CAR T…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04196413.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:20:59.968Z</video:publication_date>
      <video:duration>250</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/gd2-car-t-cells-nct04196413/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04196413.jpg</video:thumbnail_loc>
      <video:title>GD2 CAR T cells для Glioma of… (NCT04196413) | Triangle</video:title>
      <video:description>GD2 CAR T cells trial for Glioma of Spinal Cord (NCT04196413). GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) &amp; Spinal Diffuse Midline Glioma(DMG). The primary purpose of this study is to test whether CAR T…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04196413.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:20:59.968Z</video:publication_date>
      <video:duration>250</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/gemtuzumab-ozogamicin-nct05558124/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05558124.jpg</video:thumbnail_loc>
      <video:title>CPX-351 + Gemtuzumab Ozogamicin (NCT05558124) | Triangle</video:title>
      <video:description>CPX-351 + Gemtuzumab Ozogamicin trial for Newly Diagnosed Acute Myeloid Leukemia (NCT05558124). CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML. The purpose of the study is to determine the safety of combining the drugs…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05558124.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:48:37.487Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/gemtuzumab-ozogamicin-nct05558124/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05558124.jpg</video:thumbnail_loc>
      <video:title>ensayo: CPX-351 + Gemtuzumab Ozogamicin (NCT05558124) | Triangle</video:title>
      <video:description>CPX-351 + Gemtuzumab Ozogamicin trial for Newly Diagnosed Acute Myeloid Leukemia (NCT05558124). CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML. The purpose of the study is to determine the safety of combining the drugs…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05558124.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:48:37.487Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/gemtuzumab-ozogamicin-nct05558124/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05558124.jpg</video:thumbnail_loc>
      <video:title>исследование: CPX-351 +… (NCT05558124) | Triangle</video:title>
      <video:description>CPX-351 + Gemtuzumab Ozogamicin trial for Newly Diagnosed Acute Myeloid Leukemia (NCT05558124). CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML. The purpose of the study is to determine the safety of combining the drugs…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05558124.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:48:37.487Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/gilteritinib-nct06225427/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225427.jpg</video:thumbnail_loc>
      <video:title>Gilteritinib for Lung Non-Small… (NCT06225427) | Triangle</video:title>
      <video:description>Gilteritinib trial for Lung Non-Small Cell Carcinoma (NCT06225427). Gilteritinib for the Treatment of ALK NSCLC. This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225427.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:26:57.507Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/gilteritinib-nct06225427/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225427.jpg</video:thumbnail_loc>
      <video:title>Gilteritinib para Lung Non-Small… (NCT06225427) | Triangle</video:title>
      <video:description>Gilteritinib trial for Lung Non-Small Cell Carcinoma (NCT06225427). Gilteritinib for the Treatment of ALK NSCLC. This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225427.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:26:57.507Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/gilteritinib-nct06225427/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225427.jpg</video:thumbnail_loc>
      <video:title>Gilteritinib для Lung Non-Small… (NCT06225427) | Triangle</video:title>
      <video:description>Gilteritinib trial for Lung Non-Small Cell Carcinoma (NCT06225427). Gilteritinib for the Treatment of ALK NSCLC. This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06225427.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:26:57.507Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ginakit2-nct03294954/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03294954.jpg</video:thumbnail_loc>
      <video:title>GINAKIT2 for Neuroblastoma (NCT03294954) | Triangle</video:title>
      <video:description>GINAKIT2 trial for Neuroblastoma (NCT03294954). GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma. This research study combines two different ways of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03294954.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:42:11.104Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ginakit2-nct03294954/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03294954.jpg</video:thumbnail_loc>
      <video:title>GINAKIT2 para Neuroblastoma (NCT03294954) | Triangle</video:title>
      <video:description>GINAKIT2 trial for Neuroblastoma (NCT03294954). GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma. This research study combines two different ways of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03294954.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:42:11.104Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ginakit2-nct03294954/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03294954.jpg</video:thumbnail_loc>
      <video:title>GINAKIT2 для Neuroblastoma (NCT03294954) | Triangle</video:title>
      <video:description>GINAKIT2 trial for Neuroblastoma (NCT03294954). GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma. This research study combines two different ways of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03294954.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:42:11.104Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/grale-nct01555892/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01555892.jpg</video:thumbnail_loc>
      <video:title>GRALE for EBV-Positive Hodgkin… (NCT01555892) | Triangle</video:title>
      <video:description>GRALE trial for EBV-Positive Hodgkin and Non-Hodgkin Lymphoma (NCT01555892). Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE. Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01555892.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:55:50.468Z</video:publication_date>
      <video:duration>55</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/grale-nct01555892/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01555892.jpg</video:thumbnail_loc>
      <video:title>GRALE para EBV-Positive Hodgkin… (NCT01555892) | Triangle</video:title>
      <video:description>GRALE trial for EBV-Positive Hodgkin and Non-Hodgkin Lymphoma (NCT01555892). Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE. Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01555892.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:55:50.468Z</video:publication_date>
      <video:duration>55</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/grale-nct01555892/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01555892.jpg</video:thumbnail_loc>
      <video:title>GRALE для EBV-Positive Hodgkin… (NCT01555892) | Triangle</video:title>
      <video:description>GRALE trial for EBV-Positive Hodgkin and Non-Hodgkin Lymphoma (NCT01555892). Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE. Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01555892.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:55:50.468Z</video:publication_date>
      <video:duration>55</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/high-dose-ascorbate-nct07177079/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07177079.jpg</video:thumbnail_loc>
      <video:title>High-Dose Ascorbate + Aza/Ven (NCT07177079) | Triangle</video:title>
      <video:description>High-Dose Ascorbate + Aza/Ven trial for Newly Diagnosed Acute Myeloid Leukemia (NCT07177079). High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML). This is a randomized, open-label,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07177079.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:14:05.718Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/high-dose-ascorbate-nct07177079/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07177079.jpg</video:thumbnail_loc>
      <video:title>ensayo: High-Dose Ascorbate + Aza/Ven (NCT07177079) | Triangle</video:title>
      <video:description>High-Dose Ascorbate + Aza/Ven trial for Newly Diagnosed Acute Myeloid Leukemia (NCT07177079). High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML). This is a randomized, open-label,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07177079.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:14:05.718Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/high-dose-ascorbate-nct07177079/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07177079.jpg</video:thumbnail_loc>
      <video:title>исследование: High-Dose Ascorbate… (NCT07177079) | Triangle</video:title>
      <video:description>High-Dose Ascorbate + Aza/Ven trial for Newly Diagnosed Acute Myeloid Leukemia (NCT07177079). High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML). This is a randomized, open-label,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07177079.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:14:05.718Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/honokiol-nct06566443/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06566443.jpg</video:thumbnail_loc>
      <video:title>Honokiol for Early-Stage… (NCT06566443) | Triangle</video:title>
      <video:description>Honokiol trial for Early-Stage Resectable Non-Small Cell Lung Cancer (NCT06566443). Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer. This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06566443.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:26:16.599Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/honokiol-nct06566443/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06566443.jpg</video:thumbnail_loc>
      <video:title>Honokiol para Early-Stage… (NCT06566443) | Triangle</video:title>
      <video:description>Honokiol trial for Early-Stage Resectable Non-Small Cell Lung Cancer (NCT06566443). Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer. This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06566443.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:26:16.599Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/honokiol-nct06566443/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06566443.jpg</video:thumbnail_loc>
      <video:title>Honokiol для Early-Stage… (NCT06566443) | Triangle</video:title>
      <video:description>Honokiol trial for Early-Stage Resectable Non-Small Cell Lung Cancer (NCT06566443). Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer. This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06566443.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:26:16.599Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ig-imrt-nct01659203/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01659203.jpg</video:thumbnail_loc>
      <video:title>Proton or Photon RT (NCT01659203) | Triangle</video:title>
      <video:description>Proton or Photon RT trial for Retroperitoneal Sarcoma (NCT01659203). Proton or Photon RT for Retroperitoneal Sarcomas. This research study is a Phase I clinical trial.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01659203.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:46:24.370Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ig-imrt-nct01659203/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01659203.jpg</video:thumbnail_loc>
      <video:title>ensayo: Proton or Photon RT (NCT01659203) | Triangle</video:title>
      <video:description>Proton or Photon RT trial for Retroperitoneal Sarcoma (NCT01659203). Proton or Photon RT for Retroperitoneal Sarcomas. This research study is a Phase I clinical trial.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01659203.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:46:24.370Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ig-imrt-nct01659203/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01659203.jpg</video:thumbnail_loc>
      <video:title>исследование: Proton or Photon RT (NCT01659203) | Triangle</video:title>
      <video:description>Proton or Photon RT trial for Retroperitoneal Sarcoma (NCT01659203). Proton or Photon RT for Retroperitoneal Sarcomas. This research study is a Phase I clinical trial.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01659203.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:46:24.370Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/il13ralpha2-specific-hinge-optimized-41bb-co-stimulatory-nct04510051/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04510051.jpg</video:thumbnail_loc>
      <video:title>CAR T Cells After Lymphodepletion… (NCT04510051) | Triangle</video:title>
      <video:description>CAR T Cells After Lymphodepletion for the… trial for Malignant Brain Neoplasm (NCT04510051). CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children. This phase I trial investigates the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04510051.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:29:13.976Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/il13ralpha2-specific-hinge-optimized-41bb-co-stimulatory-nct04510051/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04510051.jpg</video:thumbnail_loc>
      <video:title>ensayo: CAR T Cells After… (NCT04510051) | Triangle</video:title>
      <video:description>CAR T Cells After Lymphodepletion for the… trial for Malignant Brain Neoplasm (NCT04510051). CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children. This phase I trial investigates the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04510051.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:29:13.976Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/il13ralpha2-specific-hinge-optimized-41bb-co-stimulatory-nct04510051/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04510051.jpg</video:thumbnail_loc>
      <video:title>исследование: CAR T Cells After… (NCT04510051) | Triangle</video:title>
      <video:description>CAR T Cells After Lymphodepletion for the… trial for Malignant Brain Neoplasm (NCT04510051). CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children. This phase I trial investigates the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04510051.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:29:13.976Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/impact-nct06193759/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06193759.jpg</video:thumbnail_loc>
      <video:title>IMPACT for Medulloblastoma, Childhood (NCT06193759) | Triangle</video:title>
      <video:description>IMPACT trial for Medulloblastoma, Childhood (NCT06193759). Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT). This is an open-label phase 1 safety and feasibility study…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06193759.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:46:13.677Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/impact-nct06193759/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06193759.jpg</video:thumbnail_loc>
      <video:title>IMPACT para Medulloblastoma, Childhood (NCT06193759) | Triangle</video:title>
      <video:description>IMPACT trial for Medulloblastoma, Childhood (NCT06193759). Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT). This is an open-label phase 1 safety and feasibility study…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06193759.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:46:13.677Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/impact-nct06193759/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06193759.jpg</video:thumbnail_loc>
      <video:title>IMPACT для Medulloblastoma, Childhood (NCT06193759) | Triangle</video:title>
      <video:description>IMPACT trial for Medulloblastoma, Childhood (NCT06193759). Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT). This is an open-label phase 1 safety and feasibility study…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06193759.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:46:13.677Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/impact-nct07148050/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07148050.jpg</video:thumbnail_loc>
      <video:title>IMPACT for Solid Tumor (Excluding CNS) (NCT07148050) | Triangle</video:title>
      <video:description>IMPACT trial for Solid Tumor (Excluding CNS) (NCT07148050). Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells. This…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07148050.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:51:35.445Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/impact-nct07148050/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07148050.jpg</video:thumbnail_loc>
      <video:title>IMPACT para Solid Tumor (Excluding CNS) (NCT07148050) | Triangle</video:title>
      <video:description>IMPACT trial for Solid Tumor (Excluding CNS) (NCT07148050). Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells. This…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07148050.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:51:35.445Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/impact-nct07148050/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07148050.jpg</video:thumbnail_loc>
      <video:title>IMPACT для Solid Tumor (Excluding CNS) (NCT07148050) | Triangle</video:title>
      <video:description>IMPACT trial for Solid Tumor (Excluding CNS) (NCT07148050). Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells. This…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07148050.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:51:35.445Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/implantable-microdevice-imd-nct05700461/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05700461.jpg</video:thumbnail_loc>
      <video:title>Implantable Microdevice (NCT05700461) | Triangle</video:title>
      <video:description>Implantable Microdevice trial for Metastatic Renal Cell Carcinoma (NCT05700461). Drug Screening Using Novel IMD in Renal Cell Carcinoma. This research is being done to study the safety and feasibility of implanting and retrieving a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05700461.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:41:09.500Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/implantable-microdevice-imd-nct05700461/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05700461.jpg</video:thumbnail_loc>
      <video:title>ensayo: Implantable Microdevice (NCT05700461) | Triangle</video:title>
      <video:description>Implantable Microdevice trial for Metastatic Renal Cell Carcinoma (NCT05700461). Drug Screening Using Novel IMD in Renal Cell Carcinoma. This research is being done to study the safety and feasibility of implanting and retrieving a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05700461.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:41:09.500Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/implantable-microdevice-imd-nct05700461/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05700461.jpg</video:thumbnail_loc>
      <video:title>исследование: Implantable Microdevice (NCT05700461) | Triangle</video:title>
      <video:description>Implantable Microdevice trial for Metastatic Renal Cell Carcinoma (NCT05700461). Drug Screening Using Novel IMD in Renal Cell Carcinoma. This research is being done to study the safety and feasibility of implanting and retrieving a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05700461.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:41:09.500Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/indoximod-nct05106296/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05106296.jpg</video:thumbnail_loc>
      <video:title>Ibrutinib + Indoximod (NCT05106296) | Triangle</video:title>
      <video:description>Ibrutinib + Indoximod trial for Pediatric Brain Cancer (NCT05106296). Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer. Recent lab-based discoveries suggest that IDO (indoleamine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05106296.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:48:51.137Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/indoximod-nct05106296/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05106296.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ibrutinib + Indoximod (NCT05106296) | Triangle</video:title>
      <video:description>Ibrutinib + Indoximod trial for Pediatric Brain Cancer (NCT05106296). Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer. Recent lab-based discoveries suggest that IDO (indoleamine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05106296.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:48:51.137Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/indoximod-nct05106296/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05106296.jpg</video:thumbnail_loc>
      <video:title>исследование: Ibrutinib + Indoximod (NCT05106296) | Triangle</video:title>
      <video:description>Ibrutinib + Indoximod trial for Pediatric Brain Cancer (NCT05106296). Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer. Recent lab-based discoveries suggest that IDO (indoleamine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05106296.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:48:51.137Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/inm176-nct06600698/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06600698.jpg</video:thumbnail_loc>
      <video:title>INM176 for Prostate Cancer With… (NCT06600698) | Triangle</video:title>
      <video:description>INM176 trial for Prostate Cancer With Rising PSA (NCT06600698). AGN-INM176 in Prostate Patients With Rising PSA. This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06600698.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:01:26.887Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/inm176-nct06600698/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06600698.jpg</video:thumbnail_loc>
      <video:title>INM176 para Prostate Cancer With… (NCT06600698) | Triangle</video:title>
      <video:description>INM176 trial for Prostate Cancer With Rising PSA (NCT06600698). AGN-INM176 in Prostate Patients With Rising PSA. This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06600698.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:01:26.887Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/inm176-nct06600698/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06600698.jpg</video:thumbnail_loc>
      <video:title>INM176 для Prostate Cancer With… (NCT06600698) | Triangle</video:title>
      <video:description>INM176 trial for Prostate Cancer With Rising PSA (NCT06600698). AGN-INM176 in Prostate Patients With Rising PSA. This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06600698.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:01:26.887Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/inotuzumab-ozogamicin-nct01371630/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01371630.jpg</video:thumbnail_loc>
      <video:title>Inotuzumab Ozogamicin for B Acute… (NCT01371630) | Triangle</video:title>
      <video:description>Inotuzumab Ozogamicin trial for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (NCT01371630). Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia. This phase I/II trial studies the side effects and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01371630.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:28:14.945Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/inotuzumab-ozogamicin-nct01371630/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01371630.jpg</video:thumbnail_loc>
      <video:title>ensayo: Inotuzumab Ozogamicin (NCT01371630) | Triangle</video:title>
      <video:description>Inotuzumab Ozogamicin trial for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (NCT01371630). Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia. This phase I/II trial studies the side effects and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01371630.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:28:14.945Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/inotuzumab-ozogamicin-nct01371630/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01371630.jpg</video:thumbnail_loc>
      <video:title>Inotuzumab Ozogamicin для B Acute… (NCT01371630) | Triangle</video:title>
      <video:description>Inotuzumab Ozogamicin trial for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (NCT01371630). Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia. This phase I/II trial studies the side effects and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT01371630.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:28:14.945Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/intradermal-injection-of-cadi-05-nct07455032/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07455032.jpg</video:thumbnail_loc>
      <video:title>CADI-05 + Pembrolizumab (NCT07455032) | Triangle</video:title>
      <video:description>CADI-05 + Pembrolizumab trial for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07455032). Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas. The goal of this…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07455032.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:53:43.522Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/intradermal-injection-of-cadi-05-nct07455032/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07455032.jpg</video:thumbnail_loc>
      <video:title>ensayo: CADI-05 + Pembrolizumab (NCT07455032) | Triangle</video:title>
      <video:description>CADI-05 + Pembrolizumab trial for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07455032). Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas. The goal of this…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07455032.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:53:43.522Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/intradermal-injection-of-cadi-05-nct07455032/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07455032.jpg</video:thumbnail_loc>
      <video:title>исследование: CADI-05 + Pembrolizumab (NCT07455032) | Triangle</video:title>
      <video:description>CADI-05 + Pembrolizumab trial for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07455032). Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas. The goal of this…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07455032.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:53:43.522Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ipilimumab-and-nivolumab-nct07075120/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07075120.jpg</video:thumbnail_loc>
      <video:title>Ipilimumab and Nivolumab (NCT07075120) | Triangle</video:title>
      <video:description>Ipilimumab and Nivolumab trial for Hepatocellular Carcinoma (HCC) (NCT07075120). Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer. Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07075120.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:01:49.545Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ipilimumab-and-nivolumab-nct07075120/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07075120.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ipilimumab and Nivolumab (NCT07075120) | Triangle</video:title>
      <video:description>Ipilimumab and Nivolumab trial for Hepatocellular Carcinoma (HCC) (NCT07075120). Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer. Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07075120.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:01:49.545Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ipilimumab-and-nivolumab-nct07075120/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07075120.jpg</video:thumbnail_loc>
      <video:title>исследование: Ipilimumab and Nivolumab (NCT07075120) | Triangle</video:title>
      <video:description>Ipilimumab and Nivolumab trial for Hepatocellular Carcinoma (HCC) (NCT07075120). Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer. Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07075120.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:01:49.545Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ipilimumab-nct07128680/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07128680.jpg</video:thumbnail_loc>
      <video:title>EXL01 + Nivolumab/Ipilimumab (NCT07128680) | Triangle</video:title>
      <video:description>EXL01 + Nivolumab/Ipilimumab trial for Metastatic Clear Cell or Sarcomatoid Renal Cell Carcinoma (NCT07128680). Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer. This phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07128680.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:06:44.812Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ipilimumab-nct07128680/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07128680.jpg</video:thumbnail_loc>
      <video:title>ensayo: EXL01 + Nivolumab/Ipilimumab (NCT07128680) | Triangle</video:title>
      <video:description>EXL01 + Nivolumab/Ipilimumab trial for Metastatic Clear Cell or Sarcomatoid Renal Cell Carcinoma (NCT07128680). Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer. This phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07128680.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:06:44.812Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ipilimumab-nct07128680/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07128680.jpg</video:thumbnail_loc>
      <video:title>исследование: EXL01 +… (NCT07128680) | Triangle</video:title>
      <video:description>EXL01 + Nivolumab/Ipilimumab trial for Metastatic Clear Cell or Sarcomatoid Renal Cell Carcinoma (NCT07128680). Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer. This phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07128680.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:06:44.812Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ivonescimab-nct07535463/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07535463.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab + Radiosurgery for Non… (NCT07535463) | Triangle</video:title>
      <video:description>Ivonescimab + Radiosurgery trial for Non-Small Cell Lung Cancer With Brain Metastases (NCT07535463). Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer. The researchers are doing this study to test the safety…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07535463.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:45:30.160Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ivonescimab-nct07535463/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07535463.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ivonescimab + Radiosurgery (NCT07535463) | Triangle</video:title>
      <video:description>Ivonescimab + Radiosurgery trial for Non-Small Cell Lung Cancer With Brain Metastases (NCT07535463). Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer. The researchers are doing this study to test the safety…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07535463.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:45:30.160Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ivonescimab-nct07535463/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07535463.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab + Radiosurgery для Non… (NCT07535463) | Triangle</video:title>
      <video:description>Ivonescimab + Radiosurgery trial for Non-Small Cell Lung Cancer With Brain Metastases (NCT07535463). Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer. The researchers are doing this study to test the safety…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07535463.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:45:30.160Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/leflunomide-nct04997993/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04997993.jpg</video:thumbnail_loc>
      <video:title>Leflunomide for PTEN-Altered… (NCT04997993) | Triangle</video:title>
      <video:description>Leflunomide trial for PTEN-Altered Advanced Solid Tumors and HER2-Negative Breast Cancer (NCT04997993). Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer. Leflunomide in patients with PTEN-Altered advanced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04997993.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:41:57.522Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/leflunomide-nct04997993/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04997993.jpg</video:thumbnail_loc>
      <video:title>Leflunomide para PTEN-Altered… (NCT04997993) | Triangle</video:title>
      <video:description>Leflunomide trial for PTEN-Altered Advanced Solid Tumors and HER2-Negative Breast Cancer (NCT04997993). Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer. Leflunomide in patients with PTEN-Altered advanced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04997993.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:41:57.522Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/leflunomide-nct04997993/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04997993.jpg</video:thumbnail_loc>
      <video:title>Leflunomide для PTEN-Altered… (NCT04997993) | Triangle</video:title>
      <video:description>Leflunomide trial for PTEN-Altered Advanced Solid Tumors and HER2-Negative Breast Cancer (NCT04997993). Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer. Leflunomide in patients with PTEN-Altered advanced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04997993.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:41:57.522Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/lenvatinib-nct05603910/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05603910.jpg</video:thumbnail_loc>
      <video:title>Lenvatinib + Pembrolizumab + RT (NCT05603910) | Triangle</video:title>
      <video:description>Lenvatinib + Pembrolizumab + RT trial for Recurrent or Unresectable pMMR Endometrial (Uterine) Cancer (NCT05603910). Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma. The purpose of this research…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05603910.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:32:40.160Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/lenvatinib-nct05603910/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05603910.jpg</video:thumbnail_loc>
      <video:title>ensayo: Lenvatinib + Pembrolizumab + RT (NCT05603910) | Triangle</video:title>
      <video:description>Lenvatinib + Pembrolizumab + RT trial for Recurrent or Unresectable pMMR Endometrial (Uterine) Cancer (NCT05603910). Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma. The purpose of this research…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05603910.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:32:40.160Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/lenvatinib-nct05603910/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05603910.jpg</video:thumbnail_loc>
      <video:title>исследование: Lenvatinib +… (NCT05603910) | Triangle</video:title>
      <video:description>Lenvatinib + Pembrolizumab + RT trial for Recurrent or Unresectable pMMR Endometrial (Uterine) Cancer (NCT05603910). Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma. The purpose of this research…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05603910.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:32:40.160Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/lifileucel-ln-144-ln-145-nct05607095/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05607095.jpg</video:thumbnail_loc>
      <video:title>Lifileucel (LN-144/LN-145) (NCT05607095) | Triangle</video:title>
      <video:description>Lifileucel (LN-144/LN-145) trial for Uveal Melanoma (NCT05607095). LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma. This is an open…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05607095.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:21:54.523Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/lifileucel-ln-144-ln-145-nct05607095/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05607095.jpg</video:thumbnail_loc>
      <video:title>ensayo: Lifileucel (LN-144/LN-145) (NCT05607095) | Triangle</video:title>
      <video:description>Lifileucel (LN-144/LN-145) trial for Uveal Melanoma (NCT05607095). LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma. This is an open…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05607095.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:21:54.523Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/lifileucel-ln-144-ln-145-nct05607095/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05607095.jpg</video:thumbnail_loc>
      <video:title>исследование: Lifileucel (LN-144/LN-145) (NCT05607095) | Triangle</video:title>
      <video:description>Lifileucel (LN-144/LN-145) trial for Uveal Melanoma (NCT05607095). LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma. This is an open…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05607095.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:21:54.523Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/lm-gucy2c-vaccine-nct07417488/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07417488.jpg</video:thumbnail_loc>
      <video:title>Lm-GUCY2C vaccine for Colorectal… (NCT07417488) | Triangle</video:title>
      <video:description>Lm-GUCY2C vaccine trial for Colorectal Cancer and Small Bowel Adenocarcinoma (NCT07417488). GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas. This is an open-label, non-randomized, single-center, dose-escalation…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07417488.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:50:09.080Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/lm-gucy2c-vaccine-nct07417488/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07417488.jpg</video:thumbnail_loc>
      <video:title>Lm-GUCY2C vaccine para Colorectal… (NCT07417488) | Triangle</video:title>
      <video:description>Lm-GUCY2C vaccine trial for Colorectal Cancer and Small Bowel Adenocarcinoma (NCT07417488). GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas. This is an open-label, non-randomized, single-center, dose-escalation…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07417488.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:50:09.080Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/lm-gucy2c-vaccine-nct07417488/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07417488.jpg</video:thumbnail_loc>
      <video:title>Lm-GUCY2C vaccine для Colorectal… (NCT07417488) | Triangle</video:title>
      <video:description>Lm-GUCY2C vaccine trial for Colorectal Cancer and Small Bowel Adenocarcinoma (NCT07417488). GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas. This is an open-label, non-randomized, single-center, dose-escalation…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07417488.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:50:09.080Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/lnk001-nct07564232/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07564232.jpg</video:thumbnail_loc>
      <video:title>LNK001 for Advanced or Metastatic… (NCT07564232) | Triangle</video:title>
      <video:description>LNK001 trial for Advanced or Metastatic Clear Cell Renal Cell Carcinoma (NCT07564232). LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma. There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07564232.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:06:17.595Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/lnk001-nct07564232/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07564232.jpg</video:thumbnail_loc>
      <video:title>LNK001 para Advanced or… (NCT07564232) | Triangle</video:title>
      <video:description>LNK001 trial for Advanced or Metastatic Clear Cell Renal Cell Carcinoma (NCT07564232). LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma. There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07564232.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:06:17.595Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/lnk001-nct07564232/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07564232.jpg</video:thumbnail_loc>
      <video:title>LNK001 для Advanced or Metastatic… (NCT07564232) | Triangle</video:title>
      <video:description>LNK001 trial for Advanced or Metastatic Clear Cell Renal Cell Carcinoma (NCT07564232). LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma. There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07564232.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:06:17.595Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/lomustine-nct07145112/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07145112.jpg</video:thumbnail_loc>
      <video:title>LITT + Lomustine for Recurrent… (NCT07145112) | Triangle</video:title>
      <video:description>LITT + Lomustine trial for Recurrent Glioblastoma (NCT07145112). Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma. This is a phase 1 study evaluating the safety and feasibility of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07145112.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:18:26.663Z</video:publication_date>
      <video:duration>56</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/lomustine-nct07145112/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07145112.jpg</video:thumbnail_loc>
      <video:title>LITT + Lomustine para Recurrent… (NCT07145112) | Triangle</video:title>
      <video:description>LITT + Lomustine trial for Recurrent Glioblastoma (NCT07145112). Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma. This is a phase 1 study evaluating the safety and feasibility of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07145112.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:18:26.663Z</video:publication_date>
      <video:duration>56</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/lomustine-nct07145112/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07145112.jpg</video:thumbnail_loc>
      <video:title>LITT + Lomustine для Recurrent… (NCT07145112) | Triangle</video:title>
      <video:description>LITT + Lomustine trial for Recurrent Glioblastoma (NCT07145112). Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma. This is a phase 1 study evaluating the safety and feasibility of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07145112.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:18:26.663Z</video:publication_date>
      <video:duration>56</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/lu-177-dotatate-nct04086485/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04086485.jpg</video:thumbnail_loc>
      <video:title>Lu-177-DOTATATE for Inoperable… (NCT04086485) | Triangle</video:title>
      <video:description>Lu-177-DOTATATE trial for Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) (NCT04086485). Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET). Background: A neuroendocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04086485.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:12:00.601Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/lu-177-dotatate-nct04086485/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04086485.jpg</video:thumbnail_loc>
      <video:title>Lu-177-DOTATATE para Inoperable… (NCT04086485) | Triangle</video:title>
      <video:description>Lu-177-DOTATATE trial for Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) (NCT04086485). Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET). Background: A neuroendocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04086485.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:12:00.601Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/lu-177-dotatate-nct04086485/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04086485.jpg</video:thumbnail_loc>
      <video:title>Lu-177-DOTATATE для Inoperable… (NCT04086485) | Triangle</video:title>
      <video:description>Lu-177-DOTATATE trial for Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) (NCT04086485). Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET). Background: A neuroendocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04086485.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:12:00.601Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/lutathera-lutetium-lu-177-dotatate-nct05278208/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05278208.jpg</video:thumbnail_loc>
      <video:title>LUTATHERA (Lutetium Lu 177… (NCT05278208) | Triangle</video:title>
      <video:description>LUTATHERA (Lutetium Lu 177 dotatate) trial for High Grade Glioma (NCT05278208). Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors. This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05278208.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:35:38.632Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/lutathera-lutetium-lu-177-dotatate-nct05278208/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05278208.jpg</video:thumbnail_loc>
      <video:title>ensayo: LUTATHERA (Lutetium Lu… (NCT05278208) | Triangle</video:title>
      <video:description>LUTATHERA (Lutetium Lu 177 dotatate) trial for High Grade Glioma (NCT05278208). Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors. This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05278208.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:35:38.632Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/lutathera-lutetium-lu-177-dotatate-nct05278208/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05278208.jpg</video:thumbnail_loc>
      <video:title>исследование: LUTATHERA (Lutetium… (NCT05278208) | Triangle</video:title>
      <video:description>LUTATHERA (Lutetium Lu 177 dotatate) trial for High Grade Glioma (NCT05278208). Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors. This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05278208.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:35:38.632Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/m032-nct05084430/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05084430.jpg</video:thumbnail_loc>
      <video:title>M032 + Pembrolizumab for Malignant… (NCT05084430) | Triangle</video:title>
      <video:description>M032 + Pembrolizumab trial for Malignant Glioma (NCT05084430). Pembrolizumab and M032 (NSC 733972). This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05084430.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:07:48.662Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/m032-nct05084430/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05084430.jpg</video:thumbnail_loc>
      <video:title>ensayo: M032 + Pembrolizumab (NCT05084430) | Triangle</video:title>
      <video:description>M032 + Pembrolizumab trial for Malignant Glioma (NCT05084430). Pembrolizumab and M032 (NSC 733972). This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05084430.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:07:48.662Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/m032-nct05084430/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05084430.jpg</video:thumbnail_loc>
      <video:title>M032 + Pembrolizumab для Malignant… (NCT05084430) | Triangle</video:title>
      <video:description>M032 + Pembrolizumab trial for Malignant Glioma (NCT05084430). Pembrolizumab and M032 (NSC 733972). This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05084430.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:07:48.662Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/m28z1xxpd1dnr-car-nct06623396/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06623396.jpg</video:thumbnail_loc>
      <video:title>M28z1XXPD1DNR CAR (NCT06623396) | Triangle</video:title>
      <video:description>M28z1XXPD1DNR CAR trial for Mesothelin-Expressing Tumors (NCT06623396). Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer. Participants will have a sample of their white blood cells, called T cells,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06623396.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:25:14.270Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/m28z1xxpd1dnr-car-nct06623396/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06623396.jpg</video:thumbnail_loc>
      <video:title>M28z1XXPD1DNR CAR para Mesothelin… (NCT06623396) | Triangle</video:title>
      <video:description>M28z1XXPD1DNR CAR trial for Mesothelin-Expressing Tumors (NCT06623396). Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer. Participants will have a sample of their white blood cells, called T cells,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06623396.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:25:14.270Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/m28z1xxpd1dnr-car-nct06623396/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06623396.jpg</video:thumbnail_loc>
      <video:title>исследование: M28z1XXPD1DNR CAR (NCT06623396) | Triangle</video:title>
      <video:description>M28z1XXPD1DNR CAR trial for Mesothelin-Expressing Tumors (NCT06623396). Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer. Participants will have a sample of their white blood cells, called T cells,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06623396.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:25:14.270Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/magenta-nct03081910/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03081910.jpg</video:thumbnail_loc>
      <video:title>MAGENTA for T-cell Acute… (NCT03081910) | Triangle</video:title>
      <video:description>MAGENTA trial for T-cell Acute Lymphoblastic Lymphoma (NCT03081910). Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen. Patients eligible for this study have a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03081910.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:19:58.614Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/magenta-nct03081910/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03081910.jpg</video:thumbnail_loc>
      <video:title>MAGENTA para T-cell Acute… (NCT03081910) | Triangle</video:title>
      <video:description>MAGENTA trial for T-cell Acute Lymphoblastic Lymphoma (NCT03081910). Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen. Patients eligible for this study have a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03081910.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:19:58.614Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/magenta-nct03081910/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03081910.jpg</video:thumbnail_loc>
      <video:title>MAGENTA для T-cell Acute… (NCT03081910) | Triangle</video:title>
      <video:description>MAGENTA trial for T-cell Acute Lymphoblastic Lymphoma (NCT03081910). Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen. Patients eligible for this study have a…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03081910.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:19:58.614Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/magenta-nct07032714/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07032714.jpg</video:thumbnail_loc>
      <video:title>MAGENTA for Relapsed or… (NCT07032714) | Triangle</video:title>
      <video:description>MAGENTA trial for Relapsed or Refractory Multiple Myeloma (NCT07032714). Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma. This is a phase 1 study to find the recommended dose and schedule of mezigdomide and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07032714.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:21:19.174Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/magenta-nct07032714/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07032714.jpg</video:thumbnail_loc>
      <video:title>MAGENTA para Relapsed or… (NCT07032714) | Triangle</video:title>
      <video:description>MAGENTA trial for Relapsed or Refractory Multiple Myeloma (NCT07032714). Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma. This is a phase 1 study to find the recommended dose and schedule of mezigdomide and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07032714.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:21:19.174Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/magenta-nct07032714/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07032714.jpg</video:thumbnail_loc>
      <video:title>MAGENTA для Relapsed or… (NCT07032714) | Triangle</video:title>
      <video:description>MAGENTA trial for Relapsed or Refractory Multiple Myeloma (NCT07032714). Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma. This is a phase 1 study to find the recommended dose and schedule of mezigdomide and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07032714.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:21:19.174Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/melphalan-nct04483206/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04483206.jpg</video:thumbnail_loc>
      <video:title>PK-Directed Melphalan for Multiple… (NCT04483206) | Triangle</video:title>
      <video:description>PK-Directed Melphalan trial for Multiple Myeloma (NCT04483206). Personalized Autologous Transplant for Multiple Myeloma. This phase I trial studies the best dose and side effects of mephalan in treating patients with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04483206.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:49:23.712Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/melphalan-nct04483206/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04483206.jpg</video:thumbnail_loc>
      <video:title>ensayo: PK-Directed Melphalan (NCT04483206) | Triangle</video:title>
      <video:description>PK-Directed Melphalan trial for Multiple Myeloma (NCT04483206). Personalized Autologous Transplant for Multiple Myeloma. This phase I trial studies the best dose and side effects of mephalan in treating patients with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04483206.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:49:23.712Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/melphalan-nct04483206/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04483206.jpg</video:thumbnail_loc>
      <video:title>PK-Directed Melphalan для Multiple… (NCT04483206) | Triangle</video:title>
      <video:description>PK-Directed Melphalan trial for Multiple Myeloma (NCT04483206). Personalized Autologous Transplant for Multiple Myeloma. This phase I trial studies the best dose and side effects of mephalan in treating patients with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04483206.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:49:23.712Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/mesenchymal-stromal-cells-derived-exosomes-with-kras-g12-nct03608631/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03608631.jpg</video:thumbnail_loc>
      <video:title>iExosomes in Treating… (NCT03608631) | Triangle</video:title>
      <video:description>iExosomes in Treating Participants With M… trial for Metastatic Pancreatic Adenocarcinoma (NCT03608631). IExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation. This phase I trial studies the best dose and side effects of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03608631.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:15:44.188Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/mesenchymal-stromal-cells-derived-exosomes-with-kras-g12-nct03608631/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03608631.jpg</video:thumbnail_loc>
      <video:title>ensayo: iExosomes in Treating… (NCT03608631) | Triangle</video:title>
      <video:description>iExosomes in Treating Participants With M… trial for Metastatic Pancreatic Adenocarcinoma (NCT03608631). IExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation. This phase I trial studies the best dose and side effects of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03608631.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:15:44.188Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/mesenchymal-stromal-cells-derived-exosomes-with-kras-g12-nct03608631/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03608631.jpg</video:thumbnail_loc>
      <video:title>исследование: iExosomes in… (NCT03608631) | Triangle</video:title>
      <video:description>iExosomes in Treating Participants With M… trial for Metastatic Pancreatic Adenocarcinoma (NCT03608631). IExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation. This phase I trial studies the best dose and side effects of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03608631.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:15:44.188Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/mir-126-inhibitor-miristen-nct07025564/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07025564.jpg</video:thumbnail_loc>
      <video:title>miRisten for Relapsed or… (NCT07025564) | Triangle</video:title>
      <video:description>miRisten trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT07025564). MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia. This phase I trial tests the safety, side effects, and best dose of miRisten in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07025564.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:38:30.698Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/mir-126-inhibitor-miristen-nct07025564/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07025564.jpg</video:thumbnail_loc>
      <video:title>miRisten para Relapsed or… (NCT07025564) | Triangle</video:title>
      <video:description>miRisten trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT07025564). MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia. This phase I trial tests the safety, side effects, and best dose of miRisten in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07025564.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:38:30.698Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/mir-126-inhibitor-miristen-nct07025564/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07025564.jpg</video:thumbnail_loc>
      <video:title>miRisten для Relapsed or… (NCT07025564) | Triangle</video:title>
      <video:description>miRisten trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT07025564). MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia. This phase I trial tests the safety, side effects, and best dose of miRisten in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07025564.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:38:30.698Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/mirda-nct06159166/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06159166.jpg</video:thumbnail_loc>
      <video:title>Mirdametinib for Neurofibromatosis… (NCT06159166) | Triangle</video:title>
      <video:description>Mirdametinib trial for Neurofibromatosis Type 1 With Cutaneous Neurofibromas (NCT06159166). Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). This is a Phase 1/2a, open-label, non-randomized,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06159166.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:12:50.258Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/mirda-nct06159166/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06159166.jpg</video:thumbnail_loc>
      <video:title>ensayo: Mirdametinib (NCT06159166) | Triangle</video:title>
      <video:description>Mirdametinib trial for Neurofibromatosis Type 1 With Cutaneous Neurofibromas (NCT06159166). Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). This is a Phase 1/2a, open-label, non-randomized,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06159166.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:12:50.258Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/mirda-nct06159166/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06159166.jpg</video:thumbnail_loc>
      <video:title>Mirdametinib для Neurofibromatosis… (NCT06159166) | Triangle</video:title>
      <video:description>Mirdametinib trial for Neurofibromatosis Type 1 With Cutaneous Neurofibromas (NCT06159166). Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). This is a Phase 1/2a, open-label, non-randomized,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06159166.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:12:50.258Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/mosunetuzumab-nct06249191/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06249191.jpg</video:thumbnail_loc>
      <video:title>Mosunetuzumab + Chemotherapy (NCT06249191) | Triangle</video:title>
      <video:description>Mosunetuzumab + Chemotherapy trial for C-Myc Rearranged High-Grade B-Cell Lymphoma or DLBCL (NCT06249191). Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06249191.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:59:18.528Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/mosunetuzumab-nct06249191/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06249191.jpg</video:thumbnail_loc>
      <video:title>ensayo: Mosunetuzumab + Chemotherapy (NCT06249191) | Triangle</video:title>
      <video:description>Mosunetuzumab + Chemotherapy trial for C-Myc Rearranged High-Grade B-Cell Lymphoma or DLBCL (NCT06249191). Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06249191.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:59:18.528Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/mosunetuzumab-nct06249191/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06249191.jpg</video:thumbnail_loc>
      <video:title>исследование: Mosunetuzumab +… (NCT06249191) | Triangle</video:title>
      <video:description>Mosunetuzumab + Chemotherapy trial for C-Myc Rearranged High-Grade B-Cell Lymphoma or DLBCL (NCT06249191). Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06249191.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:59:18.528Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/natural-killer-cell-therapy-nct05588453/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05588453.jpg</video:thumbnail_loc>
      <video:title>Donor NK Cells + Temozolomide (NCT05588453) | Triangle</video:title>
      <video:description>Donor NK Cells + Temozolomide trial for Stage IV Melanoma With Brain Metastases (NCT05588453). Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain. This phase I/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05588453.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:37:45.548Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/natural-killer-cell-therapy-nct05588453/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05588453.jpg</video:thumbnail_loc>
      <video:title>ensayo: Donor NK Cells + Temozolomide (NCT05588453) | Triangle</video:title>
      <video:description>Donor NK Cells + Temozolomide trial for Stage IV Melanoma With Brain Metastases (NCT05588453). Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain. This phase I/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05588453.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:37:45.548Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/natural-killer-cell-therapy-nct05588453/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05588453.jpg</video:thumbnail_loc>
      <video:title>исследование: Donor NK Cells +… (NCT05588453) | Triangle</video:title>
      <video:description>Donor NK Cells + Temozolomide trial for Stage IV Melanoma With Brain Metastases (NCT05588453). Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain. This phase I/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05588453.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:37:45.548Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/navlimetostat-nct07579221/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579221.jpg</video:thumbnail_loc>
      <video:title>Navlimetostat + Pumitamig for MTAP… (NCT07579221) | Triangle</video:title>
      <video:description>Navlimetostat + Pumitamig trial for MTAP-Deleted Advanced Non-Small Cell Lung Cancer (NCT07579221). Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer. The goal of this clinical research study is to find a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579221.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:51:52.037Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/navlimetostat-nct07579221/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579221.jpg</video:thumbnail_loc>
      <video:title>ensayo: Navlimetostat + Pumitamig (NCT07579221) | Triangle</video:title>
      <video:description>Navlimetostat + Pumitamig trial for MTAP-Deleted Advanced Non-Small Cell Lung Cancer (NCT07579221). Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer. The goal of this clinical research study is to find a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579221.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:51:52.037Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/navlimetostat-nct07579221/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579221.jpg</video:thumbnail_loc>
      <video:title>Navlimetostat + Pumitamig для MTAP… (NCT07579221) | Triangle</video:title>
      <video:description>Navlimetostat + Pumitamig trial for MTAP-Deleted Advanced Non-Small Cell Lung Cancer (NCT07579221). Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer. The goal of this clinical research study is to find a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579221.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:51:52.037Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/neo-combatxl-nct06902376/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06902376.jpg</video:thumbnail_loc>
      <video:title>NEO-COMBATXL for BRAF V600E… (NCT06902376) | Triangle</video:title>
      <video:description>NEO-COMBATXL trial for BRAF V600E Wild-Type Anaplastic Thyroid Cancer (NCT06902376). XL092 and Cemiplimab in BRAF WT Thyroid Cancer. This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06902376.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:13:43.759Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/neo-combatxl-nct06902376/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06902376.jpg</video:thumbnail_loc>
      <video:title>NEO-COMBATXL para BRAF V600E… (NCT06902376) | Triangle</video:title>
      <video:description>NEO-COMBATXL trial for BRAF V600E Wild-Type Anaplastic Thyroid Cancer (NCT06902376). XL092 and Cemiplimab in BRAF WT Thyroid Cancer. This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06902376.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:13:43.759Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/neo-combatxl-nct06902376/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06902376.jpg</video:thumbnail_loc>
      <video:title>NEO-COMBATXL для BRAF V600E… (NCT06902376) | Triangle</video:title>
      <video:description>NEO-COMBATXL trial for BRAF V600E Wild-Type Anaplastic Thyroid Cancer (NCT06902376). XL092 and Cemiplimab in BRAF WT Thyroid Cancer. This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06902376.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:13:43.759Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/neratinib-pill-nct05274048/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05274048.jpg</video:thumbnail_loc>
      <video:title>Neratinib + Trastuzumab Deruxtecan (NCT05274048) | Triangle</video:title>
      <video:description>Neratinib + Trastuzumab Deruxtecan trial for HER2-Positive Advanced Gastro-Esophageal and GI Cancers (NCT05274048). Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients. This is Phase 1 dose finding trial with potential dose expansion to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05274048.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:39:38.410Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/neratinib-pill-nct05274048/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05274048.jpg</video:thumbnail_loc>
      <video:title>ensayo: Neratinib + Trastuzumab… (NCT05274048) | Triangle</video:title>
      <video:description>Neratinib + Trastuzumab Deruxtecan trial for HER2-Positive Advanced Gastro-Esophageal and GI Cancers (NCT05274048). Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients. This is Phase 1 dose finding trial with potential dose expansion to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05274048.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:39:38.410Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/neratinib-pill-nct05274048/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05274048.jpg</video:thumbnail_loc>
      <video:title>исследование: Neratinib +… (NCT05274048) | Triangle</video:title>
      <video:description>Neratinib + Trastuzumab Deruxtecan trial for HER2-Positive Advanced Gastro-Esophageal and GI Cancers (NCT05274048). Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients. This is Phase 1 dose finding trial with potential dose expansion to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05274048.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:39:38.410Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/neural-stem-cells-expressing-crad-s-pk7-nct05139056/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05139056.jpg</video:thumbnail_loc>
      <video:title>Neural Stem Cells-expressing… (NCT05139056) | Triangle</video:title>
      <video:description>Neural Stem Cells-expressing CRAd-S-pk7 trial for Currently Only Enrolling Glioblastoma Patients at First Recurrence (NCT05139056). Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas. This phase I trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05139056.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:23:42.134Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/neural-stem-cells-expressing-crad-s-pk7-nct05139056/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05139056.jpg</video:thumbnail_loc>
      <video:title>ensayo: Neural Stem… (NCT05139056) | Triangle</video:title>
      <video:description>Neural Stem Cells-expressing CRAd-S-pk7 trial for Currently Only Enrolling Glioblastoma Patients at First Recurrence (NCT05139056). Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas. This phase I trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05139056.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:23:42.134Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/neural-stem-cells-expressing-crad-s-pk7-nct05139056/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05139056.jpg</video:thumbnail_loc>
      <video:title>исследование: Neural Stem… (NCT05139056) | Triangle</video:title>
      <video:description>Neural Stem Cells-expressing CRAd-S-pk7 trial for Currently Only Enrolling Glioblastoma Patients at First Recurrence (NCT05139056). Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas. This phase I trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05139056.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:23:42.134Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/nilotinib-nct04903119/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903119.jpg</video:thumbnail_loc>
      <video:title>Nilotinib for BRAF V600… (NCT04903119) | Triangle</video:title>
      <video:description>Nilotinib trial for BRAF V600 Metastatic or Unresectable Melanoma (NCT04903119). Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma. This is a phase 1 dose-escalation study of nilotinib in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903119.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:13:18.166Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/nilotinib-nct04903119/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903119.jpg</video:thumbnail_loc>
      <video:title>Nilotinib para BRAF V600… (NCT04903119) | Triangle</video:title>
      <video:description>Nilotinib trial for BRAF V600 Metastatic or Unresectable Melanoma (NCT04903119). Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma. This is a phase 1 dose-escalation study of nilotinib in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903119.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:13:18.166Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/nilotinib-nct04903119/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903119.jpg</video:thumbnail_loc>
      <video:title>Nilotinib для BRAF V600… (NCT04903119) | Triangle</video:title>
      <video:description>Nilotinib trial for BRAF V600 Metastatic or Unresectable Melanoma (NCT04903119). Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma. This is a phase 1 dose-escalation study of nilotinib in combination…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04903119.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:13:18.166Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/nk-cells-nct07411599/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07411599.jpg</video:thumbnail_loc>
      <video:title>TROP2-Directed CAR-NK (NCT07411599) | Triangle</video:title>
      <video:description>TROP2-Directed CAR-NK trial for Colorectal Cancer (NCT07411599). Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07411599.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:57:42.825Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/nk-cells-nct07411599/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07411599.jpg</video:thumbnail_loc>
      <video:title>ensayo: TROP2-Directed CAR-NK (NCT07411599) | Triangle</video:title>
      <video:description>TROP2-Directed CAR-NK trial for Colorectal Cancer (NCT07411599). Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07411599.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:57:42.825Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/nk-cells-nct07411599/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07411599.jpg</video:thumbnail_loc>
      <video:title>исследование: TROP2-Directed CAR-NK (NCT07411599) | Triangle</video:title>
      <video:description>TROP2-Directed CAR-NK trial for Colorectal Cancer (NCT07411599). Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07411599.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:57:42.825Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/nk-cells-nct07579208/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579208.jpg</video:thumbnail_loc>
      <video:title>NK Cells for Recurrent Glioblastoma (NCT07579208) | Triangle</video:title>
      <video:description>NK Cells trial for Recurrent Glioblastoma (NCT07579208). Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579208.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:12:12.662Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/nk-cells-nct07579208/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579208.jpg</video:thumbnail_loc>
      <video:title>NK Cells para Recurrent Glioblastoma (NCT07579208) | Triangle</video:title>
      <video:description>NK Cells trial for Recurrent Glioblastoma (NCT07579208). Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579208.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:12:12.662Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/nk-cells-nct07579208/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579208.jpg</video:thumbnail_loc>
      <video:title>NK Cells для Recurrent Glioblastoma (NCT07579208) | Triangle</video:title>
      <video:description>NK Cells trial for Recurrent Glioblastoma (NCT07579208). Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07579208.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:12:12.662Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/nt-i7-nct07052305/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07052305.jpg</video:thumbnail_loc>
      <video:title>NT-I7 for large B-cell lymphoma (NCT07052305) | Triangle</video:title>
      <video:description>NT-I7 for large B-cell lymphoma trial for Large B-cell Lymphoma (NCT07052305). NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07052305.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:55:42.288Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/nt-i7-nct07052305/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07052305.jpg</video:thumbnail_loc>
      <video:title>ensayo: NT-I7 for large B-cell lymphoma (NCT07052305) | Triangle</video:title>
      <video:description>NT-I7 for large B-cell lymphoma trial for Large B-cell Lymphoma (NCT07052305). NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07052305.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:55:42.288Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/nt-i7-nct07052305/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07052305.jpg</video:thumbnail_loc>
      <video:title>исследование: NT-I7 for large… (NCT07052305) | Triangle</video:title>
      <video:description>NT-I7 for large B-cell lymphoma trial for Large B-cell Lymphoma (NCT07052305). NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07052305.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:55:42.288Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/nt-i7-nct07200089/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200089.jpg</video:thumbnail_loc>
      <video:title>NT-I7 for multiple myeloma (NCT07200089) | Triangle</video:title>
      <video:description>NT-I7 for multiple myeloma trial for Multiple Myeloma (NCT07200089). Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel). CAR-T cell therapy is an emerging treatment…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200089.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:50:53.082Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/nt-i7-nct07200089/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200089.jpg</video:thumbnail_loc>
      <video:title>ensayo: NT-I7 for multiple myeloma (NCT07200089) | Triangle</video:title>
      <video:description>NT-I7 for multiple myeloma trial for Multiple Myeloma (NCT07200089). Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel). CAR-T cell therapy is an emerging treatment…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200089.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:50:53.082Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/nt-i7-nct07200089/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200089.jpg</video:thumbnail_loc>
      <video:title>исследование: NT-I7 for multiple myeloma (NCT07200089) | Triangle</video:title>
      <video:description>NT-I7 for multiple myeloma trial for Multiple Myeloma (NCT07200089). Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel). CAR-T cell therapy is an emerging treatment…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200089.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:50:53.082Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/oncolytic-adenovirus-ad5-dnx-2401-nct03896568/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03896568.jpg</video:thumbnail_loc>
      <video:title>Oncolytic Adenovirus Ad5-DNX-2401 (NCT03896568) | Triangle</video:title>
      <video:description>Oncolytic Adenovirus Ad5-DNX-2401 trial for Recurrent Glioblastoma (NCT03896568). MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma. This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03896568.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:23:42.652Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/oncolytic-adenovirus-ad5-dnx-2401-nct03896568/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03896568.jpg</video:thumbnail_loc>
      <video:title>ensayo: Oncolytic Adenovirus… (NCT03896568) | Triangle</video:title>
      <video:description>Oncolytic Adenovirus Ad5-DNX-2401 trial for Recurrent Glioblastoma (NCT03896568). MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma. This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03896568.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:23:42.652Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/oncolytic-adenovirus-ad5-dnx-2401-nct03896568/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03896568.jpg</video:thumbnail_loc>
      <video:title>исследование: Oncolytic… (NCT03896568) | Triangle</video:title>
      <video:description>Oncolytic Adenovirus Ad5-DNX-2401 trial for Recurrent Glioblastoma (NCT03896568). MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma. This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03896568.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:23:42.652Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ont01-nct06904378/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06904378.jpg</video:thumbnail_loc>
      <video:title>ONT01 + Gem/Nab-Paclitaxel (NCT06904378) | Triangle</video:title>
      <video:description>ONT01 + Gem/Nab-Paclitaxel trial for Metastatic Pancreatic Ductal Adenocarcinoma (Second Line) (NCT06904378). ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma. The investigators hypothesize that CD11b agonism…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06904378.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:22:06.226Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ont01-nct06904378/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06904378.jpg</video:thumbnail_loc>
      <video:title>ensayo: ONT01 + Gem/Nab-Paclitaxel (NCT06904378) | Triangle</video:title>
      <video:description>ONT01 + Gem/Nab-Paclitaxel trial for Metastatic Pancreatic Ductal Adenocarcinoma (Second Line) (NCT06904378). ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma. The investigators hypothesize that CD11b agonism…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06904378.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:22:06.226Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ont01-nct06904378/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06904378.jpg</video:thumbnail_loc>
      <video:title>исследование: ONT01 + Gem/Nab-Paclitaxel (NCT06904378) | Triangle</video:title>
      <video:description>ONT01 + Gem/Nab-Paclitaxel trial for Metastatic Pancreatic Ductal Adenocarcinoma (Second Line) (NCT06904378). ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma. The investigators hypothesize that CD11b agonism…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06904378.mp4</video:content_loc>
      <video:publication_date>2026-10-20T06:22:06.226Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/papaverine-nct05136846/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05136846.jpg</video:thumbnail_loc>
      <video:title>Papaverine for Locally Advanced… (NCT05136846) | Triangle</video:title>
      <video:description>Papaverine trial for Locally Advanced Lung Non-Small Cell Carcinoma (NCT05136846). Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer. This phase I trial finds out the best dose,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05136846.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:02:38.704Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/papaverine-nct05136846/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05136846.jpg</video:thumbnail_loc>
      <video:title>Papaverine para Locally Advanced… (NCT05136846) | Triangle</video:title>
      <video:description>Papaverine trial for Locally Advanced Lung Non-Small Cell Carcinoma (NCT05136846). Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer. This phase I trial finds out the best dose,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05136846.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:02:38.704Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/papaverine-nct05136846/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05136846.jpg</video:thumbnail_loc>
      <video:title>Papaverine для Locally Advanced… (NCT05136846) | Triangle</video:title>
      <video:description>Papaverine trial for Locally Advanced Lung Non-Small Cell Carcinoma (NCT05136846). Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer. This phase I trial finds out the best dose,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05136846.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:02:38.704Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pembrolizumab-nct03760575/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03760575.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab + Image-Guided… (NCT03760575) | Triangle</video:title>
      <video:description>Pembrolizumab + Image-Guided Surgery trial for Malignant Pleural Mesothelioma (NCT03760575). Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM). The study is a single-arm phase I trial to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03760575.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:43:41.202Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pembrolizumab-nct03760575/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03760575.jpg</video:thumbnail_loc>
      <video:title>ensayo: Pembrolizumab +… (NCT03760575) | Triangle</video:title>
      <video:description>Pembrolizumab + Image-Guided Surgery trial for Malignant Pleural Mesothelioma (NCT03760575). Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM). The study is a single-arm phase I trial to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03760575.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:43:41.202Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pembrolizumab-nct03760575/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03760575.jpg</video:thumbnail_loc>
      <video:title>исследование: Pembrolizumab +… (NCT03760575) | Triangle</video:title>
      <video:description>Pembrolizumab + Image-Guided Surgery trial for Malignant Pleural Mesothelioma (NCT03760575). Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM). The study is a single-arm phase I trial to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03760575.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:43:41.202Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pembrolizumab-nct04297605/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04297605.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab + Single-Agent… (NCT04297605) | Triangle</video:title>
      <video:description>Pembrolizumab + Single-Agent Chemotherapy trial for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2) (NCT04297605). Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04297605.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:20:56.783Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pembrolizumab-nct04297605/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04297605.jpg</video:thumbnail_loc>
      <video:title>ensayo: Pembrolizumab +… (NCT04297605) | Triangle</video:title>
      <video:description>Pembrolizumab + Single-Agent Chemotherapy trial for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2) (NCT04297605). Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04297605.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:20:56.783Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pembrolizumab-nct04297605/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04297605.jpg</video:thumbnail_loc>
      <video:title>исследование: Pembrolizumab +… (NCT04297605) | Triangle</video:title>
      <video:description>Pembrolizumab + Single-Agent Chemotherapy trial for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2) (NCT04297605). Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04297605.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:20:56.783Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pembrolizumab-nct06868433/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06868433.jpg</video:thumbnail_loc>
      <video:title>TMV Vaccine With Pembrolizumab (NCT06868433) | Triangle</video:title>
      <video:description>TMV Vaccine With Pembrolizumab trial for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06868433). TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer. This phase Ib trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06868433.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:39:37.475Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pembrolizumab-nct06868433/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06868433.jpg</video:thumbnail_loc>
      <video:title>ensayo: TMV Vaccine With Pembrolizumab (NCT06868433) | Triangle</video:title>
      <video:description>TMV Vaccine With Pembrolizumab trial for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06868433). TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer. This phase Ib trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06868433.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:39:37.475Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pembrolizumab-nct06868433/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06868433.jpg</video:thumbnail_loc>
      <video:title>исследование: TMV Vaccine With… (NCT06868433) | Triangle</video:title>
      <video:description>TMV Vaccine With Pembrolizumab trial for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06868433). TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer. This phase Ib trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06868433.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:39:37.475Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pemigatinib-nct04659616/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04659616.jpg</video:thumbnail_loc>
      <video:title>Pemigatinib After Chemotherapy (NCT04659616) | Triangle</video:title>
      <video:description>Pemigatinib After Chemotherapy trial for Newly Diagnosed Acute Myeloid Leukemia (NCT04659616). Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia. This phase I trial identifies the best dose and clinical benefit…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04659616.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:27:50.719Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pemigatinib-nct04659616/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04659616.jpg</video:thumbnail_loc>
      <video:title>ensayo: Pemigatinib After Chemotherapy (NCT04659616) | Triangle</video:title>
      <video:description>Pemigatinib After Chemotherapy trial for Newly Diagnosed Acute Myeloid Leukemia (NCT04659616). Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia. This phase I trial identifies the best dose and clinical benefit…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04659616.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:27:50.719Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pemigatinib-nct04659616/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04659616.jpg</video:thumbnail_loc>
      <video:title>исследование: Pemigatinib After… (NCT04659616) | Triangle</video:title>
      <video:description>Pemigatinib After Chemotherapy trial for Newly Diagnosed Acute Myeloid Leukemia (NCT04659616). Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia. This phase I trial identifies the best dose and clinical benefit…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04659616.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:27:50.719Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/personalized-neoantigen-dna-vaccine-nct03988283/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03988283.jpg</video:thumbnail_loc>
      <video:title>Personalized neoantigen DNA vaccine (NCT03988283) | Triangle</video:title>
      <video:description>Personalized neoantigen DNA vaccine trial for Pediatric Recurrent Central Nervous System Tumors (NCT03988283). Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors. The purpose of this research study is…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03988283.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:07:58.512Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/personalized-neoantigen-dna-vaccine-nct03988283/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03988283.jpg</video:thumbnail_loc>
      <video:title>ensayo: Personalized neoantigen… (NCT03988283) | Triangle</video:title>
      <video:description>Personalized neoantigen DNA vaccine trial for Pediatric Recurrent Central Nervous System Tumors (NCT03988283). Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors. The purpose of this research study is…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03988283.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:07:58.512Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/personalized-neoantigen-dna-vaccine-nct03988283/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03988283.jpg</video:thumbnail_loc>
      <video:title>исследование: Personalized… (NCT03988283) | Triangle</video:title>
      <video:description>Personalized neoantigen DNA vaccine trial for Pediatric Recurrent Central Nervous System Tumors (NCT03988283). Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors. The purpose of this research study is…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03988283.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:07:58.512Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/phoebe-nct05900895/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05900895.jpg</video:thumbnail_loc>
      <video:title>PHOEBE for Advanced ER-Positive… (NCT05900895) | Triangle</video:title>
      <video:description>PHOEBE trial for Advanced ER-Positive HER2-Negative Breast Cancer (NCT05900895). Estradiol Plus Olaparib for Breast Cancer (PHOEBE). Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05900895.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:47:30.156Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/phoebe-nct05900895/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05900895.jpg</video:thumbnail_loc>
      <video:title>PHOEBE para Advanced ER-Positive… (NCT05900895) | Triangle</video:title>
      <video:description>PHOEBE trial for Advanced ER-Positive HER2-Negative Breast Cancer (NCT05900895). Estradiol Plus Olaparib for Breast Cancer (PHOEBE). Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05900895.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:47:30.156Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/phoebe-nct05900895/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05900895.jpg</video:thumbnail_loc>
      <video:title>PHOEBE для Advanced ER-Positive… (NCT05900895) | Triangle</video:title>
      <video:description>PHOEBE trial for Advanced ER-Positive HER2-Negative Breast Cancer (NCT05900895). Estradiol Plus Olaparib for Breast Cancer (PHOEBE). Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05900895.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:47:30.156Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/photodynamic-therapy-nct06307548/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06307548.jpg</video:thumbnail_loc>
      <video:title>Photodynamic Therapy for Locally… (NCT06307548) | Triangle</video:title>
      <video:description>Photodynamic Therapy trial for Locally Advanced or Recurrent Colorectal Cancer (NCT06307548). Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06307548.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:54:10.110Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/photodynamic-therapy-nct06307548/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06307548.jpg</video:thumbnail_loc>
      <video:title>Photodynamic Therapy para Locally… (NCT06307548) | Triangle</video:title>
      <video:description>Photodynamic Therapy trial for Locally Advanced or Recurrent Colorectal Cancer (NCT06307548). Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06307548.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:54:10.110Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/photodynamic-therapy-nct06307548/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06307548.jpg</video:thumbnail_loc>
      <video:title>Photodynamic Therapy для Locally… (NCT06307548) | Triangle</video:title>
      <video:description>Photodynamic Therapy trial for Locally Advanced or Recurrent Colorectal Cancer (NCT06307548). Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06307548.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:54:10.110Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pmd-026-nct07379125/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07379125.jpg</video:thumbnail_loc>
      <video:title>PMD-026 for Myelofibrosis (NCT07379125) | Triangle</video:title>
      <video:description>PMD-026 trial for Myelofibrosis (NCT07379125). Therapeutic RSK1 Targeting in Myelofibrosis. This is a phase Ib study evaluating PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07379125.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:20:35.000Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pmd-026-nct07379125/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07379125.jpg</video:thumbnail_loc>
      <video:title>PMD-026 para Myelofibrosis (NCT07379125) | Triangle</video:title>
      <video:description>PMD-026 trial for Myelofibrosis (NCT07379125). Therapeutic RSK1 Targeting in Myelofibrosis. This is a phase Ib study evaluating PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07379125.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:20:35.000Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pmd-026-nct07379125/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07379125.jpg</video:thumbnail_loc>
      <video:title>PMD-026 для Myelofibrosis (NCT07379125) | Triangle</video:title>
      <video:description>PMD-026 trial for Myelofibrosis (NCT07379125). Therapeutic RSK1 Targeting in Myelofibrosis. This is a phase Ib study evaluating PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07379125.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:20:35.000Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pnoc020-nct04573140/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04573140.jpg</video:thumbnail_loc>
      <video:title>PNOC020 for Adult Glioblastoma (NCT04573140) | Triangle</video:title>
      <video:description>PNOC020 trial for Adult Glioblastoma (NCT04573140). RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM). The primary objective will be to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04573140.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:23:45.097Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pnoc020-nct04573140/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04573140.jpg</video:thumbnail_loc>
      <video:title>PNOC020 para Adult Glioblastoma (NCT04573140) | Triangle</video:title>
      <video:description>PNOC020 trial for Adult Glioblastoma (NCT04573140). RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM). The primary objective will be to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04573140.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:23:45.097Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pnoc020-nct04573140/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04573140.jpg</video:thumbnail_loc>
      <video:title>PNOC020 для Adult Glioblastoma (NCT04573140) | Triangle</video:title>
      <video:description>PNOC020 trial for Adult Glioblastoma (NCT04573140). RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM). The primary objective will be to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04573140.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:23:45.097Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pomalidomide-nct05389423/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05389423.jpg</video:thumbnail_loc>
      <video:title>Pomalidomide for HIV-associated lymphoma (NCT05389423) | Triangle</video:title>
      <video:description>Pomalidomide for HIV-associated lymphoma trial for HIV-Associated Lymphoma (NCT05389423). Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas. Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05389423.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:21:13.005Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pomalidomide-nct05389423/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05389423.jpg</video:thumbnail_loc>
      <video:title>ensayo: Pomalidomide for… (NCT05389423) | Triangle</video:title>
      <video:description>Pomalidomide for HIV-associated lymphoma trial for HIV-Associated Lymphoma (NCT05389423). Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas. Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05389423.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:21:13.005Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pomalidomide-nct05389423/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05389423.jpg</video:thumbnail_loc>
      <video:title>исследование: Pomalidomide for… (NCT05389423) | Triangle</video:title>
      <video:description>Pomalidomide for HIV-associated lymphoma trial for HIV-Associated Lymphoma (NCT05389423). Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas. Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05389423.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:21:13.005Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pomalidomide-nct07532525/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07532525.jpg</video:thumbnail_loc>
      <video:title>Pomalidomide after CAR T (NCT07532525) | Triangle</video:title>
      <video:description>Pomalidomide after CAR T trial for Recurrent B Acute Lymphoblastic Leukemia (NCT07532525). Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma. This phase I trial tests the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07532525.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:36:46.786Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pomalidomide-nct07532525/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07532525.jpg</video:thumbnail_loc>
      <video:title>ensayo: Pomalidomide after CAR T (NCT07532525) | Triangle</video:title>
      <video:description>Pomalidomide after CAR T trial for Recurrent B Acute Lymphoblastic Leukemia (NCT07532525). Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma. This phase I trial tests the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07532525.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:36:46.786Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pomalidomide-nct07532525/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07532525.jpg</video:thumbnail_loc>
      <video:title>исследование: Pomalidomide after CAR T (NCT07532525) | Triangle</video:title>
      <video:description>Pomalidomide after CAR T trial for Recurrent B Acute Lymphoblastic Leukemia (NCT07532525). Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma. This phase I trial tests the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07532525.mp4</video:content_loc>
      <video:publication_date>2026-10-18T19:36:46.786Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/pralatrexate-nct07225985/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225985.jpg</video:thumbnail_loc>
      <video:title>Pralatrexate Conditioning (NCT07225985) | Triangle</video:title>
      <video:description>Pralatrexate Conditioning trial for Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma (NCT07225985). Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225985.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:15:12.807Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/pralatrexate-nct07225985/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225985.jpg</video:thumbnail_loc>
      <video:title>ensayo: Pralatrexate Conditioning (NCT07225985) | Triangle</video:title>
      <video:description>Pralatrexate Conditioning trial for Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma (NCT07225985). Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225985.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:15:12.807Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/pralatrexate-nct07225985/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225985.jpg</video:thumbnail_loc>
      <video:title>исследование: Pralatrexate Conditioning (NCT07225985) | Triangle</video:title>
      <video:description>Pralatrexate Conditioning trial for Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma (NCT07225985). Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225985.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:15:12.807Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/prism-nct07139990/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07139990.jpg</video:thumbnail_loc>
      <video:title>PRISM for Extensive-Stage SCLC… (NCT07139990) | Triangle</video:title>
      <video:description>PRISM trial for Extensive-Stage SCLC, Brain Metastases, Soft Tissue Sarcoma and Head and Neck Cancer (NCT07139990). Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM). To characterize feasibility, safety, and/or preliminary efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07139990.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:57:44.541Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/prism-nct07139990/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07139990.jpg</video:thumbnail_loc>
      <video:title>PRISM para Extensive-Stage SCLC… (NCT07139990) | Triangle</video:title>
      <video:description>PRISM trial for Extensive-Stage SCLC, Brain Metastases, Soft Tissue Sarcoma and Head and Neck Cancer (NCT07139990). Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM). To characterize feasibility, safety, and/or preliminary efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07139990.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:57:44.541Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/prism-nct07139990/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07139990.jpg</video:thumbnail_loc>
      <video:title>PRISM для Extensive-Stage SCLC… (NCT07139990) | Triangle</video:title>
      <video:description>PRISM trial for Extensive-Stage SCLC, Brain Metastases, Soft Tissue Sarcoma and Head and Neck Cancer (NCT07139990). Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM). To characterize feasibility, safety, and/or preliminary efficacy of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07139990.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:57:44.541Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/prmt5-inhibitor-bms-986504-nct07594626/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07594626.jpg</video:thumbnail_loc>
      <video:title>BMS-986504 + Pemetrexed (NCT07594626) | Triangle</video:title>
      <video:description>BMS-986504 + Pemetrexed trial for Metastatic MTAP-Deleted Solid Tumors (NCT07594626). BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion. This phase Ib/II trial tests the safety and side…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07594626.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:48:49.834Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/prmt5-inhibitor-bms-986504-nct07594626/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07594626.jpg</video:thumbnail_loc>
      <video:title>ensayo: BMS-986504 + Pemetrexed (NCT07594626) | Triangle</video:title>
      <video:description>BMS-986504 + Pemetrexed trial for Metastatic MTAP-Deleted Solid Tumors (NCT07594626). BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion. This phase Ib/II trial tests the safety and side…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07594626.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:48:49.834Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/prmt5-inhibitor-bms-986504-nct07594626/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07594626.jpg</video:thumbnail_loc>
      <video:title>исследование: BMS-986504 + Pemetrexed (NCT07594626) | Triangle</video:title>
      <video:description>BMS-986504 + Pemetrexed trial for Metastatic MTAP-Deleted Solid Tumors (NCT07594626). BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion. This phase Ib/II trial tests the safety and side…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07594626.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:48:49.834Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/rabbit-nct06814496/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06814496.jpg</video:thumbnail_loc>
      <video:title>RABBIT for Relapsed/Refractory… (NCT06814496) | Triangle</video:title>
      <video:description>RABBIT trial for Relapsed/Refractory DLL3-Expressing Tumors (NCT06814496). Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors. Phase I study to examine safety of the addition of concurrent tarlatamab with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06814496.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:07:51.190Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/rabbit-nct06814496/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06814496.jpg</video:thumbnail_loc>
      <video:title>RABBIT para Relapsed/Refractory… (NCT06814496) | Triangle</video:title>
      <video:description>RABBIT trial for Relapsed/Refractory DLL3-Expressing Tumors (NCT06814496). Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors. Phase I study to examine safety of the addition of concurrent tarlatamab with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06814496.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:07:51.190Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/rabbit-nct06814496/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06814496.jpg</video:thumbnail_loc>
      <video:title>RABBIT для Relapsed/Refractory… (NCT06814496) | Triangle</video:title>
      <video:description>RABBIT trial for Relapsed/Refractory DLL3-Expressing Tumors (NCT06814496). Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors. Phase I study to examine safety of the addition of concurrent tarlatamab with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06814496.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:07:51.190Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ramucirumab-nct06675136/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06675136.jpg</video:thumbnail_loc>
      <video:title>PIPAC Nab-Paclitaxel for Gastric… (NCT06675136) | Triangle</video:title>
      <video:description>PIPAC Nab-Paclitaxel trial for Gastric Cancer With Peritoneal Metastases (NCT06675136). Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases. This phase I trial tests…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06675136.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:49:38.602Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ramucirumab-nct06675136/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06675136.jpg</video:thumbnail_loc>
      <video:title>PIPAC Nab-Paclitaxel para Gastric… (NCT06675136) | Triangle</video:title>
      <video:description>PIPAC Nab-Paclitaxel trial for Gastric Cancer With Peritoneal Metastases (NCT06675136). Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases. This phase I trial tests…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06675136.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:49:38.602Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ramucirumab-nct06675136/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06675136.jpg</video:thumbnail_loc>
      <video:title>PIPAC Nab-Paclitaxel для Gastric… (NCT06675136) | Triangle</video:title>
      <video:description>PIPAC Nab-Paclitaxel trial for Gastric Cancer With Peritoneal Metastases (NCT06675136). Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases. This phase I trial tests…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06675136.mp4</video:content_loc>
      <video:publication_date>2026-10-20T01:49:38.602Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/recombinant-interferon-alpha-2b-like-protein-nct04380545/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04380545.jpg</video:thumbnail_loc>
      <video:title>Nivolumab, Fluorouracil, and… (NCT04380545) | Triangle</video:title>
      <video:description>Nivolumab, Fluorouracil, and Interferon Alpha 2B trial for Unresectable Fibrolamellar Carcinoma (NCT04380545). Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer. This phase I/II trial studies the side effects and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04380545.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:46:59.020Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/recombinant-interferon-alpha-2b-like-protein-nct04380545/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04380545.jpg</video:thumbnail_loc>
      <video:title>ensayo: Nivolumab, Fluorouracil… (NCT04380545) | Triangle</video:title>
      <video:description>Nivolumab, Fluorouracil, and Interferon Alpha 2B trial for Unresectable Fibrolamellar Carcinoma (NCT04380545). Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer. This phase I/II trial studies the side effects and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04380545.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:46:59.020Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/recombinant-interferon-alpha-2b-like-protein-nct04380545/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04380545.jpg</video:thumbnail_loc>
      <video:title>исследование: Nivolumab… (NCT04380545) | Triangle</video:title>
      <video:description>Nivolumab, Fluorouracil, and Interferon Alpha 2B trial for Unresectable Fibrolamellar Carcinoma (NCT04380545). Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer. This phase I/II trial studies the side effects and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04380545.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:46:59.020Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/rely-30-nct02917083/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT02917083.jpg</video:thumbnail_loc>
      <video:title>RELY-30 for Hodgkin's Lymphoma (NCT02917083) | Triangle</video:title>
      <video:description>RELY-30 trial for Hodgkin's Lymphoma (NCT02917083). CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30). The subject has a type of lymph gland cancer called Lymphoma.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT02917083.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:30:21.899Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/rely-30-nct02917083/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT02917083.jpg</video:thumbnail_loc>
      <video:title>RELY-30 para Hodgkin's Lymphoma (NCT02917083) | Triangle</video:title>
      <video:description>RELY-30 trial for Hodgkin's Lymphoma (NCT02917083). CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30). The subject has a type of lymph gland cancer called Lymphoma.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT02917083.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:30:21.899Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/rely-30-nct02917083/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT02917083.jpg</video:thumbnail_loc>
      <video:title>RELY-30 для Hodgkin's Lymphoma (NCT02917083) | Triangle</video:title>
      <video:description>RELY-30 trial for Hodgkin's Lymphoma (NCT02917083). CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30). The subject has a type of lymph gland cancer called Lymphoma.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT02917083.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:30:21.899Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/replay-nct07237594/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07237594.jpg</video:thumbnail_loc>
      <video:title>REPLAY for Metastatic Melanoma… (NCT07237594) | Triangle</video:title>
      <video:description>REPLAY trial for Metastatic Melanoma After Immune-Related Toxicity (NCT07237594). IL-17 Blockade to Decrease irAEs (REPLAY). The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07237594.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:26:21.467Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/replay-nct07237594/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07237594.jpg</video:thumbnail_loc>
      <video:title>REPLAY para Metastatic Melanoma… (NCT07237594) | Triangle</video:title>
      <video:description>REPLAY trial for Metastatic Melanoma After Immune-Related Toxicity (NCT07237594). IL-17 Blockade to Decrease irAEs (REPLAY). The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07237594.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:26:21.467Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/replay-nct07237594/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07237594.jpg</video:thumbnail_loc>
      <video:title>REPLAY для Metastatic Melanoma… (NCT07237594) | Triangle</video:title>
      <video:description>REPLAY trial for Metastatic Melanoma After Immune-Related Toxicity (NCT07237594). IL-17 Blockade to Decrease irAEs (REPLAY). The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07237594.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:26:21.467Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/revlimid-lenalidomide-nct03223610/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03223610.jpg</video:thumbnail_loc>
      <video:title>ViPOR Combination (NCT03223610) | Triangle</video:title>
      <video:description>ViPOR Combination trial for Relapsed/Refractory B-Cell Lymphoma (NCT03223610). Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma. Background: B-cell lymphoma is a cancer of white…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03223610.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:12:52.157Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/revlimid-lenalidomide-nct03223610/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03223610.jpg</video:thumbnail_loc>
      <video:title>ensayo: ViPOR Combination (NCT03223610) | Triangle</video:title>
      <video:description>ViPOR Combination trial for Relapsed/Refractory B-Cell Lymphoma (NCT03223610). Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma. Background: B-cell lymphoma is a cancer of white…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03223610.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:12:52.157Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/revlimid-lenalidomide-nct03223610/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03223610.jpg</video:thumbnail_loc>
      <video:title>исследование: ViPOR Combination (NCT03223610) | Triangle</video:title>
      <video:description>ViPOR Combination trial for Relapsed/Refractory B-Cell Lymphoma (NCT03223610). Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma. Background: B-cell lymphoma is a cancer of white…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03223610.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:12:52.157Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/revumenib-nct06313437/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06313437.jpg</video:thumbnail_loc>
      <video:title>Revumenib + 7+3 + Midostaurin (NCT06313437) | Triangle</video:title>
      <video:description>Revumenib + 7+3 + Midostaurin trial for Newly Diagnosed NPM1- and FLT3-Mutated AML (NCT06313437). Revumenib in Combination With 7+3 + Midostaurin in AML. This research is being conducted to determine a safe and effective dose of revumenib that can be given…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06313437.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:01:48.550Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/revumenib-nct06313437/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06313437.jpg</video:thumbnail_loc>
      <video:title>ensayo: Revumenib + 7+3 + Midostaurin (NCT06313437) | Triangle</video:title>
      <video:description>Revumenib + 7+3 + Midostaurin trial for Newly Diagnosed NPM1- and FLT3-Mutated AML (NCT06313437). Revumenib in Combination With 7+3 + Midostaurin in AML. This research is being conducted to determine a safe and effective dose of revumenib that can be given…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06313437.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:01:48.550Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/revumenib-nct06313437/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06313437.jpg</video:thumbnail_loc>
      <video:title>исследование: Revumenib + 7+3 +… (NCT06313437) | Triangle</video:title>
      <video:description>Revumenib + 7+3 + Midostaurin trial for Newly Diagnosed NPM1- and FLT3-Mutated AML (NCT06313437). Revumenib in Combination With 7+3 + Midostaurin in AML. This research is being conducted to determine a safe and effective dose of revumenib that can be given…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06313437.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:01:48.550Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/rhdnase-i-nct07361224/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07361224.jpg</video:thumbnail_loc>
      <video:title>RhDNase I for Large B-Cell… (NCT07361224) | Triangle</video:title>
      <video:description>RhDNase I trial for Large B-Cell Lymphoma (LBCL) (NCT07361224). Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. This is a Phase 1,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07361224.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:05:38.316Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/rhdnase-i-nct07361224/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07361224.jpg</video:thumbnail_loc>
      <video:title>RhDNase I para Large B-Cell… (NCT07361224) | Triangle</video:title>
      <video:description>RhDNase I trial for Large B-Cell Lymphoma (LBCL) (NCT07361224). Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. This is a Phase 1,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07361224.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:05:38.316Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/rhdnase-i-nct07361224/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07361224.jpg</video:thumbnail_loc>
      <video:title>RhDNase I для Large B-Cell… (NCT07361224) | Triangle</video:title>
      <video:description>RhDNase I trial for Large B-Cell Lymphoma (LBCL) (NCT07361224). Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. This is a Phase 1,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07361224.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:05:38.316Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/riot-4a-nct07192900/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07192900.jpg</video:thumbnail_loc>
      <video:title>(RIOT 4A) for Malignant Pleural Effusion (NCT07192900) | Triangle</video:title>
      <video:description>(RIOT 4A) trial for Malignant Pleural Effusion (NCT07192900). Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease. This research study aims to evaluate the safety and effectiveness of a novel…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07192900.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:56:07.710Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/riot-4a-nct07192900/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07192900.jpg</video:thumbnail_loc>
      <video:title>(RIOT 4A) para Malignant Pleural… (NCT07192900) | Triangle</video:title>
      <video:description>(RIOT 4A) trial for Malignant Pleural Effusion (NCT07192900). Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease. This research study aims to evaluate the safety and effectiveness of a novel…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07192900.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:56:07.710Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/riot-4a-nct07192900/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07192900.jpg</video:thumbnail_loc>
      <video:title>(RIOT 4A) для Malignant Pleural Effusion (NCT07192900) | Triangle</video:title>
      <video:description>(RIOT 4A) trial for Malignant Pleural Effusion (NCT07192900). Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease. This research study aims to evaluate the safety and effectiveness of a novel…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07192900.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:56:07.710Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/riot-4b-nct07443020/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07443020.jpg</video:thumbnail_loc>
      <video:title>RIOT 4B for Malignant Pleural Effusion (NCT07443020) | Triangle</video:title>
      <video:description>RIOT 4B trial for Malignant Pleural Effusion (NCT07443020). Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors. This research study aims to evaluate the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07443020.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:45:42.418Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/riot-4b-nct07443020/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07443020.jpg</video:thumbnail_loc>
      <video:title>RIOT 4B para Malignant Pleural Effusion (NCT07443020) | Triangle</video:title>
      <video:description>RIOT 4B trial for Malignant Pleural Effusion (NCT07443020). Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors. This research study aims to evaluate the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07443020.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:45:42.418Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/riot-4b-nct07443020/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07443020.jpg</video:thumbnail_loc>
      <video:title>RIOT 4B для Malignant Pleural Effusion (NCT07443020) | Triangle</video:title>
      <video:description>RIOT 4B trial for Malignant Pleural Effusion (NCT07443020). Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors. This research study aims to evaluate the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07443020.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:45:42.418Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/rituximab-nct06209619/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06209619.jpg</video:thumbnail_loc>
      <video:title>CC-99282 + Rituximab (NCT06209619) | Triangle</video:title>
      <video:description>CC-99282 + Rituximab trial for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NCT06209619). CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma. This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06209619.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:08:29.681Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/rituximab-nct06209619/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06209619.jpg</video:thumbnail_loc>
      <video:title>ensayo: CC-99282 + Rituximab (NCT06209619) | Triangle</video:title>
      <video:description>CC-99282 + Rituximab trial for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NCT06209619). CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma. This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06209619.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:08:29.681Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/rituximab-nct06209619/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06209619.jpg</video:thumbnail_loc>
      <video:title>исследование: CC-99282 + Rituximab (NCT06209619) | Triangle</video:title>
      <video:description>CC-99282 + Rituximab trial for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NCT06209619). CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma. This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06209619.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:08:29.681Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/roginolisib-nct06644183/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06644183.jpg</video:thumbnail_loc>
      <video:title>Roginolisib + Venetoclax +… (NCT06644183) | Triangle</video:title>
      <video:description>Roginolisib + Venetoclax + Rituximab trial for Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT06644183). Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL). This research study will test the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06644183.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:15:17.471Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/roginolisib-nct06644183/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06644183.jpg</video:thumbnail_loc>
      <video:title>ensayo: Roginolisib + Venetoclax… (NCT06644183) | Triangle</video:title>
      <video:description>Roginolisib + Venetoclax + Rituximab trial for Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT06644183). Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL). This research study will test the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06644183.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:15:17.471Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/roginolisib-nct06644183/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06644183.jpg</video:thumbnail_loc>
      <video:title>исследование: Roginolisib +… (NCT06644183) | Triangle</video:title>
      <video:description>Roginolisib + Venetoclax + Rituximab trial for Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT06644183). Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL). This research study will test the safety and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06644183.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:15:17.471Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ruxolitinib-nct03874052/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03874052.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib + Venetoclax (NCT03874052) | Triangle</video:title>
      <video:description>Ruxolitinib + Venetoclax trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT03874052). Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia. This phase I…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03874052.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:54:37.648Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ruxolitinib-nct03874052/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03874052.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ruxolitinib + Venetoclax (NCT03874052) | Triangle</video:title>
      <video:description>Ruxolitinib + Venetoclax trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT03874052). Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia. This phase I…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03874052.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:54:37.648Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ruxolitinib-nct03874052/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03874052.jpg</video:thumbnail_loc>
      <video:title>исследование: Ruxolitinib + Venetoclax (NCT03874052) | Triangle</video:title>
      <video:description>Ruxolitinib + Venetoclax trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT03874052). Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia. This phase I…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03874052.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:54:37.648Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ruxolitinib-phosphate-nct07278856/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07278856.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib + CHOP for Untreated… (NCT07278856) | Triangle</video:title>
      <video:description>Ruxolitinib + CHOP trial for Untreated Nodal T Follicular Helper Cell Lymphoma (NCT07278856). Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07278856.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:02:32.921Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ruxolitinib-phosphate-nct07278856/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07278856.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib + CHOP para Untreated… (NCT07278856) | Triangle</video:title>
      <video:description>Ruxolitinib + CHOP trial for Untreated Nodal T Follicular Helper Cell Lymphoma (NCT07278856). Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07278856.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:02:32.921Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ruxolitinib-phosphate-nct07278856/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07278856.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib + CHOP для Untreated… (NCT07278856) | Triangle</video:title>
      <video:description>Ruxolitinib + CHOP trial for Untreated Nodal T Follicular Helper Cell Lymphoma (NCT07278856). Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07278856.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:02:32.921Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sabre-nct07172958/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07172958.jpg</video:thumbnail_loc>
      <video:title>SABRE for Relapsed/Refractory… (NCT07172958) | Triangle</video:title>
      <video:description>SABRE trial for Relapsed/Refractory Embryonal Tumors (NCT07172958). Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE). This is a phase I dose-escalation study to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07172958.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:15:04.890Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sabre-nct07172958/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07172958.jpg</video:thumbnail_loc>
      <video:title>SABRE para Relapsed/Refractory… (NCT07172958) | Triangle</video:title>
      <video:description>SABRE trial for Relapsed/Refractory Embryonal Tumors (NCT07172958). Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE). This is a phase I dose-escalation study to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07172958.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:15:04.890Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sabre-nct07172958/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07172958.jpg</video:thumbnail_loc>
      <video:title>SABRE для Relapsed/Refractory… (NCT07172958) | Triangle</video:title>
      <video:description>SABRE trial for Relapsed/Refractory Embryonal Tumors (NCT07172958). Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE). This is a phase I dose-escalation study to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07172958.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:15:04.890Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sacituzumab-nct06040970/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06040970.jpg</video:thumbnail_loc>
      <video:title>Sacituzumab Govitecan + Cisplatin (NCT06040970) | Triangle</video:title>
      <video:description>Sacituzumab Govitecan + Cisplatin trial for Platinum-Sensitive Recurrent Ovarian and Endometrial Cancer (NCT06040970). Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. This is an open-label, Phase 1 study with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06040970.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:24:46.983Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sacituzumab-nct06040970/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06040970.jpg</video:thumbnail_loc>
      <video:title>ensayo: Sacituzumab Govitecan +… (NCT06040970) | Triangle</video:title>
      <video:description>Sacituzumab Govitecan + Cisplatin trial for Platinum-Sensitive Recurrent Ovarian and Endometrial Cancer (NCT06040970). Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. This is an open-label, Phase 1 study with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06040970.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:24:46.983Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sacituzumab-nct06040970/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06040970.jpg</video:thumbnail_loc>
      <video:title>исследование: Sacituzumab… (NCT06040970) | Triangle</video:title>
      <video:description>Sacituzumab Govitecan + Cisplatin trial for Platinum-Sensitive Recurrent Ovarian and Endometrial Cancer (NCT06040970). Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. This is an open-label, Phase 1 study with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06040970.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:24:46.983Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sbrt-atezolizumab-and-bevacizumab-nct05488522/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05488522.jpg</video:thumbnail_loc>
      <video:title>SBRT + atezolizumab and bevacizumab (NCT05488522) | Triangle</video:title>
      <video:description>SBRT + atezolizumab and bevacizumab trial for Unresectable Hepatocellular Carcinoma (NCT05488522). SBRT With Atezo/Bev for HCC. A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05488522.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:38:06.321Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sbrt-atezolizumab-and-bevacizumab-nct05488522/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05488522.jpg</video:thumbnail_loc>
      <video:title>ensayo: SBRT + atezolizumab and… (NCT05488522) | Triangle</video:title>
      <video:description>SBRT + atezolizumab and bevacizumab trial for Unresectable Hepatocellular Carcinoma (NCT05488522). SBRT With Atezo/Bev for HCC. A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05488522.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:38:06.321Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sbrt-atezolizumab-and-bevacizumab-nct05488522/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05488522.jpg</video:thumbnail_loc>
      <video:title>исследование: SBRT + atezolizumab… (NCT05488522) | Triangle</video:title>
      <video:description>SBRT + atezolizumab and bevacizumab trial for Unresectable Hepatocellular Carcinoma (NCT05488522). SBRT With Atezo/Bev for HCC. A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05488522.mp4</video:content_loc>
      <video:publication_date>2026-10-19T11:38:06.321Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/scri-carb7h3-s-b7h3-specific-chimeric-antigen-receptor-c-nct04185038/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04185038.jpg</video:thumbnail_loc>
      <video:title>Study of B7-H3-Specific CAR T… (NCT04185038) | Triangle</video:title>
      <video:description>Study of B7-H3-Specific CAR T Cell Locore… trial for Central Nervous System Tumor (NCT04185038). B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04185038.mp4</video:content_loc>
      <video:publication_date>2026-09-12T19:58:00.472Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/scri-carb7h3-s-b7h3-specific-chimeric-antigen-receptor-c-nct04185038/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04185038.jpg</video:thumbnail_loc>
      <video:title>ensayo: Study of B7-H3-Specific… (NCT04185038) | Triangle</video:title>
      <video:description>Study of B7-H3-Specific CAR T Cell Locore… trial for Central Nervous System Tumor (NCT04185038). B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04185038.mp4</video:content_loc>
      <video:publication_date>2026-09-12T19:58:00.472Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/scri-carb7h3-s-b7h3-specific-chimeric-antigen-receptor-c-nct04185038/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04185038.jpg</video:thumbnail_loc>
      <video:title>исследование: Study of… (NCT04185038) | Triangle</video:title>
      <video:description>Study of B7-H3-Specific CAR T Cell Locore… trial for Central Nervous System Tumor (NCT04185038). B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT04185038.mp4</video:content_loc>
      <video:publication_date>2026-09-12T19:58:00.472Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/selinexor-nct07200102/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200102.jpg</video:thumbnail_loc>
      <video:title>Selinexor Maintenance for Relapsed… (NCT07200102) | Triangle</video:title>
      <video:description>Selinexor Maintenance trial for Relapsed Multiple Myeloma After CAR T-Cell Therapy (NCT07200102). Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma. The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200102.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:30:14.036Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/selinexor-nct07200102/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200102.jpg</video:thumbnail_loc>
      <video:title>ensayo: Selinexor Maintenance (NCT07200102) | Triangle</video:title>
      <video:description>Selinexor Maintenance trial for Relapsed Multiple Myeloma After CAR T-Cell Therapy (NCT07200102). Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma. The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200102.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:30:14.036Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/selinexor-nct07200102/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200102.jpg</video:thumbnail_loc>
      <video:title>Selinexor Maintenance для Relapsed… (NCT07200102) | Triangle</video:title>
      <video:description>Selinexor Maintenance trial for Relapsed Multiple Myeloma After CAR T-Cell Therapy (NCT07200102). Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma. The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07200102.mp4</video:content_loc>
      <video:publication_date>2026-10-20T00:30:14.036Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/seneca-valley-virus-001-svv-001-nct06889493/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06889493.jpg</video:thumbnail_loc>
      <video:title>Seneca Valley Virus-001 (SVV-001) (NCT06889493) | Triangle</video:title>
      <video:description>Seneca Valley Virus-001 (SVV-001) trial for Neuroendocrine Carcinoma (NCT06889493). SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06889493.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:39:38.147Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/seneca-valley-virus-001-svv-001-nct06889493/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06889493.jpg</video:thumbnail_loc>
      <video:title>ensayo: Seneca Valley Virus-001… (NCT06889493) | Triangle</video:title>
      <video:description>Seneca Valley Virus-001 (SVV-001) trial for Neuroendocrine Carcinoma (NCT06889493). SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06889493.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:39:38.147Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/seneca-valley-virus-001-svv-001-nct06889493/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06889493.jpg</video:thumbnail_loc>
      <video:title>исследование: Seneca Valley… (NCT06889493) | Triangle</video:title>
      <video:description>Seneca Valley Virus-001 (SVV-001) trial for Neuroendocrine Carcinoma (NCT06889493). SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06889493.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:39:38.147Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/siaci-of-cetuximab-and-bevacizumab-nct05956821/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05956821.jpg</video:thumbnail_loc>
      <video:title>SIACI of cetuximab and bevacizumab (NCT05956821) | Triangle</video:title>
      <video:description>SIACI of cetuximab and bevacizumab trial for Relapsed/Refractory Intracranial Glioma (NCT05956821). Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age. This study assesses the safety and efficacy of repeat monthly dosing…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05956821.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:41:42.249Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/siaci-of-cetuximab-and-bevacizumab-nct05956821/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05956821.jpg</video:thumbnail_loc>
      <video:title>ensayo: SIACI of cetuximab and… (NCT05956821) | Triangle</video:title>
      <video:description>SIACI of cetuximab and bevacizumab trial for Relapsed/Refractory Intracranial Glioma (NCT05956821). Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age. This study assesses the safety and efficacy of repeat monthly dosing…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05956821.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:41:42.249Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/siaci-of-cetuximab-and-bevacizumab-nct05956821/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05956821.jpg</video:thumbnail_loc>
      <video:title>исследование: SIACI of cetuximab… (NCT05956821) | Triangle</video:title>
      <video:description>SIACI of cetuximab and bevacizumab trial for Relapsed/Refractory Intracranial Glioma (NCT05956821). Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age. This study assesses the safety and efficacy of repeat monthly dosing…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05956821.mp4</video:content_loc>
      <video:publication_date>2026-10-19T01:41:42.249Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sirolimus-nct07581704/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07581704.jpg</video:thumbnail_loc>
      <video:title>Sirolimus for Multiple Myeloma (NCT07581704) | Triangle</video:title>
      <video:description>Sirolimus trial for Multiple Myeloma (NCT07581704). Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma. This is a single center, single arm Phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07581704.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:52:18.717Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sirolimus-nct07581704/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07581704.jpg</video:thumbnail_loc>
      <video:title>Sirolimus para Multiple Myeloma (NCT07581704) | Triangle</video:title>
      <video:description>Sirolimus trial for Multiple Myeloma (NCT07581704). Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma. This is a single center, single arm Phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07581704.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:52:18.717Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sirolimus-nct07581704/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07581704.jpg</video:thumbnail_loc>
      <video:title>Sirolimus для Multiple Myeloma (NCT07581704) | Triangle</video:title>
      <video:description>Sirolimus trial for Multiple Myeloma (NCT07581704). Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma. This is a single center, single arm Phase…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07581704.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:52:18.717Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sitagliptin-nct07541781/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07541781.jpg</video:thumbnail_loc>
      <video:title>Sitagliptin for Glioma (NCT07541781) | Triangle</video:title>
      <video:description>Sitagliptin trial for Glioma (NCT07541781). Sitagliptin in Recurrent/Progressive Grade 4 Glioma. Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07541781.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:50:46.819Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sitagliptin-nct07541781/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07541781.jpg</video:thumbnail_loc>
      <video:title>Sitagliptin para Glioma (NCT07541781) | Triangle</video:title>
      <video:description>Sitagliptin trial for Glioma (NCT07541781). Sitagliptin in Recurrent/Progressive Grade 4 Glioma. Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07541781.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:50:46.819Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sitagliptin-nct07541781/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07541781.jpg</video:thumbnail_loc>
      <video:title>Sitagliptin для Glioma (NCT07541781) | Triangle</video:title>
      <video:description>Sitagliptin trial for Glioma (NCT07541781). Sitagliptin in Recurrent/Progressive Grade 4 Glioma. Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07541781.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:50:46.819Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sl-401-nct03113643/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03113643.jpg</video:thumbnail_loc>
      <video:title>SL-401 for Acute Myeloid Leukemia (NCT03113643) | Triangle</video:title>
      <video:description>SL-401 trial for Acute Myeloid Leukemia (NCT03113643). SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03113643.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:40:15.055Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sl-401-nct03113643/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03113643.jpg</video:thumbnail_loc>
      <video:title>SL-401 para Acute Myeloid Leukemia (NCT03113643) | Triangle</video:title>
      <video:description>SL-401 trial for Acute Myeloid Leukemia (NCT03113643). SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03113643.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:40:15.055Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sl-401-nct03113643/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03113643.jpg</video:thumbnail_loc>
      <video:title>SL-401 для Acute Myeloid Leukemia (NCT03113643) | Triangle</video:title>
      <video:description>SL-401 trial for Acute Myeloid Leukemia (NCT03113643). SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03113643.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:40:15.055Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/solar-nct06607549/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06607549.jpg</video:thumbnail_loc>
      <video:title>SOLAR for Central Nervous System… (NCT06607549) | Triangle</video:title>
      <video:description>SOLAR trial for Central Nervous System Lymphoma (NCT06607549). Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR). The purpose of this…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06607549.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:07:06.006Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/solar-nct06607549/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06607549.jpg</video:thumbnail_loc>
      <video:title>SOLAR para Central Nervous System… (NCT06607549) | Triangle</video:title>
      <video:description>SOLAR trial for Central Nervous System Lymphoma (NCT06607549). Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR). The purpose of this…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06607549.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:07:06.006Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/solar-nct06607549/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06607549.jpg</video:thumbnail_loc>
      <video:title>SOLAR для Central Nervous System… (NCT06607549) | Triangle</video:title>
      <video:description>SOLAR trial for Central Nervous System Lymphoma (NCT06607549). Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR). The purpose of this…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06607549.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:07:06.006Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sorafenib-nct05468359/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05468359.jpg</video:thumbnail_loc>
      <video:title>Sorafenib, Bevacizumab and… (NCT05468359) | Triangle</video:title>
      <video:description>Sorafenib, Bevacizumab and Atezolizumab trial for Refractory Pediatric Solid Tumors (NCT05468359). Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients. This is a phase I/II study to evaluate the safety of combining…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05468359.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:23:12.050Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sorafenib-nct05468359/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05468359.jpg</video:thumbnail_loc>
      <video:title>ensayo: Sorafenib, Bevacizumab… (NCT05468359) | Triangle</video:title>
      <video:description>Sorafenib, Bevacizumab and Atezolizumab trial for Refractory Pediatric Solid Tumors (NCT05468359). Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients. This is a phase I/II study to evaluate the safety of combining…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05468359.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:23:12.050Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sorafenib-nct05468359/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05468359.jpg</video:thumbnail_loc>
      <video:title>исследование: Sorafenib… (NCT05468359) | Triangle</video:title>
      <video:description>Sorafenib, Bevacizumab and Atezolizumab trial for Refractory Pediatric Solid Tumors (NCT05468359). Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients. This is a phase I/II study to evaluate the safety of combining…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05468359.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:23:12.050Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sotorasib-nct05815173/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05815173.jpg</video:thumbnail_loc>
      <video:title>Ladarixin + Sotorasib for Advanced… (NCT05815173) | Triangle</video:title>
      <video:description>Ladarixin + Sotorasib trial for Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer (NCT05815173). Ladarixin With Sotorasib in Advanced NSCLC. This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05815173.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:01:06.298Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sotorasib-nct05815173/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05815173.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ladarixin + Sotorasib (NCT05815173) | Triangle</video:title>
      <video:description>Ladarixin + Sotorasib trial for Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer (NCT05815173). Ladarixin With Sotorasib in Advanced NSCLC. This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05815173.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:01:06.298Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sotorasib-nct05815173/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05815173.jpg</video:thumbnail_loc>
      <video:title>Ladarixin + Sotorasib для Advanced… (NCT05815173) | Triangle</video:title>
      <video:description>Ladarixin + Sotorasib trial for Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer (NCT05815173). Ladarixin With Sotorasib in Advanced NSCLC. This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05815173.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:01:06.298Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/spatially-fractionated-rt-nct06546969/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06546969.jpg</video:thumbnail_loc>
      <video:title>Chemoimmunotherapy + SFRT and… (NCT06546969) | Triangle</video:title>
      <video:description>Chemoimmunotherapy + SFRT and Hyperthermia trial for Advanced Biliary Tract Cancer (NCT06546969). Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer. This study is being done to see if the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06546969.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:47:22.054Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/spatially-fractionated-rt-nct06546969/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06546969.jpg</video:thumbnail_loc>
      <video:title>ensayo: Chemoimmunotherapy + SFRT… (NCT06546969) | Triangle</video:title>
      <video:description>Chemoimmunotherapy + SFRT and Hyperthermia trial for Advanced Biliary Tract Cancer (NCT06546969). Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer. This study is being done to see if the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06546969.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:47:22.054Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/spatially-fractionated-rt-nct06546969/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06546969.jpg</video:thumbnail_loc>
      <video:title>исследование: Chemoimmunotherapy… (NCT06546969) | Triangle</video:title>
      <video:description>Chemoimmunotherapy + SFRT and Hyperthermia trial for Advanced Biliary Tract Cancer (NCT06546969). Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer. This study is being done to see if the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06546969.mp4</video:content_loc>
      <video:publication_date>2026-10-19T12:47:22.054Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/starlite-nct06428045/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06428045.jpg</video:thumbnail_loc>
      <video:title>STARLITE for High Grade Glioma (NCT06428045) | Triangle</video:title>
      <video:description>STARLITE trial for High Grade Glioma (NCT06428045). STARLITE for Unresectable High-Grade Gliomas. The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06428045.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:38:43.467Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/starlite-nct06428045/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06428045.jpg</video:thumbnail_loc>
      <video:title>STARLITE para High Grade Glioma (NCT06428045) | Triangle</video:title>
      <video:description>STARLITE trial for High Grade Glioma (NCT06428045). STARLITE for Unresectable High-Grade Gliomas. The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06428045.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:38:43.467Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/starlite-nct06428045/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06428045.jpg</video:thumbnail_loc>
      <video:title>STARLITE для High Grade Glioma (NCT06428045) | Triangle</video:title>
      <video:description>STARLITE trial for High Grade Glioma (NCT06428045). STARLITE for Unresectable High-Grade Gliomas. The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06428045.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:38:43.467Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/sx-682-nct07814352/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07814352.jpg</video:thumbnail_loc>
      <video:title>SX-682 + Proton CSI (NCT07814352) | Triangle</video:title>
      <video:description>SX-682 + Proton CSI trial for Leptomeningeal Disease From Melanoma or NSCLC (NCT07814352). SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease. The researchers are doing this study to find out…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07814352.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:19:39.464Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/sx-682-nct07814352/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07814352.jpg</video:thumbnail_loc>
      <video:title>ensayo: SX-682 + Proton CSI (NCT07814352) | Triangle</video:title>
      <video:description>SX-682 + Proton CSI trial for Leptomeningeal Disease From Melanoma or NSCLC (NCT07814352). SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease. The researchers are doing this study to find out…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07814352.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:19:39.464Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/sx-682-nct07814352/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07814352.jpg</video:thumbnail_loc>
      <video:title>исследование: SX-682 + Proton CSI (NCT07814352) | Triangle</video:title>
      <video:description>SX-682 + Proton CSI trial for Leptomeningeal Disease From Melanoma or NSCLC (NCT07814352). SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease. The researchers are doing this study to find out…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07814352.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:19:39.464Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tafasitamab-nct07225439/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225439.jpg</video:thumbnail_loc>
      <video:title>Tafasitamab for Non Hodgkin Lymphoma (NCT07225439) | Triangle</video:title>
      <video:description>Tafasitamab trial for Non Hodgkin Lymphoma (NCT07225439). Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL). This…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225439.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:21:47.247Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tafasitamab-nct07225439/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225439.jpg</video:thumbnail_loc>
      <video:title>Tafasitamab para Non Hodgkin Lymphoma (NCT07225439) | Triangle</video:title>
      <video:description>Tafasitamab trial for Non Hodgkin Lymphoma (NCT07225439). Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL). This…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225439.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:21:47.247Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tafasitamab-nct07225439/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225439.jpg</video:thumbnail_loc>
      <video:title>Tafasitamab для Non Hodgkin Lymphoma (NCT07225439) | Triangle</video:title>
      <video:description>Tafasitamab trial for Non Hodgkin Lymphoma (NCT07225439). Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL). This…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07225439.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:21:47.247Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/talquetamab-nct07093554/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07093554.jpg</video:thumbnail_loc>
      <video:title>Talquetamab (NCT07093554) | Triangle</video:title>
      <video:description>Talquetamab trial for Relapsed/Refractory Multiple Myeloma (NCT07093554). Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07093554.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:04:25.727Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/talquetamab-nct07093554/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07093554.jpg</video:thumbnail_loc>
      <video:title>ensayo: Talquetamab (NCT07093554) | Triangle</video:title>
      <video:description>Talquetamab trial for Relapsed/Refractory Multiple Myeloma (NCT07093554). Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07093554.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:04:25.727Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/talquetamab-nct07093554/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07093554.jpg</video:thumbnail_loc>
      <video:title>исследование: Talquetamab (NCT07093554) | Triangle</video:title>
      <video:description>Talquetamab trial for Relapsed/Refractory Multiple Myeloma (NCT07093554). Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07093554.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:04:25.727Z</video:publication_date>
      <video:duration>59</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tazemetostat-nct05627232/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05627232.jpg</video:thumbnail_loc>
      <video:title>Tazemetostat for Relapsed or… (NCT05627232) | Triangle</video:title>
      <video:description>Tazemetostat trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT05627232). Tazemetostat and Palbociclib With CPX-351for R/R AML. This is a two-part phase Ib dose escalation study to evaluate the safety and preliminary efficacy of the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05627232.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:31:09.507Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tazemetostat-nct05627232/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05627232.jpg</video:thumbnail_loc>
      <video:title>Tazemetostat para Relapsed or… (NCT05627232) | Triangle</video:title>
      <video:description>Tazemetostat trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT05627232). Tazemetostat and Palbociclib With CPX-351for R/R AML. This is a two-part phase Ib dose escalation study to evaluate the safety and preliminary efficacy of the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05627232.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:31:09.507Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tazemetostat-nct05627232/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05627232.jpg</video:thumbnail_loc>
      <video:title>Tazemetostat для Relapsed or… (NCT05627232) | Triangle</video:title>
      <video:description>Tazemetostat trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT05627232). Tazemetostat and Palbociclib With CPX-351for R/R AML. This is a two-part phase Ib dose escalation study to evaluate the safety and preliminary efficacy of the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05627232.mp4</video:content_loc>
      <video:publication_date>2026-10-19T15:31:09.507Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tegavivint-nct05755087/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05755087.jpg</video:thumbnail_loc>
      <video:title>Tegavivint for Relapsed or… (NCT05755087) | Triangle</video:title>
      <video:description>Tegavivint trial for Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087). Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma. This phase I trial tests the safety, side effects, and best dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05755087.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:55:27.219Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tegavivint-nct05755087/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05755087.jpg</video:thumbnail_loc>
      <video:title>Tegavivint para Relapsed or… (NCT05755087) | Triangle</video:title>
      <video:description>Tegavivint trial for Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087). Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma. This phase I trial tests the safety, side effects, and best dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05755087.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:55:27.219Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tegavivint-nct05755087/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05755087.jpg</video:thumbnail_loc>
      <video:title>Tegavivint для Relapsed or… (NCT05755087) | Triangle</video:title>
      <video:description>Tegavivint trial for Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087). Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma. This phase I trial tests the safety, side effects, and best dose of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05755087.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:55:27.219Z</video:publication_date>
      <video:duration>58</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tepotinib-nct07619339/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07619339.jpg</video:thumbnail_loc>
      <video:title>Tepotinib + Ivonescimab for MET… (NCT07619339) | Triangle</video:title>
      <video:description>Tepotinib + Ivonescimab trial for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NCT07619339). Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer. The researchers are doing this study to find out whether the combination of tepotinib and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07619339.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:18:32.125Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tepotinib-nct07619339/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07619339.jpg</video:thumbnail_loc>
      <video:title>Tepotinib + Ivonescimab para MET… (NCT07619339) | Triangle</video:title>
      <video:description>Tepotinib + Ivonescimab trial for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NCT07619339). Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer. The researchers are doing this study to find out whether the combination of tepotinib and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07619339.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:18:32.125Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tepotinib-nct07619339/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07619339.jpg</video:thumbnail_loc>
      <video:title>Tepotinib + Ivonescimab для MET… (NCT07619339) | Triangle</video:title>
      <video:description>Tepotinib + Ivonescimab trial for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NCT07619339). Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer. The researchers are doing this study to find out whether the combination of tepotinib and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07619339.mp4</video:content_loc>
      <video:publication_date>2026-10-20T02:18:32.125Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07444632/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07444632.jpg</video:thumbnail_loc>
      <video:title>CAR.70 NK Cells for Relapsed or… (NCT07444632) | Triangle</video:title>
      <video:description>CAR.70 NK Cells trial for Relapsed or Refractory Lymphomas and B-ALL (NCT07444632). CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies. This is a phase 1 basket…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07444632.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:47:53.059Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07444632/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07444632.jpg</video:thumbnail_loc>
      <video:title>CAR.70 NK Cells para Relapsed or… (NCT07444632) | Triangle</video:title>
      <video:description>CAR.70 NK Cells trial for Relapsed or Refractory Lymphomas and B-ALL (NCT07444632). CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies. This is a phase 1 basket…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07444632.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:47:53.059Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07444632/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07444632.jpg</video:thumbnail_loc>
      <video:title>CAR.70 NK Cells для Relapsed or… (NCT07444632) | Triangle</video:title>
      <video:description>CAR.70 NK Cells trial for Relapsed or Refractory Lymphomas and B-ALL (NCT07444632). CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies. This is a phase 1 basket…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07444632.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:47:53.059Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07509008/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07509008.jpg</video:thumbnail_loc>
      <video:title>TROP2 CAR/IL-15 TGFBR2 KO NK Cells (NCT07509008) | Triangle</video:title>
      <video:description>TROP2 CAR/IL-15 TGFBR2 KO NK Cells trial for Gastric Cancer, Metastatic (NCT07509008). TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum. The goal of this clinical…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07509008.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:46:13.500Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07509008/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07509008.jpg</video:thumbnail_loc>
      <video:title>ensayo: TROP2 CAR/IL-15 TGFBR2 KO… (NCT07509008) | Triangle</video:title>
      <video:description>TROP2 CAR/IL-15 TGFBR2 KO NK Cells trial for Gastric Cancer, Metastatic (NCT07509008). TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum. The goal of this clinical…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07509008.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:46:13.500Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07509008/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07509008.jpg</video:thumbnail_loc>
      <video:title>исследование: TROP2 CAR/IL-15… (NCT07509008) | Triangle</video:title>
      <video:description>TROP2 CAR/IL-15 TGFBR2 KO NK Cells trial for Gastric Cancer, Metastatic (NCT07509008). TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum. The goal of this clinical…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07509008.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:46:13.500Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tinks-nct05634369/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05634369.jpg</video:thumbnail_loc>
      <video:title>TINKS for Relapsed/Refractory… (NCT05634369) | Triangle</video:title>
      <video:description>TINKS trial for Relapsed/Refractory Pediatric Sarcoma (NCT05634369). A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05634369.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:50:34.757Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tinks-nct05634369/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05634369.jpg</video:thumbnail_loc>
      <video:title>TINKS para Relapsed/Refractory… (NCT05634369) | Triangle</video:title>
      <video:description>TINKS trial for Relapsed/Refractory Pediatric Sarcoma (NCT05634369). A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05634369.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:50:34.757Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tinks-nct05634369/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05634369.jpg</video:thumbnail_loc>
      <video:title>TINKS для Relapsed/Refractory… (NCT05634369) | Triangle</video:title>
      <video:description>TINKS trial for Relapsed/Refractory Pediatric Sarcoma (NCT05634369). A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05634369.mp4</video:content_loc>
      <video:publication_date>2026-10-19T00:50:34.757Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tnhyp218-car-t-cells-nct06885697/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06885697.jpg</video:thumbnail_loc>
      <video:title>TNhYP218 CAR T Cells for Mesothelioma (NCT06885697) | Triangle</video:title>
      <video:description>TNhYP218 CAR T Cells trial for Mesothelioma (NCT06885697). Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma. Background:…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06885697.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:43:33.857Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tnhyp218-car-t-cells-nct06885697/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06885697.jpg</video:thumbnail_loc>
      <video:title>TNhYP218 CAR T Cells para Mesothelioma (NCT06885697) | Triangle</video:title>
      <video:description>TNhYP218 CAR T Cells trial for Mesothelioma (NCT06885697). Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma. Background:…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06885697.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:43:33.857Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tnhyp218-car-t-cells-nct06885697/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06885697.jpg</video:thumbnail_loc>
      <video:title>TNhYP218 CAR T Cells для Mesothelioma (NCT06885697) | Triangle</video:title>
      <video:description>TNhYP218 CAR T Cells trial for Mesothelioma (NCT06885697). Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma. Background:…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06885697.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:43:33.857Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/total-body-irradiation-nct06928662/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06928662.jpg</video:thumbnail_loc>
      <video:title>Decitabine + FLAG-Ida and… (NCT06928662) | Triangle</video:title>
      <video:description>Decitabine + FLAG-Ida and Total-Body Irradiation trial for Acute Myeloid Leukemia and Other Myeloid Malignancies (NCT06928662). Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06928662.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:16:47.708Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/total-body-irradiation-nct06928662/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06928662.jpg</video:thumbnail_loc>
      <video:title>ensayo: Decitabine + FLAG-Ida and… (NCT06928662) | Triangle</video:title>
      <video:description>Decitabine + FLAG-Ida and Total-Body Irradiation trial for Acute Myeloid Leukemia and Other Myeloid Malignancies (NCT06928662). Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06928662.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:16:47.708Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/total-body-irradiation-nct06928662/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06928662.jpg</video:thumbnail_loc>
      <video:title>исследование: Decitabine +… (NCT06928662) | Triangle</video:title>
      <video:description>Decitabine + FLAG-Ida and Total-Body Irradiation trial for Acute Myeloid Leukemia and Other Myeloid Malignancies (NCT06928662). Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06928662.mp4</video:content_loc>
      <video:publication_date>2026-10-19T02:16:47.708Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tpt-ced-rhgg-nct06666712/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06666712.jpg</video:thumbnail_loc>
      <video:title>TPT CED rHGG for Brain Tumor, Recurrent (NCT06666712) | Triangle</video:title>
      <video:description>TPT CED rHGG trial for Brain Tumor, Recurrent (NCT06666712). Chronic CED of TPT for Recurrent Malignant Glioma. The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06666712.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:30:58.168Z</video:publication_date>
      <video:duration>259</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tpt-ced-rhgg-nct06666712/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06666712.jpg</video:thumbnail_loc>
      <video:title>TPT CED rHGG para Brain Tumor, Recurrent (NCT06666712) | Triangle</video:title>
      <video:description>TPT CED rHGG trial for Brain Tumor, Recurrent (NCT06666712). Chronic CED of TPT for Recurrent Malignant Glioma. The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06666712.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:30:58.168Z</video:publication_date>
      <video:duration>259</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tpt-ced-rhgg-nct06666712/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06666712.jpg</video:thumbnail_loc>
      <video:title>TPT CED rHGG для Brain Tumor, Recurrent (NCT06666712) | Triangle</video:title>
      <video:description>TPT CED rHGG trial for Brain Tumor, Recurrent (NCT06666712). Chronic CED of TPT for Recurrent Malignant Glioma. The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06666712.mp4</video:content_loc>
      <video:publication_date>2026-09-12T15:30:58.168Z</video:publication_date>
      <video:duration>259</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/trabedersen-nct06579196/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06579196.jpg</video:thumbnail_loc>
      <video:title>Trabedersen for Non-small Cell… (NCT06579196) | Triangle</video:title>
      <video:description>Trabedersen trial for Non-small Cell Lung Cancer (NCT06579196). Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1. The goal of this clinical trial is to: 1) evaluate the safety…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06579196.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:19:58.663Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/trabedersen-nct06579196/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06579196.jpg</video:thumbnail_loc>
      <video:title>Trabedersen para Non-small Cell… (NCT06579196) | Triangle</video:title>
      <video:description>Trabedersen trial for Non-small Cell Lung Cancer (NCT06579196). Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1. The goal of this clinical trial is to: 1) evaluate the safety…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06579196.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:19:58.663Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/trabedersen-nct06579196/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06579196.jpg</video:thumbnail_loc>
      <video:title>Trabedersen для Non-small Cell… (NCT06579196) | Triangle</video:title>
      <video:description>Trabedersen trial for Non-small Cell Lung Cancer (NCT06579196). Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1. The goal of this clinical trial is to: 1) evaluate the safety…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06579196.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:19:58.663Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/tumor-infiltrating-lymphocytes-til-nct05681780/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05681780.jpg</video:thumbnail_loc>
      <video:title>Tumor-infiltrating Lymphocytes… (NCT05681780) | Triangle</video:title>
      <video:description>Tumor-infiltrating Lymphocytes (TIL) trial for Non Small Cell Lung Cancer (NCT05681780). CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC. To determine the effect of a special preparation of cells, called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05681780.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:13:05.644Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/tumor-infiltrating-lymphocytes-til-nct05681780/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05681780.jpg</video:thumbnail_loc>
      <video:title>ensayo: Tumor-infiltrating… (NCT05681780) | Triangle</video:title>
      <video:description>Tumor-infiltrating Lymphocytes (TIL) trial for Non Small Cell Lung Cancer (NCT05681780). CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC. To determine the effect of a special preparation of cells, called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05681780.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:13:05.644Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/tumor-infiltrating-lymphocytes-til-nct05681780/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05681780.jpg</video:thumbnail_loc>
      <video:title>исследование: Tumor-infiltrating… (NCT05681780) | Triangle</video:title>
      <video:description>Tumor-infiltrating Lymphocytes (TIL) trial for Non Small Cell Lung Cancer (NCT05681780). CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC. To determine the effect of a special preparation of cells, called…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05681780.mp4</video:content_loc>
      <video:publication_date>2026-09-12T20:13:05.644Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ultrasound-induced-microbubble-cavitation-nct07501650/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07501650.jpg</video:thumbnail_loc>
      <video:title>Ultrasound Microbubble Cavitation (NCT07501650) | Triangle</video:title>
      <video:description>Ultrasound Microbubble Cavitation trial for Recurrent or Metastatic Head and Neck Cancer (NCT07501650). Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer. This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07501650.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:08:36.195Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ultrasound-induced-microbubble-cavitation-nct07501650/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07501650.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ultrasound Microbubble… (NCT07501650) | Triangle</video:title>
      <video:description>Ultrasound Microbubble Cavitation trial for Recurrent or Metastatic Head and Neck Cancer (NCT07501650). Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer. This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07501650.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:08:36.195Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ultrasound-induced-microbubble-cavitation-nct07501650/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07501650.jpg</video:thumbnail_loc>
      <video:title>исследование: Ultrasound… (NCT07501650) | Triangle</video:title>
      <video:description>Ultrasound Microbubble Cavitation trial for Recurrent or Metastatic Head and Neck Cancer (NCT07501650). Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer. This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab)…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT07501650.mp4</video:content_loc>
      <video:publication_date>2026-10-19T16:08:36.195Z</video:publication_date>
      <video:duration>62</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/vaccine-therapy-nct06324240/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06324240.jpg</video:thumbnail_loc>
      <video:title>Personalized TMV Tumor Vaccine (NCT06324240) | Triangle</video:title>
      <video:description>Personalized TMV Tumor Vaccine trial for Triple-Negative Breast Cancer (NCT06324240). Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06324240.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:37:34.639Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/vaccine-therapy-nct06324240/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06324240.jpg</video:thumbnail_loc>
      <video:title>ensayo: Personalized TMV Tumor Vaccine (NCT06324240) | Triangle</video:title>
      <video:description>Personalized TMV Tumor Vaccine trial for Triple-Negative Breast Cancer (NCT06324240). Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06324240.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:37:34.639Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/vaccine-therapy-nct06324240/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06324240.jpg</video:thumbnail_loc>
      <video:title>исследование: Personalized TMV… (NCT06324240) | Triangle</video:title>
      <video:description>Personalized TMV Tumor Vaccine trial for Triple-Negative Breast Cancer (NCT06324240). Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer. This phase I trial tests the…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06324240.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:37:34.639Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/valemetostat-nct06807632/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06807632.jpg</video:thumbnail_loc>
      <video:title>Valemetostat for Extensive-stage… (NCT06807632) | Triangle</video:title>
      <video:description>Valemetostat trial for Extensive-stage Small-cell Lung Cancer (NCT06807632). Valemetostat in Combination With Atezolizumab in People With Lung Cancer. This study will test whether valemetostat in combination with atezolizumab is a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06807632.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:27:50.200Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/valemetostat-nct06807632/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06807632.jpg</video:thumbnail_loc>
      <video:title>Valemetostat para Extensive-stage… (NCT06807632) | Triangle</video:title>
      <video:description>Valemetostat trial for Extensive-stage Small-cell Lung Cancer (NCT06807632). Valemetostat in Combination With Atezolizumab in People With Lung Cancer. This study will test whether valemetostat in combination with atezolizumab is a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06807632.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:27:50.200Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/valemetostat-nct06807632/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06807632.jpg</video:thumbnail_loc>
      <video:title>Valemetostat для Extensive-stage… (NCT06807632) | Triangle</video:title>
      <video:description>Valemetostat trial for Extensive-stage Small-cell Lung Cancer (NCT06807632). Valemetostat in Combination With Atezolizumab in People With Lung Cancer. This study will test whether valemetostat in combination with atezolizumab is a safe…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06807632.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:27:50.200Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/venetoclax-nct03214562/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03214562.jpg</video:thumbnail_loc>
      <video:title>Venetoclax for Acute Myeloid Leukemia (NCT03214562) | Triangle</video:title>
      <video:description>Venetoclax trial for Acute Myeloid Leukemia (NCT03214562). Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia. This phase Ib/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03214562.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:48:23.484Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/venetoclax-nct03214562/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03214562.jpg</video:thumbnail_loc>
      <video:title>Venetoclax para Acute Myeloid Leukemia (NCT03214562) | Triangle</video:title>
      <video:description>Venetoclax trial for Acute Myeloid Leukemia (NCT03214562). Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia. This phase Ib/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03214562.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:48:23.484Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/venetoclax-nct03214562/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03214562.jpg</video:thumbnail_loc>
      <video:title>Venetoclax для Acute Myeloid Leukemia (NCT03214562) | Triangle</video:title>
      <video:description>Venetoclax trial for Acute Myeloid Leukemia (NCT03214562). Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia. This phase Ib/II trial…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03214562.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:48:23.484Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/venetoclax-nct06129734/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06129734.jpg</video:thumbnail_loc>
      <video:title>Decitabine + Venetoclax Maintenance (NCT06129734) | Triangle</video:title>
      <video:description>Decitabine + Venetoclax Maintenance trial for Acute Myeloid Leukemia and Myelodysplastic Syndromes After Allogeneic Transplant (NCT06129734). Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant. The goal of this interventional clinical trial is…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06129734.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:06:34.675Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/venetoclax-nct06129734/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06129734.jpg</video:thumbnail_loc>
      <video:title>ensayo: Decitabine + Venetoclax… (NCT06129734) | Triangle</video:title>
      <video:description>Decitabine + Venetoclax Maintenance trial for Acute Myeloid Leukemia and Myelodysplastic Syndromes After Allogeneic Transplant (NCT06129734). Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant. The goal of this interventional clinical trial is…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06129734.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:06:34.675Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/venetoclax-nct06129734/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06129734.jpg</video:thumbnail_loc>
      <video:title>исследование: Decitabine +… (NCT06129734) | Triangle</video:title>
      <video:description>Decitabine + Venetoclax Maintenance trial for Acute Myeloid Leukemia and Myelodysplastic Syndromes After Allogeneic Transplant (NCT06129734). Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant. The goal of this interventional clinical trial is…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06129734.mp4</video:content_loc>
      <video:publication_date>2026-10-19T14:06:34.675Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/victory-nct05609994/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05609994.jpg</video:thumbnail_loc>
      <video:title>ViCToRy for Low Grade Glioma of Brain (NCT05609994) | Triangle</video:title>
      <video:description>ViCToRy trial for Low Grade Glioma of Brain (NCT05609994). ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas. The purpose of this study is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05609994.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:00:02.588Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/victory-nct05609994/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05609994.jpg</video:thumbnail_loc>
      <video:title>ViCToRy para Low Grade Glioma of Brain (NCT05609994) | Triangle</video:title>
      <video:description>ViCToRy trial for Low Grade Glioma of Brain (NCT05609994). ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas. The purpose of this study is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05609994.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:00:02.588Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/victory-nct05609994/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05609994.jpg</video:thumbnail_loc>
      <video:title>ViCToRy для Low Grade Glioma of Brain (NCT05609994) | Triangle</video:title>
      <video:description>ViCToRy trial for Low Grade Glioma of Brain (NCT05609994). ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas. The purpose of this study is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05609994.mp4</video:content_loc>
      <video:publication_date>2026-10-18T22:00:02.588Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/vista-nct03740256/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03740256.jpg</video:thumbnail_loc>
      <video:title>VISTA for Bladder Cancer (NCT03740256) | Triangle</video:title>
      <video:description>VISTA trial for Bladder Cancer (NCT03740256). Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors. This study is a first in human Phase 1…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03740256.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:06:49.473Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/vista-nct03740256/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03740256.jpg</video:thumbnail_loc>
      <video:title>VISTA para Bladder Cancer (NCT03740256) | Triangle</video:title>
      <video:description>VISTA trial for Bladder Cancer (NCT03740256). Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors. This study is a first in human Phase 1…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03740256.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:06:49.473Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/vista-nct03740256/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03740256.jpg</video:thumbnail_loc>
      <video:title>VISTA для Bladder Cancer (NCT03740256) | Triangle</video:title>
      <video:description>VISTA trial for Bladder Cancer (NCT03740256). Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors. This study is a first in human Phase 1…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT03740256.mp4</video:content_loc>
      <video:publication_date>2026-09-12T21:06:49.473Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/withaferin-a-nct05610735/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05610735.jpg</video:thumbnail_loc>
      <video:title>Ashwagandha + Liposomal Doxorubicin (NCT05610735) | Triangle</video:title>
      <video:description>Ashwagandha + Liposomal Doxorubicin trial for Recurrent Ovarian Cancer (NCT05610735). Combination Therapy for Recurrent Ovarian Cancer. The proposed study &quot;combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05610735.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:47:11.465Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/withaferin-a-nct05610735/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05610735.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ashwagandha + Liposomal… (NCT05610735) | Triangle</video:title>
      <video:description>Ashwagandha + Liposomal Doxorubicin trial for Recurrent Ovarian Cancer (NCT05610735). Combination Therapy for Recurrent Ovarian Cancer. The proposed study &quot;combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05610735.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:47:11.465Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/withaferin-a-nct05610735/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05610735.jpg</video:thumbnail_loc>
      <video:title>исследование: Ashwagandha +… (NCT05610735) | Triangle</video:title>
      <video:description>Ashwagandha + Liposomal Doxorubicin trial for Recurrent Ovarian Cancer (NCT05610735). Combination Therapy for Recurrent Ovarian Cancer. The proposed study &quot;combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT05610735.mp4</video:content_loc>
      <video:publication_date>2026-10-19T13:47:11.465Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ws-cart-cs1-nct06185751/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06185751.jpg</video:thumbnail_loc>
      <video:title>WS-CART-CS1 for Multiple Myeloma (NCT06185751) | Triangle</video:title>
      <video:description>WS-CART-CS1 trial for Multiple Myeloma (NCT06185751). CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma. Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06185751.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:54:51.976Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ws-cart-cs1-nct06185751/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06185751.jpg</video:thumbnail_loc>
      <video:title>WS-CART-CS1 para Multiple Myeloma (NCT06185751) | Triangle</video:title>
      <video:description>WS-CART-CS1 trial for Multiple Myeloma (NCT06185751). CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma. Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06185751.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:54:51.976Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ws-cart-cs1-nct06185751/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06185751.jpg</video:thumbnail_loc>
      <video:title>WS-CART-CS1 для Multiple Myeloma (NCT06185751) | Triangle</video:title>
      <video:description>WS-CART-CS1 trial for Multiple Myeloma (NCT06185751). CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma. Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06185751.mp4</video:content_loc>
      <video:publication_date>2026-10-18T18:54:51.976Z</video:publication_date>
      <video:duration>61</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/zanu-tafa-nct06029309/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06029309.jpg</video:thumbnail_loc>
      <video:title>Zanubrutinib + Tafasitamab (NCT06029309) | Triangle</video:title>
      <video:description>Zanubrutinib + Tafasitamab trial for Mantle Cell Lymphoma (NCT06029309). Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma. The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06029309.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:59:00.526Z</video:publication_date>
      <video:duration>51</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/zanu-tafa-nct06029309/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06029309.jpg</video:thumbnail_loc>
      <video:title>ensayo: Zanubrutinib + Tafasitamab (NCT06029309) | Triangle</video:title>
      <video:description>Zanubrutinib + Tafasitamab trial for Mantle Cell Lymphoma (NCT06029309). Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma. The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06029309.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:59:00.526Z</video:publication_date>
      <video:duration>51</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/zanu-tafa-nct06029309/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06029309.jpg</video:thumbnail_loc>
      <video:title>исследование: Zanubrutinib + Tafasitamab (NCT06029309) | Triangle</video:title>
      <video:description>Zanubrutinib + Tafasitamab trial for Mantle Cell Lymphoma (NCT06029309). Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma. The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06029309.mp4</video:content_loc>
      <video:publication_date>2026-10-20T03:59:00.526Z</video:publication_date>
      <video:duration>51</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/zanubrutinib-nct06730542/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06730542.jpg</video:thumbnail_loc>
      <video:title>Zanubrutinib + Pola-R-CHP (NCT06730542) | Triangle</video:title>
      <video:description>Zanubrutinib + Pola-R-CHP trial for Secondary CNS Lymphoma (NCT06730542). Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma. The purpose of this study is to is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06730542.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:05:26.635Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/zanubrutinib-nct06730542/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06730542.jpg</video:thumbnail_loc>
      <video:title>ensayo: Zanubrutinib + Pola-R-CHP (NCT06730542) | Triangle</video:title>
      <video:description>Zanubrutinib + Pola-R-CHP trial for Secondary CNS Lymphoma (NCT06730542). Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma. The purpose of this study is to is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06730542.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:05:26.635Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/zanubrutinib-nct06730542/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06730542.jpg</video:thumbnail_loc>
      <video:title>исследование: Zanubrutinib + Pola-R-CHP (NCT06730542) | Triangle</video:title>
      <video:description>Zanubrutinib + Pola-R-CHP trial for Secondary CNS Lymphoma (NCT06730542). Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma. The purpose of this study is to is to…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06730542.mp4</video:content_loc>
      <video:publication_date>2026-10-20T04:05:26.635Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-1/ziftomenib-nct06440135/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06440135.jpg</video:thumbnail_loc>
      <video:title>Ziftomenib Maintenance (NCT06440135) | Triangle</video:title>
      <video:description>Ziftomenib Maintenance trial for NPM1-Mutated AML in Remission After Allogeneic Transplant (NCT06440135). Ziftomenib Maintenance Post Allo-HCT. The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06440135.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:07:08.263Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/es/phase-1/ziftomenib-nct06440135/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06440135.jpg</video:thumbnail_loc>
      <video:title>ensayo: Ziftomenib Maintenance (NCT06440135) | Triangle</video:title>
      <video:description>Ziftomenib Maintenance trial for NPM1-Mutated AML in Remission After Allogeneic Transplant (NCT06440135). Ziftomenib Maintenance Post Allo-HCT. The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06440135.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:07:08.263Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/ru/phase-1/ziftomenib-nct06440135/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06440135.jpg</video:thumbnail_loc>
      <video:title>исследование: Ziftomenib Maintenance (NCT06440135) | Triangle</video:title>
      <video:description>Ziftomenib Maintenance trial for NPM1-Mutated AML in Remission After Allogeneic Transplant (NCT06440135). Ziftomenib Maintenance Post Allo-HCT. The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib,…</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-1/films/NCT06440135.mp4</video:content_loc>
      <video:publication_date>2026-10-20T05:07:08.263Z</video:publication_date>
      <video:duration>64</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/24bro681-alternating-gnp-and-mfolfirinox-for-br-pdac-nct07043270/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07043270.jpg</video:thumbnail_loc>
      <video:title>Nab-paclitaxel + Gemcitabine (NCT07043270) | Triangle</video:title>
      <video:description>Nab-paclitaxel + Gemcitabine trial for Pancreas Adenocarcinoma (NCT07043270). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07043270.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07043270.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:16:43.025Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/3-5-fraction-stereotactic-body-radiation-therapy-for-palliation-nct05674396/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05674396.jpg</video:thumbnail_loc>
      <video:title>Stereotactic body radiotherapy (NCT05674396) | Triangle</video:title>
      <video:description>Stereotactic body radiotherapy trial for Head and Neck Squamous Cell Carcinoma (NCT05674396). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05674396.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05674396.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:11:41.058Z</video:publication_date>
      <video:duration>98</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/5-azacytidine-and-or-nivolumab-in-resectable-hpv-associated-hnsc-nct05317000/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05317000.jpg</video:thumbnail_loc>
      <video:title>Combination 5-azacytidine and… (NCT05317000) | Triangle</video:title>
      <video:description>Combination 5-azacytidine and nivolumab trial for Squamous Cell Carcinoma of Head and Neck (NCT05317000). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05317000.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05317000.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:07:58.978Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/5-day-preoperative-radiation-for-soft-tissue-sarcoma-nct06087861/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06087861.jpg</video:thumbnail_loc>
      <video:title>External Beam Radiotherapy (NCT06087861) | Triangle</video:title>
      <video:description>External Beam Radiotherapy trial for Soft Tissue Sarcoma (NCT06087861). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06087861.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06087861.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:05:35.745Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/5-fluorouracil-leucovorin-5fu-lv-in-combination-with-regorafenib-nct06887218/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06887218.jpg</video:thumbnail_loc>
      <video:title>Regorafenib (BAY 73-4506) (NCT06887218) | Triangle</video:title>
      <video:description>Regorafenib (BAY 73-4506) trial for Metastatic Colorectal Cancer (CRC) (NCT06887218). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06887218.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06887218.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:39:56.651Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-cancer-vaccine-stemvac-in-combination-with-chemotherapy-for-th-nct07078604/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07078604.jpg</video:thumbnail_loc>
      <video:title>CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope… (NCT07078604) | Triangle</video:title>
      <video:description>CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine trial for Anatomic Stage IV Breast Cancer AJCC v8 (NCT07078604). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07078604.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07078604.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:29:29.257Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-clinical-study-of-calderasib-mk-1084-in-people-with-advanced-s-nct07209111/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07209111.jpg</video:thumbnail_loc>
      <video:title>Calderasib for Neoplasm Malignant (NCT07209111) | Triangle</video:title>
      <video:description>Calderasib trial for Neoplasm Malignant (NCT07209111). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07209111.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07209111.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:51:23.029Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-clinical-study-of-intismeran-autogene-v940-and-pembrolizumab-m-nct06961006/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06961006.jpg</video:thumbnail_loc>
      <video:title>Intismeran autogene for Malignant… (NCT06961006) | Triangle</video:title>
      <video:description>Intismeran autogene trial for Malignant Melanoma (NCT06961006). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06961006.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06961006.mp4</video:content_loc>
      <video:publication_date>2026-10-31T14:56:25.670Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-clinical-study-of-zilovertamab-vedotin-mk-2140-plus-rituximab-nct06890884/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06890884.jpg</video:thumbnail_loc>
      <video:title>Zilovertamab vedotin for Lymphoma… (NCT06890884) | Triangle</video:title>
      <video:description>Zilovertamab vedotin trial for Lymphoma, Large B-Cell, Diffuse (NCT06890884). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06890884.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06890884.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:06:02.504Z</video:publication_date>
      <video:duration>93</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-long-term-treatment-extension-study-of-niraparib-in-participan-nct04641247/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04641247.jpg</video:thumbnail_loc>
      <video:title>Niraparib for Ovarian Neoplasms (NCT04641247) | Triangle</video:title>
      <video:description>Niraparib trial for Ovarian Neoplasms (NCT04641247). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04641247.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04641247.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:55:09.848Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-multicenter-trial-to-identify-optimal-atezolizumab-biomarkers-nct06069726/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06069726.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Recurrent Glioblastoma (NCT06069726) | Triangle</video:title>
      <video:description>Atezolizumab trial for Recurrent Glioblastoma (NCT06069726). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06069726.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06069726.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:44:12.723Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-multiple-antigen-vaccine-stemvac-for-the-treatment-of-patients-nct05242965/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05242965.jpg</video:thumbnail_loc>
      <video:title>CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope… (NCT05242965) | Triangle</video:title>
      <video:description>CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine trial for Lung Non-Small Cell Carcinoma (NCT05242965). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05242965.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05242965.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:07:38.788Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-neoadjuvant-study-of-tislelizumab-and-sx-682-for-resectable-pa-nct05604560/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05604560.jpg</video:thumbnail_loc>
      <video:title>Tislelizumab for Pancreatic Cancer (NCT05604560) | Triangle</video:title>
      <video:description>Tislelizumab trial for Pancreatic Cancer (NCT05604560). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05604560.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05604560.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:34:24.429Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-and-pharmacodynamic-study-of-sitagliptin-in-patients-w-nct07003542/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07003542.jpg</video:thumbnail_loc>
      <video:title>Sitagliptin for Glioblastoma (NCT07003542) | Triangle</video:title>
      <video:description>Sitagliptin trial for Glioblastoma (NCT07003542). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07003542.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07003542.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:16:40.902Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-neoadjuvant-study-of-zanidatamab-in-combination-with-c-nct07102381/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07102381.jpg</video:thumbnail_loc>
      <video:title>Zanidatamab for HER2-positive… (NCT07102381) | Triangle</video:title>
      <video:description>Zanidatamab trial for HER2-positive Breast Cancer (NCT07102381). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07102381.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07102381.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:25:35.534Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-open-label-single-arm-study-of-autologous-m-cenk-adopt-nct06710288/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06710288.jpg</video:thumbnail_loc>
      <video:title>Gemcitabine for Platinum-resistant… (NCT06710288) | Triangle</video:title>
      <video:description>Gemcitabine trial for Platinum-resistant Ovarian Cancer (NCT06710288). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06710288.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06710288.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:33:18.378Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-platform-study-of-immunomodulatory-compounds-in-ici-re-nct07133425/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07133425.jpg</video:thumbnail_loc>
      <video:title>SAR445877 for Non-Small Cell Lung Cancer (NCT07133425) | Triangle</video:title>
      <video:description>SAR445877 trial for Non-Small Cell Lung Cancer (NCT07133425). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07133425.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07133425.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:46:22.037Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-single-arm-open-label-pilot-trial-evaluating-zanidatam-nct05035836/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05035836.jpg</video:thumbnail_loc>
      <video:title>Zanidatamab for Breast Cancer (NCT05035836) | Triangle</video:title>
      <video:description>Zanidatamab trial for Breast Cancer (NCT05035836). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05035836.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05035836.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:44:05.053Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-evaluating-olutasidenib-in-patients-with-idh1-mu-nct06566742/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06566742.jpg</video:thumbnail_loc>
      <video:title>Olutasidenib for Myelodysplastic… (NCT06566742) | Triangle</video:title>
      <video:description>Olutasidenib trial for Myelodysplastic Syndromes (NCT06566742). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06566742.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06566742.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:13:10.078Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-of-acr-368-in-endometrial-adenocarcinoma-nct05548296/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05548296.jpg</video:thumbnail_loc>
      <video:title>ACR-368 for Endometrial Adenocarcinoma (NCT05548296) | Triangle</video:title>
      <video:description>ACR-368 trial for Endometrial Adenocarcinoma (NCT05548296). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05548296.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05548296.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:50:03.762Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-of-ptx-100-in-patients-with-relapsed-refractory-nct06854653/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06854653.jpg</video:thumbnail_loc>
      <video:title>PTX-100 for CTCL (NCT06854653) | Triangle</video:title>
      <video:description>PTX-100 trial for CTCL (NCT06854653). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06854653.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06854653.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:42:14.302Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-of-the-ketogenic-diet-vs-standard-anti-cancer-di-nct05708352/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05708352.jpg</video:thumbnail_loc>
      <video:title>Keto Diet for Glioblastoma Multiforme (NCT05708352) | Triangle</video:title>
      <video:description>Keto Diet trial for Glioblastoma Multiforme (NCT05708352). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05708352.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05708352.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:24:46.998Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-co-nct07659795/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07659795.jpg</video:thumbnail_loc>
      <video:title>VS-7375 for Colorectal Cancer (NCT07659795) | Triangle</video:title>
      <video:description>VS-7375 trial for Colorectal Cancer (NCT07659795). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07659795.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07659795.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:32:01.199Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-pa-nct07644559/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07644559.jpg</video:thumbnail_loc>
      <video:title>VS-7375 for Pancreatic Ductal… (NCT07644559) | Triangle</video:title>
      <video:description>VS-7375 trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT07644559). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07644559.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07644559.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:53:41.198Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-of-wu-cart-007-an-anti-cd7-allogeneic-car-t-cell-nct06514794/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06514794.jpg</video:thumbnail_loc>
      <video:title>WU-CART-007 for T-cell Acute… (NCT06514794) | Triangle</video:title>
      <video:description>WU-CART-007 trial for T-cell Acute Lymphoblastic Leukemia (NCT06514794). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06514794.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06514794.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:40:12.392Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-of-zanidatamab-in-patients-with-her2-expressing-nct06695845/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06695845.jpg</video:thumbnail_loc>
      <video:title>Zanidatamab for Breast Cancer (NCT06695845) | Triangle</video:title>
      <video:description>Zanidatamab trial for Breast Cancer (NCT06695845). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06695845.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06695845.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:23:52.637Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-to-evaluate-efficacy-of-calaspargase-pegol-mknl-nct06561074/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06561074.jpg</video:thumbnail_loc>
      <video:title>Decitabine for T-cell Acute… (NCT06561074) | Triangle</video:title>
      <video:description>Decitabine trial for T-cell Acute Lymphoblastic Leukemia (NCT06561074). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06561074.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06561074.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:27:53.756Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-study-to-evaluate-the-effects-of-asp5541-in-participan-nct07005154/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07005154.jpg</video:thumbnail_loc>
      <video:title>ASP5541 for Prostate Cancer (NCT07005154) | Triangle</video:title>
      <video:description>ASP5541 trial for Prostate Cancer (NCT07005154). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07005154.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07005154.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:47:30.728Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-trial-for-metastatic-melanoma-using-adoptive-cell-ther-nct02621021/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02621021.jpg</video:thumbnail_loc>
      <video:title>young TIL for Melanoma (NCT02621021) | Triangle</video:title>
      <video:description>young TIL trial for Melanoma (NCT02621021). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02621021.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02621021.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:48:46.285Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-trial-of-ivonescimab-for-patients-with-advanced-metast-nct06805617/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06805617.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab for Salivary Gland Cancer (NCT06805617) | Triangle</video:title>
      <video:description>Ivonescimab trial for Salivary Gland Cancer (NCT06805617). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06805617.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06805617.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:06:12.459Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-trial-of-mosunetuzumab-and-zanubrutinib-for-patients-w-nct06563505/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06563505.jpg</video:thumbnail_loc>
      <video:title>Mosunetuzumab for Lymphoma (NCT06563505) | Triangle</video:title>
      <video:description>Mosunetuzumab trial for Lymphoma (NCT06563505). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06563505.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06563505.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:42:16.250Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-trial-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-nct07508995/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07508995.jpg</video:thumbnail_loc>
      <video:title>BGB-16673 for Chronic Lymphocytic… (NCT07508995) | Triangle</video:title>
      <video:description>BGB-16673 trial for Chronic Lymphocytic Leukemia (CLL) (NCT07508995). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07508995.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07508995.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:19:08.079Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-trial-of-zanzalintinib-in-advanced-metastatic-bone-sar-nct07193550/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07193550.jpg</video:thumbnail_loc>
      <video:title>Zanzalintinib for Bone Sarcomas (NCT07193550) | Triangle</video:title>
      <video:description>Zanzalintinib trial for Bone Sarcomas (NCT07193550). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07193550.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07193550.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:57:35.833Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-2-trial-to-assess-safety-and-efficacy-of-tofacitinib-2-c-nct06698822/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06698822.jpg</video:thumbnail_loc>
      <video:title>tofacitinib 2% cream for Cutaneous… (NCT06698822) | Triangle</video:title>
      <video:description>tofacitinib 2% cream trial for Cutaneous T-Cell Lymphoma (NCT06698822). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06698822.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06698822.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:13:44.628Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-clinical-study-to-evaluate-hlx43-in-subjects-with-adv-nct06907615/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06907615.jpg</video:thumbnail_loc>
      <video:title>HLX43 DOSE 1 (2.0 mg/kg) for Non… (NCT06907615) | Triangle</video:title>
      <video:description>HLX43 DOSE 1 (2.0 mg/kg) trial for Non Small Cell Lung Cancer (NCT06907615). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06907615.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06907615.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:07:45.365Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-evaluation-of-afatinib-in-patients-with-persistent-or-nct02491099/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02491099.jpg</video:thumbnail_loc>
      <video:title>Afatinib for HER2/Neu+ Uterine… (NCT02491099) | Triangle</video:title>
      <video:description>Afatinib trial for HER2/Neu+ Uterine Serous Carcinoma (NCT02491099). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02491099.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02491099.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:44:20.316Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-open-label-study-of-olutasidenib-post-transplant-main-nct06668584/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06668584.jpg</video:thumbnail_loc>
      <video:title>Olutasidenib for Myeloid Malignancies (NCT06668584) | Triangle</video:title>
      <video:description>Olutasidenib trial for Myeloid Malignancies (NCT06668584). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06668584.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06668584.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:15:33.322Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-single-center-single-arm-study-evaluating-the-safety-nct06630091/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06630091.jpg</video:thumbnail_loc>
      <video:title>Golidocitinib for Peripheral T… (NCT06630091) | Triangle</video:title>
      <video:description>Golidocitinib trial for Peripheral T Cell Lymphoma (NCT06630091). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06630091.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06630091.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:15:48.780Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-study-evaluating-t-cell-clonality-after-stereotactic-nct05361798/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05361798.jpg</video:thumbnail_loc>
      <video:title>PDS01ADC for Cancer Of Prostate (NCT05361798) | Triangle</video:title>
      <video:description>PDS01ADC trial for Cancer Of Prostate (NCT05361798). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05361798.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05361798.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:06:51.336Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-axicabtagene-ciloleucel-an-anti-cd19-chimeri-nct06043323/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06043323.jpg</video:thumbnail_loc>
      <video:title>Axicabtagene Ciloleucel (NCT06043323) | Triangle</video:title>
      <video:description>Axicabtagene Ciloleucel trial for Follicular Lymphoma (NCT06043323). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06043323.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06043323.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:45:13.501Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-loncastuximab-tesirine-as-consolidation-stra-nct05464719/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05464719.jpg</video:thumbnail_loc>
      <video:title>Loncastuximab Tesirine for Large… (NCT05464719) | Triangle</video:title>
      <video:description>Loncastuximab Tesirine trial for Large B-cell Lymphoma (NCT05464719). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05464719.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05464719.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:00:33.935Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-pemigatinib-plus-durvalumab-in-previously-tr-nct06728410/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06728410.jpg</video:thumbnail_loc>
      <video:title>Pemigatinib for Intrahepatic… (NCT06728410) | Triangle</video:title>
      <video:description>Pemigatinib trial for Intrahepatic Cholangiocarcinoma (NCT06728410). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06728410.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06728410.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:33:00.999Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-the-menin-inhibitor-revumenib-in-leukemia-as-nct06229912/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06229912.jpg</video:thumbnail_loc>
      <video:title>Revumenib for Leukemia (NCT06229912) | Triangle</video:title>
      <video:description>Revumenib trial for Leukemia (NCT06229912). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06229912.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06229912.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:48:37.801Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-tucatinib-and-ado-trastuzumab-emtansine-t-dm-nct05673928/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05673928.jpg</video:thumbnail_loc>
      <video:title>Trastuzumab emtansine (NCT05673928) | Triangle</video:title>
      <video:description>Trastuzumab emtansine trial for Metastatic Solid Tumor (NCT05673928). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05673928.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05673928.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:51:21.971Z</video:publication_date>
      <video:duration>94</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-study-with-a-safety-run-in-of-the-addition-of-n-803-t-nct07085338/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07085338.jpg</video:thumbnail_loc>
      <video:title>Temozolomide for Neuroblastoma Recurrent (NCT07085338) | Triangle</video:title>
      <video:description>Temozolomide trial for Neuroblastoma Recurrent (NCT07085338). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07085338.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07085338.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:16:15.671Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-trial-of-mosunetuzumab-polatuzumab-tafasitamab-and-le-nct05615636/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05615636.jpg</video:thumbnail_loc>
      <video:title>Mosunetuzumab for Hodgkin Lymphoma (NCT05615636) | Triangle</video:title>
      <video:description>Mosunetuzumab trial for Hodgkin Lymphoma (NCT05615636). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05615636.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05615636.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:49:32.581Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-trial-of-sacituzumab-govitecan-in-patients-with-advan-nct06248515/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06248515.jpg</video:thumbnail_loc>
      <video:title>Sacituzumab govitecan-hziy for Thymoma (NCT06248515) | Triangle</video:title>
      <video:description>Sacituzumab govitecan-hziy trial for Thymoma (NCT06248515). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06248515.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06248515.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:17:09.454Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-trial-of-tebentafusp-in-hla-a-02-01-positive-patients-nct06942442/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06942442.jpg</video:thumbnail_loc>
      <video:title>Physician's Choice for HLA-A*0201… (NCT06942442) | Triangle</video:title>
      <video:description>Physician's Choice trial for HLA-A*0201 Positive Cells Present (NCT06942442). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06942442.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06942442.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:21:53.813Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-phase-ii-trial-to-evaluate-the-effect-of-itraconazole-on-patho-nct05563766/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05563766.jpg</video:thumbnail_loc>
      <video:title>Itraconazole for Esophageal… (NCT05563766) | Triangle</video:title>
      <video:description>Itraconazole trial for Esophageal Adenocarcinoma (NCT05563766). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05563766.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05563766.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:39:20.646Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-pivotal-phase-ii-clinical-trial-of-utidelone-injection-plus-ca-nct06764940/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06764940.jpg</video:thumbnail_loc>
      <video:title>Utidelone for HER2-negative… (NCT06764940) | Triangle</video:title>
      <video:description>Utidelone trial for HER2-negative Breast Cancer Patients With Brain Metastases (NCT06764940). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06764940.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06764940.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:48:14.915Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-randomized-phase-2-trial-of-fruquintinib-and-tas-102-as-compar-nct06992258/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06992258.jpg</video:thumbnail_loc>
      <video:title>Fruquintinib+ Lonsurf… (NCT06992258) | Triangle</video:title>
      <video:description>Fruquintinib+ Lonsurf (trifluridine and tipiracil) trial for Colorectal Cancer (NCT06992258). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06992258.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06992258.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:20:41.161Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-randomized-study-of-astx727-with-or-without-iadademstat-in-adv-nct06661915/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06661915.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06661915) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Accelerated Phase Myeloproliferative Neoplasm (NCT06661915). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06661915.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06661915.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:35:06.073Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-randomized-trial-of-fianlimab-and-cemiplimab-ipilimumab-or-ipi-nct07188896/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07188896.jpg</video:thumbnail_loc>
      <video:title>Fianlimab for Advanced Renal Cell… (NCT07188896) | Triangle</video:title>
      <video:description>Fianlimab trial for Advanced Renal Cell Carcinoma (aRCC) (NCT07188896). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07188896.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07188896.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:07:37.468Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-randomized-trial-of-maintenance-systemic-therapy-after-radiati-nct06004336/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06004336.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Oligometastatic… (NCT06004336) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Oligometastatic Renal Cell Carcinoma (NCT06004336). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06004336.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06004336.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:40:05.500Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-single-arm-phase-ii-study-of-neoadjuvant-intensified-androgen-nct05593497/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05593497.jpg</video:thumbnail_loc>
      <video:title>Capivasertib for High-Risk… (NCT05593497) | Triangle</video:title>
      <video:description>Capivasertib trial for High-Risk Prostate Cancer (NCT05593497). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05593497.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05593497.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:11:48.878Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-single-arm-study-of-pembrolizumab-with-gemcitabine-and-cisplat-nct05967182/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05967182.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Cholangiocarcinoma (NCT05967182) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Cholangiocarcinoma (NCT05967182). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05967182.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05967182.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:24:36.080Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-comparing-two-immunotherapy-options-for-human-papillomav-nct07179315/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07179315.jpg</video:thumbnail_loc>
      <video:title>cemiplimab+fianlimab for Head and… (NCT07179315) | Triangle</video:title>
      <video:description>cemiplimab+fianlimab trial for Head and Neck Cancer (NCT07179315). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07179315.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07179315.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:37:24.761Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-evaluating-ficerafusp-alfa-bca101-qw-in-combination-with-nct07807163/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07807163.jpg</video:thumbnail_loc>
      <video:title>Ficerafusp alfa for Metastatic… (NCT07807163) | Triangle</video:title>
      <video:description>Ficerafusp alfa trial for Metastatic Head and Neck Squamous Cell Carcinoma (NCT07807163). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07807163.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07807163.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:19:40.599Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-evaluating-the-combination-of-immunotherapy-with-radioth-nct07603856/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07603856.jpg</video:thumbnail_loc>
      <video:title>Investigator Choice Immunotherapy… (NCT07603856) | Triangle</video:title>
      <video:description>Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab) trial for Non-Small Cell Lung Cancer (NCT07603856). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07603856.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07603856.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:54:52.145Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-evaluating-the-safety-of-inavolisib-and-fulvestrant-with-nct07748208/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07748208.jpg</video:thumbnail_loc>
      <video:title>Inavolisib for Breast Cancer (NCT07748208) | Triangle</video:title>
      <video:description>Inavolisib trial for Breast Cancer (NCT07748208). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07748208.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07748208.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:19:10.905Z</video:publication_date>
      <video:duration>95</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-a-new-way-to-treat-children-and-young-adults-with-a-b-nct04684368/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04684368.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Central… (NCT04684368) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Central Nervous System Nongerminomatous Germ Cell Tumor (NCT04684368). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04684368.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04684368.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:04:39.079Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-a-vaccine-in-combination-with-beta-glucan-in-people-w-nct06057948/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06057948.jpg</video:thumbnail_loc>
      <video:title>OPT-821 (QS-21) for Neuroblastoma (NCT06057948) | Triangle</video:title>
      <video:description>OPT-821 (QS-21) trial for Neuroblastoma (NCT06057948). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06057948.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06057948.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:24:36.380Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-alisertib-in-patients-with-extensive-stage-small-cell-nct06095505/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06095505.jpg</video:thumbnail_loc>
      <video:title>Alisertib for Small Cell Lung Cancer (NCT06095505) | Triangle</video:title>
      <video:description>Alisertib trial for Small Cell Lung Cancer (NCT06095505). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06095505.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06095505.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:59:16.457Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-amivantamab-in-combination-with-lazertinib-or-amivant-nct06667076/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06667076.jpg</video:thumbnail_loc>
      <video:title>Amivantamab for Carcinoma… (NCT06667076) | Triangle</video:title>
      <video:description>Amivantamab trial for Carcinoma, Non-Small-Cell Lung (NCT06667076). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06667076.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06667076.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:07:30.710Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-amivantamab-in-participants-with-advanced-or-metastat-nct05498428/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05498428.jpg</video:thumbnail_loc>
      <video:title>Amivantamab for Carcinoma… (NCT05498428) | Triangle</video:title>
      <video:description>Amivantamab trial for Carcinoma, Non-small-Cell Lung (NCT05498428). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05498428.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05498428.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:49:41.196Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-avutometinib-and-defactinib-in-people-with-thyroid-ca-nct06007924/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06007924.jpg</video:thumbnail_loc>
      <video:title>Avutometinib for Thyroid Cancer (NCT06007924) | Triangle</video:title>
      <video:description>Avutometinib trial for Thyroid Cancer (NCT06007924). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06007924.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06007924.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:21:33.579Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-avutometinib-defactinib-and-letrozole-in-people-with-nct06394804/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06394804.jpg</video:thumbnail_loc>
      <video:title>Avutometinib for Low-Grade Serous… (NCT06394804) | Triangle</video:title>
      <video:description>Avutometinib trial for Low-Grade Serous Ovarian Cancer (NCT06394804). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06394804.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06394804.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:56:17.116Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-axicabtagene-ciloleucel-and-glofitamab-as-second-line-nct06213311/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06213311.jpg</video:thumbnail_loc>
      <video:title>Glofitamab for B Cell Lymphoma (NCT06213311) | Triangle</video:title>
      <video:description>Glofitamab trial for B Cell Lymphoma (NCT06213311). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06213311.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06213311.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:00:58.118Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-azenosertib-zn-c3-in-subjects-with-platinum-resistant-nct05128825/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05128825.jpg</video:thumbnail_loc>
      <video:title>azenosertib for High-Grade Serous… (NCT05128825) | Triangle</video:title>
      <video:description>azenosertib trial for High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT05128825). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05128825.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05128825.mp4</video:content_loc>
      <video:publication_date>2026-10-31T14:54:15.700Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-belzutifan-in-adolescent-participants-with-solid-tumo-nct07700758/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07700758.jpg</video:thumbnail_loc>
      <video:title>Belzutifan for Malignant Neoplasm (NCT07700758) | Triangle</video:title>
      <video:description>Belzutifan trial for Malignant Neoplasm (NCT07700758). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07700758.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07700758.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:52:50.647Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-botensilimab-and-balstilimab-for-colorectal-cancer-wi-nct07227636/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227636.jpg</video:thumbnail_loc>
      <video:title>Botensilimab for Colorectal Cancer (NCT07227636) | Triangle</video:title>
      <video:description>Botensilimab trial for Colorectal Cancer (NCT07227636). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07227636.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227636.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:04:57.268Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-botensilimab-and-balstilimab-for-rectal-adenocarcinom-nct06843434/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06843434.jpg</video:thumbnail_loc>
      <video:title>Balstilimab for Microsatellite… (NCT06843434) | Triangle</video:title>
      <video:description>Balstilimab trial for Microsatellite Stable Rectal Carcinoma (NCT06843434). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06843434.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06843434.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:59:52.102Z</video:publication_date>
      <video:duration>95</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-cadonilimab-combined-with-chemotherapy-in-people-with-nct07631000/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07631000.jpg</video:thumbnail_loc>
      <video:title>Cadonilimab for Gastric Cancer (NCT07631000) | Triangle</video:title>
      <video:description>Cadonilimab trial for Gastric Cancer (NCT07631000). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07631000.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07631000.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:30:52.182Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-combination-chemotherapy-for-patients-with-newly-diag-nct04322318/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04322318.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Anaplastic… (NCT04322318) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Anaplastic Kidney Wilms Tumor (NCT04322318). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04322318.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04322318.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:42:49.055Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-cybord-cyclophosphamide-bortezomib-dexamethasone-plus-nct06083922/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06083922.jpg</video:thumbnail_loc>
      <video:title>Cyclophosphamide for Multiple Myeloma (NCT06083922) | Triangle</video:title>
      <video:description>Cyclophosphamide trial for Multiple Myeloma (NCT06083922). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06083922.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06083922.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:29:48.947Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-disitamab-vedotin-alone-or-with-pembrolizumab-in-urot-nct04879329/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04879329.jpg</video:thumbnail_loc>
      <video:title>disitamab vedotin for Urothelial… (NCT04879329) | Triangle</video:title>
      <video:description>disitamab vedotin trial for Urothelial Carcinoma (NCT04879329). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04879329.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04879329.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:23:44.595Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-emavusertib-an-approved-bruton-tyrosine-kinase-inhibi-nct07271667/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07271667.jpg</video:thumbnail_loc>
      <video:title>Emavusertib for Chronic… (NCT07271667) | Triangle</video:title>
      <video:description>Emavusertib trial for Chronic Lymphocytic Leukemia (NCT07271667). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07271667.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07271667.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:00:14.636Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-enzalutamide-plus-the-glucocorticoid-receptor-antagon-nct05726292/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05726292.jpg</video:thumbnail_loc>
      <video:title>Relacorilant for Prostate Cancer (NCT05726292) | Triangle</video:title>
      <video:description>Relacorilant trial for Prostate Cancer (NCT05726292). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05726292.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05726292.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:37:43.726Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-fg-3246-in-participants-with-metastatic-castration-re-nct06842498/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06842498.jpg</video:thumbnail_loc>
      <video:title>FG-3246 for Metastatic… (NCT06842498) | Triangle</video:title>
      <video:description>FG-3246 trial for Metastatic Castration-Resistant Prostate Cancer (NCT06842498). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06842498.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06842498.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:58:19.655Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-fianlimab-cemiplimab-and-ipilimumab-in-people-with-me-nct06594991/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06594991.jpg</video:thumbnail_loc>
      <video:title>Fianlimab for Advanced Melanoma (NCT06594991) | Triangle</video:title>
      <video:description>Fianlimab trial for Advanced Melanoma (NCT06594991). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06594991.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06594991.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:17:27.996Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-imlunestrant-ly3484356-in-premenopausal-women-with-es-nct07287098/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07287098.jpg</video:thumbnail_loc>
      <video:title>Imlunestrant for Breast Neoplasms (NCT07287098) | Triangle</video:title>
      <video:description>Imlunestrant trial for Breast Neoplasms (NCT07287098). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07287098.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07287098.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:52:09.949Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-incb123667-in-participants-with-platinum-resistant-ov-nct07023627/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07023627.jpg</video:thumbnail_loc>
      <video:title>INCB123667 for Ovarian Cancer (NCT07023627) | Triangle</video:title>
      <video:description>INCB123667 trial for Ovarian Cancer (NCT07023627). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07023627.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07023627.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:18:11.227Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-investigational-agents-in-participants-with-previousl-nct06780085/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06780085.jpg</video:thumbnail_loc>
      <video:title>Raludotatug Deruxtecan (NCT06780085) | Triangle</video:title>
      <video:description>Raludotatug Deruxtecan trial for Carcinoma, Non-Small-Cell Lung (NCT06780085). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06780085.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06780085.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:22:45.192Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-ivonescimab-in-people-with-endometrial-and-cervical-c-nct06925724/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06925724.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab for Endometrial Cancer (NCT06925724) | Triangle</video:title>
      <video:description>Ivonescimab trial for Endometrial Cancer (NCT06925724). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06925724.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06925724.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:19:52.902Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-ivonescimab-in-people-with-leiomyosarcoma-nct07516925/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07516925.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab for Leiomyosarcoma (NCT07516925) | Triangle</video:title>
      <video:description>Ivonescimab trial for Leiomyosarcoma (NCT07516925). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07516925.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07516925.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:19:54.246Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-jnj-101556143-in-participants-with-metastatic-prostat-nct07832292/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07832292.jpg</video:thumbnail_loc>
      <video:title>JNJ-101556143 for Prostatic Neoplasms (NCT07832292) | Triangle</video:title>
      <video:description>JNJ-101556143 trial for Prostatic Neoplasms (NCT07832292). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07832292.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07832292.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:41:23.746Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-jnj-90301900-in-combination-with-chemoradiation-follo-nct06667908/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06667908.jpg</video:thumbnail_loc>
      <video:title>JNJ-90301900 for Carcinoma… (NCT06667908) | Triangle</video:title>
      <video:description>JNJ-90301900 trial for Carcinoma, Non-Small-Cell Lung (NCT06667908). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06667908.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06667908.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:42:25.870Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-jzp3507-onc206-in-recurrent-grade-2-or-3-meningioma-nct07533942/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07533942.jpg</video:thumbnail_loc>
      <video:title>JZP3507 for Meningioma (NCT07533942) | Triangle</video:title>
      <video:description>JZP3507 trial for Meningioma (NCT07533942). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07533942.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07533942.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:24:05.571Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-lifileucel-tumor-infiltrating-lymphocytes-in-adults-w-nct07741877/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07741877.jpg</video:thumbnail_loc>
      <video:title>Lifileucel for Sarcoma (NCT07741877) | Triangle</video:title>
      <video:description>Lifileucel trial for Sarcoma (NCT07741877). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07741877.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07741877.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:28:06.888Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-lower-dose-radiation-therapy-for-people-with-prostate-nct07635238/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07635238.jpg</video:thumbnail_loc>
      <video:title>MR-guided Stereotactic Body… (NCT07635238) | Triangle</video:title>
      <video:description>MR-guided Stereotactic Body Radiation Therapy trial for Prostate Cancer (NCT07635238). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07635238.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07635238.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:47:14.748Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-lower-radiotherapy-dose-to-treat-children-with-cns-ge-nct06368817/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06368817.jpg</video:thumbnail_loc>
      <video:title>3-Dimensional Conformal Proton… (NCT06368817) | Triangle</video:title>
      <video:description>3-Dimensional Conformal Proton Radiation Therapy trial for Basal Ganglia Germinoma (NCT06368817). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06368817.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06368817.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:40:27.824Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-lurbinectedin-in-combination-with-durvalumab-for-the-nct07459634/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07459634.jpg</video:thumbnail_loc>
      <video:title>Lurbinectedin for Extensive-stage… (NCT07459634) | Triangle</video:title>
      <video:description>Lurbinectedin trial for Extensive-stage Small-cell Lung Cancer (NCT07459634). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07459634.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07459634.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:57:52.674Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-mosunetuzumab-alone-or-with-zanubrutinib-in-people-wi-nct05389293/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05389293.jpg</video:thumbnail_loc>
      <video:title>Mosunetuzumab for Follicular Lymphoma (NCT05389293) | Triangle</video:title>
      <video:description>Mosunetuzumab trial for Follicular Lymphoma (NCT05389293). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05389293.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05389293.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:11:16.709Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-multiple-therapies-in-biomarker-selected-participants-nct04302025/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04302025.jpg</video:thumbnail_loc>
      <video:title>Alectinib for Non-small Cell Lung Cancer (NCT04302025) | Triangle</video:title>
      <video:description>Alectinib trial for Non-small Cell Lung Cancer (NCT04302025). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04302025.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04302025.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:10:07.019Z</video:publication_date>
      <video:duration>96</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-nalirifox-in-combination-with-radiation-therapy-in-pe-nct05851924/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05851924.jpg</video:thumbnail_loc>
      <video:title>NALIRIFOX for Pancreatic Ductal… (NCT05851924) | Triangle</video:title>
      <video:description>NALIRIFOX trial for Pancreatic Ductal Adenocarcinoma (NCT05851924). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05851924.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05851924.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:30:47.344Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-navlimetostat-bms-986504-alone-or-in-combination-with-nct06855771/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06855771.jpg</video:thumbnail_loc>
      <video:title>BMS-986504 for Carcinoma… (NCT06855771) | Triangle</video:title>
      <video:description>BMS-986504 trial for Carcinoma, Non-Small-Cell Lung (NCT06855771). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06855771.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06855771.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:27:26.751Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-neoadjuvant-amivantamab-with-either-lazertinib-or-che-nct07586202/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07586202.jpg</video:thumbnail_loc>
      <video:title>Amivantamab for Carcinoma… (NCT07586202) | Triangle</video:title>
      <video:description>Amivantamab trial for Carcinoma, Non-Small-Cell Lung (NCT07586202). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07586202.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07586202.mp4</video:content_loc>
      <video:publication_date>2026-10-31T14:58:33.359Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-novel-agents-or-combinations-as-perioperative-treatme-nct07069712/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07069712.jpg</video:thumbnail_loc>
      <video:title>Sonesitatug Vedotin (NCT07069712) | Triangle</video:title>
      <video:description>Sonesitatug Vedotin trial for Gastroesophageal Adenocarcinoma (NCT07069712). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07069712.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07069712.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:21:23.841Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-nuzefatide-pevedotin-bt5528-in-patients-with-metastat-nct07450859/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07450859.jpg</video:thumbnail_loc>
      <video:title>nuzefatide pevedotin (BT5528) (NCT07450859) | Triangle</video:title>
      <video:description>nuzefatide pevedotin (BT5528) trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT07450859). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07450859.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07450859.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:35:04.018Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-nx-5948-in-adults-with-cll-sll-previously-treated-wit-nct07221500/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07221500.jpg</video:thumbnail_loc>
      <video:title>NX-5948 for Chronic Lymphocytic… (NCT07221500) | Triangle</video:title>
      <video:description>NX-5948 trial for Chronic Lymphocytic Leukemia (CLL) (NCT07221500). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07221500.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07221500.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:29:55.673Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-obecabtagene-autoleucel-in-people-with-b-cell-acute-l-nct07400029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07400029.jpg</video:thumbnail_loc>
      <video:title>Obecabtagene Autoleucel for Acute… (NCT07400029) | Triangle</video:title>
      <video:description>Obecabtagene Autoleucel trial for Acute Lymphoblastic Leukemia (NCT07400029). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07400029.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07400029.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:16:38.889Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-pembrolizumab-in-people-with-ultra-rare-sarcomas-nct07089992/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07089992.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Sarcoma (NCT07089992) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Sarcoma (NCT07089992). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07089992.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07089992.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:51:36.019Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-pembrolizumab-with-or-without-chemotherapy-in-combina-nct06731907/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06731907.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Non-small Cell… (NCT06731907) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Non-small Cell Lung Cancer (NCT06731907). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06731907.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06731907.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:33:39.952Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-pembrolizumab-with-trastuzumab-and-chemotherapy-in-pe-nct06123338/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06123338.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Esophageal Cancer (NCT06123338) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Esophageal Cancer (NCT06123338). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06123338.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06123338.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:05:01.503Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-pirtobrutinib-venetoclax-and-rituximab-in-people-with-nct07231952/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07231952.jpg</video:thumbnail_loc>
      <video:title>Pirtobrutinib for Waldenstrom… (NCT07231952) | Triangle</video:title>
      <video:description>Pirtobrutinib trial for Waldenstrom Macroglobulinemia (NCT07231952). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07231952.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07231952.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:58:44.809Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-response-adapted-ultra-low-dose-4-gy-radiation-for-de-nct05929612/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05929612.jpg</video:thumbnail_loc>
      <video:title>Ultra Low Dose 4 Gy Radiation (NCT05929612) | Triangle</video:title>
      <video:description>Ultra Low Dose 4 Gy Radiation trial for Lymphoma (NCT05929612). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05929612.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05929612.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:42:48.022Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-sacituzumab-govitecan-immu-132-in-patients-with-recur-nct05838521/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05838521.jpg</video:thumbnail_loc>
      <video:title>Sacituzumab govitecan for Cervical… (NCT05838521) | Triangle</video:title>
      <video:description>Sacituzumab govitecan trial for Cervical Cancer (NCT05838521). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05838521.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05838521.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:07:08.614Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-sasanlimab-palbociclib-and-axitinib-in-metastatic-ren-nct07123090/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07123090.jpg</video:thumbnail_loc>
      <video:title>Sasanlimab for Metastatic Renal… (NCT07123090) | Triangle</video:title>
      <video:description>Sasanlimab trial for Metastatic Renal Cell Carcinoma (NCT07123090). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07123090.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07123090.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:46:58.805Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-sdx-7320-in-combination-with-eribulin-for-people-with-nct05570253/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05570253.jpg</video:thumbnail_loc>
      <video:title>Eribulin for Breast Cancer (NCT05570253) | Triangle</video:title>
      <video:description>Eribulin trial for Breast Cancer (NCT05570253). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05570253.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05570253.mp4</video:content_loc>
      <video:publication_date>2026-10-31T18:14:07.651Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-selinexor-in-combination-with-carfilzomib-daratumumab-nct04661137/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04661137.jpg</video:thumbnail_loc>
      <video:title>Selinexor 60 MG for Multiple Myeloma (NCT04661137) | Triangle</video:title>
      <video:description>Selinexor 60 MG trial for Multiple Myeloma (NCT04661137). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04661137.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04661137.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:33:57.619Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-selinexor-in-people-with-wilms-tumors-and-other-solid-nct05985161/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05985161.jpg</video:thumbnail_loc>
      <video:title>Selinexor for Wilms Tumor (NCT05985161) | Triangle</video:title>
      <video:description>Selinexor trial for Wilms Tumor (NCT05985161). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05985161.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05985161.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:56:39.974Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-sotorasib-in-people-with-non-small-cell-lung-cancer-nct06582771/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06582771.jpg</video:thumbnail_loc>
      <video:title>Sotorasib for Non Small Lung Cancer (NCT06582771) | Triangle</video:title>
      <video:description>Sotorasib trial for Non Small Lung Cancer (NCT06582771). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06582771.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06582771.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:41:37.625Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-stereotactic-radiosurgery-srs-and-standard-treatment-nct06741085/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06741085.jpg</video:thumbnail_loc>
      <video:title>osimertinib for Non Small Cell… (NCT06741085) | Triangle</video:title>
      <video:description>osimertinib trial for Non Small Cell Lung Cancer Metastatic (NCT06741085). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06741085.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06741085.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:20:09.318Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-stereotactic-radiosurgery-srs-for-people-with-lung-ca-nct05419076/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05419076.jpg</video:thumbnail_loc>
      <video:title>Stereotactic Radiosurgery for Lung… (NCT05419076) | Triangle</video:title>
      <video:description>Stereotactic Radiosurgery trial for Lung Cancer (NCT05419076). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05419076.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05419076.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:08:15.854Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-sync-t-therapy-sv-102-in-participants-with-metastatic-nct06533644/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06533644.jpg</video:thumbnail_loc>
      <video:title>Partial Oncolysis for Metastatic… (NCT06533644) | Triangle</video:title>
      <video:description>Partial Oncolysis trial for Metastatic Castration-resistant Prostate Cancer (NCT06533644). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06533644.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06533644.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:57:09.771Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-t3011-in-patients-with-bcg-unresponsive-nmibc-or-bcg-nct06971614/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06971614.jpg</video:thumbnail_loc>
      <video:title>T3011 for Nonmuscle-invasive… (NCT06971614) | Triangle</video:title>
      <video:description>T3011 trial for Nonmuscle-invasive Bladder Cancer (NCT06971614). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06971614.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06971614.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:54:02.157Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-talazoparib-with-or-without-enzalutamide-in-people-wi-nct06844383/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06844383.jpg</video:thumbnail_loc>
      <video:title>Talazoparib with enzalutamide (NCT06844383) | Triangle</video:title>
      <video:description>Talazoparib with enzalutamide trial for Prostate Cancer (Adenocarcinoma) (NCT06844383). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06844383.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06844383.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:44:29.566Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-talquetamab-in-participants-with-relapsed-or-refracto-nct04634552/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04634552.jpg</video:thumbnail_loc>
      <video:title>Talquetamab for Hematological… (NCT04634552) | Triangle</video:title>
      <video:description>Talquetamab trial for Hematological Malignancies (NCT04634552). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04634552.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04634552.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:48:44.618Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-targeted-post-surgery-radiation-therapy-for-non-small-nct07293247/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07293247.jpg</video:thumbnail_loc>
      <video:title>Chemotherapy for Lung Non-Small… (NCT07293247) | Triangle</video:title>
      <video:description>Chemotherapy trial for Lung Non-Small Cell Carcinoma (NCT07293247). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07293247.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07293247.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:09:57.117Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-tarlatamab-for-people-with-prostate-cancer-nct07111507/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07111507.jpg</video:thumbnail_loc>
      <video:title>Tarlatamab for Metastatic… (NCT07111507) | Triangle</video:title>
      <video:description>Tarlatamab trial for Metastatic Prostate Cancer (NCT07111507). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07111507.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07111507.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:21:04.395Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-trk-950-when-used-in-combination-with-ramucirumab-and-nct06038578/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06038578.jpg</video:thumbnail_loc>
      <video:title>TRK-950 for Gastric Adenocarcinoma (NCT06038578) | Triangle</video:title>
      <video:description>TRK-950 trial for Gastric Adenocarcinoma (NCT06038578). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06038578.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06038578.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:43:29.907Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-venetoclax-in-combination-with-conventional-chemother-nct05955261/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05955261.jpg</video:thumbnail_loc>
      <video:title>Venetoclax for Acute Myeloid Leukemia (NCT05955261) | Triangle</video:title>
      <video:description>Venetoclax trial for Acute Myeloid Leukemia (NCT05955261). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05955261.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05955261.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:30:24.336Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-zanzalintinib-in-participants-with-recurrent-or-progr-nct07428616/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07428616.jpg</video:thumbnail_loc>
      <video:title>Zanzalintinib for Meningioma (NCT07428616) | Triangle</video:title>
      <video:description>Zanzalintinib trial for Meningioma (NCT07428616). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07428616.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07428616.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:27:49.609Z</video:publication_date>
      <video:duration>60</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-of-zen003694-in-people-with-squamous-cell-lung-cancer-nct05607108/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05607108.jpg</video:thumbnail_loc>
      <video:title>ZEN003694 for Squamous Cell Lung Cancer (NCT05607108) | Triangle</video:title>
      <video:description>ZEN003694 trial for Squamous Cell Lung Cancer (NCT05607108). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05607108.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05607108.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:03:24.253Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-testing-the-combination-of-dasatinib-or-imatinib-to-chem-nct06124157/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06124157.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06124157) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for B Acute Lymphoblastic Leukemia (NCT06124157). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06124157.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06124157.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:53:26.391Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-assess-adverse-events-and-change-in-disease-activity-nct07023289/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07023289.jpg</video:thumbnail_loc>
      <video:title>Telisotuzumab Adizutecan (NCT07023289) | Triangle</video:title>
      <video:description>Telisotuzumab Adizutecan trial for Colorectal Cancer (NCT07023289). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07023289.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07023289.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:41:45.185Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-assess-adverse-events-and-change-in-disease-activity-nct07059845/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07059845.jpg</video:thumbnail_loc>
      <video:title>Mirvetuximab Soravtansine (NCT07059845) | Triangle</video:title>
      <video:description>Mirvetuximab Soravtansine trial for Ovarian Cancer (NCT07059845). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07059845.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07059845.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:03:02.959Z</video:publication_date>
      <video:duration>95</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-assess-adverse-events-and-how-intravenously-iv-infuse-nct06568939/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06568939.jpg</video:thumbnail_loc>
      <video:title>Telisotuzumab Vedotin (NCT06568939) | Triangle</video:title>
      <video:description>Telisotuzumab Vedotin trial for Non-Small Cell Lung Cancer (NCT06568939). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06568939.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06568939.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:29:23.651Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-assess-adverse-events-change-in-disease-activity-and-nct07744126/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07744126.jpg</video:thumbnail_loc>
      <video:title>Telisotuzumab Adizutecan for Head… (NCT07744126) | Triangle</video:title>
      <video:description>Telisotuzumab Adizutecan trial for Head and Neck Squamous Cell Carcinoma (NCT07744126). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07744126.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07744126.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:32:05.058Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-assess-anti-tumor-activity-of-intravenously-iv-infuse-nct06890338/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06890338.jpg</video:thumbnail_loc>
      <video:title>Carboplatin for Epithelial… (NCT06890338) | Triangle</video:title>
      <video:description>Carboplatin trial for Epithelial Ovarian Cancer (NCT06890338). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06890338.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06890338.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:04:16.575Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-assess-the-efficacy-and-safety-of-fore8394-in-partici-nct05503797/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05503797.jpg</video:thumbnail_loc>
      <video:title>Plixorafenib for Cancer Harboring… (NCT05503797) | Triangle</video:title>
      <video:description>Plixorafenib trial for Cancer Harboring BRAF Alterations (NCT05503797). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05503797.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05503797.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:07:41.462Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-compare-the-administration-of-encorafenib-binimetinib-nct04511013/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04511013.jpg</video:thumbnail_loc>
      <video:title>Binimetinib for Acral Lentiginous… (NCT04511013) | Triangle</video:title>
      <video:description>Binimetinib trial for Acral Lentiginous Melanoma (NCT04511013). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04511013.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04511013.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:42:00.880Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-estimate-early-clinical-efficacy-signals-of-glp-1-ago-nct07107334/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07107334.jpg</video:thumbnail_loc>
      <video:title>Glucagon-like peptide 1 receptor… (NCT07107334) | Triangle</video:title>
      <video:description>Glucagon-like peptide 1 receptor agonist trial for Endometrioid Endometrial Adenocarcinoma (NCT07107334). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07107334.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07107334.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:16:33.335Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-evaluate-efficacy-and-safety-of-ciltacabtagene-autole-nct07149857/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07149857.jpg</video:thumbnail_loc>
      <video:title>Cilta-cel for Multiple Myeloma (NCT07149857) | Triangle</video:title>
      <video:description>Cilta-cel trial for Multiple Myeloma (NCT07149857). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07149857.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07149857.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:06:43.835Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intraveno-nct06820463/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06820463.jpg</video:thumbnail_loc>
      <video:title>Telisotuzumab Adizutecan (NCT06820463) | Triangle</video:title>
      <video:description>Telisotuzumab Adizutecan trial for Metastatic Colorectal Cancer (NCT06820463). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06820463.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06820463.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:22:23.406Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-efficacy-and-safety-of-belantamab-mafodo-nct07227311/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227311.jpg</video:thumbnail_loc>
      <video:title>Belantamab mafodotin for Multiple… (NCT07227311) | Triangle</video:title>
      <video:description>Belantamab mafodotin trial for Multiple Myeloma (NCT07227311). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07227311.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227311.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:38:02.357Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-efficacy-and-safety-of-tl118-in-solid-tu-nct06010342/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06010342.jpg</video:thumbnail_loc>
      <video:title>TL118 Capsule for Solid Tumor (NCT06010342) | Triangle</video:title>
      <video:description>TL118 Capsule trial for Solid Tumor (NCT06010342). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06010342.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06010342.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:23:14.629Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-efficacy-of-cemsidomide-dexamethasone-in-nct07284758/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07284758.jpg</video:thumbnail_loc>
      <video:title>Cemsidomide for Multiple Myeloma (NCT07284758) | Triangle</video:title>
      <video:description>Cemsidomide trial for Multiple Myeloma (NCT07284758). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07284758.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07284758.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:15:37.256Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-optimal-dose-adverse-events-and-change-i-nct07155174/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07155174.jpg</video:thumbnail_loc>
      <video:title>ABBV-706 for Small Cell Lung Cancer (NCT07155174) | Triangle</video:title>
      <video:description>ABBV-706 trial for Small Cell Lung Cancer (NCT07155174). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07155174.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07155174.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:34:00.004Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-safety-and-efficacy-of-two-dose-levels-o-nct06948448/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06948448.jpg</video:thumbnail_loc>
      <video:title>ONO-4578 for Colorectal Cancer (NCT06948448) | Triangle</video:title>
      <video:description>ONO-4578 trial for Colorectal Cancer (NCT06948448). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06948448.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06948448.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:38:49.829Z</video:publication_date>
      <video:duration>96</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-find-out-if-enfortumab-vedotin-given-with-pembrolizum-nct07475806/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07475806.jpg</video:thumbnail_loc>
      <video:title>Enfortumab Vedotin (NCT07475806) | Triangle</video:title>
      <video:description>Enfortumab Vedotin trial for Muscle-invasive Bladder Cancer (NCT07475806). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07475806.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07475806.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:27:57.618Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-give-treatment-inside-the-eye-to-treat-retinoblastoma-nct05504291/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05504291.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT05504291) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Bilateral Retinoblastoma (NCT05504291). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05504291.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05504291.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:40:59.283Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-investigate-ubamatamab-with-and-without-marlotamig-re-nct07154290/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07154290.jpg</video:thumbnail_loc>
      <video:title>Ubamatamab for Non Small Cell… (NCT07154290) | Triangle</video:title>
      <video:description>Ubamatamab trial for Non Small Cell Lung Cancer (NCT07154290). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07154290.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07154290.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:21:11.456Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-learn-more-about-how-well-treatment-with-sevabertinib-nct06760819/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06760819.jpg</video:thumbnail_loc>
      <video:title>BAY2927088 for Advanced Solid Tumors (NCT06760819) | Triangle</video:title>
      <video:description>BAY2927088 trial for Advanced Solid Tumors (NCT06760819). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06760819.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06760819.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:48:41.932Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-see-if-giving-fianlimab-and-cemiplimab-together-is-be-nct06769698/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06769698.jpg</video:thumbnail_loc>
      <video:title>FDC fianlimab+cemiplimab for Head… (NCT06769698) | Triangle</video:title>
      <video:description>FDC fianlimab+cemiplimab trial for Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT06769698). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06769698.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06769698.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:22:21.323Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-test-dsp107-in-combination-with-atezolizumab-in-compa-nct07235293/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07235293.jpg</video:thumbnail_loc>
      <video:title>DSP107 + Atezolizumab (NCT07235293) | Triangle</video:title>
      <video:description>DSP107 + Atezolizumab trial for Colorectal Cancer (NCT07235293). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07235293.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07235293.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:21:31.312Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-to-test-inavolisib-treatments-in-participants-with-early-nct07054190/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07054190.jpg</video:thumbnail_loc>
      <video:title>Inavolisib for Breast Cancer (NCT07054190) | Triangle</video:title>
      <video:description>Inavolisib trial for Breast Cancer (NCT07054190). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07054190.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07054190.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:28:43.562Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-study-using-nivolumab-in-combination-with-chemotherapy-drugs-t-nct06064097/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06064097.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Stage II… (NCT06064097) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Stage II Nasopharyngeal Carcinoma AJCC v8 (NCT06064097). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06064097.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06064097.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:18:24.653Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-trial-evaluating-the-efficacy-of-ivonescimab-in-metastatic-end-nct07229417/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07229417.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab for Metastatic… (NCT07229417) | Triangle</video:title>
      <video:description>Ivonescimab trial for Metastatic Endocrine Refractory (NCT07229417). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07229417.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07229417.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:49:34.341Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-trial-of-durvalumab-medi4736-plus-monalizumab-in-non-muscle-in-nct06503614/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06503614.jpg</video:thumbnail_loc>
      <video:title>Durvalumab for Non-muscle… (NCT06503614) | Triangle</video:title>
      <video:description>Durvalumab trial for Non-muscle Invasive Bladder Cancer (NCT06503614). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06503614.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06503614.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:45:45.736Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/a-ugt1a1-genotype-directed-study-of-belinostat-pharmacokinetics-nct06406465/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06406465.jpg</video:thumbnail_loc>
      <video:title>Belinostat for Carcinoma, Neuroendocrine (NCT06406465) | Triangle</video:title>
      <video:description>Belinostat trial for Carcinoma, Neuroendocrine (NCT06406465). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06406465.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06406465.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:26:22.983Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/abemaciclib-for-bone-and-soft-tissue-sarcoma-with-cyclin-depende-nct04040205/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04040205.jpg</video:thumbnail_loc>
      <video:title>Abemaciclib for Chondrosarcoma (NCT04040205) | Triangle</video:title>
      <video:description>Abemaciclib trial for Chondrosarcoma (NCT04040205). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04040205.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04040205.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:02:13.255Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/abemaciclib-for-the-treatment-of-recurrent-ovarian-or-endometria-nct04469764/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04469764.jpg</video:thumbnail_loc>
      <video:title>Abemaciclib for Recurrent… (NCT04469764) | Triangle</video:title>
      <video:description>Abemaciclib trial for Recurrent Endometrial Carcinoma (NCT04469764). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04469764.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04469764.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:34:37.404Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/abi-pred-adt-vs-adt-in-psma-positive-conventionally-node-negativ-nct07237269/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07237269.jpg</video:thumbnail_loc>
      <video:title>Androgen Deprivation Therapy (ADT) (NCT07237269) | Triangle</video:title>
      <video:description>Androgen Deprivation Therapy (ADT) trial for Prostate Cancer (NCT07237269). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07237269.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07237269.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:10:29.225Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/abiraterone-enzalutamide-or-apalutamide-in-castrate-sensitive-pr-nct05422911/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05422911.jpg</video:thumbnail_loc>
      <video:title>Abiraterone acetate for Metastatic… (NCT05422911) | Triangle</video:title>
      <video:description>Abiraterone acetate trial for Metastatic Cancer (NCT05422911). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05422911.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05422911.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:00:24.359Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/acalabrutinib-in-combination-with-venetoclax-for-the-treatment-o-nct04941716/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04941716.jpg</video:thumbnail_loc>
      <video:title>Acalabrutinib for Recurrent… (NCT04941716) | Triangle</video:title>
      <video:description>Acalabrutinib trial for Recurrent Chronic Lymphocytic Leukemia (NCT04941716). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04941716.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04941716.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:59:12.631Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/acalabrutinib-lenalidomide-and-rituximab-for-the-treatment-of-cd-nct04404088/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04404088.jpg</video:thumbnail_loc>
      <video:title>Acalabrutinib for Ann Arbor Stage… (NCT04404088) | Triangle</video:title>
      <video:description>Acalabrutinib trial for Ann Arbor Stage III Grade 1 Follicular Lymphoma (NCT04404088). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04404088.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04404088.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:41:06.582Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/acalabrutinib-with-da-epoch-r-or-r-chop-for-people-with-untreate-nct04002947/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04002947.jpg</video:thumbnail_loc>
      <video:title>DA-EPOCH for Non-Hodgkin's Lymphoma (NCT04002947) | Triangle</video:title>
      <video:description>DA-EPOCH trial for Non-Hodgkin's Lymphoma (NCT04002947). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04002947.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04002947.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:14:44.321Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/acalabrutinib-with-or-without-obinutuzumab-in-treating-patients-nct03516617/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03516617.jpg</video:thumbnail_loc>
      <video:title>Acalabrutinib for Chronic… (NCT03516617) | Triangle</video:title>
      <video:description>Acalabrutinib trial for Chronic Lymphocytic Leukemia (NCT03516617). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03516617.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03516617.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:15:05.770Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/acoustic-cluster-therapy-act-with-chemotherapy-for-the-treatment-nct06850623/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06850623.jpg</video:thumbnail_loc>
      <video:title>Acoustic Cluster Therapy (NCT06850623) | Triangle</video:title>
      <video:description>Acoustic Cluster Therapy trial for Locally Advanced Pancreatic Adenocarcinoma (NCT06850623). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06850623.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06850623.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:47:32.111Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/act001-for-the-treatment-of-diffuse-intrinsic-pontine-gliomas-an-nct06838676/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06838676.jpg</video:thumbnail_loc>
      <video:title>ACT001 for Diffuse Intrinsic… (NCT06838676) | Triangle</video:title>
      <video:description>ACT001 trial for Diffuse Intrinsic Pontine Gliomas (DIPG) (NCT06838676). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06838676.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06838676.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:55:19.540Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ad-hoc-trial-artificial-intelligence-based-drug-dosing-in-hepato-nct05669339/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05669339.jpg</video:thumbnail_loc>
      <video:title>Irinotecan for Hepatocellular Carcinoma (NCT05669339) | Triangle</video:title>
      <video:description>Irinotecan trial for Hepatocellular Carcinoma (NCT05669339). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05669339.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05669339.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:04:49.249Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/adaptive-dosing-of-immune-checkpoint-inhibitors-for-hepatocellul-nct07689175/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07689175.jpg</video:thumbnail_loc>
      <video:title>Nivolumab for Hepatocellular… (NCT07689175) | Triangle</video:title>
      <video:description>Nivolumab trial for Hepatocellular Carcinoma (HCC) (NCT07689175). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07689175.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07689175.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:10:12.634Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/adaptive-therapy-with-capecitabine-for-treatment-of-metastatic-e-nct06525766/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06525766.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06525766) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Anatomic Stage IV Breast Cancer AJCC v8 (NCT06525766). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06525766.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06525766.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:01:50.837Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/adding-a-live-biotherapeutic-product-cbm588-to-pembrolizumab-for-nct07037004/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07037004.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Clear… (NCT07037004) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Clear Cell Renal Cell Carcinoma (NCT07037004). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07037004.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07037004.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:11:43.045Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/adding-dasatinib-or-venetoclax-to-improve-responses-in-children-nct06390319/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06390319.jpg</video:thumbnail_loc>
      <video:title>Dexamethasone for T-cell Acute… (NCT06390319) | Triangle</video:title>
      <video:description>Dexamethasone trial for T-cell Acute Lymphoblastic Leukemia (NCT06390319). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06390319.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06390319.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:08:51.443Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorec-nct06728072/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06728072.jpg</video:thumbnail_loc>
      <video:title>Standard of Care Chemotherapy +… (NCT06728072) | Triangle</video:title>
      <video:description>Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin trial for Colorectal Cancer (NCT06728072). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06728072.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06728072.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:54:48.293Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/adjuvant-chemotherapy-and-immunotherapy-for-completely-resected-nct07149363/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07149363.jpg</video:thumbnail_loc>
      <video:title>Durvalumab 50 MG/ML for Small… (NCT07149363) | Triangle</video:title>
      <video:description>Durvalumab 50 MG/ML trial for Small Cell Lung Cancer (SCLC) (NCT07149363). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07149363.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07149363.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:45:51.027Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/adjuvant-ip-001-treatment-for-hcc-patients-following-surgical-re-nct06526338/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06526338.jpg</video:thumbnail_loc>
      <video:title>1.0% IP-001 for injection (NCT06526338) | Triangle</video:title>
      <video:description>1.0% IP-001 for injection trial for Hepatocellular Carcinoma (NCT06526338). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06526338.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06526338.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:38:34.290Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/adjuvant-quisinostat-in-high-risk-uveal-melanoma-nct06932757/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06932757.jpg</video:thumbnail_loc>
      <video:title>Quisinostat for Uveal Melanoma (NCT06932757) | Triangle</video:title>
      <video:description>Quisinostat trial for Uveal Melanoma (NCT06932757). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06932757.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06932757.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:47:06.423Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/administration-of-autologous-t-cells-genetically-engineered-to-e-nct03412877/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03412877.jpg</video:thumbnail_loc>
      <video:title>Cyclophosphamide for Endocrine Tumors (NCT03412877) | Triangle</video:title>
      <video:description>Cyclophosphamide trial for Endocrine Tumors (NCT03412877). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03412877.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03412877.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:01:27.469Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/all-backbone-in-ayas-nct07227584/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227584.jpg</video:thumbnail_loc>
      <video:title>Blinatumomab for Acute… (NCT07227584) | Triangle</video:title>
      <video:description>Blinatumomab trial for Acute Lymphoblastic Leukemia (NCT07227584). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07227584.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227584.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:57:28.109Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/allo-hsct-using-ric-and-ptcy-for-hematological-diseases-nct05805605/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05805605.jpg</video:thumbnail_loc>
      <video:title>Peripheral Blood Stem Cell… (NCT05805605) | Triangle</video:title>
      <video:description>Peripheral Blood Stem Cell Transplant trial for Acute Myelogenous Leukemia (NCT05805605). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05805605.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05805605.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:26:23.145Z</video:publication_date>
      <video:duration>92</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/allosct-for-malignant-and-non-malignant-hematologic-diseases-uti-nct04099966/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04099966.jpg</video:thumbnail_loc>
      <video:title>alpha beta depletion for Acute Leukemia (NCT04099966) | Triangle</video:title>
      <video:description>alpha beta depletion trial for Acute Leukemia (NCT04099966). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04099966.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04099966.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:01:30.606Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/alternate-doses-and-dosing-schedules-of-belantamab-mafodotin-for-nct05847569/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05847569.jpg</video:thumbnail_loc>
      <video:title>Belantamab Mafodotin for Recurrent… (NCT05847569) | Triangle</video:title>
      <video:description>Belantamab Mafodotin trial for Recurrent Multiple Myeloma (NCT05847569). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05847569.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05847569.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:06:52.112Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/alternating-chemo-immunotherapy-and-fgfr-inhibitor-for-fgfr-posi-nct07780838/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07780838.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Locally… (NCT07780838) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Locally Advanced Ampulla of Vater Carcinoma (NCT07780838). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07780838.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07780838.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:29:16.305Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/an-adjuvant-study-to-evaluate-sms001-paclitaxel-in-non-small-cel-nct06693336/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06693336.jpg</video:thumbnail_loc>
      <video:title>SMS001 for Carcinoma… (NCT06693336) | Triangle</video:title>
      <video:description>SMS001 trial for Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) (NCT06693336). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06693336.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06693336.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:00:35.455Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/an-evaluation-of-maintenance-therapy-combination-mirvetuximab-so-nct05887609/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05887609.jpg</video:thumbnail_loc>
      <video:title>Mirvetuximab Soravtansine-gynx (NCT05887609) | Triangle</video:title>
      <video:description>Mirvetuximab Soravtansine-gynx trial for Ovary Cancer (NCT05887609). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05887609.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05887609.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:14:58.419Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/androgen-ablation-therapy-with-or-without-niraparib-after-radiat-nct04947254/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04947254.jpg</video:thumbnail_loc>
      <video:title>Abiraterone Acetate for Prostate… (NCT04947254) | Triangle</video:title>
      <video:description>Abiraterone Acetate trial for Prostate Carcinoma (NCT04947254). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04947254.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04947254.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:02:19.057Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/anti-pd-1-mab-plus-metabolic-modulator-in-solid-tumor-malignanci-nct04114136/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04114136.jpg</video:thumbnail_loc>
      <video:title>Nivolumab or Pembrolizumab… (NCT04114136) | Triangle</video:title>
      <video:description>Nivolumab or Pembrolizumab (dependent upon approved indication) trial for Melanoma (NCT04114136). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04114136.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04114136.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:02:55.305Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/apollo-a-randomized-phase-ii-double-blind-study-of-olaparib-vers-nct04858334/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04858334.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT04858334) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Pancreatic Acinar Cell Carcinoma (NCT04858334). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04858334.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04858334.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:50:35.027Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/asparaginase-erwinia-chrysanthemi-with-chemotherapy-for-the-trea-nct06918431/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06918431.jpg</video:thumbnail_loc>
      <video:title>Asparaginase Erwinia chrysanthemi (NCT06918431) | Triangle</video:title>
      <video:description>Asparaginase Erwinia chrysanthemi trial for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (NCT06918431). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06918431.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06918431.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:46:22.147Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/aspen-09-03-a-study-of-evorpacept-in-combination-with-trastuzuma-nct07007559/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07007559.jpg</video:thumbnail_loc>
      <video:title>Evorpacept (ALX148) for Breast… (NCT07007559) | Triangle</video:title>
      <video:description>Evorpacept (ALX148) trial for Breast Cancer, Metastatic (NCT07007559). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07007559.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07007559.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:11:14.680Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/assessment-of-decision-tool-to-select-women-for-gynecologic-spar-nct06184516/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06184516.jpg</video:thumbnail_loc>
      <video:title>Reproductive organ sparing… (NCT06184516) | Triangle</video:title>
      <video:description>Reproductive organ sparing radical cystectomy trial for Urothelial Carcinoma Bladder (NCT06184516). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06184516.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06184516.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:57:11.414Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/atempt-2-0-adjuvant-t-dm1-vs-th-nct04893109/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04893109.jpg</video:thumbnail_loc>
      <video:title>trastuzumab-emtansine for Breast Cancer (NCT04893109) | Triangle</video:title>
      <video:description>trastuzumab-emtansine trial for Breast Cancer (NCT04893109). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04893109.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04893109.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:50:51.820Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/atezolizumab-and-cabozantinib-for-the-treatment-of-adolescents-a-nct05019703/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05019703.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Locally Advanced… (NCT05019703) | Triangle</video:title>
      <video:description>Atezolizumab trial for Locally Advanced Osteosarcoma (NCT05019703). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05019703.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05019703.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:43:35.593Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/atezolizumab-in-combination-with-a-multi-kinase-inhibitor-for-th-nct05168163/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05168163.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Locally Advanced… (NCT05168163) | Triangle</video:title>
      <video:description>Atezolizumab trial for Locally Advanced Hepatocellular Carcinoma (NCT05168163). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05168163.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05168163.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:37:20.192Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/atezolizumab-plus-etoposide-and-platinum-in-small-cell-bladder-c-nct05312671/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05312671.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Small Cell… (NCT05312671) | Triangle</video:title>
      <video:description>Atezolizumab trial for Small Cell Neuroendocrine Carcinoma of Bladder (NCT05312671). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05312671.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05312671.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:49:23.425Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/autologous-ln-145-in-patients-with-metastatic-non-small-cell-lun-nct04614103/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04614103.jpg</video:thumbnail_loc>
      <video:title>LN-145 for Metastatic Non Small… (NCT04614103) | Triangle</video:title>
      <video:description>LN-145 trial for Metastatic Non Small Cell Lung Cancer (NCT04614103). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04614103.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04614103.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:48:14.401Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/azacitidine-and-enasidenib-in-treating-patients-with-idh2-mutant-nct03383575/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03383575.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Myeloid Leukemia (NCT03383575) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Myeloid Leukemia (NCT03383575). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03383575.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03383575.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:47:10.318Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/azd0901-in-participants-with-advanced-solid-tumours-expressing-c-nct06219941/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06219941.jpg</video:thumbnail_loc>
      <video:title>AZD0901 for Gastric Cancer (NCT06219941) | Triangle</video:title>
      <video:description>AZD0901 trial for Gastric Cancer (NCT06219941). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06219941.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06219941.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:30:37.508Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/bal-bot-agent-797-in-pmmr-crc-with-liver-metastases-nct07550088/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07550088.jpg</video:thumbnail_loc>
      <video:title>Balstilimab (BAL) for Colorectal… (NCT07550088) | Triangle</video:title>
      <video:description>Balstilimab (BAL) trial for Colorectal Cancer Metastatic (NCT07550088). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07550088.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07550088.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:05:34.541Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/belantamab-mafodotin-pomalidomide-and-dexamethasone-for-the-trea-nct05208307/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05208307.jpg</video:thumbnail_loc>
      <video:title>Belantamab Mafodotin for Plasma… (NCT05208307) | Triangle</video:title>
      <video:description>Belantamab Mafodotin trial for Plasma Cell Myeloma (NCT05208307). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05208307.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05208307.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:55:09.455Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/belzutifan-mk-6482-for-the-treatment-of-advanced-pheochromocytom-nct04924075/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04924075.jpg</video:thumbnail_loc>
      <video:title>Belzutifan (NCT04924075) | Triangle</video:title>
      <video:description>Belzutifan trial for Pheochromocytoma/Paraganglioma (NCT04924075). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04924075.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04924075.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:55:32.999Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/bicazo-a-study-combining-two-immunotherapies-cabozantinib-and-ni-nct05136196/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05136196.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Clinical… (NCT05136196) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Clinical Stage III Cutaneous Melanoma AJCC v8 (NCT05136196). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05136196.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05136196.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:27:10.043Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/binimetinib-and-imatinib-for-unresectable-stage-iii-iv-kit-mutan-nct04598009/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04598009.jpg</video:thumbnail_loc>
      <video:title>Binimetinib for Melanoma Stage III (NCT04598009) | Triangle</video:title>
      <video:description>Binimetinib trial for Melanoma Stage III (NCT04598009). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04598009.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04598009.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:35:49.336Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/binimetinib-for-people-with-relapsed-refractory-braf-wild-type-h-nct04322383/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04322383.jpg</video:thumbnail_loc>
      <video:title>binimetinib for Hairy Cell Leukemia (NCT04322383) | Triangle</video:title>
      <video:description>binimetinib trial for Hairy Cell Leukemia (NCT04322383). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04322383.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04322383.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:04:33.178Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/biologically-guided-radiation-therapy-bgrt-and-stereotactic-body-nct06014827/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06014827.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Lung… (NCT06014827) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Lung Non-Small Cell Carcinoma (NCT06014827). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06014827.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06014827.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:29:01.289Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/bladder-preservation-for-patients-with-muscle-invasive-bladder-c-nct06417190/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06417190.jpg</video:thumbnail_loc>
      <video:title>Trimodal therapy (TMT) within 45… (NCT06417190) | Triangle</video:title>
      <video:description>Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC) trial for Muscle-Invasive Bladder Carcinoma (NCT06417190). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06417190.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06417190.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:19:17.655Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/bms-986340-in-combination-with-nivolumab-gemcitabine-and-nab-pac-nct07226856/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07226856.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Metastatic… (NCT07226856) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Metastatic Pancreatic Adenocarcinoma (NCT07226856). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07226856.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07226856.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:23:59.738Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/brain-metastases-in-greater-size-hypofractionated-options-trial-nct07227610/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227610.jpg</video:thumbnail_loc>
      <video:title>Staged Stereotactic Radiosurgery… (NCT07227610) | Triangle</video:title>
      <video:description>Staged Stereotactic Radiosurgery (SSRS) trial for Brain Metastases (NCT07227610). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07227610.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227610.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:26:50.602Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/bre-10-biomarker-optimization-of-neoadjuvant-therapy-in-breast-c-nct06441890/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06441890.jpg</video:thumbnail_loc>
      <video:title>Paclitaxel for Breast Cancer (NCT06441890) | Triangle</video:title>
      <video:description>Paclitaxel trial for Breast Cancer (NCT06441890). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06441890.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06441890.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:49:06.540Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/brentuximab-vedotin-and-bendamustine-for-the-treatment-of-relaps-nct04587687/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04587687.jpg</video:thumbnail_loc>
      <video:title>Bendamustine Hydrochloride (NCT04587687) | Triangle</video:title>
      <video:description>Bendamustine Hydrochloride trial for Recurrent Follicular Lymphoma (NCT04587687). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04587687.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04587687.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:42:15.122Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/brentuximab-vedotin-and-nivolumab-for-the-treatment-of-patients-nct04561206/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04561206.jpg</video:thumbnail_loc>
      <video:title>Brentuximab Vedotin for Relapsed… (NCT04561206) | Triangle</video:title>
      <video:description>Brentuximab Vedotin trial for Relapsed Classic Hodgkin Lymphoma (NCT04561206). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04561206.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04561206.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:05:51.422Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/brentuximab-vedotin-and-nivolumab-for-the-treatment-of-relapsed-nct05039073/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05039073.jpg</video:thumbnail_loc>
      <video:title>Brentuximab Vedotin for Recurrent… (NCT05039073) | Triangle</video:title>
      <video:description>Brentuximab Vedotin trial for Recurrent Classic Hodgkin Lymphoma (NCT05039073). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05039073.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05039073.mp4</video:content_loc>
      <video:publication_date>2026-10-31T18:41:11.709Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cabazitaxel-carboplatin-vs-177lu-psma-617-in-metastatic-castrate-nct06738303/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06738303.jpg</video:thumbnail_loc>
      <video:title>Cabazitaxel and carboplatin (NCT06738303) | Triangle</video:title>
      <video:description>Cabazitaxel and carboplatin trial for Metastatic Prostate Cancer (NCT06738303). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06738303.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06738303.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:56:44.033Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cabozantinib-combined-with-ipilimumab-nivolumab-and-tace-in-pati-nct04472767/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04472767.jpg</video:thumbnail_loc>
      <video:title>Nivolumab for Hepatocellular Carcinoma (NCT04472767) | Triangle</video:title>
      <video:description>Nivolumab trial for Hepatocellular Carcinoma (NCT04472767). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04472767.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04472767.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:13:50.612Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cabozantinib-in-patients-with-ret-fusion-positive-advanced-non-s-nct01639508/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT01639508.jpg</video:thumbnail_loc>
      <video:title>Cabozantinib for Non-Small Cell… (NCT01639508) | Triangle</video:title>
      <video:description>Cabozantinib trial for Non-Small Cell Lung Cancer (NCT01639508). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT01639508.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT01639508.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:23:47.059Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/candida-therapeutic-vaccine-in-head-and-neck-cancer-patients-to-nct05952934/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05952934.jpg</video:thumbnail_loc>
      <video:title>0.5 mL Candin®/injection (NCT05952934) | Triangle</video:title>
      <video:description>0.5 mL Candin®/injection trial for Squamous Cell Carcinoma of Head and Neck (NCT05952934). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05952934.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05952934.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:22:12.837Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/captemy90-for-grade-2-3-net-liver-metastases-nct04339036/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04339036.jpg</video:thumbnail_loc>
      <video:title>Capecitabine Oral Product (NCT04339036) | Triangle</video:title>
      <video:description>Capecitabine Oral Product trial for Neuroendocrine Tumor Grade 2 (NCT04339036). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04339036.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04339036.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:49:36.447Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/car-t-cell-therapy-in-patients-with-renal-dysfunction-nct05909059/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05909059.jpg</video:thumbnail_loc>
      <video:title>Fludarabine for Non-hodgkin… (NCT05909059) | Triangle</video:title>
      <video:description>Fludarabine trial for Non-hodgkin Lymphoma,B Cell (NCT05909059). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05909059.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05909059.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:18:51.835Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/carboplatin-taxane-and-ramucirumab-for-patients-with-nsclc-after-nct04332367/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04332367.jpg</video:thumbnail_loc>
      <video:title>Carboplatin for Non-small Cell… (NCT04332367) | Triangle</video:title>
      <video:description>Carboplatin trial for Non-small Cell Lung Cancer (NCT04332367). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04332367.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04332367.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:09:22.133Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cd22-car-t-cells-to-extend-remission-following-commercial-cd19-c-nct07328503/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07328503.jpg</video:thumbnail_loc>
      <video:title>CD22 CAR-transduced T cells (NCT07328503) | Triangle</video:title>
      <video:description>CD22 CAR-transduced T cells trial for Acute Lymphoblastic Leukemia (NCT07328503). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07328503.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07328503.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:24:43.670Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cemiplimab-and-cetuximab-prior-salvage-surgery-in-patients-with-nct06448026/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06448026.jpg</video:thumbnail_loc>
      <video:title>Cemiplimab for Locally Recurrent… (NCT06448026) | Triangle</video:title>
      <video:description>Cemiplimab trial for Locally Recurrent Oral Cavity Squamous Cell Carcinoma (NCT06448026). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06448026.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06448026.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:43:38.775Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cemiplimab-for-the-treatment-of-incurable-metastatic-or-unresect-nct07050186/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07050186.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Metastatic… (NCT07050186) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Metastatic NUT Carcinoma (NCT07050186). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07050186.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07050186.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:52:52.354Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cemiplimab-plus-gemcitabine-in-patients-with-metastatic-pancreat-nct06790602/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06790602.jpg</video:thumbnail_loc>
      <video:title>Cemiplimab Plus Gemcitabine (NCT06790602) | Triangle</video:title>
      <video:description>Cemiplimab Plus Gemcitabine trial for Pancreatic Ductal Adenocarcinoma (mPDAC) (NCT06790602). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06790602.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06790602.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:09:27.796Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cetuximab-after-immunotherapy-for-the-treatment-of-head-and-neck-nct04375384/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04375384.jpg</video:thumbnail_loc>
      <video:title>Cetuximab for Head and Neck… (NCT04375384) | Triangle</video:title>
      <video:description>Cetuximab trial for Head and Neck Squamous Cell Carcinoma (NCT04375384). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04375384.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04375384.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:35:08.231Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/chemotherapy-anakinra-in-patients-with-pancreatic-adenocarcinoma-nct04926467/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04926467.jpg</video:thumbnail_loc>
      <video:title>Anakinra for Pancreatic Adenocarcinoma (NCT04926467) | Triangle</video:title>
      <video:description>Anakinra trial for Pancreatic Adenocarcinoma (NCT04926467). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04926467.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04926467.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:50:39.815Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/chemotherapy-and-radiation-therapy-for-the-treatment-of-idh-wild-nct04623931/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04623931.jpg</video:thumbnail_loc>
      <video:title>Quality-of-Life Assessment (NCT04623931) | Triangle</video:title>
      <video:description>Quality-of-Life Assessment trial for Anaplastic Astrocytoma, IDH-Wildtype (NCT04623931). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04623931.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04623931.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:58:55.794Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/chemotherapy-with-or-without-immunotherapy-for-peritoneal-mesoth-nct05001880/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05001880.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Peritoneal… (NCT05001880) | Triangle</video:title>
      <video:description>Atezolizumab trial for Peritoneal Malignant Mesothelioma (NCT05001880). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05001880.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05001880.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:13:15.346Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/chemotherapy-with-or-without-radiation-or-surgery-in-treating-pa-nct03161522/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03161522.jpg</video:thumbnail_loc>
      <video:title>Capecitabine for Gastric Adenocarcinoma (NCT03161522) | Triangle</video:title>
      <video:description>Capecitabine trial for Gastric Adenocarcinoma (NCT03161522). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03161522.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03161522.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:21:19.505Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/circulating-tumor-dna-nct06923527/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06923527.jpg</video:thumbnail_loc>
      <video:title>Elacestrant for ER+ Breast Cancer (NCT06923527) | Triangle</video:title>
      <video:description>Elacestrant trial for ER+ Breast Cancer (NCT06923527). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06923527.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06923527.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:21:49.412Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/circulating-tumor-dna-to-guide-changes-in-standard-of-care-chemo-nct05770531/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05770531.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT05770531) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Metastatic HER2-Negative Breast Carcinoma (NCT05770531). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05770531.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05770531.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:48:33.530Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cladribine-and-rituximab-in-treating-patients-with-hairy-cell-le-nct00412594/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT00412594.jpg</video:thumbnail_loc>
      <video:title>Cladribine for Hairy Cell Leukemia (NCT00412594) | Triangle</video:title>
      <video:description>Cladribine trial for Hairy Cell Leukemia (NCT00412594). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT00412594.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT00412594.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:04:53.671Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/clag-go-for-patients-with-persistent-relapsed-or-refractory-aml-nct04050280/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04050280.jpg</video:thumbnail_loc>
      <video:title>Cladribine, Cytarabine, and… (NCT04050280) | Triangle</video:title>
      <video:description>Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO) trial for Acute Myeloid Leukemia, Adult (NCT04050280). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04050280.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04050280.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:37:46.986Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cobimetinib-in-refractory-langerhans-cell-histiocytosis-lch-and-nct04079179/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04079179.jpg</video:thumbnail_loc>
      <video:title>Cobimetinib for Langerhan's Cell… (NCT04079179) | Triangle</video:title>
      <video:description>Cobimetinib trial for Langerhan's Cell Histiocytosis (NCT04079179). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04079179.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04079179.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:14:06.933Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/combination-chemotherapy-in-treating-patients-with-relapsed-or-r-nct03136146/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03136146.jpg</video:thumbnail_loc>
      <video:title>Bortezomib for Recurrent Acute… (NCT03136146) | Triangle</video:title>
      <video:description>Bortezomib trial for Recurrent Acute Lymphoblastic Leukemia (NCT03136146). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03136146.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03136146.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:13:08.111Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/combination-therapy-for-the-treatment-of-diffuse-midline-gliomas-nct05009992/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05009992.jpg</video:thumbnail_loc>
      <video:title>ONC201 for Diffuse Intrinsic… (NCT05009992) | Triangle</video:title>
      <video:description>ONC201 trial for Diffuse Intrinsic Pontine Glioma (NCT05009992). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05009992.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05009992.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:45:40.212Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/combination-therapy-using-durvalumab-and-histotripsy-for-treatme-nct07766187/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07766187.jpg</video:thumbnail_loc>
      <video:title>Histotripsy for Intrahepatic… (NCT07766187) | Triangle</video:title>
      <video:description>Histotripsy trial for Intrahepatic Cholangiocarcinoma (NCT07766187). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07766187.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07766187.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:20:21.888Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/combined-systemic-and-intraperitoneal-chemotherapy-for-synchrono-nct07475286/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07475286.jpg</video:thumbnail_loc>
      <video:title>Cisplatin for Synchronous Gastric… (NCT07475286) | Triangle</video:title>
      <video:description>Cisplatin trial for Synchronous Gastric Peritoneal Carcinomatosis (NCT07475286). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07475286.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07475286.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:17:31.454Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/comparing-cytarabine-daunorubicin-therapy-versus-cytarabine-daun-nct05554393/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05554393.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Myeloid Leukemia (NCT05554393) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Myeloid Leukemia (NCT05554393). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05554393.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05554393.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:30:13.977Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/comparing-different-treatment-lengths-for-venetoclax-in-older-pe-nct07437950/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07437950.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Acute… (NCT07437950) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Acute Myeloid Leukemia (NCT07437950). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07437950.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07437950.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:24:28.360Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/comparing-new-treatments-for-people-with-newly-diagnosed-acute-m-nct06672146/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06672146.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Acute… (NCT06672146) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Acute Myeloid Leukemia (NCT06672146). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06672146.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06672146.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:34:43.112Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/comparing-the-effectiveness-of-the-immunotherapy-agents-rituxima-nct05886036/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05886036.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Nodular… (NCT05886036) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Nodular Lymphocyte Predominant B-Cell Lymphoma (NCT05886036). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05886036.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05886036.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:19:16.706Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/comparing-the-radiopharmaceutical-drug-177lu-lu-dotatate-to-stan-nct06955169/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06955169.jpg</video:thumbnail_loc>
      <video:title>[177Lu]Lu-DOTATATE (NCT06955169) | Triangle</video:title>
      <video:description>[177Lu]Lu-DOTATATE trial for Intracranial Meningioma (NCT06955169). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06955169.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06955169.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:48:50.291Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/concurrent-immunotherapy-and-systemic-therapy-with-stereotactic-nct07770100/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07770100.jpg</video:thumbnail_loc>
      <video:title>Stereotactic Body Radiation… (NCT07770100) | Triangle</video:title>
      <video:description>Stereotactic Body Radiation Therapy (SBRT) trial for Head and Neck Cancer (NCT07770100). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07770100.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07770100.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:23:51.227Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/consolidation-of-first-line-mrd-remission-with-cema-cel-in-patie-nct06500273/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06500273.jpg</video:thumbnail_loc>
      <video:title>cemacabtagene ansegedleucel (NCT06500273) | Triangle</video:title>
      <video:description>cemacabtagene ansegedleucel trial for Large B-cell Lymphoma (NCT06500273). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06500273.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06500273.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:28:23.228Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/consolidative-local-therapy-clt-in-oligo-metastatic-urothelial-c-nct07048457/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07048457.jpg</video:thumbnail_loc>
      <video:title>Radical cystectomy for Locally… (NCT07048457) | Triangle</video:title>
      <video:description>Radical cystectomy trial for Locally Advanced Urothelial Carcinoma (NCT07048457). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07048457.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07048457.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:53:40.346Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cord-blood-transplant-cyclophosphamide-fludarabine-and-total-bod-nct06013423/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06013423.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Acute… (NCT06013423) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Acute Leukemia of Ambiguous Lineage (NCT06013423). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06013423.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06013423.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:09:14.734Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cpx-351-and-ivosidenib-for-the-treatment-of-idh1-mutated-acute-m-nct04493164/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04493164.jpg</video:thumbnail_loc>
      <video:title>Ivosidenib for Acute Myeloid… (NCT04493164) | Triangle</video:title>
      <video:description>Ivosidenib trial for Acute Myeloid Leukemia With Gene Mutations (NCT04493164). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04493164.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04493164.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:41:57.500Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cryoablation-ipilimumab-nivolumab-in-melanoma-nct05779423/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05779423.jpg</video:thumbnail_loc>
      <video:title>Ipilimumab for Metastatic Melanoma (NCT05779423) | Triangle</video:title>
      <video:description>Ipilimumab trial for Metastatic Melanoma (NCT05779423). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05779423.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05779423.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:55:14.084Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ctdna-guided-addition-of-ipilimumab-to-patients-receiving-nivolu-nct07504796/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07504796.jpg</video:thumbnail_loc>
      <video:title>Nivolumab for Metastatic Melanoma (NCT07504796) | Triangle</video:title>
      <video:description>Nivolumab trial for Metastatic Melanoma (NCT07504796). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07504796.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07504796.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:43:39.368Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ctdna-guided-sunitinib-and-regorafenib-therapy-for-gist-nct05366816/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05366816.jpg</video:thumbnail_loc>
      <video:title>Sunitinib for Gastrointestinal… (NCT05366816) | Triangle</video:title>
      <video:description>Sunitinib trial for Gastrointestinal Stromal Tumors (NCT05366816). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05366816.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05366816.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:57:49.263Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ctdna-guided-therapy-for-relapsed-refractory-hodgkin-lymphoma-nct07021989/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07021989.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Hodgkin… (NCT07021989) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Hodgkin Lymphoma, Adult (NCT07021989). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07021989.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07021989.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:03:26.742Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cthpvdna-response-adapted-chemoradiation-retifanlimab-treatment-nct07425054/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07425054.jpg</video:thumbnail_loc>
      <video:title>HPV ctDNA Response based radiation (NCT07425054) | Triangle</video:title>
      <video:description>HPV ctDNA Response based radiation trial for Anal Cancer (NCT07425054). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07425054.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07425054.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:40:45.408Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/cyclophosphamide-and-sirolimus-for-the-treatment-of-metastatic-r-nct03099356/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03099356.jpg</video:thumbnail_loc>
      <video:title>Cyclophosphamide for Metastatic… (NCT03099356) | Triangle</video:title>
      <video:description>Cyclophosphamide trial for Metastatic Thyroid Cancer (NCT03099356). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03099356.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03099356.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:43:12.529Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/dabrafenib-and-trametinib-for-braf-v600-mutant-low-grade-gliomas-nct07110246/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07110246.jpg</video:thumbnail_loc>
      <video:title>Dabrafenib for BRAF V600 Mutation (NCT07110246) | Triangle</video:title>
      <video:description>Dabrafenib trial for BRAF V600 Mutation (NCT07110246). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07110246.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07110246.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:27:27.432Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/daly-ii-usa-mb-cart2019-1-for-dlbcl-nct04792489/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04792489.jpg</video:thumbnail_loc>
      <video:title>zamtocabtagene autoleucel… (NCT04792489) | Triangle</video:title>
      <video:description>zamtocabtagene autoleucel (MB-CART2019.1) trial for Refractory Diffuse Large B Cell Lymphoma (DLBCL) (NCT04792489). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04792489.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04792489.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:18:29.614Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/daratumumab-for-chemotherapy-refractory-minimal-residual-disease-nct05289687/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05289687.jpg</video:thumbnail_loc>
      <video:title>Daratumumab / Hyaluronidase… (NCT05289687) | Triangle</video:title>
      <video:description>Daratumumab / Hyaluronidase Injection trial for T-cell Acute Lymphoblastic Leukemia (NCT05289687). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05289687.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05289687.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:36:36.236Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/daratumumab-for-relapsed-refractory-primary-effusion-lymphoma-pl-nct05907759/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05907759.jpg</video:thumbnail_loc>
      <video:title>Daratumumab SC for Lymphoma… (NCT05907759) | Triangle</video:title>
      <video:description>Daratumumab SC trial for Lymphoma, Primary Effusion (NCT05907759). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05907759.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05907759.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:30:03.988Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/dareontm-5-a-study-to-test-whether-different-doses-of-bi-764532-nct05882058/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05882058.jpg</video:thumbnail_loc>
      <video:title>BI 764532, dose 1 for Small Cell… (NCT05882058) | Triangle</video:title>
      <video:description>BI 764532, dose 1 trial for Small Cell Lung Carcinoma (NCT05882058). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05882058.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05882058.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:16:27.263Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/dasatinib-and-quercetin-with-car-t-therapy-for-the-treatment-of-nct06940297/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06940297.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Recurrent… (NCT06940297) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Recurrent Multiple Myeloma (NCT06940297). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06940297.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06940297.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:09:12.373Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/dato-base-datopotamab-deruxtecan-for-breast-cancer-brain-metasta-nct06176261/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06176261.jpg</video:thumbnail_loc>
      <video:title>Datopotamab Deruxtecan for Breast Cancer (NCT06176261) | Triangle</video:title>
      <video:description>Datopotamab Deruxtecan trial for Breast Cancer (NCT06176261). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06176261.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06176261.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:18:40.869Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/dcis-recast-trial-ductal-carcinoma-in-situ-re-evaluating-conditi-nct06075953/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06075953.jpg</video:thumbnail_loc>
      <video:title>Tamoxifen for Ductal Carcinoma in Situ (NCT06075953) | Triangle</video:title>
      <video:description>Tamoxifen trial for Ductal Carcinoma in Situ (NCT06075953). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06075953.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06075953.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:29:51.976Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/decitabine-cedazuridine-inqovi-an-oral-dna-demethylating-agent-i-nct05960773/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05960773.jpg</video:thumbnail_loc>
      <video:title>Decitabine/cedazuridine for Mesothelioma (NCT05960773) | Triangle</video:title>
      <video:description>Decitabine/cedazuridine trial for Mesothelioma (NCT05960773). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05960773.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05960773.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:28:58.826Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/decitabine-with-ruxolitinib-fedratinib-or-pacritinib-for-the-tre-nct04282187/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04282187.jpg</video:thumbnail_loc>
      <video:title>Decitabine for Acute Myeloid Leukemia (NCT04282187) | Triangle</video:title>
      <video:description>Decitabine trial for Acute Myeloid Leukemia (NCT04282187). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04282187.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04282187.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:32:26.376Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/defining-the-ablative-dose-for-y-90-tare-nct07586046/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07586046.jpg</video:thumbnail_loc>
      <video:title>Yttrium-90 Radiation… (NCT07586046) | Triangle</video:title>
      <video:description>Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres trial for HCC - Hepatocellular Carcinoma (NCT07586046). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07586046.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07586046.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:36:29.849Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/dfmo-as-maintenance-therapy-for-molecular-high-very-high-risk-an-nct04696029/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04696029.jpg</video:thumbnail_loc>
      <video:title>Difluoromethylornithine (NCT04696029) | Triangle</video:title>
      <video:description>Difluoromethylornithine trial for Medulloblastoma (NCT04696029). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04696029.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04696029.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:01:00.751Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/digoxin-medulloblastoma-study-nct06701812/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06701812.jpg</video:thumbnail_loc>
      <video:title>Digoxin for Medulloblastoma (NCT06701812) | Triangle</video:title>
      <video:description>Digoxin trial for Medulloblastoma (NCT06701812). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06701812.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06701812.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:09:28.825Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/discern-dual-versus-single-icb-in-pdl-1-negative-nsclc-nct06364917/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06364917.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Non Small Cell… (NCT06364917) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Non Small Cell Lung Cancer (NCT06364917). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06364917.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06364917.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:59:45.646Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/doc1021-dendritic-cell-immunotherapy-for-treatment-of-newly-diag-nct06805305/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06805305.jpg</video:thumbnail_loc>
      <video:title>DOC1021 for Glioblastoma (GBM) (NCT06805305) | Triangle</video:title>
      <video:description>DOC1021 trial for Glioblastoma (GBM) (NCT06805305). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06805305.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06805305.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:29:57.049Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/dose-adjusted-epoch-with-or-without-rituximab-plus-ponatinib-for-nct07224100/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07224100.jpg</video:thumbnail_loc>
      <video:title>Cyclophosphamide for B Acute… (NCT07224100) | Triangle</video:title>
      <video:description>Cyclophosphamide trial for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (NCT07224100). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07224100.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07224100.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:00:19.502Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/durvalumab-in-combination-with-chemotherapy-in-treating-patients-nct03907475/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03907475.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Locally… (NCT03907475) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Locally Advanced Malignant Solid Neoplasm (NCT03907475). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03907475.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03907475.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:18:21.990Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/duvelisib-maintenance-for-the-treatment-of-peripheral-t-cell-lym-nct07293403/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07293403.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07293403) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Follicular Helper T-Cell Lymphoma (NCT07293403). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07293403.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07293403.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:09:20.161Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/e7-tcr-t-cell-immunotherapy-for-human-papillomavirus-hpv-associa-nct05686226/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05686226.jpg</video:thumbnail_loc>
      <video:title>E7 TCR-T cells for Cervical Cancer (NCT05686226) | Triangle</video:title>
      <video:description>E7 TCR-T cells trial for Cervical Cancer (NCT05686226). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05686226.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05686226.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:29:48.571Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/effects-of-infusion-timing-on-treatment-response-in-solid-tumors-nct07630168/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07630168.jpg</video:thumbnail_loc>
      <video:title>PD-1/PD-L1 inhibitor monotherapy… (NCT07630168) | Triangle</video:title>
      <video:description>PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM trial for Lung Cancer (NCT07630168). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07630168.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07630168.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:06:18.277Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/efficacy-and-safety-of-nemtabrutinib-mk-1026-in-participants-wit-nct04728893/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04728893.jpg</video:thumbnail_loc>
      <video:title>Nemtabrutinib for Hematologic… (NCT04728893) | Triangle</video:title>
      <video:description>Nemtabrutinib trial for Hematologic Malignancies (NCT04728893). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04728893.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04728893.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:18:34.078Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/efficacy-and-safety-of-tyra-300-in-participants-with-fgfr3-alter-nct06995677/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06995677.jpg</video:thumbnail_loc>
      <video:title>TYRA-300 60mg for Low-grade NMIBC (NCT06995677) | Triangle</video:title>
      <video:description>TYRA-300 60mg trial for Low-grade NMIBC (NCT06995677). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06995677.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06995677.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:34:21.827Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/efficacy-of-hypomethylating-agents-vs-intensive-chemotherapy-in-nct07060001/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07060001.jpg</video:thumbnail_loc>
      <video:title>5hmC Biomarker for Acute Myeloid… (NCT07060001) | Triangle</video:title>
      <video:description>5hmC Biomarker trial for Acute Myeloid Leukemia (AML) (NCT07060001). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07060001.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07060001.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:00:21.663Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/elranatamab-in-r-r-multiple-myeloma-nct06138275/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06138275.jpg</video:thumbnail_loc>
      <video:title>Elranatamab for Refractory… (NCT06138275) | Triangle</video:title>
      <video:description>Elranatamab trial for Refractory Multiple Myeloma (NCT06138275). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06138275.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06138275.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:32:16.606Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/enasidenib-and-azacitidine-in-treating-patients-with-recurrent-o-nct03683433/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03683433.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Bilineal Leukemia (NCT03683433) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Bilineal Leukemia (NCT03683433). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03683433.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03683433.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:40:51.272Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/enasidenib-in-idh2-mutated-malignant-sinonasal-and-skull-base-tu-nct06176989/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06176989.jpg</video:thumbnail_loc>
      <video:title>Enasidenib for Metastatic Chondrosarcoma (NCT06176989) | Triangle</video:title>
      <video:description>Enasidenib trial for Metastatic Chondrosarcoma (NCT06176989). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06176989.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06176989.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:24:47.590Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/endocrine-treatment-alone-for-elderly-patients-with-estrogen-rec-nct02476786/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02476786.jpg</video:thumbnail_loc>
      <video:title>FACT-B for Breast Cancer (NCT02476786) | Triangle</video:title>
      <video:description>FACT-B trial for Breast Cancer (NCT02476786). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02476786.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02476786.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:12:10.740Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/enfortumab-vedotin-with-or-without-pembrolizumab-in-rare-genitou-nct06041503/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06041503.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Adenocarcinoma… (NCT06041503) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Adenocarcinoma of the Bladder (NCT06041503). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06041503.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06041503.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:00:41.798Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/enzalutamide-and-pds01adc-in-pet-positive-recurrent-prostate-can-nct06096870/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06096870.jpg</video:thumbnail_loc>
      <video:title>Enzalutamide for Prostate Cancer (NCT06096870) | Triangle</video:title>
      <video:description>Enzalutamide trial for Prostate Cancer (NCT06096870). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06096870.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06096870.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:27:38.223Z</video:publication_date>
      <video:duration>96</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/epco-zanu-ritux-for-r-r-fl-or-mzl-nct06563596/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06563596.jpg</video:thumbnail_loc>
      <video:title>Zanubrutinib for Follicular Lymphoma (NCT06563596) | Triangle</video:title>
      <video:description>Zanubrutinib trial for Follicular Lymphoma (NCT06563596). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06563596.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06563596.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:17:37.738Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/epcoritamab-and-lenalidomide-in-treating-patients-with-refractor-nct06723457/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06723457.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06723457) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Recurrent B-Cell Non-Hodgkin Lymphoma (NCT06723457). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06723457.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06723457.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:21:36.541Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/epcoritamab-in-combination-with-loncastuximab-tesirine-in-relaps-nct06919939/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06919939.jpg</video:thumbnail_loc>
      <video:title>Epcoritamab for Large B-cell Lymphoma (NCT06919939) | Triangle</video:title>
      <video:description>Epcoritamab trial for Large B-cell Lymphoma (NCT06919939). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06919939.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06919939.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:21:06.847Z</video:publication_date>
      <video:duration>96</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/epcoritamab-rituximab-gemcitabine-and-oxaliplatin-r-gemox-as-sal-nct07365306/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07365306.jpg</video:thumbnail_loc>
      <video:title>Autologous Hematopoietic Stem… (NCT07365306) | Triangle</video:title>
      <video:description>Autologous Hematopoietic Stem Cell Transplantation trial for Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (NCT07365306). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07365306.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07365306.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:48:17.554Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/epcoritamab-with-dose-adjusted-etoposide-cyclophosphamide-vincri-nct07097363/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07097363.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for B-Cell… (NCT07097363) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for B-Cell Non-Hodgkin Lymphoma (NCT07097363). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07097363.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07097363.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:24:44.979Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/estrogen-to-improve-quality-of-life-for-men-with-newly-diagnosed-nct07466498/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07466498.jpg</video:thumbnail_loc>
      <video:title>Androgen Receptor Pathway Inhibitor (NCT07466498) | Triangle</video:title>
      <video:description>Androgen Receptor Pathway Inhibitor trial for Castration-Sensitive Prostate Adenocarcinoma (NCT07466498). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07466498.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07466498.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:16:10.249Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ethan-et-for-male-bc-nct05501704/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05501704.jpg</video:thumbnail_loc>
      <video:title>Tamoxifen for Male Breast Cancer (NCT05501704) | Triangle</video:title>
      <video:description>Tamoxifen trial for Male Breast Cancer (NCT05501704). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05501704.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05501704.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:42:24.917Z</video:publication_date>
      <video:duration>93</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/eus-rfa-pancardinal-1-trial-nct04990609/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04990609.jpg</video:thumbnail_loc>
      <video:title>Endoscopic Ultrasound… (NCT04990609) | Triangle</video:title>
      <video:description>Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT04990609). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04990609.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04990609.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:50:51.123Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/evaluate-optimization-of-crs-profile-for-glofit-monotherapy-and-nct06806033/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06806033.jpg</video:thumbnail_loc>
      <video:title>Obinutuzumab for Relapsed or… (NCT06806033) | Triangle</video:title>
      <video:description>Obinutuzumab trial for Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma (NCT06806033). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06806033.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06806033.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:35:14.817Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/evaluating-a-decreased-dose-of-radiation-therapy-to-the-elective-nct07178301/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07178301.jpg</video:thumbnail_loc>
      <video:title>Computed Tomography for Clinical… (NCT07178301) | Triangle</video:title>
      <video:description>Computed Tomography trial for Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (NCT07178301). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07178301.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07178301.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:03:48.463Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/evaluating-efficacy-of-b7-h3-car-t-cells-administered-at-the-end-nct07428993/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07428993.jpg</video:thumbnail_loc>
      <video:title>Cyclophosphamide for Pediatric… (NCT07428993) | Triangle</video:title>
      <video:description>Cyclophosphamide trial for Pediatric Osteosarcoma (NCT07428993). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07428993.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07428993.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:02:03.478Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/evaluation-of-alternative-site-goserelin-acetate-injection-for-o-nct07460752/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07460752.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07460752) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Anatomic Stage I Breast Cancer AJCC v8 (NCT07460752). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07460752.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07460752.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:03:36.670Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/evaluation-of-mirvetuximab-soravtansine-imgn853-in-women-with-fo-nct03832361/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03832361.jpg</video:thumbnail_loc>
      <video:title>IMGN853 for Endometrial Cancer (NCT03832361) | Triangle</video:title>
      <video:description>IMGN853 trial for Endometrial Cancer (NCT03832361). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03832361.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03832361.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:47:44.450Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-m-nct06607458/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06607458.jpg</video:thumbnail_loc>
      <video:title>Melphalan/HDS Followed by… (NCT06607458) | Triangle</video:title>
      <video:description>Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab trial for Refractory Metastatic Colorectal Cancer (NCT06607458). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06607458.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06607458.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:05:19.926Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-m-nct06875128/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06875128.jpg</video:thumbnail_loc>
      <video:title>Melphalan/HDS followed by… (NCT06875128) | Triangle</video:title>
      <video:description>Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) trial for Metastatic Breast Cancer in the Liver (NCT06875128). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06875128.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06875128.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:12:19.550Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/evaluation-of-two-dose-levels-of-quizartinib-as-maintenance-in-f-nct06824168/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06824168.jpg</video:thumbnail_loc>
      <video:title>Quizartinib High Dose for Acute… (NCT06824168) | Triangle</video:title>
      <video:description>Quizartinib High Dose trial for Acute Myeloid Leukemia (NCT06824168). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06824168.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06824168.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:33:12.097Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/exclaim-exploring-combined-local-and-systemic-approaches-in-brai-nct06649058/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06649058.jpg</video:thumbnail_loc>
      <video:title>Systemic Therapy for Brain Metastases (NCT06649058) | Triangle</video:title>
      <video:description>Systemic Therapy trial for Brain Metastases (NCT06649058). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06649058.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06649058.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:37:05.538Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/extracorporeal-photopheresis-and-mogamulizumab-for-the-treatment-nct04930653/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04930653.jpg</video:thumbnail_loc>
      <video:title>Extracorporeal Photopheresis (NCT04930653) | Triangle</video:title>
      <video:description>Extracorporeal Photopheresis trial for Folliculotropic Mycosis Fungoides (NCT04930653). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04930653.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04930653.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:00:28.534Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/fdg-pet-guided-metastasis-directed-radiation-therapy-for-the-tre-nct06244004/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06244004.jpg</video:thumbnail_loc>
      <video:title>Antiandrogen Therapy (NCT06244004) | Triangle</video:title>
      <video:description>Antiandrogen Therapy trial for Castration-Sensitive Prostate Carcinoma (NCT06244004). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06244004.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06244004.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:41:10.674Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/feasibility-study-to-treat-lung-cancer-with-the-permanently-impl-nct03290534/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03290534.jpg</video:thumbnail_loc>
      <video:title>CivaSheet for Lung Cancer (NCT03290534) | Triangle</video:title>
      <video:description>CivaSheet trial for Lung Cancer (NCT03290534). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03290534.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03290534.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:18:43.289Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/fludarabine-phosphate-cytarabine-filgrastim-sndz-gemtuzumab-ozog-nct00801489/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT00801489.jpg</video:thumbnail_loc>
      <video:title>Cytarabine for Acute Myeloid… (NCT00801489) | Triangle</video:title>
      <video:description>Cytarabine trial for Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 (NCT00801489). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT00801489.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT00801489.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:27:00.703Z</video:publication_date>
      <video:duration>92</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/fluorescence-guided-surgical-resection-for-reducing-unexpected-p-nct07650656/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07650656.jpg</video:thumbnail_loc>
      <video:title>Electronic Health Record Review (NCT07650656) | Triangle</video:title>
      <video:description>Electronic Health Record Review trial for High Grade Sarcoma (NCT07650656). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07650656.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07650656.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:15:44.219Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/focal-therapy-with-stereotactic-body-radiation-therapy-sbrt-for-nct05616650/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05616650.jpg</video:thumbnail_loc>
      <video:title>18F-DCFPyL for Prostatic Neoplasms (NCT05616650) | Triangle</video:title>
      <video:description>18F-DCFPyL trial for Prostatic Neoplasms (NCT05616650). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05616650.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05616650.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:30:56.750Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/folate-receptor-alpha-dendritic-cells-fr-dcs-or-placebo-for-the-nct06639074/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06639074.jpg</video:thumbnail_loc>
      <video:title>Biopsy for Advanced Fallopian… (NCT06639074) | Triangle</video:title>
      <video:description>Biopsy trial for Advanced Fallopian Tube Carcinoma (NCT06639074). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06639074.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06639074.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:57:59.549Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-li-nct07446322/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07446322.jpg</video:thumbnail_loc>
      <video:title>Bevacizumab for Ras-mutated… (NCT07446322) | Triangle</video:title>
      <video:description>Bevacizumab trial for Ras-mutated Metastatic Colorectal Cancer (NCT07446322). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07446322.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07446322.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:21:55.658Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/folfox-botensilimab-and-balstilimab-for-the-treatment-of-localiz-nct06780787/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06780787.jpg</video:thumbnail_loc>
      <video:title>Balstilimab for Rectal Adenocarcinoma (NCT06780787) | Triangle</video:title>
      <video:description>Balstilimab trial for Rectal Adenocarcinoma (NCT06780787). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06780787.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06780787.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:39:31.467Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/fractionated-gemtuzumab-ozogamicin-in-treating-measurable-residu-nct03737955/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03737955.jpg</video:thumbnail_loc>
      <video:title>Gemtuzumab Ozogamicin for Acute… (NCT03737955) | Triangle</video:title>
      <video:description>Gemtuzumab Ozogamicin trial for Acute Myeloid Leukemia (NCT03737955). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03737955.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03737955.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:01:08.654Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/frameless-stereotactic-radiosurgery-for-intact-brain-metastases-nct02747303/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02747303.jpg</video:thumbnail_loc>
      <video:title>Stereotactic Radiosurgery (NCT02747303) | Triangle</video:title>
      <video:description>Stereotactic Radiosurgery trial for Brain Metastases (NCT02747303). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02747303.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02747303.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:00:20.324Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/functional-precision-oncology-to-predict-prevent-and-treat-early-nct05464082/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05464082.jpg</video:thumbnail_loc>
      <video:title>Functional Precision Oncology (NCT05464082) | Triangle</video:title>
      <video:description>Functional Precision Oncology trial for Breast Cancer Recurrent (NCT05464082). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05464082.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05464082.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:43:02.341Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/futibatinib-in-combination-with-durvalumab-prior-to-cystectomy-f-nct06263153/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06263153.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Bladder… (NCT06263153) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Bladder Urothelial Carcinoma (NCT06263153). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06263153.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06263153.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:28:52.765Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/gemcitabine-and-oxaliplatin-chemotherapy-with-or-without-a-floxu-nct04891289/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04891289.jpg</video:thumbnail_loc>
      <video:title>Gemcitabine for Intrahepatic… (NCT04891289) | Triangle</video:title>
      <video:description>Gemcitabine trial for Intrahepatic Cholangiocarcinoma (NCT04891289). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04891289.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04891289.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:04:16.421Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/gemcitabine-cisplatin-and-nab-paclitaxel-as-neoadjuvant-treatmen-nct06423326/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06423326.jpg</video:thumbnail_loc>
      <video:title>Biopsy for Borderline Resectable… (NCT06423326) | Triangle</video:title>
      <video:description>Biopsy trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT06423326). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06423326.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06423326.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:29:33.831Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/gemcitabine-docetaxel-toripalimab-induction-in-epstein-barr-viru-nct06592599/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06592599.jpg</video:thumbnail_loc>
      <video:title>Toripalimab for Nasopharyngeal Carcinoma (NCT06592599) | Triangle</video:title>
      <video:description>Toripalimab trial for Nasopharyngeal Carcinoma (NCT06592599). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06592599.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06592599.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:53:28.823Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/gemcitabine-nab-paclitaxel-plus-the-therabionic-p1-an-amplitude-nct06576115/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06576115.jpg</video:thumbnail_loc>
      <video:title>Nab paclitaxel for Metastatic… (NCT06576115) | Triangle</video:title>
      <video:description>Nab paclitaxel trial for Metastatic Pancreatic Adenocarcinoma (NCT06576115). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06576115.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06576115.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:07:04.019Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/genetic-testing-to-select-therapy-for-the-treatment-of-advanced-nct05361720/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05361720.jpg</video:thumbnail_loc>
      <video:title>Cabozantinib for Advanced Clear… (NCT05361720) | Triangle</video:title>
      <video:description>Cabozantinib trial for Advanced Clear Cell Renal Cell Carcinoma (NCT05361720). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05361720.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05361720.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:17:14.203Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/genomic-biomarker-selected-umbrella-neoadjuvant-study-for-high-r-nct04812366/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04812366.jpg</video:thumbnail_loc>
      <video:title>Apalutamide 60mg Tab for Prostate Cancer (NCT04812366) | Triangle</video:title>
      <video:description>Apalutamide 60mg Tab trial for Prostate Cancer (NCT04812366). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04812366.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04812366.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:59:55.732Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/genomically-guided-radiation-therapy-in-the-management-of-triple-nct05528133/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05528133.jpg</video:thumbnail_loc>
      <video:title>Genomically Guided Radiation… (NCT05528133) | Triangle</video:title>
      <video:description>Genomically Guided Radiation Therapy trial for Triple Negative Breast Cancer (NCT05528133). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05528133.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05528133.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:44:58.555Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/gi-102-alone-or-with-pembrolizumab-before-surgery-for-treatment-nct07301268/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07301268.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07301268) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Glioblastoma, IDH-Wildtype (NCT07301268). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07301268.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07301268.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:57:16.031Z</video:publication_date>
      <video:duration>94</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/glioblastoma-temozolomide-with-or-without-wsd0922-fu-nct07708961/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07708961.jpg</video:thumbnail_loc>
      <video:title>Archive Sample Retrieval (NCT07708961) | Triangle</video:title>
      <video:description>Archive Sample Retrieval trial for Glioblastoma, IDH-Wildtype (NCT07708961). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07708961.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07708961.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:17:53.369Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/glofitamab-with-pirtobrutinib-for-relapsed-or-refractory-mantle-nct06252675/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06252675.jpg</video:thumbnail_loc>
      <video:title>Obinutuzumab for Mantle Cell Lymphoma (NCT06252675) | Triangle</video:title>
      <video:description>Obinutuzumab trial for Mantle Cell Lymphoma (NCT06252675). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06252675.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06252675.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:57:41.395Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/glory-glofit-gemox-with-liso-cel-for-lymphoma-nct07711483/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07711483.jpg</video:thumbnail_loc>
      <video:title>Obinutuzumab for Lymphoma (NCT07711483) | Triangle</video:title>
      <video:description>Obinutuzumab trial for Lymphoma (NCT07711483). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07711483.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07711483.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:26:32.418Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/golcadomide-and-rituximab-as-bridging-therapy-for-relapsed-or-re-nct06834373/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06834373.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Large… (NCT06834373) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Large B-Cell Lymphoma With IRF4 Rearrangement (NCT06834373). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06834373.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06834373.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:04:58.828Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/graft-versus-host-disease-reduction-strategies-for-donor-blood-s-nct03970096/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03970096.jpg</video:thumbnail_loc>
      <video:title>Total-Body Irradiation for Acute… (NCT03970096) | Triangle</video:title>
      <video:description>Total-Body Irradiation trial for Acute Leukemia (NCT03970096). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03970096.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03970096.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:07:25.688Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/gt103-in-combination-with-pembrolizumab-for-the-treatment-of-adv-nct07017829/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07017829.jpg</video:thumbnail_loc>
      <video:title>Anti-CFH Monoclonal Antibody GT103 (NCT07017829) | Triangle</video:title>
      <video:description>Anti-CFH Monoclonal Antibody GT103 trial for Advanced Lung Non-Small Cell Carcinoma (NCT07017829). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07017829.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07017829.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:49:47.041Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/haplo-identical-transplantation-for-severe-aplastic-anemia-hypo-nct03520647/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03520647.jpg</video:thumbnail_loc>
      <video:title>Cyclophosphamide for Severe… (NCT03520647) | Triangle</video:title>
      <video:description>Cyclophosphamide trial for Severe Aplastic Anemia (SAA) (NCT03520647). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03520647.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03520647.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:00:46.210Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/haploidentical-donor-cytokine-induced-memory-like-natural-killer-nct07635056/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07635056.jpg</video:thumbnail_loc>
      <video:title>CIML-NK Cells for Neuroblastoma (NCT07635056) | Triangle</video:title>
      <video:description>CIML-NK Cells trial for Neuroblastoma (NCT07635056). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07635056.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07635056.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:43:17.412Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/hcmt-mm2401-ph2-study-of-selinexor-bispecific-antibody-for-rrmm-nct06822972/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06822972.jpg</video:thumbnail_loc>
      <video:title>Selinexor 40 mg for Multiple… (NCT06822972) | Triangle</video:title>
      <video:description>Selinexor 40 mg trial for Multiple Myeloma in Relapse (NCT06822972). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06822972.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06822972.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:54:45.062Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/herizon-breast-a-ctdna-guided-adaptive-study-of-sequential-anti-nct07459673/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07459673.jpg</video:thumbnail_loc>
      <video:title>Personalis NeXT Personal (NCT07459673) | Triangle</video:title>
      <video:description>Personalis NeXT Personal trial for Breast Cancer (NCT07459673). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07459673.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07459673.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:23:42.488Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/high-dose-ruxolitinib-and-allogeneic-stem-cell-transplantation-i-nct06345495/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06345495.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib for Splenomegaly (NCT06345495) | Triangle</video:title>
      <video:description>Ruxolitinib trial for Splenomegaly (NCT06345495). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06345495.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06345495.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:35:10.004Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/high-dose-testosterone-for-atm-cdk12-or-chek2-altered-prostate-c-nct05011383/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05011383.jpg</video:thumbnail_loc>
      <video:title>High dose testosterone (NCT05011383) | Triangle</video:title>
      <video:description>High dose testosterone trial for Metastatic Prostate Cancer (NCT05011383). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05011383.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05011383.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:31:56.277Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/hippocampal-avoidance-in-craniospinal-irradiation-for-the-treatm-nct06518057/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06518057.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06518057) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Anatomic Stage IV Breast Cancer AJCC v8 (NCT06518057). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06518057.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06518057.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:59:35.091Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/hormone-therapy-apalutamide-and-image-guided-stereotactic-body-r-nct06067269/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06067269.jpg</video:thumbnail_loc>
      <video:title>Apalutamide for Prostate Adenocarcinoma (NCT06067269) | Triangle</video:title>
      <video:description>Apalutamide trial for Prostate Adenocarcinoma (NCT06067269). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06067269.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06067269.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:34:59.166Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/hotspot-stereotactic-ablative-radiotherapy-versus-traditional-st-nct07718672/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07718672.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Early… (NCT07718672) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Early Stage Lung Non-Small Cell Carcinoma (NCT07718672). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07718672.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07718672.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:01:11.790Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/hypofractionated-radiation-therapy-for-merkel-cell-carcinoma-nct05100095/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05100095.jpg</video:thumbnail_loc>
      <video:title>Radiation therapy for Merkel Cell… (NCT05100095) | Triangle</video:title>
      <video:description>Radiation therapy trial for Merkel Cell Carcinoma (NCT05100095). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05100095.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05100095.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:49:19.652Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/hypofractionated-radiochemotherapy-nct06331468/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06331468.jpg</video:thumbnail_loc>
      <video:title>Cisplatin for Uterine Cervix Cancer (NCT06331468) | Triangle</video:title>
      <video:description>Cisplatin trial for Uterine Cervix Cancer (NCT06331468). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06331468.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06331468.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:48:07.633Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/iberdomide-and-daratumumab-as-maintenance-therapy-after-an-autol-nct06107738/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06107738.jpg</video:thumbnail_loc>
      <video:title>Iberdomide for Multiple Myeloma (NCT06107738) | Triangle</video:title>
      <video:description>Iberdomide trial for Multiple Myeloma (NCT06107738). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06107738.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06107738.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:47:47.873Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/identifying-effective-and-cost-conscious-maintenance-daratumumab-nct07485647/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07485647.jpg</video:thumbnail_loc>
      <video:title>Daratumumab and Recombinant Human… (NCT07485647) | Triangle</video:title>
      <video:description>Daratumumab and Recombinant Human Hyaluronidase trial for Multiple Myeloma (NCT07485647). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07485647.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07485647.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:49:24.124Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/idh-targeted-non-targeted-vs-non-targeted-idh-targeted-approache-nct05401097/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05401097.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Myeloid Leukemia (NCT05401097) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Myeloid Leukemia (NCT05401097). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05401097.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05401097.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:57:41.354Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/igfbp-2-vaccine-to-prevent-ovarian-cancer-progression-in-patient-nct07495124/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07495124.jpg</video:thumbnail_loc>
      <video:title>pUMVC3-hIGFBP-2 Multi-epitope… (NCT07495124) | Triangle</video:title>
      <video:description>pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine trial for Fallopian Tube Carcinoma (NCT07495124). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07495124.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07495124.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:24:01.170Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/iit2023-09-chung-upfronttad-upfront-tad-snb-in-patients-with-bre-nct06092892/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06092892.jpg</video:thumbnail_loc>
      <video:title>Breast Surgery (BCS or… (NCT06092892) | Triangle</video:title>
      <video:description>Breast Surgery (BCS or mastectomy) with TAD/SNB trial for Breast Cancer (NCT06092892). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06092892.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06092892.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:09:00.638Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ilkn421h-plus-pembrolizumab-in-advanced-non-small-cell-lung-canc-nct07452224/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07452224.jpg</video:thumbnail_loc>
      <video:title>ILKN421H for Locally Advanced or… (NCT07452224) | Triangle</video:title>
      <video:description>ILKN421H trial for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT07452224). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07452224.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07452224.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:18:24.939Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/illuminate-a-clinical-study-evaluating-car-t-immune-cell-therapy-nct07680439/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07680439.jpg</video:thumbnail_loc>
      <video:title>BCB-276 for Diffuse Intrinsic… (NCT07680439) | Triangle</video:title>
      <video:description>BCB-276 trial for Diffuse Intrinsic Pontine Glioma (NCT07680439). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07680439.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07680439.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:27:32.367Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/imlunestrant-and-abemaciclib-for-the-treatment-of-estrogen-recep-nct07191717/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07191717.jpg</video:thumbnail_loc>
      <video:title>Abemaciclib for Anatomic Stage I… (NCT07191717) | Triangle</video:title>
      <video:description>Abemaciclib trial for Anatomic Stage I Breast Cancer AJCC v8 (NCT07191717). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07191717.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07191717.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:46:04.250Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/immunoplant-for-newly-diagnosed-multiple-myeloma-nct06376526/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06376526.jpg</video:thumbnail_loc>
      <video:title>Linvoseltamab for Multiple Myeloma (NCT06376526) | Triangle</video:title>
      <video:description>Linvoseltamab trial for Multiple Myeloma (NCT06376526). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06376526.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06376526.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:56:13.303Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/immunotherapy-and-nodal-sparing-irradiation-for-t-cell-induction-nct07773987/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07773987.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Head and Neck… (NCT07773987) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Head and Neck Cancer Squamous Cell Carcinoma (NCT07773987). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07773987.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07773987.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:08:27.315Z</video:publication_date>
      <video:duration>95</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/immunotherapy-biomarkers-to-predict-first-line-pd-l-1-based-immu-nct07288034/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07288034.jpg</video:thumbnail_loc>
      <video:title>Adagrasib for Lung Non-Small Cell… (NCT07288034) | Triangle</video:title>
      <video:description>Adagrasib trial for Lung Non-Small Cell Carcinoma (NCT07288034). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07288034.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07288034.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:16:08.247Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/immunotherapy-platform-study-in-platinum-resistant-high-grade-se-nct04918186/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04918186.jpg</video:thumbnail_loc>
      <video:title>Durvalumab for Ovarian Cancer (NCT04918186) | Triangle</video:title>
      <video:description>Durvalumab trial for Ovarian Cancer (NCT04918186). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04918186.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04918186.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:28:11.374Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/immunotherapy-toripalimab-for-reducing-recurrence-risk-after-sur-nct07140679/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07140679.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Localized… (NCT07140679) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Localized Colon Carcinoma (NCT07140679). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07140679.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07140679.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:32:31.885Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-nct01174121/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT01174121.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab (Keytruda) (NCT01174121) | Triangle</video:title>
      <video:description>Pembrolizumab (Keytruda) trial for Metastatic Colorectal Cancer (NCT01174121). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT01174121.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT01174121.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:04:53.406Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/impact-of-vitamin-d-supplementation-on-the-rate-of-pathologic-co-nct04677816/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04677816.jpg</video:thumbnail_loc>
      <video:title>Standard of Care Neoadjuvant… (NCT04677816) | Triangle</video:title>
      <video:description>Standard of Care Neoadjuvant Chemotherapy (NAC) trial for Triple Negative Breast Cancer (NCT04677816). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04677816.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04677816.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:38:51.480Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/individualized-screening-trial-of-innovative-glioblastoma-therap-nct02977780/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02977780.jpg</video:thumbnail_loc>
      <video:title>Temozolomide for Glioblastoma (NCT02977780) | Triangle</video:title>
      <video:description>Temozolomide trial for Glioblastoma (NCT02977780). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02977780.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02977780.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:26:49.433Z</video:publication_date>
      <video:duration>95</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/innovative-trial-for-understanding-the-impact-of-targeted-therap-nct04374305/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04374305.jpg</video:thumbnail_loc>
      <video:title>Brigatinib for Neurofibromatosis Type 2 (NCT04374305) | Triangle</video:title>
      <video:description>Brigatinib trial for Neurofibromatosis Type 2 (NCT04374305). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04374305.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04374305.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:20:55.579Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/inobrodib-pomalidomide-and-dexamethasone-in-relapsed-or-refracto-nct07096778/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07096778.jpg</video:thumbnail_loc>
      <video:title>Inobrodib for Multiple Myeloma… (NCT07096778) | Triangle</video:title>
      <video:description>Inobrodib trial for Multiple Myeloma Refractory (NCT07096778). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07096778.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07096778.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:18:00.819Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/inotuzumab-ozogamicin-and-blinatumomab-with-or-without-ponatinib-nct03739814/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03739814.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT03739814) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (NCT03739814). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03739814.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03739814.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:31:43.233Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/intensity-modulated-total-marrow-irradiation-in-fully-human-leuk-nct06802315/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06802315.jpg</video:thumbnail_loc>
      <video:title>Intensity modulated total marrow… (NCT06802315) | Triangle</video:title>
      <video:description>Intensity modulated total marrow irradiation trial for Acute Myeloid Leukemia, Relapsed, Adult (NCT06802315). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06802315.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06802315.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:46:59.564Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/interleukin-6-receptor-inhibitor-sarilumab-in-combination-with-i-nct05428007/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05428007.jpg</video:thumbnail_loc>
      <video:title>Sarilumab for Melanoma (NCT05428007) | Triangle</video:title>
      <video:description>Sarilumab trial for Melanoma (NCT05428007). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05428007.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05428007.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:30:36.842Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/intermittent-fasting-using-a-fasting-mimicking-diet-to-improve-p-nct05832086/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05832086.jpg</video:thumbnail_loc>
      <video:title>Fasting Mimicking Diet (FMD) (NCT05832086) | Triangle</video:title>
      <video:description>Fasting Mimicking Diet (FMD) trial for Prostate Adenocarcinoma (NCT05832086). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05832086.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05832086.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:09:57.567Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/intralesional-chemotherapy-ic-cisplatin-epinephrine-nct07392580/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07392580.jpg</video:thumbnail_loc>
      <video:title>Cisplatin for Laryngeal Squamous… (NCT07392580) | Triangle</video:title>
      <video:description>Cisplatin trial for Laryngeal Squamous Cell Carcinoma (NCT07392580). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07392580.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07392580.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:02:54.144Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/investigation-of-ubamatamab-combination-therapy-in-adult-partici-nct06787612/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06787612.jpg</video:thumbnail_loc>
      <video:title>Ubamatamab for Ovarian Cancer (NCT06787612) | Triangle</video:title>
      <video:description>Ubamatamab trial for Ovarian Cancer (NCT06787612). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06787612.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06787612.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:39:57.735Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ivonescimab-alone-and-with-carboplatin-pemetrexed-for-nsclc-nct07405190/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07405190.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab for Lung Cancer (NSCLC) (NCT07405190) | Triangle</video:title>
      <video:description>Ivonescimab trial for Lung Cancer (NSCLC) (NCT07405190). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07405190.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07405190.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:01:24.801Z</video:publication_date>
      <video:duration>101</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ivonescimab-before-surgery-for-the-treatment-of-resectable-stage-nct07094685/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07094685.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Advanced… (NCT07094685) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Advanced Head and Neck Squamous Cell Carcinoma (NCT07094685). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07094685.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07094685.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:41:22.625Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ivonescimab-for-the-treatment-of-thymic-cancer-nct06980077/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06980077.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Thymus Carcinoma (NCT06980077) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Thymus Carcinoma (NCT06980077). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06980077.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06980077.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:29:47.231Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ivonescimab-in-comb-with-folfox-in-advanced-her2-neg-gea-nct07070466/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07070466.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab for Stomach Cancer Stage IV (NCT07070466) | Triangle</video:title>
      <video:description>Ivonescimab trial for Stomach Cancer Stage IV (NCT07070466). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07070466.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07070466.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:06:58.278Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ivonescimab-prior-to-surgery-for-the-treatment-of-high-risk-loca-nct07226544/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07226544.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Localized… (NCT07226544) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Localized Clear Cell Renal Cell Carcinoma (NCT07226544). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07226544.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07226544.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:54:28.971Z</video:publication_date>
      <video:duration>68</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ivosidenib-as-post-hsct-maintenance-for-aml-nct06707493/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06707493.jpg</video:thumbnail_loc>
      <video:title>Ivosidenib for IDH1 Mutation (NCT06707493) | Triangle</video:title>
      <video:description>Ivosidenib trial for IDH1 Mutation (NCT06707493). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06707493.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06707493.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:36:22.545Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/keymaker-u01-substudy-01j-a-study-of-pembrolizumab-plus-mk-1084-nct07252739/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07252739.jpg</video:thumbnail_loc>
      <video:title>MK-1084 for Malignant Neoplasm (NCT07252739) | Triangle</video:title>
      <video:description>MK-1084 trial for Malignant Neoplasm (NCT07252739). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07252739.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07252739.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:59:02.613Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/kqb198-in-combination-with-imatinib-in-participants-with-advance-nct07406633/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07406633.jpg</video:thumbnail_loc>
      <video:title>KQB198 for GIST… (NCT07406633) | Triangle</video:title>
      <video:description>KQB198 trial for GIST - Gastrointestinal Stromal Tumor (NCT07406633). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07406633.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07406633.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:08:17.264Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/l19il2-l19tnf-in-patients-with-cutaneous-squamous-cell-carcinoma-nct07228442/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07228442.jpg</video:thumbnail_loc>
      <video:title>L19IL2/L19TNF for Locally… (NCT07228442) | Triangle</video:title>
      <video:description>L19IL2/L19TNF trial for Locally Advanced Cutaneous Squamous Cell Carcinoma (NCT07228442). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07228442.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07228442.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:08:30.458Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/l19il2-tnf-in-patients-with-basal-cell-carcinoma-nct07227870/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227870.jpg</video:thumbnail_loc>
      <video:title>L19IL2/L19TNF for Locally… (NCT07227870) | Triangle</video:title>
      <video:description>L19IL2/L19TNF trial for Locally Advanced Basal Cell Carcinoma (NCT07227870). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07227870.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07227870.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:27:06.419Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/lerapolturev-pvsripo-in-gbm-nct06177964/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06177964.jpg</video:thumbnail_loc>
      <video:title>Lerapolturev for Recurrent… (NCT06177964) | Triangle</video:title>
      <video:description>Lerapolturev trial for Recurrent Supratentorial Glioblastoma (NCT06177964). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06177964.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06177964.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:30:47.527Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/letrozole-in-uterine-leiomyosarcoma-nct05649956/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05649956.jpg</video:thumbnail_loc>
      <video:title>Letrozole for Uterine Leiomyosarcoma (NCT05649956) | Triangle</video:title>
      <video:description>Letrozole trial for Uterine Leiomyosarcoma (NCT05649956). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05649956.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05649956.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:47:47.824Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/leuprolide-and-goserelin-for-ovarian-function-suppression-in-pre-nct07158021/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07158021.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07158021) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Anatomic Stage I Breast Cancer AJCC v8 (NCT07158021). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07158021.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07158021.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:58:27.968Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-wi-nct05854498/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05854498.jpg</video:thumbnail_loc>
      <video:title>Liposomal irinotecan (NCT05854498) | Triangle</video:title>
      <video:description>Liposomal irinotecan trial for Metastatic Colorectal Cancer (NCT05854498). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05854498.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05854498.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:27:22.494Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/liposome-encapsulated-daunorubicin-cytarabine-and-venetoclax-in-nct03629171/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03629171.jpg</video:thumbnail_loc>
      <video:title>Liposome-encapsulated… (NCT03629171) | Triangle</video:title>
      <video:description>Liposome-encapsulated Daunorubicin-Cytarabine trial for Recurrent Acute Myeloid Leukemia (NCT03629171). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03629171.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03629171.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:25:36.955Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/liquid-nitrogen-spray-cryotherapy-prior-to-neoadjuvant-systemic-nct07222657/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07222657.jpg</video:thumbnail_loc>
      <video:title>Standard of care chemotherapy (NCT07222657) | Triangle</video:title>
      <video:description>Standard of care chemotherapy trial for Esophageal Adenocarcinoma (NCT07222657). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07222657.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07222657.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:52:08.484Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/local-consolidative-therapy-and-durvalumab-for-oligoprogressive-nct04892953/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04892953.jpg</video:thumbnail_loc>
      <video:title>Carboplatin for Stage III Lung… (NCT04892953) | Triangle</video:title>
      <video:description>Carboplatin trial for Stage III Lung Cancer AJCC v8 (NCT04892953). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04892953.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04892953.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:56:43.218Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/loncastuximab-tesirine-and-mosunetuzumab-for-the-treatment-of-re-nct05672251/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05672251.jpg</video:thumbnail_loc>
      <video:title>Biopsy for Recurrent Diffuse… (NCT05672251) | Triangle</video:title>
      <video:description>Biopsy trial for Recurrent Diffuse Large B-Cell Lymphoma (NCT05672251). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05672251.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05672251.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:45:33.273Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/loncastuximab-tesirine-and-rituximab-as-bridging-therapy-before-nct06788964/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06788964.jpg</video:thumbnail_loc>
      <video:title>Loncastuximab Tesirine (NCT06788964) | Triangle</video:title>
      <video:description>Loncastuximab Tesirine trial for Relapsed or Refractory Large B-cell Lymphoma (NCT06788964). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06788964.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06788964.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:33:14.946Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/low-dose-mosunetuzumab-for-the-treatment-of-patients-with-indole-nct06442475/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06442475.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Ann… (NCT06442475) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Ann Arbor Stage II Follicular Lymphoma (NCT06442475). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06442475.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06442475.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:51:50.745Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/low-psma-suv-boost-lps-boost-intensified-177lu-psma-617-treatmen-nct06526299/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06526299.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06526299) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Metastatic Castration-Resistant Prostate Carcinoma (NCT06526299). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06526299.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06526299.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:23:33.513Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/lu-177-dotatate-lutathera-in-therapy-of-inoperable-pheochromocyt-nct03206060/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03206060.jpg</video:thumbnail_loc>
      <video:title>Lu-177-DOTATATE for Pheochromocytoma (NCT03206060) | Triangle</video:title>
      <video:description>Lu-177-DOTATATE trial for Pheochromocytoma (NCT03206060). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03206060.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03206060.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:52:22.658Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/luminal-bladder-cancer-effective-response-to-neoadjuvant-chemoth-nct07762586/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07762586.jpg</video:thumbnail_loc>
      <video:title>Neoadjuvant Therapy for Bladder Cancer (NCT07762586) | Triangle</video:title>
      <video:description>Neoadjuvant Therapy trial for Bladder Cancer (NCT07762586). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07762586.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07762586.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:46:16.846Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/lurbinectedin-with-or-without-avelumab-in-small-cell-carcinoma-o-nct06228066/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06228066.jpg</video:thumbnail_loc>
      <video:title>Lurbinectedin for Small Cell… (NCT06228066) | Triangle</video:title>
      <video:description>Lurbinectedin trial for Small Cell Carcinoma of the Bladder (NCT06228066). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06228066.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06228066.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:23:33.352Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/lutathera-for-the-treatment-of-inoperable-progressive-meningioma-nct04082520/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04082520.jpg</video:thumbnail_loc>
      <video:title>Gallium Ga 68-DOTATATE for Grade… (NCT04082520) | Triangle</video:title>
      <video:description>Gallium Ga 68-DOTATATE trial for Grade 1 Meningioma (NCT04082520). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04082520.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04082520.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:14:32.325Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/maintenance-combinatorial-myeloid-immunotherapy-for-unresectable-nct07199764/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07199764.jpg</video:thumbnail_loc>
      <video:title>Odetiglucan for Pancreatic Ductal… (NCT07199764) | Triangle</video:title>
      <video:description>Odetiglucan trial for Pancreatic Ductal Adenocarcinoma (NCT07199764). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07199764.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07199764.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:06:33.793Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/maintenance-niraparib-plus-ipilimumab-in-patients-with-metastati-nct06747845/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06747845.jpg</video:thumbnail_loc>
      <video:title>Niraparib for Pancreatic… (NCT06747845) | Triangle</video:title>
      <video:description>Niraparib trial for Pancreatic Adenocarcinoma Metastatic (NCT06747845). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06747845.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06747845.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:49:05.294Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/maintenance-obinutuzumab-in-treating-patients-with-central-nervo-nct06175000/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06175000.jpg</video:thumbnail_loc>
      <video:title>Cognitive Assessment for Primary… (NCT06175000) | Triangle</video:title>
      <video:description>Cognitive Assessment trial for Primary Central Nervous System Lymphoma (NCT06175000). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06175000.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06175000.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:01:37.585Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/marginal-zone-lymphoma-nemtabrutinib-and-rituximab-nct07583810/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07583810.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Conjunctival… (NCT07583810) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma (NCT07583810). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07583810.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07583810.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:16:33.740Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mavric-studies-2l-treatment-with-av-in-patients-with-cll-sll-who-nct07024706/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07024706.jpg</video:thumbnail_loc>
      <video:title>Acalabrutinib for Chronic… (NCT07024706) | Triangle</video:title>
      <video:description>Acalabrutinib trial for Chronic Lymphocytic Leukemia (CLL) (NCT07024706). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07024706.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07024706.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:54:53.309Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mdrt-in-prostate-cancer-treated-with-long-term-androgen-deprivat-nct06150417/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06150417.jpg</video:thumbnail_loc>
      <video:title>Androgen deprivation therapy (ADT) (NCT06150417) | Triangle</video:title>
      <video:description>Androgen deprivation therapy (ADT) trial for Prostate Cancer (NCT06150417). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06150417.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06150417.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:37:19.705Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/measurable-residual-disease-guided-post-transplant-elranatamab-m-nct06483100/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06483100.jpg</video:thumbnail_loc>
      <video:title>Elrantamab for Multiple Myeloma (NCT06483100) | Triangle</video:title>
      <video:description>Elrantamab trial for Multiple Myeloma (NCT06483100). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06483100.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06483100.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:16:07.153Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/metformin-hydrochloride-in-combination-with-standard-of-care-sys-nct07291297/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07291297.jpg</video:thumbnail_loc>
      <video:title>Metformin Hydrochloride ER (NCT07291297) | Triangle</video:title>
      <video:description>Metformin Hydrochloride ER trial for Sarcoma Metastatic (NCT07291297). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07291297.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07291297.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:14:44.501Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/metformin-in-pseudomyxoma-peritonei-secondary-to-appendiceal-muc-nct07693452/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07693452.jpg</video:thumbnail_loc>
      <video:title>Metformin for Appendiceal… (NCT07693452) | Triangle</video:title>
      <video:description>Metformin trial for Appendiceal Mucinous Neoplasm (NCT07693452). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07693452.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07693452.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:13:12.129Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/methylprednisolone-horse-anti-thymocyte-globulin-cyclosporine-fi-nct01624805/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT01624805.jpg</video:thumbnail_loc>
      <video:title>Anti-Thymocyte Globulin (NCT01624805) | Triangle</video:title>
      <video:description>Anti-Thymocyte Globulin trial for Aplastic Anemia (NCT01624805). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT01624805.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT01624805.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:43:07.074Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/metronomic-decitabine-cedazuridine-and-venetoclax-in-r-r-aml-hr-nct07710534/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07710534.jpg</video:thumbnail_loc>
      <video:title>Decitabine-cedazuridine plus… (NCT07710534) | Triangle</video:title>
      <video:description>Decitabine-cedazuridine plus venetoclax (DEC-C+VEN) trial for Relapsed / Refractory AML (NCT07710534). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07710534.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07710534.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:09:40.058Z</video:publication_date>
      <video:duration>92</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/metronomic-gemcitabine-mitomycin-c-and-thalidomide-for-advanced-nct07671534/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07671534.jpg</video:thumbnail_loc>
      <video:title>Gemcitabine for Solid Tumor Cancer (NCT07671534) | Triangle</video:title>
      <video:description>Gemcitabine trial for Solid Tumor Cancer (NCT07671534). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07671534.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07671534.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:41:28.725Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mezigdomide-carfilzomib-and-dexamethasone-for-the-treatment-of-r-nct06627751/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06627751.jpg</video:thumbnail_loc>
      <video:title>Mezigdomide for Extramedullary… (NCT06627751) | Triangle</video:title>
      <video:description>Mezigdomide trial for Extramedullary Disease in Multiple Myeloma (NCT06627751). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06627751.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06627751.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:55:32.038Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mogamulizumab-low-dose-total-skin-electron-beam-tx-in-mycosis-fu-nct04256018/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04256018.jpg</video:thumbnail_loc>
      <video:title>Mogamulizumab for Sezary Syndrome (NCT04256018) | Triangle</video:title>
      <video:description>Mogamulizumab trial for Sezary Syndrome (NCT04256018). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04256018.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04256018.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:34:43.038Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/molecular-analyses-to-predict-pathways-of-endocrine-resistance-f-nct06361940/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06361940.jpg</video:thumbnail_loc>
      <video:title>Aromatase inhibitors or tamoxifen (NCT06361940) | Triangle</video:title>
      <video:description>Aromatase inhibitors or tamoxifen trial for Breast Cancer (NCT06361940). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06361940.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06361940.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:05:44.324Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/molecular-and-clinical-risk-directed-therapy-for-infants-and-you-nct05535166/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05535166.jpg</video:thumbnail_loc>
      <video:title>Surgical resection for Medulloblastoma (NCT05535166) | Triangle</video:title>
      <video:description>Surgical resection trial for Medulloblastoma (NCT05535166). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05535166.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05535166.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:38:22.360Z</video:publication_date>
      <video:duration>95</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/monthly-alternating-nalirifox-and-gnp-in-the-first-line-setting-nct07163273/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07163273.jpg</video:thumbnail_loc>
      <video:title>NALIRIFOX for Pancreatic Ductal… (NCT07163273) | Triangle</video:title>
      <video:description>NALIRIFOX trial for Pancreatic Ductal Adenocarcinoma (NCT07163273). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07163273.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07163273.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:02:18.256Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mosunetuzumab-and-polatuzumab-vedotin-for-the-treatment-of-patie-nct06453044/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06453044.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06453044) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Recurrent Grade 1 Follicular Lymphoma (NCT06453044). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06453044.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06453044.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:05:20.739Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mosunetuzumab-and-polatuzumab-vedotin-with-split-dose-chp-chemot-nct06594939/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06594939.jpg</video:thumbnail_loc>
      <video:title>Polatuzumab Vedotin for Diffuse… (NCT06594939) | Triangle</video:title>
      <video:description>Polatuzumab Vedotin trial for Diffuse Large B Cell Lymphoma (DLBCL) (NCT06594939). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06594939.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06594939.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:40:04.361Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mosunetuzumab-with-lenalidomide-augmentation-as-first-line-thera-nct04792502/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04792502.jpg</video:thumbnail_loc>
      <video:title>Mosunetuzumab for Follicular Lymphoma (NCT04792502) | Triangle</video:title>
      <video:description>Mosunetuzumab trial for Follicular Lymphoma (NCT04792502). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04792502.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04792502.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:48:12.540Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mri-based-focal-intraprostatic-simultaneous-integrated-boost-sib-nct07644598/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07644598.jpg</video:thumbnail_loc>
      <video:title>Microboost SBRT for Prostate Cancer (NCT07644598) | Triangle</video:title>
      <video:description>Microboost SBRT trial for Prostate Cancer (NCT07644598). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07644598.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07644598.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:50:26.562Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/mt2022-60-ph-2-study-of-pembro-beam-with-asct-for-relapsed-hodgk-nct06377540/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06377540.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Autologous Stem… (NCT06377540) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Autologous Stem Cell Transplant (NCT06377540). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06377540.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06377540.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:39:37.282Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/myeloablative-consolidation-therapy-and-tandem-autologous-stem-c-nct02605421/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02605421.jpg</video:thumbnail_loc>
      <video:title>Thiotepa for Neuroblastoma (NCT02605421) | Triangle</video:title>
      <video:description>Thiotepa trial for Neuroblastoma (NCT02605421). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02605421.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02605421.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:16:38.539Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nalirifox-before-surgery-for-the-treatment-of-borderline-resecta-nct06821997/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06821997.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06821997) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT06821997). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06821997.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06821997.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:32:00.069Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nant-2021-01-phase-ii-sting-sequential-temozolomide-irinotecan-n-nct06450041/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06450041.jpg</video:thumbnail_loc>
      <video:title>Universal Donor (UD) TGFβi NK Cells (NCT06450041) | Triangle</video:title>
      <video:description>Universal Donor (UD) TGFβi NK Cells trial for Neuroblastoma (NCT06450041). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06450041.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06450041.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:28:25.965Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/naxitamab-added-to-induction-for-newly-diagnosed-high-risk-neuro-nct05489887/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05489887.jpg</video:thumbnail_loc>
      <video:title>Naxitamab for Neuroblastoma (NCT05489887) | Triangle</video:title>
      <video:description>Naxitamab trial for Neuroblastoma (NCT05489887). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05489887.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05489887.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:02:37.791Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nemtabrutinib-and-lisocabtagene-maraleucel-for-the-treatment-of-nct07194980/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07194980.jpg</video:thumbnail_loc>
      <video:title>Nemtabrutinib for Recurrent… (NCT07194980) | Triangle</video:title>
      <video:description>Nemtabrutinib trial for Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT07194980). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07194980.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07194980.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:25:14.638Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nemtabrutinib-and-pembrolizumab-for-the-treatment-of-richter-tra-nct06863402/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06863402.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Richter… (NCT06863402) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Richter Syndrome (NCT06863402). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06863402.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06863402.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:50:35.410Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nemtabrutinib-and-venetoclax-for-the-treatment-of-patients-with-nct07557056/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07557056.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Chronic… (NCT07557056) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Chronic Lymphocytic Leukemia (NCT07557056). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07557056.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07557056.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:35:46.070Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nemtabrutinib-with-car-t-therapy-in-relapsed-refractory-mantle-c-nct07673367/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07673367.jpg</video:thumbnail_loc>
      <video:title>Nemtabrutinib for Recurrent… (NCT07673367) | Triangle</video:title>
      <video:description>Nemtabrutinib trial for Recurrent Mantle Cell Lymphoma (NCT07673367). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07673367.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07673367.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:56:39.621Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-and-adjuvant-treatment-in-resectable-non-small-cell-nct05061550/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05061550.jpg</video:thumbnail_loc>
      <video:title>Durvalumab for Non-small Cell… (NCT05061550) | Triangle</video:title>
      <video:description>Durvalumab trial for Non-small Cell Lung Cancer (NCT05061550). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05061550.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05061550.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:17:26.357Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-botensilimab-and-balstilimab-for-the-treatment-of-ad-nct07595874/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07595874.jpg</video:thumbnail_loc>
      <video:title>Balstilimab for Advanced Colon… (NCT07595874) | Triangle</video:title>
      <video:description>Balstilimab trial for Advanced Colon Adenocarcinoma (NCT07595874). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07595874.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07595874.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:08:51.211Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-chemo-immunotherapy-and-surgical-resection-in-locall-nct06449313/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06449313.jpg</video:thumbnail_loc>
      <video:title>Cemiplimab-Rwlc for Non-small… (NCT06449313) | Triangle</video:title>
      <video:description>Cemiplimab-Rwlc trial for Non-small Cell Lung Cancer Stage III (NCT06449313). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06449313.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06449313.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:17:18.156Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-chemotherapy-for-borderline-resectable-and-locally-a-nct05825066/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05825066.jpg</video:thumbnail_loc>
      <video:title>Nab paclitaxel for Pancreas… (NCT05825066) | Triangle</video:title>
      <video:description>Nab paclitaxel trial for Pancreas Adenocarcinoma (NCT05825066). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05825066.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05825066.mp4</video:content_loc>
      <video:publication_date>2026-10-31T14:57:37.136Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-folfirinox-combined-with-pembrolizumab-followed-by-s-nct05132504/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05132504.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Pancreatic… (NCT05132504) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Pancreatic Ductal Adenocarcinoma (NCT05132504). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05132504.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05132504.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:42:56.032Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-inbrx-106-in-combination-with-pembrolizumab-for-stag-nct06353997/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06353997.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Triple Negative… (NCT06353997) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Triple Negative Breast Cancer (NCT06353997). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06353997.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06353997.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:34:36.220Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-lenvatinib-and-pembrolizumab-for-ivc-tumor-thrombus-nct05319015/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05319015.jpg</video:thumbnail_loc>
      <video:title>Neoadjuvant Lenvatinib for Renal… (NCT05319015) | Triangle</video:title>
      <video:description>Neoadjuvant Lenvatinib trial for Renal Cell Carcinoma (NCT05319015). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05319015.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05319015.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:36:09.039Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-neratinib-in-stage-i-iii-her2-mutated-lobular-breast-nct05919108/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05919108.jpg</video:thumbnail_loc>
      <video:title>Endocrine Therapy for Anatomic… (NCT05919108) | Triangle</video:title>
      <video:description>Endocrine Therapy trial for Anatomic Stage I Breast Cancer (NCT05919108). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05919108.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05919108.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:50:07.387Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-pembrolizumab-and-porustobart-in-resectable-pmmr-mss-nct07808151/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07808151.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Colon Cancer (NCT07808151) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Colon Cancer (NCT07808151). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07808151.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07808151.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:21:18.584Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-spare-adjuvant-nasa-in-stage-iiib-iv-m1a-melanoma-nct07740941/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07740941.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Melanoma (Skin Cancer) (NCT07740941) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Melanoma (Skin Cancer) (NCT07740941). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07740941.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07740941.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:58:26.060Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-tebentafusp-for-uveal-melanoma-nct06414590/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06414590.jpg</video:thumbnail_loc>
      <video:title>Tebentafusp-Tebn for Locally… (NCT06414590) | Triangle</video:title>
      <video:description>Tebentafusp-Tebn trial for Locally Advanced Unresectable Uveal Melanoma (NCT06414590). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06414590.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06414590.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:02:58.166Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/neoadjuvant-zanzalintinib-plus-nivolumab-in-patients-with-locall-nct06794229/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06794229.jpg</video:thumbnail_loc>
      <video:title>Zanzalintinib for Locally… (NCT06794229) | Triangle</video:title>
      <video:description>Zanzalintinib trial for Locally Advanced Renal Cell Carcinoma (NCT06794229). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06794229.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06794229.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:21:02.239Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/newly-diagnosed-stage-iii-iv-ovarian-cancer-neoadjuvant-carbo-ta-nct05952453/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05952453.jpg</video:thumbnail_loc>
      <video:title>Carboplatin for Ovarian Cancer (NCT05952453) | Triangle</video:title>
      <video:description>Carboplatin trial for Ovarian Cancer (NCT05952453). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05952453.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05952453.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:40:25.397Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nirogacestat-in-patients-with-kaposi-sarcoma-nct07539454/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07539454.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07539454) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for AIDS-Related Kaposi Sarcoma (NCT07539454). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07539454.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07539454.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:02:32.528Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nivolumab-in-epstein-barr-virus-ebv-positive-lymphoproliferative-nct03258567/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03258567.jpg</video:thumbnail_loc>
      <video:title>Nivolumab for Epstein-Barr Virus… (NCT03258567) | Triangle</video:title>
      <video:description>Nivolumab trial for Epstein-Barr Virus Infections (NCT03258567). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03258567.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03258567.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:10:19.919Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/nodal-radiation-therapy-for-sentinel-lymph-node-positive-melanom-nct04594187/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04594187.jpg</video:thumbnail_loc>
      <video:title>Immunotherapy for Melanoma (NCT04594187) | Triangle</video:title>
      <video:description>Immunotherapy trial for Melanoma (NCT04594187). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04594187.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04594187.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:13:11.046Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/obinutuzumab-and-ice-chemotherapy-in-refractory-recurrent-cd20-m-nct02393157/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02393157.jpg</video:thumbnail_loc>
      <video:title>Obinutuzumab for Non-Hodgkin Lymphoma (NCT02393157) | Triangle</video:title>
      <video:description>Obinutuzumab trial for Non-Hodgkin Lymphoma (NCT02393157). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02393157.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02393157.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:04:21.288Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/odronextamab-for-relapsed-and-refractory-large-b-cell-lymphomas-nct06784726/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06784726.jpg</video:thumbnail_loc>
      <video:title>Odronextamab for Recurrent… (NCT06784726) | Triangle</video:title>
      <video:description>Odronextamab trial for Recurrent Diffuse Large B-Cell Lymphoma (NCT06784726). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06784726.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06784726.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:25:09.402Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/olaparib-with-cediranib-or-azd6738-for-the-treatment-of-advanced-nct04090567/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04090567.jpg</video:thumbnail_loc>
      <video:title>Cediranib for Advanced Breast Carcinoma (NCT04090567) | Triangle</video:title>
      <video:description>Cediranib trial for Advanced Breast Carcinoma (NCT04090567). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04090567.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04090567.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:57:21.493Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/olutasidenib-in-relapsed-idh1-mutated-aml-patients-who-have-prev-nct07471841/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07471841.jpg</video:thumbnail_loc>
      <video:title>Olutasidenib for IDH1 Mutation (NCT07471841) | Triangle</video:title>
      <video:description>Olutasidenib trial for IDH1 Mutation (NCT07471841). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07471841.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07471841.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:59:56.227Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/olutasidenib-with-azacitidine-followed-by-olutasidenib-maintenan-nct07304011/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07304011.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Myeloid Leukemia (NCT07304011) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Myeloid Leukemia (NCT07304011). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07304011.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07304011.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:33:17.273Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/open-label-of-loncastuximab-tesirine-adct-402-in-relapsed-refrac-nct05296070/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05296070.jpg</video:thumbnail_loc>
      <video:title>Loncastuximab tesirine 150 µg/Kg (NCT05296070) | Triangle</video:title>
      <video:description>Loncastuximab tesirine 150 µg/Kg trial for Marginal Zone Lymphoma (NCT05296070). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05296070.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05296070.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:33:06.918Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combin-nct06369259/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06369259.jpg</video:thumbnail_loc>
      <video:title>Defactinib for Advanced… (NCT06369259) | Triangle</video:title>
      <video:description>Defactinib trial for Advanced Colorectal Cancer (NCT06369259). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06369259.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06369259.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:26:48.768Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/optimal-psa-triggered-individual-management-of-androgen-sensitiv-nct07216248/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07216248.jpg</video:thumbnail_loc>
      <video:title>relugolix + ARPI for Metastatic… (NCT07216248) | Triangle</video:title>
      <video:description>relugolix + ARPI trial for Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (NCT07216248). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07216248.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07216248.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:52:37.298Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/optimizing-neurocognition-with-whole-brain-radiation-therapy-wbr-nct05045950/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05045950.jpg</video:thumbnail_loc>
      <video:title>Memantine -Twice Daily or… (NCT05045950) | Triangle</video:title>
      <video:description>Memantine -Twice Daily or Extended Release trial for Brain Metastases (NCT05045950). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05045950.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05045950.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:55:32.302Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/oral-tgf-beta-receptor-i-inhibitor-vactosertib-in-soc-chemoradio-nct06044311/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06044311.jpg</video:thumbnail_loc>
      <video:title>Vactosertib for Adenocarcinoma Esophagus (NCT06044311) | Triangle</video:title>
      <video:description>Vactosertib trial for Adenocarcinoma Esophagus (NCT06044311). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06044311.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06044311.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:39:01.257Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/osimertinib-alone-or-with-chemotherapy-for-egfr-mutant-lung-canc-nct04410796/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04410796.jpg</video:thumbnail_loc>
      <video:title>Osimertinib for Metastatic… (NCT04410796) | Triangle</video:title>
      <video:description>Osimertinib trial for Metastatic Non-small Cell Lung Cancer (NCT04410796). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04410796.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04410796.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:28:28.835Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/osimertinib-and-cyclosporine-a-to-enhance-antitumor-efficacy-in-nct07874490/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07874490.jpg</video:thumbnail_loc>
      <video:title>Osimertinib for Non-Small Cell… (NCT07874490) | Triangle</video:title>
      <video:description>Osimertinib trial for Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (NCT07874490). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07874490.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07874490.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:18:59.106Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/oxaliplatin-and-liposomal-irinotecan-plus-trastuzumab-for-her2-p-nct04150640/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04150640.jpg</video:thumbnail_loc>
      <video:title>Nal-IRI for Esophageal Adenocarcinoma (NCT04150640) | Triangle</video:title>
      <video:description>Nal-IRI trial for Esophageal Adenocarcinoma (NCT04150640). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04150640.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04150640.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:03:18.319Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pacritinib-in-participants-with-metastatic-castrate-resistant-pr-nct07226713/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07226713.jpg</video:thumbnail_loc>
      <video:title>Pacritinib for Prostate Cancer (NCT07226713) | Triangle</video:title>
      <video:description>Pacritinib trial for Prostate Cancer (NCT07226713). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07226713.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07226713.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:28:15.896Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pacritinib-vs-hydroxyurea-in-advanced-proliferative-chronic-myel-nct07033598/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07033598.jpg</video:thumbnail_loc>
      <video:title>Pacritinib for Leukemia… (NCT07033598) | Triangle</video:title>
      <video:description>Pacritinib trial for Leukemia, Myelomonocytic, Chronic (NCT07033598). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07033598.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07033598.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:53:34.643Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/palbociclib-and-pembrolizumab-in-central-nervous-system-metastas-nct02896335/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02896335.jpg</video:thumbnail_loc>
      <video:title>Palbociclib for Metastatic… (NCT02896335) | Triangle</video:title>
      <video:description>Palbociclib trial for Metastatic Malignant Neoplasm to Brain (NCT02896335). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02896335.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02896335.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:26:30.413Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pancreatic-cancer-choose-preoperative-chemotherapy-by-smad4-stat-nct07748611/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07748611.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07748611) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT07748611). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07748611.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07748611.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:18:50.066Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/paxalisib-gdc-0084-in-recurrent-or-refractory-pcnsl-nct04906096/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04906096.jpg</video:thumbnail_loc>
      <video:title>PAXALISIB for Primary Central… (NCT04906096) | Triangle</video:title>
      <video:description>PAXALISIB trial for Primary Central Nervous System Lymphoma (NCT04906096). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04906096.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04906096.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:24:43.252Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pbi-11-ta-hpv-with-pembrolizumab-as-treatment-for-patients-w-adv-nct05799144/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05799144.jpg</video:thumbnail_loc>
      <video:title>DNA Vaccine for Metastatic… (NCT05799144) | Triangle</video:title>
      <video:description>DNA Vaccine trial for Metastatic Oropharyngeal Carcinoma (NCT05799144). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05799144.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05799144.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:00:59.182Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pd-l1-t-hank-nai-il-15sa-and-cetuximab-for-recurrent-metastatic-nct06239220/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06239220.jpg</video:thumbnail_loc>
      <video:title>PD-L1 t-haNK for Head and Neck Cancer (NCT06239220) | Triangle</video:title>
      <video:description>PD-L1 t-haNK trial for Head and Neck Cancer (NCT06239220). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06239220.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06239220.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:48:17.705Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pds01adc-in-combination-with-hepatic-artery-infusion-pump-haip-a-nct05286814/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05286814.jpg</video:thumbnail_loc>
      <video:title>Dexamethasone for Metastatic… (NCT05286814) | Triangle</video:title>
      <video:description>Dexamethasone trial for Metastatic Colorectal Cancer (Mcrc) (NCT05286814). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05286814.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05286814.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:43:37.869Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembro-with-radiation-with-or-without-olaparib-nct05568550/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05568550.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Prostate Cancer (NCT05568550) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Prostate Cancer (NCT05568550). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05568550.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05568550.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:09:48.027Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-and-enfortumab-vedotin-with-pembrolizumab-prior-to-nct05775471/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05775471.jpg</video:thumbnail_loc>
      <video:title>Biopsy for Renal Pelvis and… (NCT05775471) | Triangle</video:title>
      <video:description>Biopsy trial for Renal Pelvis and Ureter Urothelial Carcinoma (NCT05775471). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05775471.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05775471.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:51:01.555Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-and-hypofractionated-radiation-therapy-for-the-tre-nct04318717/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04318717.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Mucosal… (NCT04318717) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Mucosal Melanoma of the Head and Neck (NCT04318717). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04318717.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04318717.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:57:50.346Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-and-lenvatinib-in-advanced-cervical-cancer-nct04865887/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04865887.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Cervical Cancer (NCT04865887) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Cervical Cancer (NCT04865887). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04865887.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04865887.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:44:17.561Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-and-lenvatinib-in-mismatch-repair-proficient-recur-nct07594015/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07594015.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Recurrent… (NCT07594015) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Recurrent Endometrial Cancer (NCT07594015). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07594015.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07594015.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:07:22.857Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-and-odetiglucan-in-liver-predominant-metastatic-co-nct07082439/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07082439.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Colorectal… (NCT07082439) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Colorectal Adenocarcinoma Metastatic in the Liver (NCT07082439). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07082439.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07082439.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:45:00.095Z</video:publication_date>
      <video:duration>92</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-combined-with-bevacizumab-with-or-without-agonist-nct05231122/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05231122.jpg</video:thumbnail_loc>
      <video:title>Anti-CD40 Agonist Monoclonal… (NCT05231122) | Triangle</video:title>
      <video:description>Anti-CD40 Agonist Monoclonal Antibody CDX-1140 trial for Ovarian Clear Cell Adenocarcinoma (NCT05231122). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05231122.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05231122.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:45:44.708Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-in-combination-with-chemotherapy-for-the-treatment-nct07275216/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07275216.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Classic… (NCT07275216) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Classic Hodgkin Lymphoma (NCT07275216). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07275216.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07275216.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:18:54.699Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-n-803-alone-or-in-combination-with-pd-l1-t-hank-ce-nct06161545/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06161545.jpg</video:thumbnail_loc>
      <video:title>PD-L1 t-haNK cells for Stage II… (NCT06161545) | Triangle</video:title>
      <video:description>PD-L1 t-haNK cells trial for Stage II Squamous Cell Carcinoma of the Head and Neck (NCT06161545). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06161545.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06161545.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:28:35.325Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-olaparib-and-temozolomide-for-people-with-glioma-nct05188508/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05188508.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Glioma (NCT05188508) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Glioma (NCT05188508). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05188508.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05188508.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:22:25.873Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pembrolizumab-plus-177lu-psma-617-in-patients-with-castration-re-nct05766371/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05766371.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Castrate… (NCT05766371) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Castrate Resistant Prostate Cancer (NCT05766371). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05766371.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05766371.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:31:47.131Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pemetrexed-response-in-relation-to-tumor-alterations-of-gene-sta-nct06630416/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06630416.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06630416) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Metastatic Bladder Urothelial Carcinoma (NCT06630416). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06630416.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06630416.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:01:40.644Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pep-cmv-vaccine-targeting-cmv-antigen-to-treat-newly-diagnosed-p-nct05096481/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05096481.jpg</video:thumbnail_loc>
      <video:title>PEP-CMV for High Grade Glioma (NCT05096481) | Triangle</video:title>
      <video:description>PEP-CMV trial for High Grade Glioma (NCT05096481). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05096481.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05096481.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:43:42.493Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/personalized-neck-radiation-therapy-directed-by-sentinel-lymph-n-nct07121595/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07121595.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Oral… (NCT07121595) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Oral Cavity Squamous Cell Carcinoma (NCT07121595). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07121595.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07121595.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:40:40.199Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/personalized-reduction-of-chemotherapy-intensity-through-ctdna-e-nct06745076/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06745076.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06745076) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Advanced Hodgkin Lymphoma (NCT06745076). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06745076.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06745076.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:50:13.889Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pet-dynamics-to-response-adapted-neoadjuvant-therapy-in-tnbc-nct06245889/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06245889.jpg</video:thumbnail_loc>
      <video:title>Paclitaxel for Triple Negative… (NCT06245889) | Triangle</video:title>
      <video:description>Paclitaxel trial for Triple Negative Breast Cancer (NCT06245889). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06245889.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06245889.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:02:42.010Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ph-ii-intraperitoneal-paclitaxel-system-therapy-in-gi-ca-w-perit-nct07795749/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07795749.jpg</video:thumbnail_loc>
      <video:title>Paclitaxel Q2W for Esophageal Carcinoma (NCT07795749) | Triangle</video:title>
      <video:description>Paclitaxel Q2W trial for Esophageal Carcinoma (NCT07795749). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07795749.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07795749.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:10:50.196Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-single-arm-rectal-cancer-brachytherapy-for-patients-with-nct07292298/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07292298.jpg</video:thumbnail_loc>
      <video:title>High Rare Dose Rectal… (NCT07292298) | Triangle</video:title>
      <video:description>High Rare Dose Rectal Brachytherapy Boost trial for Rectal Adenocarcinoma (NCT07292298). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07292298.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07292298.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:59:25.508Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-study-assessing-the-clinical-activity-and-safety-of-obec-nct07053059/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07053059.jpg</video:thumbnail_loc>
      <video:title>Obecabtagene autoleucel for Acute… (NCT07053059) | Triangle</video:title>
      <video:description>Obecabtagene autoleucel trial for Acute Lymphocytic Leukemia (ALL) (NCT07053059). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07053059.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07053059.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:50:23.089Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-study-of-combination-tivozanib-and-nivolumab-in-advanced-nct06053658/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06053658.jpg</video:thumbnail_loc>
      <video:title>Tivozanib for Renal Cell Carcinoma (NCT06053658) | Triangle</video:title>
      <video:description>Tivozanib trial for Renal Cell Carcinoma (NCT06053658). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06053658.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06053658.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:54:08.049Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-study-of-glofitamab-monotherapy-with-polatuzumab-vedotin-nct06043674/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06043674.jpg</video:thumbnail_loc>
      <video:title>Glofitamab for Chronic… (NCT06043674) | Triangle</video:title>
      <video:description>Glofitamab trial for Chronic Lymphocytic Leukemia (NCT06043674). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06043674.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06043674.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:17:02.956Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-study-of-mosunetuzumab-in-patients-with-chronic-lymphocy-nct07566364/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07566364.jpg</video:thumbnail_loc>
      <video:title>Mosunetuzumab for Lymphocytic Leukemia (NCT07566364) | Triangle</video:title>
      <video:description>Mosunetuzumab trial for Lymphocytic Leukemia (NCT07566364). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07566364.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07566364.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:03:08.999Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-study-of-sr-8541a-in-combination-with-botensilimab-and-b-nct06589440/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06589440.jpg</video:thumbnail_loc>
      <video:title>SR-8541A for Refractory… (NCT06589440) | Triangle</video:title>
      <video:description>SR-8541A trial for Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) (NCT06589440). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06589440.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06589440.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:54:08.724Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-study-to-evaluate-safety-and-efficacy-of-cretostimogene-nct06567743/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06567743.jpg</video:thumbnail_loc>
      <video:title>Cretostimogene Grenadenorepvec (NCT06567743) | Triangle</video:title>
      <video:description>Cretostimogene Grenadenorepvec trial for High-Risk Non-Muscle-Invasive Bladder Cancer (NCT06567743). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06567743.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06567743.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:54:50.782Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-trial-of-epcoritamab-in-combination-with-rituximab-mini-nct06045247/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06045247.jpg</video:thumbnail_loc>
      <video:title>Prednisone for Large B-cell Lymphoma (NCT06045247) | Triangle</video:title>
      <video:description>Prednisone trial for Large B-cell Lymphoma (NCT06045247). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06045247.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06045247.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:21:09.371Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-trial-of-lisocabtagene-maraleucel-for-minimal-residual-d-nct07316010/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07316010.jpg</video:thumbnail_loc>
      <video:title>Leukapheresis for Large B-cell Lymphoma (NCT07316010) | Triangle</video:title>
      <video:description>Leukapheresis trial for Large B-cell Lymphoma (NCT07316010). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07316010.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07316010.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:39:28.734Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-trial-of-obinutuzumab-and-cc-99282-for-patients-with-pre-nct06108232/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06108232.jpg</video:thumbnail_loc>
      <video:title>Obinutuzumab for Follicular Lymphoma (NCT06108232) | Triangle</video:title>
      <video:description>Obinutuzumab trial for Follicular Lymphoma (NCT06108232). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06108232.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06108232.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:03:51.365Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-2-trial-of-zanzalintinib-and-pembrolizumab-in-select-subty-nct07283731/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07283731.jpg</video:thumbnail_loc>
      <video:title>Zanzalintinib for Phase 2 (NCT07283731) | Triangle</video:title>
      <video:description>Zanzalintinib trial for Phase 2 (NCT07283731). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07283731.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07283731.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:45:40.006Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-decentralized-pragmatic-trial-of-adjuvant-doxorubicin-t-nct07076186/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07076186.jpg</video:thumbnail_loc>
      <video:title>Trabectedin for Uterine Leiomyosarcoma (NCT07076186) | Triangle</video:title>
      <video:description>Trabectedin trial for Uterine Leiomyosarcoma (NCT07076186). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07076186.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07076186.mp4</video:content_loc>
      <video:publication_date>2026-10-31T14:54:14.082Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-protocol-of-proton-therapy-for-partial-breast-irradiati-nct01766297/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT01766297.jpg</video:thumbnail_loc>
      <video:title>Proton Radiotherapy for Breast Cancer (NCT01766297) | Triangle</video:title>
      <video:description>Proton Radiotherapy trial for Breast Cancer (NCT01766297). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT01766297.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT01766297.mp4</video:content_loc>
      <video:publication_date>2026-10-31T14:55:32.362Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-study-assessing-efficacy-and-safety-of-asciminib-in-pat-nct06236724/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06236724.jpg</video:thumbnail_loc>
      <video:title>Asciminib for Chronic Myeloid Leukemia (NCT06236724) | Triangle</video:title>
      <video:description>Asciminib trial for Chronic Myeloid Leukemia (NCT06236724). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06236724.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06236724.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:00:22.072Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-study-assessing-the-safety-and-efficacy-of-dasatinib-in-nct07269470/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07269470.jpg</video:thumbnail_loc>
      <video:title>Dasatinib for Chronic Myeloid Leukemia (NCT07269470) | Triangle</video:title>
      <video:description>Dasatinib trial for Chronic Myeloid Leukemia (NCT07269470). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07269470.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07269470.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:24:22.314Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-study-of-asciminib-for-second-line-treatment-of-chronic-nct06629584/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06629584.jpg</video:thumbnail_loc>
      <video:title>Asciminib for Malignant Solid Tumors (NCT06629584) | Triangle</video:title>
      <video:description>Asciminib trial for Malignant Solid Tumors (NCT06629584). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06629584.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06629584.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:51:38.750Z</video:publication_date>
      <video:duration>94</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-study-of-nivolumab-plus-avd-in-pediatric-adolescent-and-nct07551583/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07551583.jpg</video:thumbnail_loc>
      <video:title>Nivolumab for Hodgkin Lymphoma (NCT07551583) | Triangle</video:title>
      <video:description>Nivolumab trial for Hodgkin Lymphoma (NCT07551583). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07551583.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07551583.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:18:36.615Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-study-of-peptide-receptor-radionuclide-therapy-in-combi-nct05583708/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05583708.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Merkel Cell Carcinoma (NCT05583708) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Merkel Cell Carcinoma (NCT05583708). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05583708.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05583708.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:38:07.822Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-study-of-platinum-etoposide-plus-ivonescimab-for-extens-nct07057791/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07057791.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab 10 mg/kg for Extensive… (NCT07057791) | Triangle</video:title>
      <video:description>Ivonescimab 10 mg/kg trial for Extensive Stage Lung Small Cell Cancer (NCT07057791). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07057791.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07057791.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:16:51.433Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-study-of-second-line-pembrolizumab-plus-gvd-for-relapse-nct03618550/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03618550.jpg</video:thumbnail_loc>
      <video:title>pembrolizumab for Hodgkin Lymphoma (NCT03618550) | Triangle</video:title>
      <video:description>pembrolizumab trial for Hodgkin Lymphoma (NCT03618550). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03618550.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03618550.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:55:38.000Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-study-of-the-effects-of-laparoscopic-hyperthermic-intra-nct04107077/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04107077.jpg</video:thumbnail_loc>
      <video:title>Cisplatin for Gastric Cancer (NCT04107077) | Triangle</video:title>
      <video:description>Cisplatin trial for Gastric Cancer (NCT04107077). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04107077.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04107077.mp4</video:content_loc>
      <video:publication_date>2026-10-31T18:53:37.805Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-comparison-of-3-vs-4-fractions-brachy-fit-nct07022470/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07022470.jpg</video:thumbnail_loc>
      <video:title>3-Fraction HDR Brachytherapy (NCT07022470) | Triangle</video:title>
      <video:description>3-Fraction HDR Brachytherapy trial for Cervical Cancers (NCT07022470). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07022470.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07022470.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:00:12.015Z</video:publication_date>
      <video:duration>66</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-of-combination-anti-pd-1-and-aldesleukin-for-meta-nct05155033/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05155033.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Metastatic Melanoma (NCT05155033) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Metastatic Melanoma (NCT05155033). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05155033.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05155033.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:45:54.932Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-of-ivonescimab-in-combination-with-carboplatin-do-nct07017673/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07017673.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab for TNBC (NCT07017673) | Triangle</video:title>
      <video:description>Ivonescimab trial for TNBC (NCT07017673). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07017673.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07017673.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:29:10.204Z</video:publication_date>
      <video:duration>92</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-of-ivonescimab-in-previously-treated-patients-wit-nct06940518/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06940518.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab (NCT06940518) | Triangle</video:title>
      <video:description>Ivonescimab trial for Ivonescimab (NCT06940518). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06940518.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06940518.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:47:21.886Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-of-neoadjuvant-chemotherapy-nac-alone-or-in-combi-nct06223568/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06223568.jpg</video:thumbnail_loc>
      <video:title>Docetaxel for Squamous Cell… (NCT06223568) | Triangle</video:title>
      <video:description>Docetaxel trial for Squamous Cell Carcinoma of the Head and Neck (NCT06223568). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06223568.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06223568.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:14:47.141Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-of-psa-response-based-androgen-deprivation-therap-nct07313241/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07313241.jpg</video:thumbnail_loc>
      <video:title>Prostate Fossa Radiotherapy (NCT07313241) | Triangle</video:title>
      <video:description>Prostate Fossa Radiotherapy trial for Prostate Cancer (NCT07313241). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07313241.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07313241.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:37:17.549Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-of-puxitatug-samrotecan-azd8205-in-advanced-recur-nct07162480/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07162480.jpg</video:thumbnail_loc>
      <video:title>P-Sam for Adenoid Cystic Carcinoma (NCT07162480) | Triangle</video:title>
      <video:description>P-Sam trial for Adenoid Cystic Carcinoma (NCT07162480). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07162480.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07162480.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:14:32.084Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-of-sacituzumab-govitecan-in-recurrent-and-or-meta-nct05884320/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05884320.jpg</video:thumbnail_loc>
      <video:title>Sacituzumab Govitecan for Gland (NCT05884320) | Triangle</video:title>
      <video:description>Sacituzumab Govitecan trial for Gland (NCT05884320). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05884320.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05884320.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:44:33.902Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/phase-ii-trial-of-sacituzumab-tirumotecan-in-patients-with-smarc-nct07438626/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07438626.jpg</video:thumbnail_loc>
      <video:title>Sacituzumab tirumotecan for Phase II (NCT07438626) | Triangle</video:title>
      <video:description>Sacituzumab tirumotecan trial for Phase II (NCT07438626). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07438626.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07438626.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:58:48.535Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pilot-study-of-ivonescimab-in-advanced-metastatic-cutaneous-angi-nct07655570/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07655570.jpg</video:thumbnail_loc>
      <video:title>Ivonescimab for Cutaneous Angiosarcoma (NCT07655570) | Triangle</video:title>
      <video:description>Ivonescimab trial for Cutaneous Angiosarcoma (NCT07655570). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07655570.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07655570.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:35:59.318Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pilot-trial-of-fecal-microbiota-transplantation-for-lymphoma-pat-nct06218602/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06218602.jpg</video:thumbnail_loc>
      <video:title>Fecal Microbiota Transplantation (NCT06218602) | Triangle</video:title>
      <video:description>Fecal Microbiota Transplantation trial for Lymphoma (NCT06218602). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06218602.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06218602.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:58:53.772Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pirtobrutinib-for-the-treatment-of-elderly-patients-with-chronic-nct07685717/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07685717.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Chronic… (NCT07685717) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT07685717). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07685717.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07685717.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:46:51.653Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/post-autologous-transplant-maintenance-with-isatuximab-and-lenal-nct05344833/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05344833.jpg</video:thumbnail_loc>
      <video:title>Isatuximab for Multiple Myeloma (NCT05344833) | Triangle</video:title>
      <video:description>Isatuximab trial for Multiple Myeloma (NCT05344833). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05344833.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05344833.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:33:52.431Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/post-transplant-maintenance-therapy-with-isatuximab-plus-lenalid-nct05776979/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05776979.jpg</video:thumbnail_loc>
      <video:title>Isatuximab for Multiple Myeloma (NCT05776979) | Triangle</video:title>
      <video:description>Isatuximab trial for Multiple Myeloma (NCT05776979). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05776979.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05776979.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:06:14.386Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pre-operative-atezolizumab-in-patients-with-resectable-human-pap-nct06254911/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06254911.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Oropharynx… (NCT06254911) | Triangle</video:title>
      <video:description>Atezolizumab trial for Oropharynx Cancer, Stage I (NCT06254911). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06254911.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06254911.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:21:44.987Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pre-radiation-chemotherapy-for-newly-diagnosed-high-grade-glioma-nct07439172/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07439172.jpg</video:thumbnail_loc>
      <video:title>Pre-radiation temozolomide. (NCT07439172) | Triangle</video:title>
      <video:description>Pre-radiation temozolomide. trial for High Grade Gliomas (NCT07439172). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07439172.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07439172.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:31:59.936Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pre-transplant-purging-and-post-transplant-mrd-guided-maintenanc-nct06207799/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06207799.jpg</video:thumbnail_loc>
      <video:title>Elranatamab for Multiple Myeloma (NCT06207799) | Triangle</video:title>
      <video:description>Elranatamab trial for Multiple Myeloma (NCT06207799). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06207799.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06207799.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:07:41.048Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/precision-medicine-in-action-phase-ii-trial-of-response-adaptive-nct06444269/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06444269.jpg</video:thumbnail_loc>
      <video:title>Radiomics on MRI for Breast Cancer (NCT06444269) | Triangle</video:title>
      <video:description>Radiomics on MRI trial for Breast Cancer (NCT06444269). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06444269.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06444269.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:22:17.764Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/preoperative-pembrolizumab-and-chemotherapy-in-resectable-recurr-nct05726370/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05726370.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Head and Neck… (NCT05726370) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Head and Neck Squamous Cell Carcinoma (NCT05726370). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05726370.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05726370.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:54:33.256Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/preoperative-radiotherapy-and-immunotherapy-for-sinonasal-and-an-nct05546827/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05546827.jpg</video:thumbnail_loc>
      <video:title>Surgical resection for Sinonasal… (NCT05546827) | Triangle</video:title>
      <video:description>Surgical resection trial for Sinonasal Melanoma (NCT05546827). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05546827.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05546827.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:34:24.744Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/propranolol-with-chemotherapy-or-chemoradiation-for-esophageal-a-nct04682158/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04682158.jpg</video:thumbnail_loc>
      <video:title>Carboplatin for Esophageal… (NCT04682158) | Triangle</video:title>
      <video:description>Carboplatin trial for Esophageal Adenocarcinoma (NCT04682158). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04682158.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04682158.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:23:33.995Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/prorad-5-prostate-radiation-in-5-fractions-phase-ii-five-fractio-nct06369246/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06369246.jpg</video:thumbnail_loc>
      <video:title>Stereotactic Body Radiation Therapy (NCT06369246) | Triangle</video:title>
      <video:description>Stereotactic Body Radiation Therapy trial for Advanced Prostate Cancer (NCT06369246). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06369246.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06369246.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:49:38.973Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/prospective-trial-assessing-real-world-outcomes-response-to-pemb-nct06745882/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06745882.jpg</video:thumbnail_loc>
      <video:title>Cisplatin for Non-small Cell Lung Cancer (NCT06745882) | Triangle</video:title>
      <video:description>Cisplatin trial for Non-small Cell Lung Cancer (NCT06745882). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06745882.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06745882.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:32:30.980Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/prostate-cancer-treatment-using-androgen-deprivation-therapy-and-nct05790213/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05790213.jpg</video:thumbnail_loc>
      <video:title>Androgen Deprivation Therapy (ADT) (NCT05790213) | Triangle</video:title>
      <video:description>Androgen Deprivation Therapy (ADT) trial for Prostate Cancer (NCT05790213). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05790213.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05790213.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:57:42.879Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/prostate-specific-membrane-antigen-psma-or-facbc-pet-ct-site-dir-nct04175431/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04175431.jpg</video:thumbnail_loc>
      <video:title>Positron Emission Tomography (NCT04175431) | Triangle</video:title>
      <video:description>Positron Emission Tomography trial for Prostate Adenocarcinoma (NCT04175431). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04175431.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04175431.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:24:07.708Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/protocol-number-hjkc3-0003-treatment-free-remission-after-ascimi-nct04838041/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04838041.jpg</video:thumbnail_loc>
      <video:title>Asciminib 40 MG for Chronic Phase… (NCT04838041) | Triangle</video:title>
      <video:description>Asciminib 40 MG trial for Chronic Phase Chronic Myelogenous Leukemia (NCT04838041). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04838041.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04838041.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:41:29.184Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/proton-beam-radiation-therapy-after-treatment-for-resected-n2-no-nct06008730/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06008730.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06008730) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Resectable Lung Non-Small Cell Carcinoma (NCT06008730). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06008730.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06008730.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:35:38.222Z</video:publication_date>
      <video:duration>63</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/proton-radiation-for-unresectable-borderline-resectable-or-medic-nct02598349/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02598349.jpg</video:thumbnail_loc>
      <video:title>Proton Radiation for Pancreatic Cancer (NCT02598349) | Triangle</video:title>
      <video:description>Proton Radiation trial for Pancreatic Cancer (NCT02598349). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02598349.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02598349.mp4</video:content_loc>
      <video:publication_date>2026-10-31T14:54:52.934Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/proton-therapy-for-post-surgical-treatment-of-gynecologic-cancer-nct05758688/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05758688.jpg</video:thumbnail_loc>
      <video:title>Whole Pelvis (WP) Pencil Beam… (NCT05758688) | Triangle</video:title>
      <video:description>Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) trial for Cervical Cancer (NCT05758688). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05758688.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05758688.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:31:09.590Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/psma-directed-para-aortic-radiation-therapy-for-oligorecurrent-p-nct06392295/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06392295.jpg</video:thumbnail_loc>
      <video:title>Para Aortic Radiation Therapy… (NCT06392295) | Triangle</video:title>
      <video:description>Para Aortic Radiation Therapy: Photon Therapy trial for Prostate Cancer (NCT06392295). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06392295.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06392295.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:56:05.972Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/psma-pet-guided-de-escalation-of-salvage-radiation-treatment-in-nct07234981/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07234981.jpg</video:thumbnail_loc>
      <video:title>PSMA-guided Salvage Radiation (NCT07234981) | Triangle</video:title>
      <video:description>PSMA-guided Salvage Radiation trial for Prostate Cancer (NCT07234981). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07234981.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07234981.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:11:19.412Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pt-112-in-subjects-with-thymoma-and-thymic-carcinoma-nct05104736/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05104736.jpg</video:thumbnail_loc>
      <video:title>PT-112 for Thymic Epithelial Tumor (NCT05104736) | Triangle</video:title>
      <video:description>PT-112 trial for Thymic Epithelial Tumor (NCT05104736). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05104736.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05104736.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:53:06.878Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/pulso-trial-pulsed-low-dose-rate-pldr-radiation-chemoradiation-c-nct06906887/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06906887.jpg</video:thumbnail_loc>
      <video:title>Induction Chemotherapy (modified… (NCT06906887) | Triangle</video:title>
      <video:description>Induction Chemotherapy (modified FLOT or modified FOLFOX-6) trial for Esophageal Cancer (NCT06906887). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06906887.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06906887.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:00:34.010Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/radiation-and-tsr-042-dostarlimab-in-people-with-endometrial-can-nct04774419/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04774419.jpg</video:thumbnail_loc>
      <video:title>Intensity modulated radiation… (NCT04774419) | Triangle</video:title>
      <video:description>Intensity modulated radiation therapy (IMRT) trial for Endometrial Cancer (NCT04774419). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04774419.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04774419.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:23:16.008Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/radiation-prior-to-tki-to-delay-progression-in-advanced-driver-m-nct06305715/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06305715.jpg</video:thumbnail_loc>
      <video:title>Radiation Therapy for Non Small… (NCT06305715) | Triangle</video:title>
      <video:description>Radiation Therapy trial for Non Small Cell Lung Cancer (NCT06305715). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06305715.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06305715.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:14:09.471Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/radiation-therapy-approaches-for-people-with-prostate-cancer-nct07751159/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07751159.jpg</video:thumbnail_loc>
      <video:title>Standard of Care HDR Brachytherapy (NCT07751159) | Triangle</video:title>
      <video:description>Standard of Care HDR Brachytherapy trial for Prostate Cancer Patients (NCT07751159). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07751159.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07751159.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:55:29.571Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/radiation-therapy-with-or-without-cisplatin-in-treating-patients-nct02734537/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02734537.jpg</video:thumbnail_loc>
      <video:title>Cisplatin for Head and Neck… (NCT02734537) | Triangle</video:title>
      <video:description>Cisplatin trial for Head and Neck Squamous Cell Carcinoma (NCT02734537). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02734537.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02734537.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:02:41.059Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/radiotherapy-in-combination-with-checkpoint-inhibition-for-patie-nct06601296/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06601296.jpg</video:thumbnail_loc>
      <video:title>IMSA101 for Metastatic Renal Cell… (NCT06601296) | Triangle</video:title>
      <video:description>IMSA101 trial for Metastatic Renal Cell Carcinoma ( mRCC) (NCT06601296). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06601296.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06601296.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:19:29.932Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ramucirumab-and-paclitaxel-or-folfiri-in-advanced-small-bowel-ca-nct04205968/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04205968.jpg</video:thumbnail_loc>
      <video:title>Fluorouracil for Metastatic Small… (NCT04205968) | Triangle</video:title>
      <video:description>Fluorouracil trial for Metastatic Small Intestinal Adenocarcinoma (NCT04205968). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04205968.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04205968.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:59:39.211Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/rapid-analysis-and-response-evaluation-of-combination-anti-neopl-nct04449549/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04449549.jpg</video:thumbnail_loc>
      <video:title>Nilotinib and Paclitaxel for Neoplasms (NCT04449549) | Triangle</video:title>
      <video:description>Nilotinib and Paclitaxel trial for Neoplasms (NCT04449549). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04449549.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04449549.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:31:51.385Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/real-time-mri-guided-3-fraction-accelerated-partial-breast-irrad-nct03936478/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03936478.jpg</video:thumbnail_loc>
      <video:title>MRIdian Radiation Treatment Unit (NCT03936478) | Triangle</video:title>
      <video:description>MRIdian Radiation Treatment Unit trial for Breast Cancer (NCT03936478). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03936478.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03936478.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:03:51.271Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/recombinant-glycosylated-human-interleukin-7-cyt107-for-the-trea-nct07308886/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07308886.jpg</video:thumbnail_loc>
      <video:title>CYT107 for Kaposi Sarcoma (NCT07308886) | Triangle</video:title>
      <video:description>CYT107 trial for Kaposi Sarcoma (NCT07308886). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07308886.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07308886.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:36:26.076Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/rectify-1-neoadjuvant-botensilimab-balstilimab-in-mss-pmmr-early-nct07735624/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07735624.jpg</video:thumbnail_loc>
      <video:title>Botensilimab for Early Rectal Cancer (NCT07735624) | Triangle</video:title>
      <video:description>Botensilimab trial for Early Rectal Cancer (NCT07735624). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07735624.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07735624.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:51:25.216Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/recurrent-ovarian-cancers-after-parp-maintenance-sacituzumab-gov-nct07504588/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07504588.jpg</video:thumbnail_loc>
      <video:title>Anti-VEGF Monoclonal Antibody (NCT07504588) | Triangle</video:title>
      <video:description>Anti-VEGF Monoclonal Antibody trial for Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma (NCT07504588). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07504588.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07504588.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:21:22.813Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/regorafenib-reg-and-lorigerlimab-lor-relo-regimen-in-treatment-o-nct07071961/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07071961.jpg</video:thumbnail_loc>
      <video:title>Regorafenib (CT) for Colorectal Cancer (NCT07071961) | Triangle</video:title>
      <video:description>Regorafenib (CT) trial for Colorectal Cancer (NCT07071961). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07071961.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07071961.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:43:57.262Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/regulus-mri-guided-adaptive-sabr-for-liver-cancers-nct07223307/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07223307.jpg</video:thumbnail_loc>
      <video:title>MRI-guided adaptive stereotactic… (NCT07223307) | Triangle</video:title>
      <video:description>MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) trial for Liver Cancer (NCT07223307). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07223307.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07223307.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:33:37.219Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/relacorilant-in-combination-with-different-treatment-regimens-in-nct06906341/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06906341.jpg</video:thumbnail_loc>
      <video:title>Relacorilant 150 mg once daily (QD) (NCT06906341) | Triangle</video:title>
      <video:description>Relacorilant 150 mg once daily (QD) trial for Ovarian Cancer (NCT06906341). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06906341.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06906341.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:38:23.046Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/relacorilant-with-nab-paclitaxel-and-gemcitabine-in-patients-wit-nct07259317/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07259317.jpg</video:thumbnail_loc>
      <video:title>Relacorilant for Adenocarcinoma (NCT07259317) | Triangle</video:title>
      <video:description>Relacorilant trial for Adenocarcinoma (NCT07259317). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07259317.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07259317.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:52:54.080Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/repeat-breast-conserving-surgery-followed-by-daily-partial-breas-nct06129747/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06129747.jpg</video:thumbnail_loc>
      <video:title>Radiation Therapy for Breast Cancer (NCT06129747) | Triangle</video:title>
      <video:description>Radiation Therapy trial for Breast Cancer (NCT06129747). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06129747.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06129747.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:20:21.192Z</video:publication_date>
      <video:duration>67</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/repurposing-atovaquone-for-the-treatment-of-platinum-resistant-o-nct05998135/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05998135.jpg</video:thumbnail_loc>
      <video:title>Atovaquone for Ovarian High Grade… (NCT05998135) | Triangle</video:title>
      <video:description>Atovaquone trial for Ovarian High Grade Serous Adenocarcinoma (NCT05998135). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05998135.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05998135.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:57:56.513Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/resectable-lung-cancer-cemiplimab-and-fianlimab-before-surgery-nct06918132/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06918132.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Lung… (NCT06918132) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Lung Non-Small Cell Carcinoma (NCT06918132). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06918132.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06918132.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:16:51.846Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/restoring-lymphocytes-using-nktr-255-after-chemoradiotherapy-in-nct05632809/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05632809.jpg</video:thumbnail_loc>
      <video:title>NKTR-255 for Lung Cancer (NCT05632809) | Triangle</video:title>
      <video:description>NKTR-255 trial for Lung Cancer (NCT05632809). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05632809.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05632809.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:57:28.726Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ribociclib-and-endocrine-treatment-of-physicians-choice-for-loco-nct05467891/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05467891.jpg</video:thumbnail_loc>
      <video:title>Ribociclib for Locoregional Recurrence (NCT05467891) | Triangle</video:title>
      <video:description>Ribociclib trial for Locoregional Recurrence (NCT05467891). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05467891.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05467891.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:52:54.448Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/risk-adapted-proteomic-guided-systemic-therapy-for-previously-un-nct07250477/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07250477.jpg</video:thumbnail_loc>
      <video:title>Systemic (ICI)-based therapy… (NCT07250477) | Triangle</video:title>
      <video:description>Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment. trial for Non-small Cell Lung Cancer Stage IIIC (NCT07250477). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07250477.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07250477.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:36:57.194Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/risk-adapted-therapy-in-hpv-oropharyngeal-cancer-using-circulati-nct04900623/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04900623.jpg</video:thumbnail_loc>
      <video:title>NavDx HPV ctDNA Testing (NCT04900623) | Triangle</video:title>
      <video:description>NavDx HPV ctDNA Testing trial for HPV-Associated Oropharyngeal Squamous Cell Carcinoma (NCT04900623). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04900623.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04900623.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:25:03.335Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/rituximab-and-zanubrutinib-in-patients-with-indolent-b-cell-lymp-nct06350318/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06350318.jpg</video:thumbnail_loc>
      <video:title>Zanubrutinib for Follicular Lymphoma (NCT06350318) | Triangle</video:title>
      <video:description>Zanubrutinib trial for Follicular Lymphoma (NCT06350318). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06350318.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06350318.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:48:13.198Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ruxolitinib-before-during-and-after-hematopoietic-cell-transplan-nct07228624/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07228624.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib (NCT07228624) | Triangle</video:title>
      <video:description>Ruxolitinib trial for Myelodysplastic/Myeloproliferative Neoplasm (NCT07228624). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07228624.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07228624.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:10:58.138Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ruxolitinib-for-the-treatment-of-t-cell-large-granular-lymphocyt-nct05592015/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05592015.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib for T-Cell Large… (NCT05592015) | Triangle</video:title>
      <video:description>Ruxolitinib trial for T-Cell Large Granular Lymphocyte Leukemia (NCT05592015). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05592015.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05592015.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:58:10.877Z</video:publication_date>
      <video:duration>65</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ruxolitinib-maintenance-post-hematopoietic-stem-cell-transplant-nct07356245/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07356245.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib for T-cell Lymphoma (NCT07356245) | Triangle</video:title>
      <video:description>Ruxolitinib trial for T-cell Lymphoma (NCT07356245). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07356245.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07356245.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:32:51.132Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ruxolitinib-with-radiation-and-temozolomide-compared-to-radiatio-nct06991101/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06991101.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib for Glioblastoma (NCT06991101) | Triangle</video:title>
      <video:description>Ruxolitinib trial for Glioblastoma (NCT06991101). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06991101.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06991101.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:38:25.241Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/sacituzumab-govitecan-with-or-without-atezolizumab-immunotherapy-nct06161532/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06161532.jpg</video:thumbnail_loc>
      <video:title>Sacituzumab govitecan for Small… (NCT06161532) | Triangle</video:title>
      <video:description>Sacituzumab govitecan trial for Small Cell Carcinoma of the Bladder (NCT06161532). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06161532.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06161532.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:26:01.104Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/safety-and-efficacy-study-of-intravesical-instillation-of-tara-0-nct05951179/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05951179.jpg</video:thumbnail_loc>
      <video:title>TARA-002 for Non-muscle Invasive… (NCT05951179) | Triangle</video:title>
      <video:description>TARA-002 trial for Non-muscle Invasive Bladder Cancer (NCT05951179). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05951179.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05951179.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:44:05.125Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/safety-and-efficacy-study-of-safusidenib-in-participants-with-id-nct07703436/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07703436.jpg</video:thumbnail_loc>
      <video:title>Safusidenib for Grade 2… (NCT07703436) | Triangle</video:title>
      <video:description>Safusidenib trial for Grade 2 IDH1-mutant Glioma (NCT07703436). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07703436.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07703436.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:02:13.128Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/selinexor-and-pacritinib-in-jak-inhibitor-nai-ve-mf-patients-wit-nct07447817/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07447817.jpg</video:thumbnail_loc>
      <video:title>Pacritinib for Myelofibrosis (NCT07447817) | Triangle</video:title>
      <video:description>Pacritinib trial for Myelofibrosis (NCT07447817). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07447817.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07447817.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:32:25.785Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/selpercatinib-pre-rai-in-patients-with-ret-fusion-thyroid-cancer-nct06458036/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06458036.jpg</video:thumbnail_loc>
      <video:title>Selpercatinib Monotherapy (NCT06458036) | Triangle</video:title>
      <video:description>Selpercatinib Monotherapy trial for Differentiated Thyroid Cancer (NCT06458036). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06458036.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06458036.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:11:24.142Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/sequencing-antibody-drug-conjugates-in-er-her2-low-ultra-low-mbc-nct06263543/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06263543.jpg</video:thumbnail_loc>
      <video:title>Sacituzumab govitecan for Breast Cancer (NCT06263543) | Triangle</video:title>
      <video:description>Sacituzumab govitecan trial for Breast Cancer (NCT06263543). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06263543.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06263543.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:57:49.106Z</video:publication_date>
      <video:duration>92</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/sequential-testosterone-and-enzalutamide-prevents-unfavorable-pr-nct04363164/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04363164.jpg</video:thumbnail_loc>
      <video:title>Testosterone cypionate (NCT04363164) | Triangle</video:title>
      <video:description>Testosterone cypionate trial for Castration Resistant Metastatic Prostate Cancer (NCT04363164). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04363164.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04363164.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:39:32.009Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/sequential-treatment-of-cabozantinib-for-advanced-renal-cell-car-nct05931393/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05931393.jpg</video:thumbnail_loc>
      <video:title>Cabozantinib 80 MG for RCC (NCT05931393) | Triangle</video:title>
      <video:description>Cabozantinib 80 MG trial for RCC (NCT05931393). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05931393.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05931393.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:57:01.728Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/sfolfoxiri-in-advanced-gastroesophageal-cancer-sage-nct05332002/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05332002.jpg</video:thumbnail_loc>
      <video:title>Four week alternating FOLFOX and… (NCT05332002) | Triangle</video:title>
      <video:description>Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI) trial for Gastro-Intestinal Cancer (NCT05332002). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05332002.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05332002.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:03:47.034Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/short-course-adt-for-high-risk-low-intermediate-risk-artera-pros-nct07801664/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07801664.jpg</video:thumbnail_loc>
      <video:title>Androgen Deprivation Therapy (ADT) (NCT07801664) | Triangle</video:title>
      <video:description>Androgen Deprivation Therapy (ADT) trial for Prostate Cancer (NCT07801664). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07801664.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07801664.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:49:01.725Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/shortening-adjuvant-photon-and-proton-irradiation-sapphire-ii-a-nct07076485/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07076485.jpg</video:thumbnail_loc>
      <video:title>Ultrahypofractionated Radiation (NCT07076485) | Triangle</video:title>
      <video:description>Ultrahypofractionated Radiation trial for Breast Cancer (NCT07076485). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07076485.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07076485.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:59:01.582Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/single-arm-study-of-neoadjuvant-dostarlimab-in-stage-ii-and-iii-nct05239546/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05239546.jpg</video:thumbnail_loc>
      <video:title>Dostarlimab for Colon Cancer (NCT05239546) | Triangle</video:title>
      <video:description>Dostarlimab trial for Colon Cancer (NCT05239546). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05239546.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05239546.mp4</video:content_loc>
      <video:publication_date>2026-11-01T00:03:54.069Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/single-fraction-interstitial-breast-brachytherapy-nct07654257/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07654257.jpg</video:thumbnail_loc>
      <video:title>Partial Breast Irradiation (NCT07654257) | Triangle</video:title>
      <video:description>Partial Breast Irradiation trial for Breast Cancer (NCT07654257). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07654257.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07654257.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:53:17.559Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/smarca4-2-inhibitor-for-pou2f3-positive-sclc-nct07551635/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07551635.jpg</video:thumbnail_loc>
      <video:title>FHD-286 for Small Cell Lung Cancer (NCT07551635) | Triangle</video:title>
      <video:description>FHD-286 trial for Small Cell Lung Cancer (NCT07551635). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07551635.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07551635.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:23:35.423Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/srs-compared-with-fsrs-for-treatment-of-intact-metastatic-brain-nct05222620/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05222620.jpg</video:thumbnail_loc>
      <video:title>Questionnaire Administration (NCT05222620) | Triangle</video:title>
      <video:description>Questionnaire Administration trial for Metastatic Malignant Neoplasm in the Brain (NCT05222620). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05222620.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05222620.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:12:13.048Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/statins-in-patients-with-clonal-cytopenia-of-undetermined-signif-nct05483010/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05483010.jpg</video:thumbnail_loc>
      <video:title>Atorvastatin for Clonal Cytopenia… (NCT05483010) | Triangle</video:title>
      <video:description>Atorvastatin trial for Clonal Cytopenia of Undetermined Significance (NCT05483010). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05483010.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05483010.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:16:56.984Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/stereotactic-body-radiation-therapy-plus-immediate-or-delayed-an-nct06378866/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06378866.jpg</video:thumbnail_loc>
      <video:title>Abiraterone for Recurrent… (NCT06378866) | Triangle</video:title>
      <video:description>Abiraterone trial for Recurrent Castration-Sensitive Prostate Carcinoma (NCT06378866). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06378866.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06378866.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:29:57.474Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/stereotactic-brain-directed-radiation-with-or-without-aguix-gado-nct04899908/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04899908.jpg</video:thumbnail_loc>
      <video:title>Stereotactic Radiation for Brain Cancer (NCT04899908) | Triangle</video:title>
      <video:description>Stereotactic Radiation trial for Brain Cancer (NCT04899908). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04899908.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04899908.mp4</video:content_loc>
      <video:publication_date>2026-10-31T18:20:20.522Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/stereotactic-radiation-for-growing-changing-brain-metastases-wit-nct07132190/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07132190.jpg</video:thumbnail_loc>
      <video:title>Linear accelerator-based… (NCT07132190) | Triangle</video:title>
      <video:description>Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV trial for Brain Metastases, Adult (NCT07132190). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07132190.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07132190.mp4</video:content_loc>
      <video:publication_date>2026-10-31T18:32:24.512Z</video:publication_date>
      <video:duration>69</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/strategic-endocrine-therapy-and-targeted-radiotherapy-for-prosta-nct07364071/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07364071.jpg</video:thumbnail_loc>
      <video:title>Radiation therapy for Prostate… (NCT07364071) | Triangle</video:title>
      <video:description>Radiation therapy trial for Prostate Adenocarcinoma (NCT07364071). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07364071.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07364071.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:26:40.983Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-adding-drugs-to-usual-treatment-for-large-b-cell-lymphoma-nct05890352/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05890352.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Grade… (NCT05890352) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Grade 3b Follicular Lymphoma (NCT05890352). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05890352.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05890352.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:29:23.943Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-evaluating-dosimetry-randomized-dose-optimization-dose-esc-nct06549465/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06549465.jpg</video:thumbnail_loc>
      <video:title>In-111 rosopatamab tetraxetan (NCT06549465) | Triangle</video:title>
      <video:description>In-111 rosopatamab tetraxetan trial for PSMA PET-Positive Castration-Resistant Prostate Cancer (NCT06549465). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06549465.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06549465.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:55:00.227Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-ar-suppression-with-carotuximab-in-metastatic-castratio-nct05534646/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05534646.jpg</video:thumbnail_loc>
      <video:title>AR Blockade (NCT05534646) | Triangle</video:title>
      <video:description>AR Blockade trial for Castration-resistant Prostate Cancer (NCT05534646). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05534646.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05534646.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:39:29.780Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-belantamab-mafodotin-with-carfilzomib-pomalidomide-and-nct05789303/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05789303.jpg</video:thumbnail_loc>
      <video:title>Belantamab mafodotin for Multiple… (NCT05789303) | Triangle</video:title>
      <video:description>Belantamab mafodotin trial for Multiple Myeloma (NCT05789303). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05789303.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05789303.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:02:52.046Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-bevacizumab-in-combination-with-chemoimmunotherapy-and-nct05588388/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05588388.jpg</video:thumbnail_loc>
      <video:title>Bevacizumab for Extensive-stage… (NCT05588388) | Triangle</video:title>
      <video:description>Bevacizumab trial for Extensive-stage Small-cell Lung Cancer (NCT05588388). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05588388.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05588388.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:47:34.652Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-carboplatin-and-mirvetuximab-soravtansine-in-first-line-nct04606914/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04606914.jpg</video:thumbnail_loc>
      <video:title>mirvetuximab soravtansine (MIRV… (NCT04606914) | Triangle</video:title>
      <video:description>mirvetuximab soravtansine (MIRV; IMGN853) trial for Ovarian Cancer (NCT04606914). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04606914.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04606914.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:13:18.464Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-cryoablation-and-nirogacestat-for-desmoid-tumor-nct05949099/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05949099.jpg</video:thumbnail_loc>
      <video:title>Nirogacestat for Desmoid Tumor (NCT05949099) | Triangle</video:title>
      <video:description>Nirogacestat trial for Desmoid Tumor (NCT05949099). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05949099.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05949099.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:54:17.134Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-denikitug-gs-1811-given-alone-or-with-nivolumab-or-chem-nct07546812/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07546812.jpg</video:thumbnail_loc>
      <video:title>Denikitug for HER2-negative (NCT07546812) | Triangle</video:title>
      <video:description>Denikitug trial for HER2-negative (NCT07546812). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07546812.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07546812.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:24:50.616Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-denikitug-gs-1811-given-alone-or-with-nivolumab-or-with-nct07527858/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07527858.jpg</video:thumbnail_loc>
      <video:title>Denikitug for Advanced… (NCT07527858) | Triangle</video:title>
      <video:description>Denikitug trial for Advanced Microsatellite Stable Colorectal Cancer (NCT07527858). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07527858.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07527858.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:02:54.878Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-ev-for-recurrent-endometrial-carcinoma-nct07139977/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07139977.jpg</video:thumbnail_loc>
      <video:title>Enfortumab Vedotin for Endometrial… (NCT07139977) | Triangle</video:title>
      <video:description>Enfortumab Vedotin trial for Endometrial Cancer (NCT07139977). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07139977.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07139977.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:16:39.262Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-induction-pd-1-blockade-in-subjects-with-locally-advanc-nct04165772/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04165772.jpg</video:thumbnail_loc>
      <video:title>TSR-042 or Dostarlimab for Rectal… (NCT04165772) | Triangle</video:title>
      <video:description>TSR-042 or Dostarlimab trial for Rectal Adenocarcinoma (NCT04165772). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04165772.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04165772.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:00:46.375Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-kte-x19-in-minimal-residual-disease-mrd-positive-b-cell-nct06144606/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06144606.jpg</video:thumbnail_loc>
      <video:title>Tecartus for B-Cell Lymphoblastic… (NCT06144606) | Triangle</video:title>
      <video:description>Tecartus trial for B-Cell Lymphoblastic Leukemia (NCT06144606). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06144606.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06144606.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:35:43.091Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-nalirifox-in-advanced-unresectable-small-bowel-tumors-nct06835387/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06835387.jpg</video:thumbnail_loc>
      <video:title>Nanoliposomal irinotecan for Small… (NCT06835387) | Triangle</video:title>
      <video:description>Nanoliposomal irinotecan trial for Small Bowel Adenocarcinoma (NCT06835387). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06835387.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06835387.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:02:59.764Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-olutasidenib-and-temozolomide-in-hgg-nct06161974/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06161974.jpg</video:thumbnail_loc>
      <video:title>Olutasidenib + TMZ for High Grade Glioma (NCT06161974) | Triangle</video:title>
      <video:description>Olutasidenib + TMZ trial for High Grade Glioma (NCT06161974). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06161974.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06161974.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:05:32.174Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-onc206-jzp3507-in-advanced-pheochromocytoma-and-paragan-nct07282587/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07282587.jpg</video:thumbnail_loc>
      <video:title>ONC206 for Advanced… (NCT07282587) | Triangle</video:title>
      <video:description>ONC206 trial for Advanced Pheochromocytoma and Paraganglioma (NCT07282587). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07282587.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07282587.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:24:51.559Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-oral-mrt-2359-with-apalutamide-in-prostate-cancer-nct07745361/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07745361.jpg</video:thumbnail_loc>
      <video:title>Oral MRT-2359 (NCT07745361) | Triangle</video:title>
      <video:description>Oral MRT-2359 trial for Castration-Resistant Prostate Cancer (CRPC) (NCT07745361). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07745361.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07745361.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:04:17.420Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-patritumab-deruxtecan-plus-pembrolizumab-with-other-ant-nct06797635/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06797635.jpg</video:thumbnail_loc>
      <video:title>Patritumab deruxtecan for Breast… (NCT06797635) | Triangle</video:title>
      <video:description>Patritumab deruxtecan trial for Breast Neoplasms (NCT06797635). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06797635.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06797635.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:30:10.301Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-pembrolizumab-carboplatin-paclitaxel-and-radiation-for-nct06493019/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06493019.jpg</video:thumbnail_loc>
      <video:title>Pembrolizumab for Anal Cancer (NCT06493019) | Triangle</video:title>
      <video:description>Pembrolizumab trial for Anal Cancer (NCT06493019). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06493019.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06493019.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:57:25.417Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-ruxolitinib-in-relapsed-or-refractory-t-or-nk-cell-lymp-nct02974647/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02974647.jpg</video:thumbnail_loc>
      <video:title>Ruxolitinib for Lymphoma (NCT02974647) | Triangle</video:title>
      <video:description>Ruxolitinib trial for Lymphoma (NCT02974647). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02974647.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02974647.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:03:56.774Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-silevertinib-with-temozolomide-for-the-treatment-of-new-nct07326566/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07326566.jpg</video:thumbnail_loc>
      <video:title>silevertinib in combination with… (NCT07326566) | Triangle</video:title>
      <video:description>silevertinib in combination with temozolomide trial for Glioblastoma (GBM) (NCT07326566). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07326566.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07326566.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:54:07.491Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-of-the-efficacy-of-intratumoral-l19il2-or-l19tnf-or-l19il2-nct06284590/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06284590.jpg</video:thumbnail_loc>
      <video:title>L19IL2 for Melanoma Stage III (NCT06284590) | Triangle</video:title>
      <video:description>L19IL2 trial for Melanoma Stage III (NCT06284590). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06284590.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06284590.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:00:11.102Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-to-assess-the-efficacy-and-safety-of-rina-s-in-participant-nct07288177/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07288177.jpg</video:thumbnail_loc>
      <video:title>Rina-S for Non-small Cell Lung… (NCT07288177) | Triangle</video:title>
      <video:description>Rina-S trial for Non-small Cell Lung Cancer (NSCLC) (NCT07288177). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07288177.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07288177.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:55:12.144Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-to-determine-the-efficacy-and-safety-of-asciminib-in-pedia-nct07354074/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07354074.jpg</video:thumbnail_loc>
      <video:title>Asciminib single agent for Chronic… (NCT07354074) | Triangle</video:title>
      <video:description>Asciminib single agent trial for Chronic Myelogenous Leukemia (NCT07354074). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07354074.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07354074.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:40:44.939Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-to-evaluate-sutetinib-maleate-capsule-in-locally-advanced-nct05168566/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05168566.jpg</video:thumbnail_loc>
      <video:title>Sutetinib Maleate Capsule for Non… (NCT05168566) | Triangle</video:title>
      <video:description>Sutetinib Maleate Capsule trial for Non-small Cell Lung Cancer (NCT05168566). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05168566.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05168566.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:35:56.335Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/study-to-evaluate-the-safety-and-tolerability-of-camizestrant-in-nct07427394/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07427394.jpg</video:thumbnail_loc>
      <video:title>Camizestrant for Advanced Breast Cancer (NCT07427394) | Triangle</video:title>
      <video:description>Camizestrant trial for Advanced Breast Cancer (NCT07427394). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07427394.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07427394.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:37:11.721Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/subcutaneous-talquetamab-in-elderly-patients-with-multiple-myelo-nct06827860/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06827860.jpg</video:thumbnail_loc>
      <video:title>Talquetamab for Multiple Myeloma… (NCT06827860) | Triangle</video:title>
      <video:description>Talquetamab trial for Multiple Myeloma in Relapse (NCT06827860). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06827860.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06827860.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:50:49.097Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/substudy-01i-a-study-of-investigational-agents-in-participants-w-nct06780098/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06780098.jpg</video:thumbnail_loc>
      <video:title>R-DXD for Lung Neoplasm (NCT06780098) | Triangle</video:title>
      <video:description>R-DXD trial for Lung Neoplasm (NCT06780098). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06780098.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06780098.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:55:37.991Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/suprachoroidal-administration-in-subjects-with-metastases-to-the-nct06643884/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06643884.jpg</video:thumbnail_loc>
      <video:title>AU-011 for Eye Cancer (NCT06643884) | Triangle</video:title>
      <video:description>AU-011 trial for Eye Cancer (NCT06643884). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06643884.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06643884.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:08:03.842Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/supraphysiological-androgen-to-enhance-treatment-activity-in-met-nct06039371/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06039371.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure (NCT06039371) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Castration-Resistant Prostate Carcinoma (NCT06039371). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06039371.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06039371.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:27:10.620Z</video:publication_date>
      <video:duration>94</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/surovatamig-azd0486-as-monotherapy-in-participants-with-relapsed-nct06526793/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06526793.jpg</video:thumbnail_loc>
      <video:title>Surovatamig for B-cell… (NCT06526793) | Triangle</video:title>
      <video:description>Surovatamig trial for B-cell Non-Hodgkin Lymphoma (NCT06526793). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06526793.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06526793.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:16:52.763Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/sx-682-and-atezolizumab-for-the-treatment-of-advanced-or-metasta-nct07322341/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07322341.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Advanced Lung… (NCT07322341) | Triangle</video:title>
      <video:description>Atezolizumab trial for Advanced Lung Non-Small Cell Carcinoma (NCT07322341). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07322341.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07322341.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:23:47.663Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/sx-682-with-pembrolizumab-for-the-treatment-of-metastatic-or-rec-nct05570825/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05570825.jpg</video:thumbnail_loc>
      <video:title>Biopsy for Metastatic Lung… (NCT05570825) | Triangle</video:title>
      <video:description>Biopsy trial for Metastatic Lung Non-Small Cell Carcinoma (NCT05570825). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05570825.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05570825.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:55:19.013Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/t-cell-receptor-immunotherapy-for-patients-with-metastatic-non-s-nct02133196/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02133196.jpg</video:thumbnail_loc>
      <video:title>Aldesleukin for Advanced… (NCT02133196) | Triangle</video:title>
      <video:description>Aldesleukin trial for Advanced Non-Small Cell Lung Cancer (NCT02133196). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02133196.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02133196.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:07:59.034Z</video:publication_date>
      <video:duration>71</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/tafasitamab-and-rituximab-for-the-treatment-of-newly-diagnosed-f-nct07731789/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07731789.jpg</video:thumbnail_loc>
      <video:title>Rituximab for Classic Follicular… (NCT07731789) | Triangle</video:title>
      <video:description>Rituximab trial for Classic Follicular Lymphoma (NCT07731789). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07731789.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07731789.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:26:49.574Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/tagraxofusp-and-azacitidine-with-venetoclax-in-newly-diagnosed-s-nct05442216/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05442216.jpg</video:thumbnail_loc>
      <video:title>Tagraxofusp for Acute Myeloid Leukemia (NCT05442216) | Triangle</video:title>
      <video:description>Tagraxofusp trial for Acute Myeloid Leukemia (NCT05442216). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05442216.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05442216.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:21:17.344Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/tapur-testing-the-use-of-food-and-drug-administration-fda-approv-nct02693535/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02693535.jpg</video:thumbnail_loc>
      <video:title>Sunitinib (CLOSED TO ENROLLMENT) (NCT02693535) | Triangle</video:title>
      <video:description>Sunitinib (CLOSED TO ENROLLMENT) trial for Lymphoma, Non-Hodgkin (NCT02693535). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02693535.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02693535.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:06:25.839Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/targeted-treatment-for-advanced-non-small-cell-lung-cancer-that-nct06116682/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06116682.jpg</video:thumbnail_loc>
      <video:title>Amivantamab for Lung Non-Small… (NCT06116682) | Triangle</video:title>
      <video:description>Amivantamab trial for Lung Non-Small Cell Carcinoma (NCT06116682). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06116682.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06116682.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:37:29.540Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/tarlatamab-for-the-treatment-of-extensive-stage-small-cell-lung-nct07423585/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07423585.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Extensive… (NCT07423585) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Extensive Stage Lung Small Cell Carcinoma (NCT07423585). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07423585.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07423585.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:25:25.942Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/tebentafusp-in-hla-a-0201-positive-previously-untreated-metastat-nct06070012/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06070012.jpg</video:thumbnail_loc>
      <video:title>Tebentafusp for Uveal Melanoma (NCT06070012) | Triangle</video:title>
      <video:description>Tebentafusp trial for Uveal Melanoma (NCT06070012). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06070012.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06070012.mp4</video:content_loc>
      <video:publication_date>2026-10-31T18:04:33.572Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-an-experimental-approach-to-treat-patients-with-plasma-c-nct07605416/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07605416.jpg</video:thumbnail_loc>
      <video:title>Autologous Hematopoietic Stem… (NCT07605416) | Triangle</video:title>
      <video:description>Autologous Hematopoietic Stem Cell Transplantation trial for Plasma Cell Leukemia (NCT07605416). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07605416.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07605416.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:32:34.261Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-atezolizumab-with-selinexor-in-people-12-years-old-with-nct05333458/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05333458.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Advanced… (NCT05333458) | Triangle</video:title>
      <video:description>Atezolizumab trial for Advanced Alveolar Soft Part Sarcoma (NCT05333458). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05333458.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05333458.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:59:42.212Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-drug-treatments-after-car-t-cell-therapy-in-patients-wit-nct05633615/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05633615.jpg</video:thumbnail_loc>
      <video:title>Axicabtagene Ciloleucel (NCT05633615) | Triangle</video:title>
      <video:description>Axicabtagene Ciloleucel trial for Diffuse Large B-Cell Lymphoma (NCT05633615). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05633615.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05633615.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:22:45.932Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-new-therapies-for-patients-with-acute-myeloid-leukemia-w-nct05554406/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05554406.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Myeloid Leukemia (NCT05554406) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Myeloid Leukemia (NCT05554406). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05554406.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05554406.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:19:49.471Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-nivolumab-with-or-without-ipilimumab-in-deficient-mismat-nct05112601/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05112601.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT05112601) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Endometrial Adenocarcinoma (NCT05112601). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05112601.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05112601.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:20:38.218Z</video:publication_date>
      <video:duration>76</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-of-bevacizumab-erlotinib-and-atezolizumab-in-combination-nct04981509/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04981509.jpg</video:thumbnail_loc>
      <video:title>Atezolizumab for Hereditary… (NCT04981509) | Triangle</video:title>
      <video:description>Atezolizumab trial for Hereditary Leiomyomatosis and Renal Cell Carcinoma (NCT04981509). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04981509.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04981509.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:30:59.603Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-osimertinib-as-a-treatment-for-lung-cancers-with-an-egfr-nct03191149/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03191149.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT03191149) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Advanced Lung Non-Small Cell Carcinoma (NCT03191149). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03191149.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03191149.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:42:03.393Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-an-anti-cancer-drug-cabozantinib-to-the-nct06900595/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06900595.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Locally… (NCT06900595) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Locally Advanced Adrenal Cortical Carcinoma (NCT06900595). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06900595.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06900595.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:27:07.549Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-an-idh2-inhibitor-enasidenib-to-usual-tr-nct06577441/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06577441.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06577441) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Myelodysplastic Syndrome (NCT06577441). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06577441.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06577441.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:17:18.597Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-an-individualized-vaccine-to-durvalumab-nct03606967/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03606967.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Anatomic… (NCT03606967) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Anatomic Stage IV Breast Cancer AJCC v8 (NCT03606967). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03606967.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03606967.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:18:56.109Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-bms-986016-relatlimab-to-the-usual-immun-nct06029270/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06029270.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06029270) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Metastatic Nasopharyngeal Carcinoma (NCT06029270). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06029270.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06029270.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:30:50.698Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-cemiplimab-regn2810-to-chemotherapy-trea-nct07281417/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07281417.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Sinonasal… (NCT07281417) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Sinonasal Squamous Cell Carcinoma (NCT07281417). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07281417.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07281417.mp4</video:content_loc>
      <video:publication_date>2026-10-31T07:25:29.947Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-chemotherapy-or-chemo-immunotherapy-to-t-nct07195734/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07195734.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07195734) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (NCT07195734). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07195734.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07195734.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:25:57.972Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-immunotherapy-before-surgery-for-patient-nct05647265/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05647265.jpg</video:thumbnail_loc>
      <video:title>Nivolumab for Pleural Biphasic… (NCT05647265) | Triangle</video:title>
      <video:description>Nivolumab trial for Pleural Biphasic Mesothelioma (NCT05647265). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05647265.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05647265.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:24:50.012Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-stereotactic-radiation-therapy-with-immu-nct05327686/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05327686.jpg</video:thumbnail_loc>
      <video:title>Avelumab for Metastatic Renal… (NCT05327686) | Triangle</video:title>
      <video:description>Avelumab trial for Metastatic Renal Cell Carcinoma (NCT05327686). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05327686.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05327686.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:58:30.477Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-the-anti-cancer-drug-venetoclax-and-or-t-nct06317662/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06317662.jpg</video:thumbnail_loc>
      <video:title>Asparaginase Erwinia chrysanthemi (NCT06317662) | Triangle</video:title>
      <video:description>Asparaginase Erwinia chrysanthemi trial for Acute Leukemia of Ambiguous Lineage (NCT06317662). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06317662.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06317662.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:35:31.384Z</video:publication_date>
      <video:duration>88</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-the-immunotherapy-drug-pembrolizumab-to-nct06770582/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06770582.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06770582) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Non-Muscle Invasive Bladder Urothelial Carcinoma (NCT06770582). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06770582.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06770582.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:13:41.476Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-addition-of-venetoclax-or-gemtuzumab-ozogamicin-go-t-nct06917911/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06917911.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Core… (NCT06917911) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Core Binding Factor Acute Myeloid Leukemia (NCT06917911). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06917911.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06917911.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:26:01.275Z</video:publication_date>
      <video:duration>94</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-anti-cancer-drug-glofitamab-in-patients-with-mantle-nct07003295/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07003295.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07003295) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Recurrent Mantle Cell Lymphoma (NCT07003295). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07003295.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07003295.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:35:32.682Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-combination-of-anti-cancer-drugs-botensilimab-agen11-nct07551596/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07551596.jpg</video:thumbnail_loc>
      <video:title>Balstilimab for Colorectal… (NCT07551596) | Triangle</video:title>
      <video:description>Balstilimab trial for Colorectal Adenocarcinoma (NCT07551596). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07551596.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07551596.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:05:58.151Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-combination-of-venetoclax-and-rituximab-in-compariso-nct04840602/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04840602.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT04840602) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Lymphoplasmacytic Lymphoma (NCT04840602). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04840602.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04840602.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:13:33.195Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-effectiveness-of-a-combination-targeted-therapy-vipo-nct06649812/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06649812.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for High Grade… (NCT06649812) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements (NCT06649812). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06649812.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06649812.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:44:41.729Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-effectiveness-of-the-anti-cancer-drug-mirdametinib-i-nct07061951/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07061951.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07061951) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Recurrent Chronic Lymphocytic Leukemia (NCT07061951). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07061951.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07061951.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:44:54.421Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-effectiveness-of-two-immunotherapy-drugs-nivolumab-a-nct03866382/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03866382.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Bladder… (NCT03866382) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Bladder Adenocarcinoma (NCT03866382). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03866382.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03866382.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:31:20.717Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-investigational-agent-combination-of-daratumumab-bor-nct07085728/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07085728.jpg</video:thumbnail_loc>
      <video:title>Cyclophosphamide for Myeloma Multiple (NCT07085728) | Triangle</video:title>
      <video:description>Cyclophosphamide trial for Myeloma Multiple (NCT07085728). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07085728.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07085728.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:46:54.209Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-investigational-medication-combination-of-daratumuma-nct06948084/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06948084.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06948084) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Recurrent Multiple Myeloma (NCT06948084). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06948084.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06948084.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:28:14.628Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-safety-and-effectiveness-of-radiation-based-treatmen-nct05691465/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05691465.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT05691465) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation (NCT05691465). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05691465.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05691465.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:11:46.360Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-safety-and-feasibility-of-immunotherapy-drugs-botens-nct07516366/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07516366.jpg</video:thumbnail_loc>
      <video:title>Balstilimab for Clear Cell Renal… (NCT07516366) | Triangle</video:title>
      <video:description>Balstilimab trial for Clear Cell Renal Cell Carcinoma (NCT07516366). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07516366.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07516366.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:13:47.896Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-use-of-ado-trastuzumab-emtansine-compared-to-the-usu-nct05408845/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05408845.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Metastatic… (NCT05408845) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Metastatic Salivary Gland Carcinoma (NCT05408845). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05408845.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05408845.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:57:27.403Z</video:publication_date>
      <video:duration>90</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-the-use-of-neratinib-or-the-combination-of-neratinib-and-nct06126276/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06126276.jpg</video:thumbnail_loc>
      <video:title>Biopsy Procedure for Malignant… (NCT06126276) | Triangle</video:title>
      <video:description>Biopsy Procedure trial for Malignant Female Reproductive System Neoplasm (NCT06126276). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06126276.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06126276.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:26:46.739Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-what-happens-when-an-immunotherapy-drug-pembrolizumab-is-nct04671667/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04671667.jpg</video:thumbnail_loc>
      <video:title>Carboplatin for Recurrent Head… (NCT04671667) | Triangle</video:title>
      <video:description>Carboplatin trial for Recurrent Head and Neck Squamous Cell Carcinoma (NCT04671667). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04671667.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04671667.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:17:59.650Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/testing-whether-cemiplimab-regn2810-plus-cdx-1140-given-prior-to-nct06980038/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06980038.jpg</video:thumbnail_loc>
      <video:title>Anti-CD40 Agonist Monoclonal… (NCT06980038) | Triangle</video:title>
      <video:description>Anti-CD40 Agonist Monoclonal Antibody CDX-1140 trial for Head and Neck Squamous Cell Carcinoma (NCT06980038). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06980038.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06980038.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:20:20.975Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/the-cosmyc-trial-combined-suppression-of-myc-nct06922318/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06922318.jpg</video:thumbnail_loc>
      <video:title>ZEN-3694 for Metastatic… (NCT06922318) | Triangle</video:title>
      <video:description>ZEN-3694 trial for Metastatic Castration-resistant Prostate Cancer (NCT06922318). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06922318.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06922318.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:52:07.805Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/the-miami-empire-trial-eradication-of-metastatic-pancreatic-canc-nct06843551/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06843551.jpg</video:thumbnail_loc>
      <video:title>Stereotactic Body Radiation Therapy (NCT06843551) | Triangle</video:title>
      <video:description>Stereotactic Body Radiation Therapy trial for Metastatic Pancreatic Ductal Adenocarcinoma (NCT06843551). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06843551.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06843551.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:45:53.685Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/the-minimalist-trial-2-nct06702033/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06702033.jpg</video:thumbnail_loc>
      <video:title>Radiation therapy for HPV-Related… (NCT06702033) | Triangle</video:title>
      <video:description>Radiation therapy trial for HPV-Related Oropharynx Squamous Cell Carcinoma (NCT06702033). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06702033.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06702033.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:10:53.399Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/the-sappho-study-sequential-therapy-with-curative-intent-in-de-n-nct06439693/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06439693.jpg</video:thumbnail_loc>
      <video:title>Nab-Paclitaxel for Breast Cancer Female (NCT06439693) | Triangle</video:title>
      <video:description>Nab-Paclitaxel trial for Breast Cancer Female (NCT06439693). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06439693.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06439693.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:17:27.539Z</video:publication_date>
      <video:duration>91</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/the-study-of-atezolizumab-bevacizumab-and-memantine-in-patients-nct06789757/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06789757.jpg</video:thumbnail_loc>
      <video:title>Memantine Hydrochloride (NCT06789757) | Triangle</video:title>
      <video:description>Memantine Hydrochloride trial for Hepatocellular Carcinoma (NCT06789757). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06789757.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06789757.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:32:47.515Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/the-sugar-study-sbrt-and-relugolix-for-prostate-cancer-nct06111781/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06111781.jpg</video:thumbnail_loc>
      <video:title>Relugolix 120 MG [Orgovyx] (NCT06111781) | Triangle</video:title>
      <video:description>Relugolix 120 MG [Orgovyx] trial for Prostate Cancer (NCT06111781). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06111781.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06111781.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:54:03.404Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/therapy-for-newly-diagnosed-patients-with-b-cell-precursor-acute-nct06533748/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06533748.jpg</video:thumbnail_loc>
      <video:title>Dexamethasone for Acute… (NCT06533748) | Triangle</video:title>
      <video:description>Dexamethasone trial for Acute Lymphoblastic Leukemia (NCT06533748). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06533748.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06533748.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:41:17.788Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/three-schedules-of-cue-101-administered-before-surgery-or-defini-nct04852328/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04852328.jpg</video:thumbnail_loc>
      <video:title>CUE-101 for Oropharyngeal… (NCT04852328) | Triangle</video:title>
      <video:description>CUE-101 trial for Oropharyngeal Squamous Cell Carcinoma (NCT04852328). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04852328.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04852328.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:32:40.590Z</video:publication_date>
      <video:duration>94</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/to-study-the-effect-of-inavolisib-in-combination-with-fulvestran-nct07368998/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07368998.jpg</video:thumbnail_loc>
      <video:title>Inavolisib for Breast Cancer (NCT07368998) | Triangle</video:title>
      <video:description>Inavolisib trial for Breast Cancer (NCT07368998). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07368998.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07368998.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:43:35.724Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/top-2301-neoadjuvant-chemo-for-nsclc-nct06385262/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06385262.jpg</video:thumbnail_loc>
      <video:title>Alirocumab for Non Small Cell… (NCT06385262) | Triangle</video:title>
      <video:description>Alirocumab trial for Non Small Cell Lung Cancer (NCT06385262). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06385262.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06385262.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:22:23.135Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/total-marrow-and-lymphoid-irradiation-in-combination-with-fludar-nct07582172/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07582172.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Acute… (NCT07582172) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Acute Myeloid Leukemia With Complex Karyotype (NCT07582172). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07582172.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07582172.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:41:29.776Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/total-neoadjuvant-therapy-with-mfolfox-and-short-course-radiatio-nct04643366/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04643366.jpg</video:thumbnail_loc>
      <video:title>Chemotherapy for Rectal Cancer (NCT04643366) | Triangle</video:title>
      <video:description>Chemotherapy trial for Rectal Cancer (NCT04643366). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04643366.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04643366.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:34:40.175Z</video:publication_date>
      <video:duration>92</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/transoral-surgical-resection-followed-by-de-escalated-adjuvant-i-nct05388773/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05388773.jpg</video:thumbnail_loc>
      <video:title>therapeutic conventional surgery (NCT05388773) | Triangle</video:title>
      <video:description>therapeutic conventional surgery trial for Oropharynx Cancer (NCT05388773). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05388773.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05388773.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:26:20.435Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/treatment-for-advanced-non-small-cell-lung-cancer-with-actionabl-nct07393555/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07393555.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT07393555) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Recurrent Lung Non-Small Cell Carcinoma (NCT07393555). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07393555.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07393555.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:22:10.163Z</video:publication_date>
      <video:duration>98</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/treatment-of-adc-refractory-breast-cancer-with-dato-dxd-or-t-dxd-nct06533826/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06533826.jpg</video:thumbnail_loc>
      <video:title>Trastuzumab Deruxtecan for Breast Cancer (NCT06533826) | Triangle</video:title>
      <video:description>Trastuzumab Deruxtecan trial for Breast Cancer (NCT06533826). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06533826.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06533826.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:09:50.060Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/triage-of-advanced-cervical-cancer-through-immunotherapy-inducti-nct05475171/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05475171.jpg</video:thumbnail_loc>
      <video:title>Lorigerlimab for Metastatic Cancer (NCT05475171) | Triangle</video:title>
      <video:description>Lorigerlimab trial for Metastatic Cancer (NCT05475171). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05475171.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05475171.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:31:34.547Z</video:publication_date>
      <video:duration>75</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-comparing-lattice-radiotherapy-vs-moderately-dose-escalate-nct07594431/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07594431.jpg</video:thumbnail_loc>
      <video:title>LATTICE Radiotherapy for Metastases (NCT07594431) | Triangle</video:title>
      <video:description>LATTICE Radiotherapy trial for Metastases (NCT07594431). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07594431.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07594431.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:21:17.517Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-investigating-visugromab-and-nivolumab-with-or-without-doc-nct07246863/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07246863.jpg</video:thumbnail_loc>
      <video:title>Visugromab RDE (recommended dose… (NCT07246863) | Triangle</video:title>
      <video:description>Visugromab RDE (recommended dose for expansion) trial for Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT07246863). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07246863.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07246863.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:19:35.078Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-investigating-visugromab-in-combination-with-immunochemoth-nct07098988/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07098988.jpg</video:thumbnail_loc>
      <video:title>Visugromab for Metastatic… (NCT07098988) | Triangle</video:title>
      <video:description>Visugromab trial for Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT07098988). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07098988.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07098988.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:11:20.710Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-of-2-step-atg-for-acute-gvhd-prevention-post-myeloablative-nct06315309/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06315309.jpg</video:thumbnail_loc>
      <video:title>ATG Combined with Tacrolimus and… (NCT06315309) | Triangle</video:title>
      <video:description>ATG Combined with Tacrolimus and Mini Methotrexate trial for GVHD,Acute (NCT06315309). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06315309.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06315309.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:40:25.806Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-of-amb-05x-for-patients-with-ctdna-colorectal-cancer-after-nct06617858/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06617858.jpg</video:thumbnail_loc>
      <video:title>AMB-05X for Colorectal Cancer (NCT06617858) | Triangle</video:title>
      <video:description>AMB-05X trial for Colorectal Cancer (NCT06617858). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06617858.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06617858.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:39:04.603Z</video:publication_date>
      <video:duration>72</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-of-an-alternative-cabozantinib-dosing-schedule-in-metastat-nct05263050/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05263050.jpg</video:thumbnail_loc>
      <video:title>Cabozantinib for Metastatic Renal… (NCT05263050) | Triangle</video:title>
      <video:description>Cabozantinib trial for Metastatic Renal Cell Carcinoma (NCT05263050). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05263050.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05263050.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:00:33.087Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-of-orca-t-following-reduced-intensity-or-nonmyeloablative-nct07216443/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07216443.jpg</video:thumbnail_loc>
      <video:title>Orca-T for Leukemia, Myeloid, Acute (NCT07216443) | Triangle</video:title>
      <video:description>Orca-T trial for Leukemia, Myeloid, Acute (NCT07216443). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07216443.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07216443.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:23:03.418Z</video:publication_date>
      <video:duration>87</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-of-therapies-with-it-cdc1s-combined-w-it-trastuzamab-for-h-nct07694986/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07694986.jpg</video:thumbnail_loc>
      <video:title>cDC1 Vaccine for Breast Cancer (NCT07694986) | Triangle</video:title>
      <video:description>cDC1 Vaccine trial for Breast Cancer (NCT07694986). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07694986.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07694986.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:17:56.510Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-of-trastuzumab-deruxtecan-in-previously-treated-her2-nct06750484/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06750484.jpg</video:thumbnail_loc>
      <video:title>Trastuzumab Deruxtecan for Breast… (NCT06750484) | Triangle</video:title>
      <video:description>Trastuzumab Deruxtecan trial for Breast Cancer Metastatic (NCT06750484). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06750484.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06750484.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:55:12.640Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-to-study-anti-hcmv-therapy-in-breast-cancer-patients-with-nct07383649/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07383649.jpg</video:thumbnail_loc>
      <video:title>Valganciclovir for Brain Cancer… (NCT07383649) | Triangle</video:title>
      <video:description>Valganciclovir trial for Brain Cancer Metastatic (NCT07383649). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07383649.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07383649.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:06:52.883Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/trial-utilizing-metronidazole-to-optimize-the-microbiome-of-rect-nct06569368/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06569368.jpg</video:thumbnail_loc>
      <video:title>Metronidazole for Rectal Adenocarcinoma (NCT06569368) | Triangle</video:title>
      <video:description>Metronidazole trial for Rectal Adenocarcinoma (NCT06569368). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06569368.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06569368.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:38:35.895Z</video:publication_date>
      <video:duration>70</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/turkey-tail-mushroom-for-treating-post-menopausal-women-with-her-nct06450873/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06450873.jpg</video:thumbnail_loc>
      <video:title>Coriolus Versicolor Extract (NCT06450873) | Triangle</video:title>
      <video:description>Coriolus Versicolor Extract trial for Estrogen Receptor-Positive Breast Carcinoma (NCT06450873). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06450873.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06450873.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:34:07.285Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ucsd-image-guided-cognitive-sparing-radiosurgery-for-intracrania-nct04343157/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04343157.jpg</video:thumbnail_loc>
      <video:title>Cognitive Sparing Brain… (NCT04343157) | Triangle</video:title>
      <video:description>Cognitive Sparing Brain Stereotactic Radiosurgery (SRS) trial for Brain Metastases, Adult (NCT04343157). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04343157.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04343157.mp4</video:content_loc>
      <video:publication_date>2026-10-31T18:46:30.047Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ultra-hypo-fractionated-adjuvant-whole-breast-radiation-therapy-nct06902311/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06902311.jpg</video:thumbnail_loc>
      <video:title>Breast Radiotherapy for Breast Cancer (NCT06902311) | Triangle</video:title>
      <video:description>Breast Radiotherapy trial for Breast Cancer (NCT06902311). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06902311.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06902311.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:52:10.746Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/upfront-chemotherapy-with-radiation-therapy-crt-followed-by-chem-nct07603375/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07603375.jpg</video:thumbnail_loc>
      <video:title>FOLFOX (5-fluorouracil… (NCT07603375) | Triangle</video:title>
      <video:description>FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) trial for Esophageal Adenocarcinoma (NCT07603375). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07603375.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07603375.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:59:03.186Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/use-of-isatuximab-dexamethasone-and-lenalidomide-in-a-go-slow-fa-nct06517017/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06517017.jpg</video:thumbnail_loc>
      <video:title>Isatuximab for Multiple Myeloma (NCT06517017) | Triangle</video:title>
      <video:description>Isatuximab trial for Multiple Myeloma (NCT06517017). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06517017.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06517017.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:55:53.296Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/using-circulating-tumor-dna-to-risk-adapt-post-operative-therapy-nct06445114/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06445114.jpg</video:thumbnail_loc>
      <video:title>Cisplatin for Oropharyngeal Cancer (NCT06445114) | Triangle</video:title>
      <video:description>Cisplatin trial for Oropharyngeal Cancer (NCT06445114). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06445114.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06445114.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:20:33.095Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/venetoclax-and-hma-treatment-of-older-and-unfit-adults-with-flt3-nct06317649/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06317649.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Myeloid Leukemia (NCT06317649) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Myeloid Leukemia (NCT06317649). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06317649.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06317649.mp4</video:content_loc>
      <video:publication_date>2026-10-31T05:28:38.104Z</video:publication_date>
      <video:duration>86</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/venetoclax-cladribine-low-dose-cytarabine-and-azacitidine-in-tre-nct03586609/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03586609.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Myeloid Leukemia (NCT03586609) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Myeloid Leukemia (NCT03586609). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03586609.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT03586609.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:47:15.482Z</video:publication_date>
      <video:duration>95</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/venetoclax-in-combination-with-cladribine-and-cytarabine-alterna-nct06504459/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06504459.jpg</video:thumbnail_loc>
      <video:title>Azacitidine for Acute Monocytic Leukemia (NCT06504459) | Triangle</video:title>
      <video:description>Azacitidine trial for Acute Monocytic Leukemia (NCT06504459). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06504459.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06504459.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:33:38.588Z</video:publication_date>
      <video:duration>83</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/venetoclax-plus-zanubrutinib-for-the-treatment-of-chronic-lympho-nct07734038/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07734038.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Chronic… (NCT07734038) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Chronic Lymphocytic Leukemia (NCT07734038). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07734038.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07734038.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:16:07.369Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/venetoclax-sl-401-and-chemotherapy-for-the-treatment-of-blastic-nct04216524/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04216524.jpg</video:thumbnail_loc>
      <video:title>Cyclophosphamide for Blastic… (NCT04216524) | Triangle</video:title>
      <video:description>Cyclophosphamide trial for Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT04216524). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04216524.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT04216524.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:47:40.127Z</video:publication_date>
      <video:duration>81</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/vismodegib-combined-with-atezolizumab-in-platinum-resistant-ovar-nct05538091/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05538091.jpg</video:thumbnail_loc>
      <video:title>Vismodegib for Platinum-Resistant… (NCT05538091) | Triangle</video:title>
      <video:description>Vismodegib trial for Platinum-Resistant Fallopian Tube Carcinoma (NCT05538091). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05538091.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05538091.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:52:21.109Z</video:publication_date>
      <video:duration>78</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/vismodegib-fak-inhibitor-gsk2256098-capivasertib-and-abemaciclib-nct02523014/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02523014.jpg</video:thumbnail_loc>
      <video:title>Vismodegib for Intracranial Meningioma (NCT02523014) | Triangle</video:title>
      <video:description>Vismodegib trial for Intracranial Meningioma (NCT02523014). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02523014.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT02523014.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:15:20.471Z</video:publication_date>
      <video:duration>95</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/vista-valproic-acid-irinotecan-and-simvastatin-for-recurrent-gli-nct07831369/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07831369.jpg</video:thumbnail_loc>
      <video:title>Valproic Acid (VPA) for Glioblastoma (NCT07831369) | Triangle</video:title>
      <video:description>Valproic Acid (VPA) trial for Glioblastoma (NCT07831369). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07831369.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07831369.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:07:40.381Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/vorasidenib-study-in-pediatric-participants-with-grade-2-astrocy-nct07286292/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07286292.jpg</video:thumbnail_loc>
      <video:title>Vorasidenib for Grade 2… (NCT07286292) | Triangle</video:title>
      <video:description>Vorasidenib trial for Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation (NCT07286292). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07286292.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07286292.mp4</video:content_loc>
      <video:publication_date>2026-10-31T18:25:48.071Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/wp1066-and-radiation-therapy-in-treating-patients-with-newly-dia-nct05879250/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05879250.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT05879250) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Glioblastoma, IDH-Wildtype (NCT05879250). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05879250.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05879250.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:19:52.229Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/xl092-for-the-treatment-of-locally-advanced-or-metastatic-radioi-nct06959641/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06959641.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Locally… (NCT06959641) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Locally Advanced Differentiated Thyroid Gland Carcinoma (NCT06959641). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06959641.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06959641.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:47:58.429Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/xl092-in-patients-with-metastatic-castration-resistant-prostate-nct06568562/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06568562.jpg</video:thumbnail_loc>
      <video:title>XL092 for Metastatic… (NCT06568562) | Triangle</video:title>
      <video:description>XL092 trial for Metastatic Castration-resistant Prostate Cancer (NCT06568562). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06568562.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06568562.mp4</video:content_loc>
      <video:publication_date>2026-10-31T22:40:16.558Z</video:publication_date>
      <video:duration>92</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/xl092-zanzalintinib-for-the-treatment-of-patients-with-metastati-nct06571734/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06571734.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection (NCT06571734) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Metastatic Leiomyosarcoma (NCT06571734). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06571734.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06571734.mp4</video:content_loc>
      <video:publication_date>2026-10-31T06:55:48.284Z</video:publication_date>
      <video:duration>77</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc-nct06555133/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06555133.jpg</video:thumbnail_loc>
      <video:title>yttrium-90 radioembolization (NCT06555133) | Triangle</video:title>
      <video:description>yttrium-90 radioembolization trial for Colorectal Carcinoma Metastatic in the Liver (NCT06555133). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06555133.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06555133.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:47:39.823Z</video:publication_date>
      <video:duration>73</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/zanubrutinib-bendamustine-rituximab-prev-untreated-wm-nct06561347/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06561347.jpg</video:thumbnail_loc>
      <video:title>Zanubrutinib for Waldenstrom… (NCT06561347) | Triangle</video:title>
      <video:description>Zanubrutinib trial for Waldenstrom Macroglobulinemia (NCT06561347). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06561347.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06561347.mp4</video:content_loc>
      <video:publication_date>2026-10-31T20:04:45.633Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/zanubrutinib-obinutuzumab-sonrotoclax-boson-or-bgb-16673-obinutu-nct06849713/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06849713.jpg</video:thumbnail_loc>
      <video:title>Zanubrutinib for Chronic… (NCT06849713) | Triangle</video:title>
      <video:description>Zanubrutinib trial for Chronic Lymphocytic Leukemia (NCT06849713). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06849713.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06849713.mp4</video:content_loc>
      <video:publication_date>2026-10-31T17:02:56.982Z</video:publication_date>
      <video:duration>82</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/zanzalintinib-for-metastatic-clear-cell-renal-cell-carcinoma-wit-nct07043608/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07043608.jpg</video:thumbnail_loc>
      <video:title>Zanzalintinib for Clear Cell… (NCT07043608) | Triangle</video:title>
      <video:description>Zanzalintinib trial for Clear Cell Renal Cell Cancer (ccRCC) (NCT07043608). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07043608.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07043608.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:03:10.056Z</video:publication_date>
      <video:duration>79</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/zanzalintinib-for-the-treatment-of-advanced-thyroid-cancer-befor-nct06959511/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06959511.jpg</video:thumbnail_loc>
      <video:title>Zanzalintinib for Neoadjuvant Treatment (NCT06959511) | Triangle</video:title>
      <video:description>Zanzalintinib trial for Neoadjuvant Treatment (NCT06959511). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06959511.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06959511.mp4</video:content_loc>
      <video:publication_date>2026-10-31T19:14:07.606Z</video:publication_date>
      <video:duration>80</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/zanzalintinib-in-men-with-aggressive-variant-prostate-cancer-nct07218666/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07218666.jpg</video:thumbnail_loc>
      <video:title>Zanzalintinib for Aggressive… (NCT07218666) | Triangle</video:title>
      <video:description>Zanzalintinib trial for Aggressive Variant Prostate Carcinoma (NCT07218666). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07218666.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT07218666.mp4</video:content_loc>
      <video:publication_date>2026-10-31T15:57:57.138Z</video:publication_date>
      <video:duration>85</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/zanzalintinib-maintenance-in-patients-with-high-grade-neuroendoc-nct06926634/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06926634.jpg</video:thumbnail_loc>
      <video:title>Zanzalintinib for High Grade… (NCT06926634) | Triangle</video:title>
      <video:description>Zanzalintinib trial for High Grade Neuroendocrine Neoplasms (NCT06926634). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06926634.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06926634.mp4</video:content_loc>
      <video:publication_date>2026-10-31T21:24:14.332Z</video:publication_date>
      <video:duration>84</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/zen003694-combined-with-talazoparib-in-patients-with-recurrent-o-nct05071937/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05071937.jpg</video:thumbnail_loc>
      <video:title>ZEN003694 for Ovarian Cancer (NCT05071937) | Triangle</video:title>
      <video:description>ZEN003694 trial for Ovarian Cancer (NCT05071937). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05071937.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT05071937.mp4</video:content_loc>
      <video:publication_date>2026-10-31T23:54:24.369Z</video:publication_date>
      <video:duration>89</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
  <url>
    <loc>https://www.trianglehealth.com/phase-2/ziftomenib-for-the-treatment-of-patients-with-npm1-mutated-or-km-nct06930352/video</loc>
    <video:video>
      <video:thumbnail_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06930352.jpg</video:thumbnail_loc>
      <video:title>Biospecimen Collection for Acute… (NCT06930352) | Triangle</video:title>
      <video:description>Biospecimen Collection trial for Acute Myeloid Leukemia (NCT06930352). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06930352.</video:description>
      <video:content_loc>https://x3enz3z8axsop9x3.public.blob.vercel-storage.com/phase-2/films/NCT06930352.mp4</video:content_loc>
      <video:publication_date>2026-10-31T16:47:50.593Z</video:publication_date>
      <video:duration>74</video:duration>
      <video:family_friendly>yes</video:family_friendly>
      <video:live>no</video:live>
    </video:video>
  </url>
</urlset>
